{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000002745","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":121229410}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000004478","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":2799164}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST90025964"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44115817}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44259056}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90018966"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44251253}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44251636}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44251636}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44260608}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44251636}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44243364}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44251636}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000004939","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":44251636}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025985"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":58279141}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002351"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":58270865}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002292"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":58278036}},"trait_info":{"ontology":["EFO_0005090"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":58281068}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":58268002}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":58279141}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002380"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":58278036}},"trait_info":{"ontology":["EFO_0007992"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000005381","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":58278036}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90038628"},"gold_standard_info":{"gene_id":"ENSG00000005471","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"7","position":87504050}},"trait_info":{"ontology":["EFO_0003832"]}}
{"association_info":{"otg_id":"GCST007209"},"gold_standard_info":{"gene_id":"ENSG00000005471","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"7","position":87476479}},"trait_info":{"ontology":["EFO_0004210"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000005471","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"7","position":87445103}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST90018819"},"gold_standard_info":{"gene_id":"ENSG00000005471","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":87477049}},"trait_info":{"ontology":["EFO_0004799"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000005961","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44369052}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000005961","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44369052}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000005961","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":44419706}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90038595"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1973321}},"trait_info":{"ontology":["EFO_0000319"]}}
{"association_info":{"otg_id":"GCST90038604"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":2030652}},"trait_info":{"ontology":["EFO_0000537"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":2036420}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1947003}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":1600945}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025965"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1783507}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":2160451}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000008710","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1788603}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000009950","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":73623036}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":45671788}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":45679046}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":45679046}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"NEALE2_23112_raw"},"gold_standard_info":{"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":45679046}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"GCST008734"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":52603470}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST90025992"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":52234850}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CGT","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":52377756}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90002412"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":52793899}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":52467435}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":52333916}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":52603470}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000010327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":52042003}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000010803","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":41041806}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST004988"},"gold_standard_info":{"gene_id":"ENSG00000012048","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":42684371}},"trait_info":{"ontology":["EFO_0000305"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000012504","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":100504439}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000012504","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":100481123}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000012504","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":100532530}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000013016","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":31202917}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000014914","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":149934520}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":44544952}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":44542732}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":44542732}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000019991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":81729735}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000021488","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":32911513}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000021488","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":32920233}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000021488","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":32692906}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000022840","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":120293151}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000022840","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":120293151}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000022840","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":120442071}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025973"},"gold_standard_info":{"gene_id":"ENSG00000023839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":99836239}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000023839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":100152307}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"NEALE2_23130_raw"},"gold_standard_info":{"gene_id":"ENSG00000024048","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":43010588}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000025293","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":35437976}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000025293","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":35437976}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000025293","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":35437976}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000025434","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":46970257}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000025708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":50523425}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000025708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":50532837}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002396"},"gold_standard_info":{"gene_id":"ENSG00000025708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":50511382}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000026652","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":161705393}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":41772929}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":41772929}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":41652396}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":41684575}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":41652396}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CACAGCAGAGTCTAT"},"locus_GRCh38":{"chromosome":"8","position":41655062}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":41649718}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000029534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":41652396}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000030110","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":33584425}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000030110","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":33573730}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90018852"},"gold_standard_info":{"gene_id":"ENSG00000034971","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":171636338}},"trait_info":{"ontology":["EFO_0000516"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000034971","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":171763223}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90016620"},"gold_standard_info":{"gene_id":"ENSG00000036257","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":224526579}},"trait_info":{"ontology":["EFO_0003756"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000036828","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":122026002}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000038945","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":16155085}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000042062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AC"},"locus_GRCh38":{"chromosome":"20","position":50482003}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025996"},"gold_standard_info":{"gene_id":"ENSG00000042286","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":70124080}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000042429","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":94163987}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018862"},"gold_standard_info":{"gene_id":"ENSG00000042832","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":132918938}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST010571"},"gold_standard_info":{"gene_id":"ENSG00000042832","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":132908273}},"trait_info":{"ontology":["EFO_0006812"]}}
{"association_info":{"otg_id":"GCST90038635"},"gold_standard_info":{"gene_id":"ENSG00000042832","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":132906524}},"trait_info":{"ontology":["EFO_1000627"]}}
{"association_info":{"otg_id":"NEALE2_20002_1226"},"gold_standard_info":{"gene_id":"ENSG00000042832","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":132917082}},"trait_info":{"ontology":["EFO_1001055"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000048405","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":127375029}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000048405","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":127375029}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000048405","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":127375029}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000049192","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":65349044}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST007576"},"gold_standard_info":{"gene_id":"ENSG00000049246","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":7788883}},"trait_info":{"ontology":["EFO_0008328"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000054219","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159820864}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000054219","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159748003}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000054219","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159820864}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000060566","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":4139443}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000060566","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":4028785}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025973"},"gold_standard_info":{"gene_id":"ENSG00000062282","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":75743976}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000064687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":807442}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000064687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":1277428}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000064687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":1050875}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000064687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":807442}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025985"},"gold_standard_info":{"gene_id":"ENSG00000064932","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":1004741}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000064932","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":1079960}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST008996"},"gold_standard_info":{"gene_id":"ENSG00000064989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":187250671}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000064989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":187250671}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST009867"},"gold_standard_info":{"gene_id":"ENSG00000064989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":187349092}},"trait_info":{"ontology":["EFO_0007789"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000065054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":2036420}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000065054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":2036420}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000065054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":2036420}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90000062"},"gold_standard_info":{"gene_id":"ENSG00000065054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":2020567}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST90000059"},"gold_standard_info":{"gene_id":"ENSG00000065054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":2020567}},"trait_info":{"ontology":["EFO_0006336"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000065600","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":212027833}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002380"},"gold_standard_info":{"gene_id":"ENSG00000065600","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":212277057}},"trait_info":{"ontology":["EFO_0007992"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":134733189}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"NEALE2_3062_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134564765}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":134560054}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":134641292}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134638240}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CAAAAAAAAAAAAA","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":134566393}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":134635797}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"NEALE2_23112_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":134635797}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"GCST90000062"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":134625094}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134653155}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134637605}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_30090_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134638240}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":134637605}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000066827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GAA"},"locus_GRCh38":{"chromosome":"8","position":134549442}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000068078","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":1743759}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000068078","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":1347765}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000068097","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATT"},"locus_GRCh38":{"chromosome":"17","position":59659453}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000068831","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":64624772}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST008972_4"},"gold_standard_info":{"gene_id":"ENSG00000068976","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":64566642}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000070182","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":65020976}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000070182","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"14","position":64782334}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000070182","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":64789470}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000070182","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":64765709}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST008972_4"},"gold_standard_info":{"gene_id":"ENSG00000071127","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":9982917}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000071205","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":148378986}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000072110","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":69087518}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000072274","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AGAGAGG","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":196103509}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000072274","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":196080754}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000072274","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":196064995}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000072274","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":196066468}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000072274","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":196077150}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000073008","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":44623160}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000073008","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44631381}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000073060","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":124853983}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000073060","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":124601871}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_8"},"gold_standard_info":{"gene_id":"ENSG00000073060","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":124869264}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000073734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":169009904}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000073734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":169003323}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000073792","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":185772396}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000073792","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":185772396}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000073792","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":185828362}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025991"},"gold_standard_info":{"gene_id":"ENSG00000074803","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":47845301}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000075151","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90095129"},"gold_standard_info":{"gene_id":"ENSG00000075275","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":46364584}},"trait_info":{"ontology":["EFO_0004464"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000075651","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":171741390}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000075651","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":171810165}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000075651","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":171620779}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000075785","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":128544578}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000076258","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":171763223}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000076344","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000076344","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000076344","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":165380}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000076864","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000077044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000077044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":233327103}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000077498","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GA"},"locus_GRCh38":{"chromosome":"11","position":89154784}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST007451"},"gold_standard_info":{"gene_id":"ENSG00000077498","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":88778356}},"trait_info":{"ontology":["EFO_0007009"]}}
{"association_info":{"otg_id":"GCST007082"},"gold_standard_info":{"gene_id":"ENSG00000077498","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":88721001}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000078269","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":158063872}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000078269","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":157961955}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000078747","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":34651177}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000079689","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":26098246}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000079689","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":26123274}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000079689","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":25365897}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000079689","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26072764}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000079689","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":26104404}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025996"},"gold_standard_info":{"gene_id":"ENSG00000079999","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":10757176}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":55181876}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":55251894}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":55181918}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":55180533}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":55182101}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000080031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":54761378}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000080166","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"13","position":94551023}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000080839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":37044679}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000081041","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":74097332}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000081041","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73837092}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000081041","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73837092}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST007069"},"gold_standard_info":{"gene_id":"ENSG00000081052","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":227314612}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000081052","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":227297564}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002310"},"gold_standard_info":{"gene_id":"ENSG00000081052","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":227350000}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST008790"},"gold_standard_info":{"gene_id":"ENSG00000081052","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":227077265}},"trait_info":{"ontology":["EFO_0007778"]}}
{"association_info":{"otg_id":"SAIGE_593"},"gold_standard_info":{"gene_id":"ENSG00000081052","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":227077364}},"trait_info":{"ontology":["HP_0000790"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000081479","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":169346594}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000081479","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":169154948}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000081479","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":169259162}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_CANCER"},"gold_standard_info":{"gene_id":"ENSG00000083093","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":23636404}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_BREAST"},"gold_standard_info":{"gene_id":"ENSG00000083093","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":23636404}},"trait_info":{"ontology":["EFO_0003869"]}}
{"association_info":{"otg_id":"FINNGEN_R6_Z21_FAMILY_HISTORY_MALIG_NEOPLASM"},"gold_standard_info":{"gene_id":"ENSG00000083093","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":23699191}},"trait_info":{"ontology":["EFO_0009640"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_BREAST_EXALLC"},"gold_standard_info":{"gene_id":"ENSG00000083093","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":23636404}},"trait_info":{"ontology":["MONDO_0007254"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000084110","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":95981904}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST004045"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":21065449}},"trait_info":{"ontology":["EFO_0000400"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":21041028}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":21003688}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":21071042}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025983"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":21063185}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":21065449}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":21044589}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":21008652}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":20799760}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":21011100}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST003665_3"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":21051295}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"NEALE2_20003_1141146138"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":21009932}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST90038690"},"gold_standard_info":{"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":21011100}},"trait_info":{"ontology":["HP_0003124"]}}
{"association_info":{"otg_id":"GCST011334"},"gold_standard_info":{"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000084774","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":27719021}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90018966"},"gold_standard_info":{"gene_id":"ENSG00000084774","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27375230}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000084774","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":26893231}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000084774","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000084774","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000085982","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000086232","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":5531994}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000086232","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"7","position":6026819}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000086232","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":6014788}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000086506","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000086506","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000086506","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":165380}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000086991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":89491285}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025980"},"gold_standard_info":{"gene_id":"ENSG00000086991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":89491285}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST90018972"},"gold_standard_info":{"gene_id":"ENSG00000086991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":89491285}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000087237","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":56546049}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000087237","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":56818910}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST003665_13"},"gold_standard_info":{"gene_id":"ENSG00000087237","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":56956804}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000088826","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":4121153}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000088827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":3711698}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000089234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000089234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000089234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111151263}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000089234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000089234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111151263}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000090534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":184372478}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000090534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GAA"},"locus_GRCh38":{"chromosome":"3","position":183999102}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90060281"},"gold_standard_info":{"gene_id":"ENSG00000090661","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8224635}},"trait_info":{"ontology":["EFO_0010118"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":151849112}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":151406410}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":151836746}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000092067","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000092067","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":23120140}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000092067","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"14","position":23118629}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000092067","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":22966124}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000092148","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":30692211}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000092853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":35746946}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002390"},"gold_standard_info":{"gene_id":"ENSG00000092853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":35746946}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002396"},"gold_standard_info":{"gene_id":"ENSG00000092853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":35578698}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025978"},"gold_standard_info":{"gene_id":"ENSG00000092969","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":218348267}},"trait_info":{"ontology":["EFO_0004713"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000095539","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":100904851}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000095906","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1370340}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000095906","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1778029}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000095906","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CAA"},"locus_GRCh38":{"chromosome":"16","position":1480497}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000096088","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":42013339}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"SAIGE_200_1"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":5049092}},"trait_info":{"ontology":["EFO_0002429"]}}
{"association_info":{"otg_id":"GCST90000032"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":4999303}},"trait_info":{"ontology":["EFO_0004251"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":4758972}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":4658995}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":4840877}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":4763491}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"FINNGEN_R6_D3_BLOOD"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":5073770}},"trait_info":{"ontology":["EFO_0005803"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":4661574}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":4856877}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":4763176}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":4763176}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":4852599}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":4852599}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":4763176}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000099331","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":17144924}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000099331","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":17091936}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000099937","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":20826200}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000099937","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":20881101}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000099940","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":20826200}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000099940","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":20881101}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000099991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000100014","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000100024","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000100031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000100209","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":28738571}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000100345","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":36282733}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST007432"},"gold_standard_info":{"gene_id":"ENSG00000100354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":40485399}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"NEALE2_46_raw"},"gold_standard_info":{"gene_id":"ENSG00000100354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":40215008}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000100368","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":36862944}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000100368","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":36862944}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000100979","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":45923216}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":44413724}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":59023753}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":59022590}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":59023552}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":59022916}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000101310","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":18050639}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000101342","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":37164857}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90019504"},"gold_standard_info":{"gene_id":"ENSG00000101435","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":23653118}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90019504"},"gold_standard_info":{"gene_id":"ENSG00000101439","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":23653118}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000101440","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":33712828}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90019504"},"gold_standard_info":{"gene_id":"ENSG00000101441","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":23653118}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000101670","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"18","position":49583585}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000101670","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":49254644}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_8"},"gold_standard_info":{"gene_id":"ENSG00000101670","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"18","position":49649891}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000101670","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"18","position":49583585}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000101745","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"18","position":8801353}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000101745","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":9284988}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000101745","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"18","position":9191862}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000101782","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23477246}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000101782","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23477246}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000101782","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23477246}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST011518"},"gold_standard_info":{"gene_id":"ENSG00000102053","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AG"},"locus_GRCh38":{"chromosome":"X","position":64619110}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000102572","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"13","position":98917634}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000102981","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000102981","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000103196","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":84717440}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88787321}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":88715642}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88789676}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88714064}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88789676}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88287421}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88287421}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":88484146}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30280_raw"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":88686194}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88265189}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TGCAC","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88443441}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88265189}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018939"},"gold_standard_info":{"gene_id":"ENSG00000103335","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":88775709}},"trait_info":{"ontology":["HP_0002619"]}}
{"association_info":{"otg_id":"FINNGEN_R6_CD2_INSITU"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":27983407}},"trait_info":{"ontology":["EFO_0000616"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":27793789}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90018921"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":27983407}},"trait_info":{"ontology":["EFO_0004198"]}}
{"association_info":{"otg_id":"GCST007452"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":28120472}},"trait_info":{"ontology":["EFO_0007009"]}}
{"association_info":{"otg_id":"GCST90041839"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":28118342}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"NEALE2_2217_raw"},"gold_standard_info":{"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":27985101}},"trait_info":{"ontology":["MONDO_0004892"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000104320","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":89983198}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST011335"},"gold_standard_info":{"gene_id":"ENSG00000104859","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44892362}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000104859","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44631381}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":49597038}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":49592704}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":49592704}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002322"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49904472}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025947"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":49514281}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49534760}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49513502}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90025980"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":49514281}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000104870","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":49465983}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000104973","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49534760}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000104973","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49513502}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000105122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":15542858}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000105383","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":51225221}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000105397","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":10285007}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000105397","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":10247963}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000105397","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":10293551}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000105472","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":50739310}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000105523","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":48703160}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":12888644}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":13018047}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":12888644}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":12888644}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":12890733}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000105610","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12887391}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000105707","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":35059974}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000106128","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":30971870}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000106266","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":2256917}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000106266","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":2256917}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100624226}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":100638579}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100621008}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100621008}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000106571","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":42061332}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000106624","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":44157984}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"FINNGEN_R6_DIABETES_FG"},"gold_standard_info":{"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":44216044}},"trait_info":{"ontology":["EFO_0000400"]}}
{"association_info":{"otg_id":"GCST90018955"},"gold_standard_info":{"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":44200725}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":44109097}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST010557"},"gold_standard_info":{"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":44184122}},"trait_info":{"ontology":["MONDO_0005148"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000106819","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":92186746}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000107099","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":331490}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000107099","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":304670}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000107165","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AAAC"},"locus_GRCh38":{"chromosome":"9","position":12661227}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST007082"},"gold_standard_info":{"gene_id":"ENSG00000107165","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":12712157}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST008790"},"gold_standard_info":{"gene_id":"ENSG00000107611","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":16890385}},"trait_info":{"ontology":["EFO_0007778"]}}
{"association_info":{"otg_id":"GCST90019514"},"gold_standard_info":{"gene_id":"ENSG00000107611","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":16876998}},"trait_info":{"ontology":["EFO_0010967"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000107984","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":52585842}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST009600"},"gold_standard_info":{"gene_id":"ENSG00000108557","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":18053145}},"trait_info":{"ontology":["EFO_0003756"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000108582","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":30699275}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000108821","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":50178266}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025983"},"gold_standard_info":{"gene_id":"ENSG00000108846","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":50673753}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000109062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":74720763}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000109062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":74703245}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000109667","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":9489561}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000109684","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":9993616}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000110090","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":68433827}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000110243","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000110243","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_21"},"gold_standard_info":{"gene_id":"ENSG00000110243","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST004037"},"gold_standard_info":{"gene_id":"ENSG00000110243","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116781707}},"trait_info":{"ontology":["EFO_0007929"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000110243","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116830638}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90038599"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GAA"},"locus_GRCh38":{"chromosome":"11","position":117150989}},"trait_info":{"ontology":["EFO_0000400"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TA"},"locus_GRCh38":{"chromosome":"11","position":116752497}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST003665_21"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":116960300}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"NEALE2_20003_1141146138"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST004037"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116781707}},"trait_info":{"ontology":["EFO_0007929"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116830638}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000110245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025960"},"gold_standard_info":{"gene_id":"ENSG00000110768","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":18365795}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"FINNGEN_R6_D3_COAGDEF"},"gold_standard_info":{"gene_id":"ENSG00000110799","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":5987855}},"trait_info":{"ontology":["EFO_0009314"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000110934","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":51288062}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000111249","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111034102}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000111249","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CAAAAAAAAAAAA","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":110797526}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111034102}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111494996}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111494996}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111702865}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111427245}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111535554}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111569952}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST011336"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111472415}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111569952}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111034102}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111034102}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111569952}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":111407152}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000111252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111446804}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000111700","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":21227696}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000111801","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":26017370}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000111802","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":24469684}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000111913","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":24469684}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000112077","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":49392304}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000112077","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":49492439}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000112079","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":36526101}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000112110","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":159418032}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000112293","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":24469684}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000112294","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":24469684}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000112339","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":135037429}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000112339","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CAAAAAAAAAAAACAA"},"locus_GRCh38":{"chromosome":"6","position":135042813}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000112343","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26072764}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000112499","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CCT"},"locus_GRCh38":{"chromosome":"6","position":160247154}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000112499","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000112541","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":165366858}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000112576","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":42013339}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000112576","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":41957421}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000112576","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":41688076}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002316"},"gold_standard_info":{"gene_id":"ENSG00000112787","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":132887914}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000113013","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":138601216}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000113389","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":32818967}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000113389","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":32711527}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"GCST009867"},"gold_standard_info":{"gene_id":"ENSG00000113389","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":32711527}},"trait_info":{"ontology":["EFO_0007789"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000113389","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":32717122}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000113504","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CTG"},"locus_GRCh38":{"chromosome":"5","position":1042262}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":132449992}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":132077562}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":173352472}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":173057038}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":173058037}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":173058037}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":173058037}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000113739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":173326552}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000114126","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142582597}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000114126","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AT","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142557120}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000114126","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":141515062}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000114395","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":50292395}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000114395","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":50150357}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000114656","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":128564563}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000114737","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":51020911}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"NEALE2_30210_raw"},"gold_standard_info":{"gene_id":"ENSG00000114737","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":50734193}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000114786","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":52333916}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST004521"},"gold_standard_info":{"gene_id":"ENSG00000114861","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":71522194}},"trait_info":{"ontology":["EFO_0003756"]}}
{"association_info":{"otg_id":"GCST90025991"},"gold_standard_info":{"gene_id":"ENSG00000115112","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":121243169}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST011334"},"gold_standard_info":{"gene_id":"ENSG00000115194","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000115232","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":181147287}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST011334"},"gold_standard_info":{"gene_id":"ENSG00000115234","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST011990"},"gold_standard_info":{"gene_id":"ENSG00000115267","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0000676"]}}
{"association_info":{"otg_id":"GCST90018862"},"gold_standard_info":{"gene_id":"ENSG00000115267","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST90038635"},"gold_standard_info":{"gene_id":"ENSG00000115267","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_1000627"]}}
{"association_info":{"otg_id":"GCST90025973"},"gold_standard_info":{"gene_id":"ENSG00000115488","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":232633959}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST007069"},"gold_standard_info":{"gene_id":"ENSG00000115524","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":197778907}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002397"},"gold_standard_info":{"gene_id":"ENSG00000115524","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AC"},"locus_GRCh38":{"chromosome":"2","position":197463296}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000115657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":219216694}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000115657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":219216694}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000115657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TAGG"},"locus_GRCh38":{"chromosome":"2","position":218856229}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000115956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":68388414}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000115956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":68388414}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000115956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":68813372}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000115956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":68388414}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000115956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":68388414}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000116183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":176337251}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000116183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":176532695}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000116183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":176530924}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000116183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":176530924}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000116183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":176241593}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000117139","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":203085523}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000117298","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000117400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":43375311}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000117400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":43338669}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000117877","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":44915229}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018944"},"gold_standard_info":{"gene_id":"ENSG00000117984","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":1758975}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000118137","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_21"},"gold_standard_info":{"gene_id":"ENSG00000118137","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST004037"},"gold_standard_info":{"gene_id":"ENSG00000118137","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116781707}},"trait_info":{"ontology":["EFO_0007929"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000118520","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":131552195}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000118702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":36950277}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000118702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":36890036}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000118702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":36890036}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000118762","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":88047191}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"FINNGEN_R6_Q17_CYSTIC_KIDNEY_DISEA"},"gold_standard_info":{"gene_id":"ENSG00000118762","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GC"},"locus_GRCh38":{"chromosome":"4","position":87714051}},"trait_info":{"ontology":["EFO_0008615"]}}
{"association_info":{"otg_id":"GCST008970"},"gold_standard_info":{"gene_id":"ENSG00000118777","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":88131171}},"trait_info":{"ontology":["EFO_0004274"]}}
{"association_info":{"otg_id":"GCST008972_2"},"gold_standard_info":{"gene_id":"ENSG00000118777","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":88165592}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"NEALE2_20003_1140875486"},"gold_standard_info":{"gene_id":"ENSG00000118777","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":88133515}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"NEALE2_23129_raw"},"gold_standard_info":{"gene_id":"ENSG00000119403","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":120714674}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000119535","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":36478315}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000119535","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":36478315}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000119574","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":58025281}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000119681","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":74517665}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90038595"},"gold_standard_info":{"gene_id":"ENSG00000119772","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":24939798}},"trait_info":{"ontology":["EFO_0000319"]}}
{"association_info":{"otg_id":"GCST90038604"},"gold_standard_info":{"gene_id":"ENSG00000119772","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TC","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":24947289}},"trait_info":{"ontology":["EFO_0000537"]}}
{"association_info":{"otg_id":"GCST90025980"},"gold_standard_info":{"gene_id":"ENSG00000120053","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CT"},"locus_GRCh38":{"chromosome":"10","position":99406115}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"NEALE2_4194_raw"},"gold_standard_info":{"gene_id":"ENSG00000120457","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":128897140}},"trait_info":{"ontology":["EFO_0004326"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000120889","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":23222622}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000121005","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":74891184}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000121005","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":74934374}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000121281","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":50301163}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000121281","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":50301163}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000121807","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":46364876}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000121807","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":46280680}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST001956"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":172208583}},"trait_info":{"ontology":["EFO_0004302"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":172251287}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":172407882}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":172251287}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":172251287}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":172251287}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000121853","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":172251287}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000121966","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":135991239}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000121966","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":135945143}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000121966","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":136128164}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000122025","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"13","position":28029870}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000122025","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":27972629}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000122406","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":92568466}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000122406","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":92961849}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000122406","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AT"},"locus_GRCh38":{"chromosome":"1","position":92506133}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000122729","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":32431933}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000122729","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":32450189}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000122729","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":32450189}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"NEALE2_30020_raw"},"gold_standard_info":{"gene_id":"ENSG00000122729","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":32450189}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90011822"},"gold_standard_info":{"gene_id":"ENSG00000123106","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":28021884}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000123191","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"13","position":51946299}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST007072"},"gold_standard_info":{"gene_id":"ENSG00000123454","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133657152}},"trait_info":{"ontology":["EFO_0000319"]}}
{"association_info":{"otg_id":"GCST90018972"},"gold_standard_info":{"gene_id":"ENSG00000123454","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":133636634}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST90000059"},"gold_standard_info":{"gene_id":"ENSG00000123454","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":133458632}},"trait_info":{"ontology":["EFO_0006336"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000123485","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018739"},"gold_standard_info":{"gene_id":"ENSG00000123572","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"X","position":105694686}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST008996"},"gold_standard_info":{"gene_id":"ENSG00000123612","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":157556189}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST008362"},"gold_standard_info":{"gene_id":"ENSG00000123612","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":157487943}},"trait_info":{"ontology":["EFO_0004344"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000123612","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":157647227}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":110021121}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":109933275}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":109603883}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":109717668}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":109648464}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":109717668}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":109717668}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000123739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":109966833}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000123892","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":88102042}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000124089","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":56270663}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000124089","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":56283978}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000124253","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":57525580}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000124508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26090951}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000124508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GA","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":25897971}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018972"},"gold_standard_info":{"gene_id":"ENSG00000124749","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":56070770}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST90018951"},"gold_standard_info":{"gene_id":"ENSG00000124827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":10877164}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000124875","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":74081277}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000124875","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":74097332}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000124875","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73837092}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000124875","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73837092}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018887"},"gold_standard_info":{"gene_id":"ENSG00000125084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":48995693}},"trait_info":{"ontology":["EFO_0003882"]}}
{"association_info":{"otg_id":"NEALE2_3147_raw"},"gold_standard_info":{"gene_id":"ENSG00000125084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":48985754}},"trait_info":{"ontology":["EFO_0004514"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000125084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":48985754}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000125084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":48985754}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000125149","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000125149","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000125844","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":17863848}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000125844","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":17823423}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000125844","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"20","position":17811678}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":3203964}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":3203964}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":3179886}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":3179519}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":3179886}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":2812155}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":3179519}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002380"},"gold_standard_info":{"gene_id":"ENSG00000125910","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":3179886}},"trait_info":{"ontology":["EFO_0007992"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000126456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49534760}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000126456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":49513502}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000127452","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":10143085}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000127586","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":314008}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000127586","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":383078}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000127586","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TGGGC"},"locus_GRCh38":{"chromosome":"16","position":578994}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000127948","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":75533848}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000127948","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":76035603}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000127948","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":76006538}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST011124"},"gold_standard_info":{"gene_id":"ENSG00000127948","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":75986787}},"trait_info":{"ontology":["EFO_0010091"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000128655","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":177680838}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000128849","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":57533524}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000128849","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":57377629}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000129173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":19199971}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000129173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":19199971}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000129173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":19228617}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000129173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":19201602}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7473092}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_3147_raw"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":7463300}},"trait_info":{"ontology":["EFO_0004514"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7176997}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GTC"},"locus_GRCh38":{"chromosome":"17","position":7446325}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7192188}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7190147}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000129245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000129245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GTC"},"locus_GRCh38":{"chromosome":"17","position":7446325}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000129993","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":88515282}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90038595"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11079858}},"trait_info":{"ontology":["EFO_0000319"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11079868}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"GCST011365"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11078223}},"trait_info":{"ontology":["EFO_0000612"]}}
{"association_info":{"otg_id":"GCST010866"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":11081517}},"trait_info":{"ontology":["EFO_0001645"]}}
{"association_info":{"otg_id":"GCST90038605"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AC"},"locus_GRCh38":{"chromosome":"19","position":11078298}},"trait_info":{"ontology":["EFO_0003777"]}}
{"association_info":{"otg_id":"GCST90018793"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11080521}},"trait_info":{"ontology":["EFO_0003913"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11079858}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11076648}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11076648}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST003665_4"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11079976}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"NEALE2_20003_1141192410"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11077441}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST90038690"},"gold_standard_info":{"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11086585}},"trait_info":{"ontology":["HP_0003124"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000130173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11239812}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000130173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":11159217}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_4"},"gold_standard_info":{"gene_id":"ENSG00000130173","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11079976}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000130202","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":44820877}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000130300","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":17141341}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000130427","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000130427","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000130427","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000130427","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90042882"},"gold_standard_info":{"gene_id":"ENSG00000130487","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":50517688}},"trait_info":{"ontology":["EFO_0004238"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000130561","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000130700","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":62474494}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000130700","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":62475466}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000130779","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":121924526}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000131183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":177388765}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000131183","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":177301457}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000131459","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"5","position":180302519}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23121_raw"},"gold_standard_info":{"gene_id":"ENSG00000131459","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":180300399}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000131482","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":42583623}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000131482","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":43020464}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST010244"},"gold_standard_info":{"gene_id":"ENSG00000131482","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":42546057}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST012490"},"gold_standard_info":{"gene_id":"ENSG00000131482","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":42903335}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90038594"},"gold_standard_info":{"gene_id":"ENSG00000131482","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":42561053}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000131504","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000131873","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":101018931}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000132004","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12668356}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":12285932}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":12447843}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90020232"},"gold_standard_info":{"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":12344838}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST007576"},"gold_standard_info":{"gene_id":"ENSG00000132326","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":238235960}},"trait_info":{"ontology":["EFO_0008328"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000132507","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000132514","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000132669","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":19903179}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000132693","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":159359193}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000132703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":159359193}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TA"},"locus_GRCh38":{"chromosome":"1","position":62463707}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TA"},"locus_GRCh38":{"chromosome":"1","position":62463707}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":62670407}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":62690372}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":62620330}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90038690"},"gold_standard_info":{"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":62460700}},"trait_info":{"ontology":["HP_0003124"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000133069","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":205284711}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000133135","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"X","position":106773038}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90013407"},"gold_standard_info":{"gene_id":"ENSG00000133460","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":23992517}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000133742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":85341753}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000133742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":85341753}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000133742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":85395020}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000133742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":85356084}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":10182063}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":10156890}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"NEALE2_30020_raw"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":10173735}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":10456681}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":10487356}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000133805","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":10487356}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90038599"},"gold_standard_info":{"gene_id":"ENSG00000133895","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":64333304}},"trait_info":{"ontology":["EFO_0001379"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000134013","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":23311574}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000134109","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":4716175}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000134538","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":21227696}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST007576"},"gold_standard_info":{"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":92993923}},"trait_info":{"ontology":["EFO_0008328"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000134873","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":95476621}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000134873","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"13","position":95427192}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90038633"},"gold_standard_info":{"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TATGTATGTATGTATG"},"locus_GRCh38":{"chromosome":"12","position":120991613}},"trait_info":{"ontology":["EFO_0000400"]}}
{"association_info":{"otg_id":"NEALE2_20003_1141146234"},"gold_standard_info":{"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"ACTCC","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":120979734}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST010557"},"gold_standard_info":{"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":120994314}},"trait_info":{"ontology":["MONDO_0005148"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":80593092}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":80656687}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018956"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":80656687}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90002351"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":80485118}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"NEALE2_30110_raw"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":80471252}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"7","position":80582107}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AGCACAAATAAAGCACT"},"locus_GRCh38":{"chromosome":"7","position":80674384}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000135587","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GGCCCCT"},"locus_GRCh38":{"chromosome":"6","position":109290531}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST007070"},"gold_standard_info":{"gene_id":"ENSG00000135636","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":71450816}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000135766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":231426482}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000135766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":231422308}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000135766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":231422308}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000135776","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":229629404}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000135837","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":180020449}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000136011","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":103089316}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000136068","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":58033152}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000136122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"13","position":72859987}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000136122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"13","position":72859987}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000136859","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":126884749}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000136872","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":101427574}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000136872","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":101427574}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90081463"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":6255967}},"trait_info":{"ontology":["EFO_0002686"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":6197392}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90038664"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":6197392}},"trait_info":{"ontology":["EFO_0005854"]}}
{"association_info":{"otg_id":"GCST90078998"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":6255967}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST007075"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":6074936}},"trait_info":{"ontology":["HP_0000964"]}}
{"association_info":{"otg_id":"GCST009798"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":6209697}},"trait_info":{"ontology":["MONDO_0004979"]}}
{"association_info":{"otg_id":"GCST90038661"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":6197392}},"trait_info":{"ontology":["MONDO_0005271"]}}
{"association_info":{"otg_id":"GCST90018895"},"gold_standard_info":{"gene_id":"ENSG00000137033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":6209697}},"trait_info":{"ontology":["MONDO_0005405"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":16294491}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":16288384}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":16294491}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":16294491}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":16290530}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":16280956}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":16280956}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":16266007}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000137204","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":42929336}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000137343","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":30527904}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST010083"},"gold_standard_info":{"gene_id":"ENSG00000137404","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":30490287}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90025964"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":66579928}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":66651066}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002322"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":66320627}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018972"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":66648746}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":67122573}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":66719608}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST010989"},"gold_standard_info":{"gene_id":"ENSG00000138031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":24927772}},"trait_info":{"ontology":["EFO_0009819"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43845437}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"FINNGEN_R6_GAST_OPER"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43839108}},"trait_info":{"ontology":["EFO_0002571"]}}
{"association_info":{"otg_id":"GCST90038628"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":43806615}},"trait_info":{"ontology":["EFO_0003832"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43845437}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":43455520}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":43455520}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018819"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43842633}},"trait_info":{"ontology":["EFO_0004799"]}}
{"association_info":{"otg_id":"SAIGE_575"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43842633}},"trait_info":{"ontology":["EFO_0009534"]}}
{"association_info":{"otg_id":"SAIGE_577"},"gold_standard_info":{"gene_id":"ENSG00000138075","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":43859452}},"trait_info":{"ontology":["EFO_0009605"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000138193","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":93982576}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000138336","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":68343515}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000138685","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":122906887}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000138685","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":122827461}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000138685","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":122827461}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":122271085}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"NEALE2_23126_raw"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000138688","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":121792708}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000138709","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":127647811}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000138709","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":127625245}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000138829","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":128032306}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"GCST90020232"},"gold_standard_info":{"gene_id":"ENSG00000138829","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":128021834}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000139044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":481093}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000139044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":461674}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000139044","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":479206}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000139083","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":11869562}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000139083","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":11869562}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST004988"},"gold_standard_info":{"gene_id":"ENSG00000139618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":32398489}},"trait_info":{"ontology":["EFO_0000305"]}}
{"association_info":{"otg_id":"GCST003587"},"gold_standard_info":{"gene_id":"ENSG00000139618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":32398489}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST003587"},"gold_standard_info":{"gene_id":"ENSG00000139618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":32398489}},"trait_info":{"ontology":["EFO_0001075"]}}
{"association_info":{"otg_id":"GCST003587"},"gold_standard_info":{"gene_id":"ENSG00000139618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"13","position":32398489}},"trait_info":{"ontology":["EFO_0001663"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000139718","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":121924526}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000139725","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":121924526}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000139835","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"13","position":113362571}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000140092","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":91963840}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":98651667}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":98651667}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":98643259}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":98643259}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":98643259}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000140443","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":98561597}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":99952136}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":100152748}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":100152748}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST009867"},"gold_standard_info":{"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":100152748}},"trait_info":{"ontology":["EFO_0007789"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":99973858}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000140505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST011125"},"gold_standard_info":{"gene_id":"ENSG00000140505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0006781"]}}
{"association_info":{"otg_id":"NEALE2_30510_raw"},"gold_standard_info":{"gene_id":"ENSG00000140505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0007934"]}}
{"association_info":{"otg_id":"GCST011124"},"gold_standard_info":{"gene_id":"ENSG00000140505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0010091"]}}
{"association_info":{"otg_id":"GCST90018966"},"gold_standard_info":{"gene_id":"ENSG00000140694","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":14646435}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000140694","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":14558363}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000140961","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":83946924}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000140968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":85912233}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000140968","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":85663029}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST006414"},"gold_standard_info":{"gene_id":"ENSG00000140986","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1953015}},"trait_info":{"ontology":["EFO_0000275"]}}
{"association_info":{"otg_id":"SAIGE_427_2"},"gold_standard_info":{"gene_id":"ENSG00000140986","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1953015}},"trait_info":{"ontology":["EFO_0003911"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000140986","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1947003}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000141002","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89571498}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041837"},"gold_standard_info":{"gene_id":"ENSG00000141002","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89919683}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000141013","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89571498}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041840"},"gold_standard_info":{"gene_id":"ENSG00000141013","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":89677219}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90025976"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":23503774}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002390"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":23524924}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23494958}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23141009}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":23507567}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000141458","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":23494958}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000141499","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000141505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":7166093}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000141505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":7166093}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000141505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7176997}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000141505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7176997}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90011822"},"gold_standard_info":{"gene_id":"ENSG00000141510","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":7668434}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST90011814"},"gold_standard_info":{"gene_id":"ENSG00000141510","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":7668434}},"trait_info":{"ontology":["EFO_0004289"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000141738","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":39250882}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000141959","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"21","position":44301827}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90090616"},"gold_standard_info":{"gene_id":"ENSG00000141959","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"21","position":44240952}},"trait_info":{"ontology":["EFO_0007937"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000142002","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":4488929}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST011391"},"gold_standard_info":{"gene_id":"ENSG00000142156","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"21","position":45993879}},"trait_info":{"ontology":["EFO_0010066"]}}
{"association_info":{"otg_id":"GCST011390"},"gold_standard_info":{"gene_id":"ENSG00000142156","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"21","position":45993879}},"trait_info":{"ontology":["EFO_0010067"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST007485_3"},"gold_standard_info":{"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0004324"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23126_raw"},"gold_standard_info":{"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"NEALE2_23127_raw"},"gold_standard_info":{"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000142327","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":240571486}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000142494","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":19571562}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90041836"},"gold_standard_info":{"gene_id":"ENSG00000142619","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":17270928}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000142794","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000142798","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000142871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":85582843}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000142871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":85771251}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000142961","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":46525445}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000143257","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":161696843}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90025973"},"gold_standard_info":{"gene_id":"ENSG00000143257","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":161229914}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000143341","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":186122944}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"GCST90025978"},"gold_standard_info":{"gene_id":"ENSG00000143341","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":185885139}},"trait_info":{"ontology":["EFO_0004713"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000143365","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":151831737}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000143375","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":151831737}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000143382","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":150195892}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000143382","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":150452900}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000143382","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CTCCTCT"},"locus_GRCh38":{"chromosome":"1","position":150226707}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000143412","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":150559900}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000143476","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":212027833}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000143476","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":212066721}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000143476","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":212037832}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000143554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":153711264}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":155208991}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":155208991}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":155208991}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":155205599}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90019383"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":155062156}},"trait_info":{"ontology":["EFO_0007937"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":155196150}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000143627","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":155196150}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90027161"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CACTG"},"locus_GRCh38":{"chromosome":"1","position":152312600}},"trait_info":{"ontology":["EFO_0000274"]}}
{"association_info":{"otg_id":"GCST007076"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":151829204}},"trait_info":{"ontology":["EFO_0000684"]}}
{"association_info":{"otg_id":"GCST90038602"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":152215426}},"trait_info":{"ontology":["EFO_0000701"]}}
{"association_info":{"otg_id":"NEALE2_6152_9"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":151829204}},"trait_info":{"ontology":["EFO_0003956"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":152027641}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST010985"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":152057072}},"trait_info":{"ontology":["EFO_0004847"]}}
{"association_info":{"otg_id":"GCST90018830"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":152313385}},"trait_info":{"ontology":["EFO_0005319"]}}
{"association_info":{"otg_id":"GCST90038602"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":152215426}},"trait_info":{"ontology":["EFO_0005803"]}}
{"association_info":{"otg_id":"GCST90038680"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":152206676}},"trait_info":{"ontology":["HP_0000964"]}}
{"association_info":{"otg_id":"GCST90038680"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":152206676}},"trait_info":{"ontology":["MONDO_0002406"]}}
{"association_info":{"otg_id":"GCST009798"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":152313385}},"trait_info":{"ontology":["MONDO_0004979"]}}
{"association_info":{"otg_id":"GCST90018881"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":152313385}},"trait_info":{"ontology":["MONDO_0005271"]}}
{"association_info":{"otg_id":"GCST90018895"},"gold_standard_info":{"gene_id":"ENSG00000143631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":152206676}},"trait_info":{"ontology":["MONDO_0005405"]}}
{"association_info":{"otg_id":"NEALE2_23119_raw"},"gold_standard_info":{"gene_id":"ENSG00000143924","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":42803547}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000144481","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_L12_FOLLICULARCYST"},"gold_standard_info":{"gene_id":"ENSG00000144671","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":38009720}},"trait_info":{"ontology":["EFO_1001329"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000144908","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":126188549}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000145321","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":71688442}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":76701084}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":76723219}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":76701084}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":76572052}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":76665143}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":76298918}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000145703","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"5","position":76298632}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90042676"},"gold_standard_info":{"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":103003035}},"trait_info":{"ontology":["EFO_0000493"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":103003035}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"GCST010557"},"gold_standard_info":{"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":103250706}},"trait_info":{"ontology":["MONDO_0005148"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000146039","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26072764}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST001956"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":35037307}},"trait_info":{"ontology":["EFO_0004302"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":35427841}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":34807319}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23116_raw"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":34724697}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AT","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":35276963}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AT","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":35276963}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000146197","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CT"},"locus_GRCh38":{"chromosome":"6","position":34922016}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000146376","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":129703055}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000146433","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":158365633}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000146477","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST011335"},"gold_standard_info":{"gene_id":"ENSG00000146477","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":160351810}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000146477","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":160099774}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000146477","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000146674","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":45874631}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90041836"},"gold_standard_info":{"gene_id":"ENSG00000146828","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"7","position":100859956}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90038599"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"ATTTTTTT","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100691506}},"trait_info":{"ontology":["EFO_0000400"]}}
{"association_info":{"otg_id":"GCST90038599"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"ATTTTTTT","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100691506}},"trait_info":{"ontology":["EFO_0001379"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90025986"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100689872}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100621008}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100762744}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100732869}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100619150}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100918383}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"GCST010557"},"gold_standard_info":{"gene_id":"ENSG00000146830","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100715797}},"trait_info":{"ontology":["MONDO_0005148"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000147459","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":25321768}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000147799","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":144506731}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST90027051"},"gold_standard_info":{"gene_id":"ENSG00000147889","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":22053688}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST010302"},"gold_standard_info":{"gene_id":"ENSG00000147889","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":22067594}},"trait_info":{"ontology":["EFO_0000389"]}}
{"association_info":{"otg_id":"GCST90011809"},"gold_standard_info":{"gene_id":"ENSG00000147889","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":21803881}},"trait_info":{"ontology":["EFO_0000756"]}}
{"association_info":{"otg_id":"GCST90025947"},"gold_standard_info":{"gene_id":"ENSG00000148288","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":133101979}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025947"},"gold_standard_info":{"gene_id":"ENSG00000148291","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":133101979}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000148400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":136425395}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000148400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":137032610}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000148400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":136378050}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000148400","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":136322635}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000148584","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":50814012}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000148584","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":50882756}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000148584","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"10","position":50613485}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90025947"},"gold_standard_info":{"gene_id":"ENSG00000148835","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":103273258}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000149177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":48059700}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_23116_raw"},"gold_standard_info":{"gene_id":"ENSG00000149177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":47508395}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000149257","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":75564434}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST005077"},"gold_standard_info":{"gene_id":"ENSG00000149311","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GA","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":108474788}},"trait_info":{"ontology":["EFO_0000305"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_CANCER"},"gold_standard_info":{"gene_id":"ENSG00000149311","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":108278480}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST011049"},"gold_standard_info":{"gene_id":"ENSG00000149311","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":108486410}},"trait_info":{"ontology":["EFO_0001663"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000149311","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":108418081}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000149577","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116778201}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST004037"},"gold_standard_info":{"gene_id":"ENSG00000149577","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":116781707}},"trait_info":{"ontology":["EFO_0007929"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000149781","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64207494}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000149781","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64207494}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000150637","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":69872156}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000151422","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":108754433}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST010302"},"gold_standard_info":{"gene_id":"ENSG00000152104","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":214499928}},"trait_info":{"ontology":["EFO_0000389"]}}
{"association_info":{"otg_id":"GCST90018955"},"gold_standard_info":{"gene_id":"ENSG00000152254","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":168906638}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000152254","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":168900844}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":14372712}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":14526043}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST007067"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14338889}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST010244"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14540399}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":14422997}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14274783}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":14316029}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"NEALE2_23126_raw"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14391667}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14274783}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"GCST90025996"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14359282}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002385"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":14403740}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":14505588}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000152270","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":14798282}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000152382","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":166755941}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000152556","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":48118502}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000152556","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":48105348}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000152556","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":47784730}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90019509"},"gold_standard_info":{"gene_id":"ENSG00000152556","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":48201099}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90089126"},"gold_standard_info":{"gene_id":"ENSG00000152556","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":47740431}},"trait_info":{"ontology":["EFO_0007937"]}}
{"association_info":{"otg_id":"NEALE2_3147_raw"},"gold_standard_info":{"gene_id":"ENSG00000152595","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":87829652}},"trait_info":{"ontology":["EFO_0004514"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000152595","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":87910097}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000152684","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":52711384}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000152684","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":52711384}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000152684","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CTG"},"locus_GRCh38":{"chromosome":"5","position":52704227}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST004643_2"},"gold_standard_info":{"gene_id":"ENSG00000154025","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":19020368}},"trait_info":{"ontology":["EFO_0008009"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000154122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":14751196}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000154262","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":69085137}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000154358","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":227969662}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000154358","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":228372293}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000155506","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":154648189}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST006414"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":178546938}},"trait_info":{"ontology":["EFO_0000275"]}}
{"association_info":{"otg_id":"GCST011202"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":178693639}},"trait_info":{"ontology":["EFO_0000407"]}}
{"association_info":{"otg_id":"SAIGE_427_2"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":178651047}},"trait_info":{"ontology":["EFO_0003911"]}}
{"association_info":{"otg_id":"FINNGEN_R6_CARDIAC_ARRHYTM"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":178556567}},"trait_info":{"ontology":["EFO_0004269"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":178761353}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"GCST007432"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":178395655}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"NEALE2_4194_raw"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":178856319}},"trait_info":{"ontology":["EFO_0004326"]}}
{"association_info":{"otg_id":"GCST007087"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":178820256}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":178771857}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"NEALE2_20003_1141182628"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":178368728}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000155657","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":178715250}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025963"},"gold_standard_info":{"gene_id":"ENSG00000155827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":101557958}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002390"},"gold_standard_info":{"gene_id":"ENSG00000155827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":101562920}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000155903","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":141431184}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000155903","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":141194330}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000156140","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":72649596}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000156140","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":72315920}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"NEALE2_23099_raw"},"gold_standard_info":{"gene_id":"ENSG00000156140","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":72683842}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000156515","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"10","position":69245824}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST001956"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":88852395}},"trait_info":{"ontology":["EFO_0004302"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":88872016}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":88854596}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":88843421}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":88824331}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000157766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":88714503}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90019524"},"gold_standard_info":{"gene_id":"ENSG00000158125","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":31341378}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000158158","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":96757889}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000158553","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":26873156}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002390"},"gold_standard_info":{"gene_id":"ENSG00000158553","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26904630}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000158578","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"X","position":54940614}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90018746"},"gold_standard_info":{"gene_id":"ENSG00000158578","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"X","position":55111545}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000158578","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"X","position":54940614}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000158716","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":159359193}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000159023","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":29090128}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000159023","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":28993501}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000159023","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":29112504}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000159023","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":29090128}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST011320"},"gold_standard_info":{"gene_id":"ENSG00000159184","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":48959662}},"trait_info":{"ontology":["EFO_0001663"]}}
{"association_info":{"otg_id":"GCST90042670"},"gold_standard_info":{"gene_id":"ENSG00000159184","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":48728343}},"trait_info":{"ontology":["MONDO_0008315"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000159216","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"21","position":34996362}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000159216","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"21","position":34887027}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000159388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":203312047}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000159388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":203239237}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000159723","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":67893221}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000159723","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000159723","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000159723","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":67180020}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000159899","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":35754503}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000160145","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":124618265}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000160145","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":124658479}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002245"},"gold_standard_info":{"gene_id":"ENSG00000160211","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"X","position":154663327}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000160271","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000160271","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000160271","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000160271","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132988251}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000160271","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989049}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025947"},"gold_standard_info":{"gene_id":"ENSG00000160326","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":133101979}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000160593","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":118210555}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000160593","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":118210555}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90025991"},"gold_standard_info":{"gene_id":"ENSG00000160685","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":155060832}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000160716","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":154409573}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000161542","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":76277084}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025956"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76244232}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":76516251}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76424960}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76330185}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AG","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":76477511}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000161547","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":76296276}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000161649","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":43848758}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000161649","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":43848758}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90002403"},"gold_standard_info":{"gene_id":"ENSG00000161671","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CAGAG"},"locus_GRCh38":{"chromosome":"19","position":50500130}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002304"},"gold_standard_info":{"gene_id":"ENSG00000161671","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":50485608}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000161714","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":45111523}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000161905","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":4632019}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000161905","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":4612330}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000161921","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":4933086}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000161955","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7559652}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000161955","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000162009","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":870870}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST007490"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":2246196}},"trait_info":{"ontology":["EFO_0004324"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":1370340}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1656573}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1778029}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":2110502}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1778029}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000162032","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CAA"},"locus_GRCh38":{"chromosome":"16","position":1480497}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000162063","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":2505437}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000162241","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TG","reference":"T"},"locus_GRCh38":{"chromosome":"11","position":65789645}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90018887"},"gold_standard_info":{"gene_id":"ENSG00000162337","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":68424479}},"trait_info":{"ontology":["EFO_0003882"]}}
{"association_info":{"otg_id":"NEALE2_3147_raw"},"gold_standard_info":{"gene_id":"ENSG00000162337","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":68351641}},"trait_info":{"ontology":["EFO_0004514"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000162337","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":68450822}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000162368","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":47205239}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000162511","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":30735195}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000162551","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21563267}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025990"},"gold_standard_info":{"gene_id":"ENSG00000162551","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":21320730}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90025978"},"gold_standard_info":{"gene_id":"ENSG00000162591","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":3509303}},"trait_info":{"ontology":["EFO_0004713"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000162711","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":247556467}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000162711","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":247383031}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000162711","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":247875023}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000162711","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":247442974}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000162722","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":247875023}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000162733","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":162688693}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002397"},"gold_standard_info":{"gene_id":"ENSG00000163050","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":226907643}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018744"},"gold_standard_info":{"gene_id":"ENSG00000163050","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":226951321}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025987"},"gold_standard_info":{"gene_id":"ENSG00000163154","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":150686495}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000163219","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":68813372}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000163219","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":68813372}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000163466","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":218135259}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000163466","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":218135259}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000163466","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":218104993}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000163466","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":218156235}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000163466","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":218156235}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"NEALE2_20153_raw"},"gold_standard_info":{"gene_id":"ENSG00000163501","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":219037931}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000163501","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":219082280}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23129_raw"},"gold_standard_info":{"gene_id":"ENSG00000163501","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":219064672}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000163531","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":205284711}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158626734}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158617176}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":158642758}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158617176}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":158627717}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":158515656}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":158615440}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73646563}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":73409403}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":73858668}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST005448"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":73167847}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST90002412"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":73311680}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":73311680}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90018951"},"gold_standard_info":{"gene_id":"ENSG00000163631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":73408646}},"trait_info":{"ontology":["EFO_0004838"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000163694","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":40419122}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025991"},"gold_standard_info":{"gene_id":"ENSG00000163694","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":40426074}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000164061","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":49128636}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000164061","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GTTTTTTT","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":49275519}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":49855463}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002304"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":49632515}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST010083"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":49715570}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":49542443}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":49324936}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":49641218}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000164062","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":49324358}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000164068","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":49641218}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000164068","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"3","position":49305313}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000164175","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":33640560}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST007451"},"gold_standard_info":{"gene_id":"ENSG00000164175","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":33958854}},"trait_info":{"ontology":["EFO_0007009"]}}
{"association_info":{"otg_id":"GCST90041838"},"gold_standard_info":{"gene_id":"ENSG00000164175","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":33880779}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000164180","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":88387060}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000164181","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":60830439}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018863"},"gold_standard_info":{"gene_id":"ENSG00000164362","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":1280013}},"trait_info":{"ontology":["EFO_0004244"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000164362","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":1285859}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000164362","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":1285859}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90018908"},"gold_standard_info":{"gene_id":"ENSG00000164362","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0009448"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000164362","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"5","position":1104823}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000164631","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":6677785}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000164741","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":12809602}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018955"},"gold_standard_info":{"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":117191781}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":104899461}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":104660330}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_17"},"gold_standard_info":{"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":104903458}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":105125457}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST011390"},"gold_standard_info":{"gene_id":"ENSG00000165072","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":70108288}},"trait_info":{"ontology":["EFO_0010067"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000165124","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":110549951}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90038599"},"gold_standard_info":{"gene_id":"ENSG00000165409","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":80990913}},"trait_info":{"ontology":["EFO_0001379"]}}
{"association_info":{"otg_id":"GCST90018862"},"gold_standard_info":{"gene_id":"ENSG00000165409","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":80938791}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"NEALE2_20003_1140874866"},"gold_standard_info":{"gene_id":"ENSG00000165409","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":80992418}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST90038635"},"gold_standard_info":{"gene_id":"ENSG00000165409","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"14","position":80966694}},"trait_info":{"ontology":["EFO_1000627"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133266456}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133255354}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133256028}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989049}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133266456}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90019522"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":133255935}},"trait_info":{"ontology":["EFO_0007937"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132988251}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989049}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989049}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132982259}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989126}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000165702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":132989049}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018814"},"gold_standard_info":{"gene_id":"ENSG00000165806","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":113725526}},"trait_info":{"ontology":["MONDO_0005129"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000166033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":122471096}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000166033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":122473399}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000166033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":122380394}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000166033","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CTT"},"locus_GRCh38":{"chromosome":"10","position":122395212}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000166035","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":58431740}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000166035","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":58431476}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000166035","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":58284964}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_22"},"gold_standard_info":{"gene_id":"ENSG00000166035","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":58282767}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90018783"},"gold_standard_info":{"gene_id":"ENSG00000166147","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":48622578}},"trait_info":{"ontology":["EFO_0001666"]}}
{"association_info":{"otg_id":"FINNGEN_R6_I9_AORTDIS"},"gold_standard_info":{"gene_id":"ENSG00000166147","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":48400837}},"trait_info":{"ontology":["HP_0002647"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000166509","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":78028160}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"SAIGE_278"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60185354}},"trait_info":{"ontology":["EFO_0001073"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60181298}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"GCST009004"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0004340"]}}
{"association_info":{"otg_id":"NEALE2_48_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0004342"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"NEALE2_23112_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":60182196}},"trait_info":{"ontology":["EFO_0005409"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"GCST90085925"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":60067625}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":60161902}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"GCST010989"},"gold_standard_info":{"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":60171168}},"trait_info":{"ontology":["EFO_0009819"]}}
{"association_info":{"otg_id":"GCST006611"},"gold_standard_info":{"gene_id":"ENSG00000166819","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":89671546}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST008994"},"gold_standard_info":{"gene_id":"ENSG00000166819","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":89671546}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000166819","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":89753861}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000166855","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":65073281}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000166925","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"7","position":100621008}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000166947","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":43434427}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000166947","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":43207238}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000167165","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000167165","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000167165","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000167202","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":78058702}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"NEALE2_20002_1462"},"gold_standard_info":{"gene_id":"ENSG00000167207","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":50722629}},"trait_info":{"ontology":["EFO_0000384"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000167325","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":4110350}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000167325","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":4107256}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000167460","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":16095202}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000167460","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":16095202}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000167491","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":19606247}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90041836"},"gold_standard_info":{"gene_id":"ENSG00000167522","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88988609}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000167523","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89175837}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041840"},"gold_standard_info":{"gene_id":"ENSG00000167523","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":89677219}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000167658","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":4070165}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST007067"},"gold_standard_info":{"gene_id":"ENSG00000167676","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":4020529}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"NEALE2_49_raw"},"gold_standard_info":{"gene_id":"ENSG00000167676","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":4067316}},"trait_info":{"ontology":["EFO_0005093"]}}
{"association_info":{"otg_id":"GCST90025996"},"gold_standard_info":{"gene_id":"ENSG00000167676","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":4029058}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"NEALE2_23111_raw"},"gold_standard_info":{"gene_id":"ENSG00000167676","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":4050426}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000167701","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":144506731}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000167772","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":8364439}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000167772","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":7911813}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000167779","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":53055537}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000167895","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":78122806}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025986"},"gold_standard_info":{"gene_id":"ENSG00000167930","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":260244}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90025978"},"gold_standard_info":{"gene_id":"ENSG00000167972","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":2317763}},"trait_info":{"ontology":["EFO_0004713"]}}
{"association_info":{"otg_id":"GCST90002316"},"gold_standard_info":{"gene_id":"ENSG00000167984","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":3601578}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000168056","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":65179998}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST008972_4"},"gold_standard_info":{"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":64566642}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":64599577}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST008972_2"},"gold_standard_info":{"gene_id":"ENSG00000168070","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64600382}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST008972_3"},"gold_standard_info":{"gene_id":"ENSG00000168071","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":64506358}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000168071","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64207494}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000168071","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64207494}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000168298","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26072764}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000168497","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":191831529}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000168763","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":96617939}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GA","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":105051219}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ACT"},"locus_GRCh38":{"chromosome":"4","position":104943372}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":105112927}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002304"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":105264118}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":105112927}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":105140377}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":105121535}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":104884951}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":104884951}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000168792","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":29562968}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000168792","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":29342515}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST008790"},"gold_standard_info":{"gene_id":"ENSG00000169031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":227077265}},"trait_info":{"ontology":["EFO_0007778"]}}
{"association_info":{"otg_id":"SAIGE_593"},"gold_standard_info":{"gene_id":"ENSG00000169031","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":227077364}},"trait_info":{"ontology":["HP_0000790"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":226503350}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018949"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":226785762}},"trait_info":{"ontology":["EFO_0004338"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":226439934}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":226395248}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":226385086}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":226398866}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":226342417}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000169047","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":226461917}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_METABOLIA"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000589"]}}
{"association_info":{"otg_id":"GCST90025983"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010245"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"NEALE2_20003_1140862380"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":55455216}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"GCST90038690"},"gold_standard_info":{"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":55025188}},"trait_info":{"ontology":["HP_0003124"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000169214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":247875023}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000169231","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":155033974}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000169231","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":155022502}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23099_raw"},"gold_standard_info":{"gene_id":"ENSG00000169231","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":155202934}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000169231","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":155033974}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018822"},"gold_standard_info":{"gene_id":"ENSG00000169344","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":20381010}},"trait_info":{"ontology":["EFO_0003884"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000169607","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":112738876}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000169704","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":129057049}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000169704","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":128598430}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000169704","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":129061921}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST007078"},"gold_standard_info":{"gene_id":"ENSG00000169836","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":103666820}},"trait_info":{"ontology":["EFO_0004703"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000169877","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":31525221}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000169877","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":31508674}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000169877","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":31393250}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000169992","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000170004","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":7393580}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90012114"},"gold_standard_info":{"gene_id":"ENSG00000170004","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GTC"},"locus_GRCh38":{"chromosome":"17","position":7446325}},"trait_info":{"ontology":["EFO_0004908"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000170180","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":144112490}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000170180","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":143992750}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000170214","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":160132400}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000170608","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":45884086}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90042882"},"gold_standard_info":{"gene_id":"ENSG00000170615","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":103421378}},"trait_info":{"ontology":["EFO_0004238"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000170927","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":51627086}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST008996"},"gold_standard_info":{"gene_id":"ENSG00000171105","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":7199967}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000171105","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":7223951}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90025996"},"gold_standard_info":{"gene_id":"ENSG00000171105","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":7125508}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90020024"},"gold_standard_info":{"gene_id":"ENSG00000171105","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":7125508}},"trait_info":{"ontology":["EFO_0007789"]}}
{"association_info":{"otg_id":"GCST007611"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32182402}},"trait_info":{"ontology":["EFO_0000537"]}}
{"association_info":{"otg_id":"GCST008496"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32790884}},"trait_info":{"ontology":["EFO_0003768"]}}
{"association_info":{"otg_id":"GCST007464"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":32380110}},"trait_info":{"ontology":["EFO_0004319"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32535789}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32593666}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002298"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":32577303}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":32603213}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST009096"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":32557613}},"trait_info":{"ontology":["EFO_0005671"]}}
{"association_info":{"otg_id":"GCST007468"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32587456}},"trait_info":{"ontology":["EFO_0006527"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32517220}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":32608669}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":32575763}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":32792266}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":32517791}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000171456","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":32625305}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000171552","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":31495230}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000171564","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":154568456}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000171564","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":154568456}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000171714","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":22250324}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST90018944"},"gold_standard_info":{"gene_id":"ENSG00000171714","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":22250324}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST007385_11"},"gold_standard_info":{"gene_id":"ENSG00000171759","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":102878908}},"trait_info":{"ontology":["EFO_0005001"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000171766","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":45424227}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000171812","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":36246432}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90000025"},"gold_standard_info":{"gene_id":"ENSG00000171812","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":35868714}},"trait_info":{"ontology":["EFO_0004980"]}}
{"association_info":{"otg_id":"NEALE2_23127_raw"},"gold_standard_info":{"gene_id":"ENSG00000171812","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":36045666}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST006412"},"gold_standard_info":{"gene_id":"ENSG00000171819","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":11328735}},"trait_info":{"ontology":["EFO_0004695"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000171848","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":10122732}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000171914","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":62541660}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000171914","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":62506836}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000171988","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"10","position":63203689}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000172057","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":39475835}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000172354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000172354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000172354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100711557}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000172354","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100642673}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000172893","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":71346865}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000172936","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":37920981}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":112445672}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":111702865}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":112135137}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":112433568}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":111925435}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":112142267}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":112372104}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000173064","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TCCC"},"locus_GRCh38":{"chromosome":"12","position":112170508}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"NEALE2_48_raw"},"gold_standard_info":{"gene_id":"ENSG00000173250","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":146515831}},"trait_info":{"ontology":["EFO_0004342"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000173480","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":58414978}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000174358","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":1212338}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000174358","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":1193915}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST008972_2"},"gold_standard_info":{"gene_id":"ENSG00000174827","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":145709649}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142582597}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AT","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142557120}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142469495}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142541720}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":142564971}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000175054","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":141963983}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000175318","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":71926571}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000175318","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":71906889}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":19962213}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":19805426}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_12"},"gold_standard_info":{"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":20028002}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST004037"},"gold_standard_info":{"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"8","position":20041535}},"trait_info":{"ontology":["EFO_0007929"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":19956018}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000175634","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":67435355}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000175634","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":67430286}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000175634","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":67417254}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000175727","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":121924526}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002380"},"gold_standard_info":{"gene_id":"ENSG00000175938","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":31251707}},"trait_info":{"ontology":["EFO_0007992"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000175984","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":114587887}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000175984","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":114587887}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025985"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":76437921}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76387028}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76330185}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":76219850}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76330185}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":76286316}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000176170","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":76437921}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000176225","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"18","position":70020730}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000176225","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"18","position":69902328}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002396"},"gold_standard_info":{"gene_id":"ENSG00000176225","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"18","position":70179769}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000176387","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":67110212}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000176390","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30879403}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000176390","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30773850}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000176715","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":88654604}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041836"},"gold_standard_info":{"gene_id":"ENSG00000176715","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88988609}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90093298"},"gold_standard_info":{"gene_id":"ENSG00000176742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5227003}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90093294_2"},"gold_standard_info":{"gene_id":"ENSG00000176742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":5095314}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000176742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5293687}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000176742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":5297978}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000176742","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":5297978}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000176971","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":26994864}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000177084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":132474016}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000177084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":132474624}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000177084","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"12","position":132474624}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000177453","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"5","position":42717890}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST009325"},"gold_standard_info":{"gene_id":"ENSG00000177628","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":154925709}},"trait_info":{"ontology":["MONDO_0005180"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":17105867}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002351"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":17076156}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":17105867}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":17116671}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":17038743}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000177663","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":17105867}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000178026","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST008972_3"},"gold_standard_info":{"gene_id":"ENSG00000178163","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":9983752}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"GCST001956"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":17950585}},"trait_info":{"ontology":["EFO_0004302"]}}
{"association_info":{"otg_id":"NEALE2_3063_raw"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":17902031}},"trait_info":{"ontology":["EFO_0004314"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"4","position":17878793}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":17872466}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":17908613}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":17908613}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000178177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TG"},"locus_GRCh38":{"chromosome":"4","position":17901000}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000178252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":49125150}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000178252","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":48697428}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000178828","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":19814567}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000178997","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":41151726}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000178997","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CTG","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":41664928}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":12888644}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":12864794}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":12895871}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":13018047}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":12890733}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":13100756}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":13012374}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12668356}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":12913436}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":12885926}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GATTTCGAAACCAGCCTGGCCAGC"},"locus_GRCh38":{"chromosome":"19","position":12883502}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GATTTCGAAACCAGCCTGGCCAGC"},"locus_GRCh38":{"chromosome":"19","position":12883502}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12887391}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":12874762}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":12837420}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002396"},"gold_standard_info":{"gene_id":"ENSG00000179218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"GTCTC","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12821202}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90025959"},"gold_standard_info":{"gene_id":"ENSG00000179639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":159359193}},"trait_info":{"ontology":["EFO_0004458"]}}
{"association_info":{"otg_id":"GCST011335"},"gold_standard_info":{"gene_id":"ENSG00000179846","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44892362}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000179846","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":44711285}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000180448","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":1079960}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000180708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158626734}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000180708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":158642758}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000180708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":158627717}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000180708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158617176}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000180708","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":158615440}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018955"},"gold_standard_info":{"gene_id":"ENSG00000180815","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"X","position":19361522}},"trait_info":{"ontology":["EFO_0004468"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000180871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":218135259}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000180871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":218135259}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000180871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":218104993}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000180871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":218156235}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000180871","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":218156235}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90095129"},"gold_standard_info":{"gene_id":"ENSG00000180900","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"8","position":143787940}},"trait_info":{"ontology":["EFO_0004464"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000180953","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":79966732}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000180953","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"15","position":79930230}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000181284","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000181323","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000181690","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"8","position":56226117}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST007841"},"gold_standard_info":{"gene_id":"ENSG00000182218","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":99644715}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90038604"},"gold_standard_info":{"gene_id":"ENSG00000182511","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"15","position":90884382}},"trait_info":{"ontology":["EFO_0000537"]}}
{"association_info":{"otg_id":"GCST90000062"},"gold_standard_info":{"gene_id":"ENSG00000182511","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":90873320}},"trait_info":{"ontology":["EFO_0006335"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000182752","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":116366978}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000182752","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TAA","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":116362256}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000182752","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":116173212}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000183508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":117708521}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000183508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":117708521}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000183508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":117611953}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000183508","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CCT","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":117598889}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000183625","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":46425057}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002382"},"gold_standard_info":{"gene_id":"ENSG00000183625","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":45884551}},"trait_info":{"ontology":["EFO_0007991"]}}
{"association_info":{"otg_id":"GCST90041886"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0000305"]}}
{"association_info":{"otg_id":"GCST90043946"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0000311"]}}
{"association_info":{"otg_id":"GCST90018905"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0001663"]}}
{"association_info":{"otg_id":"FINNGEN_R6_CD2_BENIGN"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":29054205}},"trait_info":{"ontology":["EFO_0002422"]}}
{"association_info":{"otg_id":"GCST90043889"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0003869"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002357"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":29096124}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002397"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":29220276}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28820734}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28365160}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002316"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":28500558}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST005312"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":28237583}},"trait_info":{"ontology":["EFO_0004704"]}}
{"association_info":{"otg_id":"GCST90002355"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":28707610}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AG"},"locus_GRCh38":{"chromosome":"22","position":28695868}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":28739370}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"FINNGEN_R6_CD2_BENIGN_LEIOMYOMA_UTERI_EXALLC"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":28725099}},"trait_info":{"ontology":["HP_0000131"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_BREAST_EXALLC"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":29020414}},"trait_info":{"ontology":["MONDO_0007254"]}}
{"association_info":{"otg_id":"FINNGEN_R6_C3_PROSTATE_EXALLC"},"gold_standard_info":{"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":29020414}},"trait_info":{"ontology":["MONDO_0008315"]}}
{"association_info":{"otg_id":"NEALE2_2247_1"},"gold_standard_info":{"gene_id":"ENSG00000184009","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TG"},"locus_GRCh38":{"chromosome":"17","position":81557698}},"trait_info":{"ontology":["EFO_0004238"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000184560","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000185038","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90002316"},"gold_standard_info":{"gene_id":"ENSG00000185187","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":196606}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000185245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":4937573}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000185245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":4933086}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000185245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":4892102}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000185245","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":4933900}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000185359","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":81510330}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000185480","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":102076854}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000185615","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000185989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"13","position":114155392}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000185989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"13","position":113506191}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000185989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"13","position":114003428}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000186104","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":14641176}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"NEALE2_2247_1"},"gold_standard_info":{"gene_id":"ENSG00000186765","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TG"},"locus_GRCh38":{"chromosome":"17","position":81557698}},"trait_info":{"ontology":["EFO_0004238"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000186943","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":104660330}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST003665_17"},"gold_standard_info":{"gene_id":"ENSG00000186943","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":104903458}},"trait_info":{"ontology":["EFO_0004732"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000186951","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":46231883}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000186951","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":46011227}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":37066896}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":37071352}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"22","position":37088904}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":37066896}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"22","position":37016092}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"22","position":37066896}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000187091","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":37977937}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000187091","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":37977937}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000187098","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":69747341}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90041839"},"gold_standard_info":{"gene_id":"ENSG00000187098","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":70012226}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000187244","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44631381}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000187266","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":11386116}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000187266","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":11400737}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000187741","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89369470}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041838"},"gold_standard_info":{"gene_id":"ENSG00000187741","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":89677219}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000187800","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":156899922}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018964"},"gold_standard_info":{"gene_id":"ENSG00000187837","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":26072764}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"NEALE2_3147_raw"},"gold_standard_info":{"gene_id":"ENSG00000188487","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":15204641}},"trait_info":{"ontology":["EFO_0004514"]}}
{"association_info":{"otg_id":"GCST90000618"},"gold_standard_info":{"gene_id":"ENSG00000188487","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":14641176}},"trait_info":{"ontology":["EFO_0004631"]}}
{"association_info":{"otg_id":"GCST007066"},"gold_standard_info":{"gene_id":"ENSG00000188487","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":15221513}},"trait_info":{"ontology":["EFO_0009270"]}}
{"association_info":{"otg_id":"GCST90025964"},"gold_standard_info":{"gene_id":"ENSG00000188536","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":120329}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000188536","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000188536","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000188536","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":120329}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000188868","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":12318968}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000189050","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TTG","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":59873258}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000189134","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":27916234}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST008996"},"gold_standard_info":{"gene_id":"ENSG00000189367","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":127133748}},"trait_info":{"ontology":["EFO_0004343"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000196171","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158626734}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"NEALE2_47_raw"},"gold_standard_info":{"gene_id":"ENSG00000196296","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":28899988}},"trait_info":{"ontology":["EFO_0006941"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000196408","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":1778029}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000196616","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":98867329}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90025979"},"gold_standard_info":{"gene_id":"ENSG00000196660","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":219452511}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST90025980"},"gold_standard_info":{"gene_id":"ENSG00000196660","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":219452511}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST007490"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":30838916}},"trait_info":{"ontology":["EFO_0004324"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30879403}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":31313207}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":31326275}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90002351"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30841059}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"NEALE2_23113_raw"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30879403}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90002340"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":31353508}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30841059}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TA","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":30771235}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":30879403}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000196739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":114207835}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_23129_raw"},"gold_standard_info":{"gene_id":"ENSG00000196739","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"ACC","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":114427780}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"GCST90038637"},"gold_standard_info":{"gene_id":"ENSG00000196812","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":27867657}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000197249","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"14","position":94378610}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000197479","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"NEALE2_4194_raw"},"gold_standard_info":{"gene_id":"ENSG00000197616","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"14","position":23392602}},"trait_info":{"ontology":["EFO_0004326"]}}
{"association_info":{"otg_id":"GCST007081"},"gold_standard_info":{"gene_id":"ENSG00000197859","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":133271182}},"trait_info":{"ontology":["EFO_0004312"]}}
{"association_info":{"otg_id":"GCST90038687"},"gold_standard_info":{"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":64560372}},"trait_info":{"ontology":["EFO_0004274"]}}
{"association_info":{"otg_id":"GCST008972"},"gold_standard_info":{"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":64584591}},"trait_info":{"ontology":["EFO_0004531"]}}
{"association_info":{"otg_id":"NEALE2_20003_1140875408"},"gold_standard_info":{"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":64582330}},"trait_info":{"ontology":["EFO_0007010"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000197912","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89175837}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90025976"},"gold_standard_info":{"gene_id":"ENSG00000197969","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"9","position":77339629}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000198055","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":177315505}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000198055","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"5","position":177315505}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000198146","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"15","position":35010668}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90044158"},"gold_standard_info":{"gene_id":"ENSG00000198502","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":32368768}},"trait_info":{"ontology":["EFO_0001060"]}}
{"association_info":{"otg_id":"GCST005973"},"gold_standard_info":{"gene_id":"ENSG00000198502","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32216247}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90056178"},"gold_standard_info":{"gene_id":"ENSG00000198502","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":32082290}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST009798"},"gold_standard_info":{"gene_id":"ENSG00000198502","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":32644653}},"trait_info":{"ontology":["MONDO_0004979"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000198535","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":62088060}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST011990"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31274397}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST005993"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31266866}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002244"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31554892}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000198563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":137205865}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002304"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":137327051}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90025969"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"9","position":136943538}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90018979"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":137464104}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":137205865}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":137236154}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST90019525"},"gold_standard_info":{"gene_id":"ENSG00000198569","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"9","position":137233223}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST012232"},"gold_standard_info":{"gene_id":"ENSG00000198670","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0006925"]}}
{"association_info":{"otg_id":"GCST90025945"},"gold_standard_info":{"gene_id":"ENSG00000198743","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"21","position":33916942}},"trait_info":{"ontology":["EFO_0004617"]}}
{"association_info":{"otg_id":"GCST008733"},"gold_standard_info":{"gene_id":"ENSG00000198743","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"21","position":34223520}},"trait_info":{"ontology":["EFO_0007788"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000198837","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AG","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":153651711}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000198858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":807442}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000198858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":807442}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000198858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":468870}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000198931","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":88714064}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000198965","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":158626734}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000198965","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"1","position":158642758}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000198965","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"1","position":158615440}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000203618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":19724571}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000203618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":19724571}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000203618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":19724571}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000203618","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":19996490}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025946"},"gold_standard_info":{"gene_id":"ENSG00000204001","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"9","position":137236154}},"trait_info":{"ontology":["EFO_0004518"]}}
{"association_info":{"otg_id":"GCST90019509"},"gold_standard_info":{"gene_id":"ENSG00000204130","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"10","position":68150699}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_HYTHYNAS"},"gold_standard_info":{"gene_id":"ENSG00000204264","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":32815309}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST005973"},"gold_standard_info":{"gene_id":"ENSG00000204296","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32216247}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000204296","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31977453}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002302"},"gold_standard_info":{"gene_id":"ENSG00000204296","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":32619436}},"trait_info":{"ontology":["EFO_0004842"]}}
{"association_info":{"otg_id":"GCST90002393"},"gold_standard_info":{"gene_id":"ENSG00000204296","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":32488188}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90018944"},"gold_standard_info":{"gene_id":"ENSG00000204301","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32614824}},"trait_info":{"ontology":["EFO_0004736"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000204305","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31977453}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90054785"},"gold_standard_info":{"gene_id":"ENSG00000204305","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32182024}},"trait_info":{"ontology":["EFO_0004713"]}}
{"association_info":{"otg_id":"GCST005973"},"gold_standard_info":{"gene_id":"ENSG00000204388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32216247}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000204388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31410197}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000204388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31977453}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000204388","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST011991"},"gold_standard_info":{"gene_id":"ENSG00000204396","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31287231}},"trait_info":{"ontology":["EFO_0000676"]}}
{"association_info":{"otg_id":"GCST002112"},"gold_standard_info":{"gene_id":"ENSG00000204396","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32240547}},"trait_info":{"ontology":["EFO_0001060"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000204396","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000204396","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90020232"},"gold_standard_info":{"gene_id":"ENSG00000204396","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31628105}},"trait_info":{"ontology":["EFO_0007800"]}}
{"association_info":{"otg_id":"GCST90056174"},"gold_standard_info":{"gene_id":"ENSG00000204421","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31962664}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000204424","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31274397}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000204424","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31410197}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST005993"},"gold_standard_info":{"gene_id":"ENSG00000204424","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31266866}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000204424","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000204424","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000204469","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90018642"},"gold_standard_info":{"gene_id":"ENSG00000204511","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31358389}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000204516","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31410197}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90056174"},"gold_standard_info":{"gene_id":"ENSG00000204516","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31962664}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST005993"},"gold_standard_info":{"gene_id":"ENSG00000204516","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31266866}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000204516","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST010988"},"gold_standard_info":{"gene_id":"ENSG00000204520","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":31624141}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000204525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31274397}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST010988"},"gold_standard_info":{"gene_id":"ENSG00000204525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":31624141}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000204525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90018968"},"gold_standard_info":{"gene_id":"ENSG00000204525","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31274397}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000204539","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":30633455}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000204542","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":30633455}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST005529_3"},"gold_standard_info":{"gene_id":"ENSG00000204580","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31377139}},"trait_info":{"ontology":["EFO_0003898"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000204580","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000204590","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":30527904}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST010988"},"gold_standard_info":{"gene_id":"ENSG00000204614","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":29941440}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000204616","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":29762408}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST006101_8"},"gold_standard_info":{"gene_id":"ENSG00000204687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":29150970}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST010988"},"gold_standard_info":{"gene_id":"ENSG00000204687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":29941440}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90056178"},"gold_standard_info":{"gene_id":"ENSG00000204687","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":29952936}},"trait_info":{"ontology":["EFO_0004833"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000204713","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":28505754}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000204713","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"AT","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":28506693}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000204956","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90041838"},"gold_standard_info":{"gene_id":"ENSG00000204991","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":89677219}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000205045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":35557105}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000205250","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000205250","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67198457}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000205250","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":67180020}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000205436","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"14","position":103100498}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000205436","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"14","position":103097084}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000205436","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CAA","reference":"C"},"locus_GRCh38":{"chromosome":"14","position":103098598}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000205544","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TCTGA","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":23701033}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":23678492}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"TCCTGGC","reference":"T"},"locus_GRCh38":{"chromosome":"2","position":24016319}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":23678492}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":24008253}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":23887787}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"2","position":23926569}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000205639","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"2","position":23743577}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000206013","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":297970}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025964"},"gold_standard_info":{"gene_id":"ENSG00000206172","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":120329}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000206172","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000206172","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025964"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":120329}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":165380}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90025974"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":59559}},"trait_info":{"ontology":["EFO_0004541"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":115782}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":98491}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000206177","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"16","position":120329}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000213398","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":67955620}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000213398","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":67942417}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST010242"},"gold_standard_info":{"gene_id":"ENSG00000213398","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":67906447}},"trait_info":{"ontology":["EFO_0004612"]}}
{"association_info":{"otg_id":"GCST90018943"},"gold_standard_info":{"gene_id":"ENSG00000213563","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"8","position":144506731}},"trait_info":{"ontology":["EFO_0004735"]}}
{"association_info":{"otg_id":"GCST005973"},"gold_standard_info":{"gene_id":"ENSG00000213654","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32216247}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000213654","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31977453}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90018975"},"gold_standard_info":{"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":19268740}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000214706","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":50292395}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90025971"},"gold_standard_info":{"gene_id":"ENSG00000214706","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"3","position":50150357}},"trait_info":{"ontology":["EFO_0009253"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000214706","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"3","position":50143703}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000214706","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":50292395}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST010660"},"gold_standard_info":{"gene_id":"ENSG00000224389","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31604867}},"trait_info":{"ontology":["EFO_0004530"]}}
{"association_info":{"otg_id":"GCST010984"},"gold_standard_info":{"gene_id":"ENSG00000231852","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31550126}},"trait_info":{"ontology":["MONDO_0005271"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000235169","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AGTCAGCCTAGGGGCTGT"},"locus_GRCh38":{"chromosome":"1","position":3775433}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000235169","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":3774964}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002387"},"gold_standard_info":{"gene_id":"ENSG00000235169","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"1","position":3774964}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025961"},"gold_standard_info":{"gene_id":"ENSG00000236320","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":35557105}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":16972322}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90025985"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":16939677}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018945"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":16939677}},"trait_info":{"ontology":["EFO_0004535"]}}
{"association_info":{"otg_id":"GCST90018976"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"17","position":16939677}},"trait_info":{"ontology":["EFO_0004536"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":17009366}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":17264178}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002394"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0007989"]}}
{"association_info":{"otg_id":"GCST90002399"},"gold_standard_info":{"gene_id":"ENSG00000240505","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":16948873}},"trait_info":{"ontology":["EFO_0007990"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000241119","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_GILBERT"},"gold_standard_info":{"gene_id":"ENSG00000241119","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0005556"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000241119","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000241119","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"FINNGEN_R6_L12_PSORIASIS"},"gold_standard_info":{"gene_id":"ENSG00000241404","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32522029}},"trait_info":{"ontology":["EFO_0000676"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000241635","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_GILBERT"},"gold_standard_info":{"gene_id":"ENSG00000241635","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0005556"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000241635","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000241635","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90002401"},"gold_standard_info":{"gene_id":"ENSG00000241839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh38":{"chromosome":"15","position":64785987}},"trait_info":{"ontology":["EFO_0007984"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000242366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000242366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000242366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000242515","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000242515","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000242515","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000242612","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh38":{"chromosome":"16","position":126447}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000242612","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":108326}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90025991"},"gold_standard_info":{"gene_id":"ENSG00000243364","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"1","position":155060832}},"trait_info":{"ontology":["EFO_0009795"]}}
{"association_info":{"otg_id":"GCST005973"},"gold_standard_info":{"gene_id":"ENSG00000243649","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":32216247}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90085815"},"gold_standard_info":{"gene_id":"ENSG00000243649","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31977453}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90056177"},"gold_standard_info":{"gene_id":"ENSG00000243649","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31475005}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000243989","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"3","position":52333916}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000244122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000244122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000244122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000244462","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":35437976}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000244474","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000244474","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000244474","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90093298"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5227003}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST001779_2"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":5281833}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90093294_2"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":5095314}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002334"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5293687}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":5297978}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002332"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5227003}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5679844}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":5297978}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"NEALE2_30070_raw"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh38":{"chromosome":"11","position":5238497}},"trait_info":{"ontology":["EFO_0009188"]}}
{"association_info":{"otg_id":"GCST90002386"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"11","position":5293687}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000244734","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"11","position":5297978}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST009799"},"gold_standard_info":{"gene_id":"ENSG00000248144","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":99318162}},"trait_info":{"ontology":["EFO_0004329"]}}
{"association_info":{"otg_id":"GCST90018942"},"gold_standard_info":{"gene_id":"ENSG00000248144","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh38":{"chromosome":"4","position":99126006}},"trait_info":{"ontology":["EFO_0004533"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000248144","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"4","position":99127263}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"GCST007472"},"gold_standard_info":{"gene_id":"ENSG00000248144","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"4","position":98837981}},"trait_info":{"ontology":["EFO_0007878"]}}
{"association_info":{"otg_id":"GCST90002361"},"gold_standard_info":{"gene_id":"ENSG00000248672","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159820864}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000248672","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159748003}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90002389"},"gold_standard_info":{"gene_id":"ENSG00000248672","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"2","position":159820864}},"trait_info":{"ontology":["EFO_0007993"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000250641","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"6","position":31274397}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90056183"},"gold_standard_info":{"gene_id":"ENSG00000250641","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31410197}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST005993"},"gold_standard_info":{"gene_id":"ENSG00000250641","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31266866}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002320"},"gold_standard_info":{"gene_id":"ENSG00000250641","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31272944}},"trait_info":{"ontology":["EFO_0004587"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000250641","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"6","position":31362841}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000253305","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000253767","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000254122","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"5","position":141535069}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000257046","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh38":{"chromosome":"12","position":21227696}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000257727","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"12","position":56316135}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90018971"},"gold_standard_info":{"gene_id":"ENSG00000258366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":63844250}},"trait_info":{"ontology":["EFO_0004305"]}}
{"association_info":{"otg_id":"GCST90002338"},"gold_standard_info":{"gene_id":"ENSG00000258366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":64080106}},"trait_info":{"ontology":["EFO_0004526"]}}
{"association_info":{"otg_id":"GCST007068"},"gold_standard_info":{"gene_id":"ENSG00000258366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"20","position":63689775}},"trait_info":{"ontology":["EFO_0004527"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000258366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"20","position":63636980}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000258366","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh38":{"chromosome":"20","position":63917861}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018954"},"gold_standard_info":{"gene_id":"ENSG00000258555","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh38":{"chromosome":"22","position":24603137}},"trait_info":{"ontology":["EFO_0004532"]}}
{"association_info":{"otg_id":"NEALE2_1717"},"gold_standard_info":{"gene_id":"ENSG00000258839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"16","position":89571498}},"trait_info":{"ontology":["EFO_0003784"]}}
{"association_info":{"otg_id":"GCST90041836"},"gold_standard_info":{"gene_id":"ENSG00000258839","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"16","position":90040361}},"trait_info":{"ontology":["EFO_0007822"]}}
{"association_info":{"otg_id":"GCST90025951"},"gold_standard_info":{"gene_id":"ENSG00000259207","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":46775246}},"trait_info":{"ontology":["EFO_0004309"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000259207","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":47166540}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002400"},"gold_standard_info":{"gene_id":"ENSG00000259207","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":47572031}},"trait_info":{"ontology":["EFO_0007985"]}}
{"association_info":{"otg_id":"GCST001956"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":63901188}},"trait_info":{"ontology":["EFO_0004302"]}}
{"association_info":{"otg_id":"GCST90025949"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"17","position":63631768}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90025989"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh38":{"chromosome":"17","position":63768065}},"trait_info":{"ontology":["EFO_0004627"]}}
{"association_info":{"otg_id":"NEALE2_23114_raw"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":63918895}},"trait_info":{"ontology":["EFO_0004995"]}}
{"association_info":{"otg_id":"NEALE2_23105_raw"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":63918895}},"trait_info":{"ontology":["EFO_0007777"]}}
{"association_info":{"otg_id":"NEALE2_23102_raw"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":63918895}},"trait_info":{"ontology":["EFO_0009805"]}}
{"association_info":{"otg_id":"NEALE2_20015_raw"},"gold_standard_info":{"gene_id":"ENSG00000259384","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":63918895}},"trait_info":{"ontology":["EFO_0011011"]}}
{"association_info":{"otg_id":"GCST90025958"},"gold_standard_info":{"gene_id":"ENSG00000262481","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"17","position":7229141}},"trait_info":{"ontology":["EFO_0004696"]}}
{"association_info":{"otg_id":"GCST90018978"},"gold_standard_info":{"gene_id":"ENSG00000267534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":10280935}},"trait_info":{"ontology":["EFO_0004308"]}}
{"association_info":{"otg_id":"GCST90002344"},"gold_standard_info":{"gene_id":"ENSG00000267534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":10224049}},"trait_info":{"ontology":["EFO_0005091"]}}
{"association_info":{"otg_id":"GCST90025970"},"gold_standard_info":{"gene_id":"ENSG00000267534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":10223987}},"trait_info":{"ontology":["EFO_0007986"]}}
{"association_info":{"otg_id":"GCST90002406"},"gold_standard_info":{"gene_id":"ENSG00000267534","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"19","position":10223987}},"trait_info":{"ontology":["EFO_0010700"]}}
{"association_info":{"otg_id":"GCST90019496"},"gold_standard_info":{"gene_id":"ENSG00000267680","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":43792537}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90002308"},"gold_standard_info":{"gene_id":"ENSG00000269858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":40799233}},"trait_info":{"ontology":["EFO_0004348"]}}
{"association_info":{"otg_id":"GCST90002314"},"gold_standard_info":{"gene_id":"ENSG00000269858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":40799233}},"trait_info":{"ontology":["EFO_0004509"]}}
{"association_info":{"otg_id":"GCST90002326"},"gold_standard_info":{"gene_id":"ENSG00000269858","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":41264985}},"trait_info":{"ontology":["EFO_0004528"]}}
{"association_info":{"otg_id":"GCST90038637"},"gold_standard_info":{"gene_id":"ENSG00000275379","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"6","position":27867657}},"trait_info":{"ontology":["EFO_0004705"]}}
{"association_info":{"otg_id":"GCST90018959"},"gold_standard_info":{"gene_id":"ENSG00000276043","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"19","position":4954443}},"trait_info":{"ontology":["EFO_0004339"]}}
{"association_info":{"otg_id":"GCST90002349"},"gold_standard_info":{"gene_id":"ENSG00000276045","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh38":{"chromosome":"12","position":121924526}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90002346"},"gold_standard_info":{"gene_id":"ENSG00000276368","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh38":{"chromosome":"6","position":27685296}},"trait_info":{"ontology":["EFO_0004584"]}}
{"association_info":{"otg_id":"GCST90018974"},"gold_standard_info":{"gene_id":"ENSG00000278318","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh38":{"chromosome":"19","position":44908822}},"trait_info":{"ontology":["EFO_0004574"]}}
{"association_info":{"otg_id":"GCST011335"},"gold_standard_info":{"gene_id":"ENSG00000278318","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44892362}},"trait_info":{"ontology":["EFO_0004611"]}}
{"association_info":{"otg_id":"GCST010243"},"gold_standard_info":{"gene_id":"ENSG00000278318","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"19","position":44631381}},"trait_info":{"ontology":["EFO_0004615"]}}
{"association_info":{"otg_id":"GCST90025975"},"gold_standard_info":{"gene_id":"ENSG00000282301","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh38":{"chromosome":"7","position":100111122}},"trait_info":{"ontology":["EFO_0010701"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000288702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000288702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000288702","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"otg_id":"GCST90018973"},"gold_standard_info":{"gene_id":"ENSG00000288705","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["EFO_0004570"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000288705","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0024431"]}}
{"association_info":{"otg_id":"FINNGEN_R6_E4_PORBILIR"},"gold_standard_info":{"gene_id":"ENSG00000288705","highest_confidence":"High"},"metadata":{"set_label":"rv_burden_tests"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"ATC"},"locus_GRCh38":{"chromosome":"2","position":233755940}},"trait_info":{"ontology":["MONDO_0037821"]}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000324","neg_log_pval":23.699,"otg_id":"GCST000324_3","pubmed_id":"19185284"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"BCO1 (previously referred to as BCMO1) encodes beta-carotene oxygenase 1 which uses a molecule of oxygen to produce two molecules of retinol from beta-carotene.  Enzyme deficiency results in accumulation of beta-carotene.","pubmed_id":"11401432"}],"gene_id":"ENSG00000135697","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":81264597},"locus_GRCh38":{"chromosome":"16","position":81230992},"rsid":"rs6564851"},"trait_info":{"ontology":["HMDB0000561"],"reported_trait_name":"Carotenoid and tocopherol levels (beta-carotene)","standard_trait_name":"B-Carotene"}}
{"association_info":{"ancestry":["unknown"],"gwas_catalog_id":"GCST000386","neg_log_pval":323.301,"otg_id":"GCST000386","pubmed_id":"19414484"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"UGT1A1 encodes an enzyme with bilirubin glucuronidating activity.  Bilirubin is derived from biliverdin.","pubmed_id":"01898728"}],"gene_id":"ENSG00000242366","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":234672639},"locus_GRCh38":{"chromosome":"2","position":233763993},"rsid":"rs6742078"},"trait_info":{"ontology":["HMDB0000054"],"reported_trait_name":"Bilirubin levels","standard_trait_name":"Bilirubin"}}
{"association_info":{"ancestry":["ASW","EUR"],"gwas_catalog_id":"GCST000388","neg_log_pval":8.046,"otg_id":"GCST000388","pubmed_id":"19419973"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"G6PD encodes the glucose-6-phosphate dehydrogenase, an enzyme critical to red blood cell metabolism.  G6PD deficiency results in accumulation of bilirubin, a breakdown product of heme.","pubmed_id":"11445808"}],"gene_id":"ENSG00000160211","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":153554404},"locus_GRCh38":{"chromosome":"X","position":154326058},"rsid":"rs766420"},"trait_info":{"ontology":["HMDB0000054"],"reported_trait_name":"Bilirubin levels","standard_trait_name":"Bilirubin"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000493","neg_log_pval":65.046,"otg_id":"GCST000493_3","pubmed_id":"19798445"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SGPP1 encodes a sphingosine-1-phosphate phosphatase which dephosphorylates sphingosine-1-phosphate to sphingosine which can then be incorporated into sphingomyelin.","pubmed_id":"10859351"}],"gene_id":"ENSG00000126821","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":64235556},"locus_GRCh38":{"chromosome":"14","position":63768838},"rsid":"rs7157785"},"trait_info":{"ontology":["HMDB0012097"],"reported_trait_name":"Sphingolipid levels (SM 14:0Mol%)","standard_trait_name":"sphingomyelin 14∶0 molar percentage"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000568","neg_log_pval":217.046,"otg_id":"GCST000568","pubmed_id":"20081858"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"G6PC2 encodes a pancreas-specific glucose-6-phosphatase. This enzyme influences the fasting glucose set point for basal insulin secretion.","pubmed_id":"23274894"}],"gene_id":"ENSG00000152254","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":169763148},"locus_GRCh38":{"chromosome":"2","position":168906638},"rsid":"rs560887"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"Fasting glucose-related traits (FPG)","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000697","neg_log_pval":108.699,"otg_id":"GCST000697","pubmed_id":"20541252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GC encodes the vitamin D binding protein which transports multiple forms of vitamin D","pubmed_id":"00049052"}],"gene_id":"ENSG00000145321","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":72608383},"locus_GRCh38":{"chromosome":"4","position":71742666},"rsid":"rs2282679"},"trait_info":{"ontology":["HMDB0001438"],"reported_trait_name":"Vitamin D insufficiency","standard_trait_name":"25-Hydroxyvitamin D2"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000697","neg_log_pval":19.523,"otg_id":"GCST000697","pubmed_id":"20541252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP2R1 encodes the vitamin D 25-hydroxylase which produces the detected metabolite.","pubmed_id":"12867411"}],"gene_id":"ENSG00000186104","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":14914878},"locus_GRCh38":{"chromosome":"11","position":14893332},"rsid":"rs10741657"},"trait_info":{"ontology":["HMDB0001438"],"reported_trait_name":"Vitamin D insufficiency","standard_trait_name":"25-Hydroxyvitamin D2"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000697","neg_log_pval":26.699,"otg_id":"GCST000697","pubmed_id":"20541252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DHCR7 encodes 7-dehydrocholesterol reductase, which acts on 7-dehydrocholesterol, a precursor of vitamin D.","pubmed_id":"10807690"}],"gene_id":"ENSG00000172893","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":71167449},"locus_GRCh38":{"chromosome":"11","position":71456403},"rsid":"rs12785878"},"trait_info":{"ontology":["HMDB0001438"],"reported_trait_name":"Vitamin D insufficiency","standard_trait_name":"25-Hydroxyvitamin D2"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000703","neg_log_pval":27.0,"otg_id":"GCST000703","pubmed_id":"20558539"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALPL encodes the liver alkaline phosphatase.  Loss of function of alkaline phosphatase causes hypophosphatasia.","pubmed_id":"03174660"}],"gene_id":"ENSG00000162551","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":21823292},"locus_GRCh38":{"chromosome":"1","position":21496799},"rsid":"rs1697421"},"trait_info":{"ontology":["HMDB0001315"],"reported_trait_name":"Phosphorus levels","standard_trait_name":"Phosphorus"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000703","neg_log_pval":8.398,"otg_id":"GCST000703","pubmed_id":"20558539"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FGF23 encodes a fibroblast growth factor which regulates phosphate levels through multiple mechanisms, including regulation of levels of kidney phosphate transporters","pubmed_id":"15863037"}],"gene_id":"ENSG00000118972","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":4606168},"locus_GRCh38":{"chromosome":"12","position":4497002},"rsid":"rs2970818"},"trait_info":{"ontology":["HMDB0001315"],"reported_trait_name":"Phosphorus levels","standard_trait_name":"Phosphorus"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000756","neg_log_pval":35.699,"otg_id":"GCST000756","pubmed_id":"20700443"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MUC1 encodes a mucin protein which forms a mucosal layer in intestines and kidney and may regulate absorption of magnesium","pubmed_id":"01983814"}],"gene_id":"ENSG00000185499","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":155162067},"locus_GRCh38":{"chromosome":"1","position":155192276},"rsid":"rs4072037"},"trait_info":{"ontology":["HMDB0000547"],"reported_trait_name":"Magnesium levels","standard_trait_name":"Magneseium"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000756","neg_log_pval":14.097,"otg_id":"GCST000756","pubmed_id":"20700443"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TRPM6 encodes a cation transporter with demonstrated activity toward magnesium.","pubmed_id":"14576148"}],"gene_id":"ENSG00000119121","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"9","position":77499796},"locus_GRCh38":{"chromosome":"9","position":74884880},"rsid":"rs11144134"},"trait_info":{"ontology":["HMDB0000547"],"reported_trait_name":"Magnesium levels","standard_trait_name":"Magnesium"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST000925","neg_log_pval":17.523,"otg_id":"GCST000925_3","pubmed_id":"21203500"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FUT8 encodes a fucosyltransferase that catalyzes the transfer of fucose to complex glycopeptides.","pubmed_id":"00985526"}],"gene_id":"ENSG00000033170","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":65758642},"locus_GRCh38":{"chromosome":"14","position":65291924},"rsid":"rs7159888"},"trait_info":{"ontology":["EFO_0004999"],"reported_trait_name":"N-glycan levels (DG1)","standard_trait_name":"N-glycan measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001049","neg_log_pval":51.222,"otg_id":"GCST001049","pubmed_id":"21502573"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"F3 encodes coagulation factor 3, also known as tissue factor, which is involved in the initiation of the clotting cascade, which eventually results in the production of fibrin.  The D-dimer metabolite is a degredation product of fibrin clots.","pubmed_id":"12223078"}],"gene_id":"ENSG00000117525","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":95053353},"locus_GRCh38":{"chromosome":"1","position":94587797},"rsid":"rs12029080"},"trait_info":{"ontology":["EFO_0004507"],"reported_trait_name":"D-dimer levels","standard_trait_name":"D dimer measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001049","neg_log_pval":13.699,"otg_id":"GCST001049","pubmed_id":"21502573"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"F5 encodes coagulation factor 5, an essential element of the clotting cascade, which eventually results in the production of fibrin.  The D-dimer metabolite is a degredation product of fibrin clots.","pubmed_id":"25231258"}],"gene_id":"ENSG00000198734","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":169477574},"locus_GRCh38":{"chromosome":"1","position":169508336},"rsid":"rs6687813"},"trait_info":{"ontology":["EFO_0004507"],"reported_trait_name":"D-dimer levels","standard_trait_name":"D dimer measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001142","neg_log_pval":10.0,"otg_id":"GCST001142","pubmed_id":"21729881"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP4F2 encodes a cytochrome P450 with a special role in the production of Vitamin E","pubmed_id":"11997390"}],"gene_id":"ENSG00000186115","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":15990431},"locus_GRCh38":{"chromosome":"19","position":15879621},"rsid":"rs2108622"},"trait_info":{"ontology":["HMDB0001893"],"reported_trait_name":"Vitamin E levels","standard_trait_name":"Alpha-Tocopherol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001179","neg_log_pval":43.0,"otg_id":"GCST001179","pubmed_id":"21829377"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ELOVL2 encodes a long chain fatty acid elongase.  The coenzyme A derivative of DPA (22:5n3) is both a product and a substrate for the enzyme. ","pubmed_id":"12371743"}],"gene_id":"ENSG00000197977","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":10982973},"locus_GRCh38":{"chromosome":"6","position":10982740},"rsid":"rs3734398"},"trait_info":{"ontology":["HMDB0006528"],"reported_trait_name":"Phospholipid levels (plasma) (DPA)","standard_trait_name":"Docosapentaenoic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001216","neg_log_pval":14.155,"otg_id":"GCST001216","pubmed_id":"21878437"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"RBP4 encodes a retinol-binding protein that transports retinol in the blood. ","pubmed_id":"02444024"}],"gene_id":"ENSG00000138207","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":95348182},"locus_GRCh38":{"chromosome":"10","position":93588425},"rsid":"rs10882272"},"trait_info":{"ontology":["HMDB0000305"],"reported_trait_name":"Retinol levels","standard_trait_name":"Vitamin A"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001216","neg_log_pval":13.222,"otg_id":"GCST001216","pubmed_id":"21878437"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TTR encodes a thyroid hormone-binding protein which transports thryroxine and retinol.","pubmed_id":"04607556"}],"gene_id":"ENSG00000118271","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":29187279},"locus_GRCh38":{"chromosome":"18","position":31607316},"rsid":"rs1667255"},"trait_info":{"ontology":["HMDB0000305"],"reported_trait_name":"Retinol levels","standard_trait_name":"Vitamin A"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001217","neg_log_pval":14.301,"otg_id":"GCST001217_23","pubmed_id":"21886157"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2.  These enzymes metabolize caffeine.","pubmed_id":"10605936"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2.  These enzymes metabolize caffeine.","pubmed_id":"08095225"}],"gene_id":"ENSG00000106546","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":17309279},"locus_GRCh38":{"chromosome":"7","position":17269655},"rsid":"rs12670403"},"trait_info":{"ontology":["HMDB0001847","HMDB0003072"],"reported_trait_name":"Metabolic traits (caffeine/quinate + 3 other traits)","standard_trait_name":"Caffeine / Quinic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001217","neg_log_pval":12.155,"otg_id":"GCST001217_30","pubmed_id":"21886157"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NT5E encodes the ecto-5'-nucleotidase which can generate inosine","pubmed_id":"06271180"}],"gene_id":"ENSG00000135318","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":86117129},"locus_GRCh38":{"chromosome":"6","position":85407411},"rsid":"rs494562"},"trait_info":{"ontology":["HMDB0000195"],"reported_trait_name":"Metabolic traits (inosine + 1 other trait)","standard_trait_name":"Inosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001264","neg_log_pval":41.0,"otg_id":"GCST001264_2","pubmed_id":"21998597"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SHBG encodes the sex-hormone binding globulin which binds which binds to and transports testosterone.","pubmed_id":"07626508"}],"gene_id":"ENSG00000129214","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":7521915},"locus_GRCh38":{"chromosome":"17","position":7618597},"rsid":"rs12150660"},"trait_info":{"ontology":["HMDB0000234"],"reported_trait_name":"Testosterone levels (Testosterone)","standard_trait_name":"Testosterone"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001391","neg_log_pval":21.523,"otg_id":"GCST001391_3","pubmed_id":"22286219"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC1A4 encodes a neutral amino acid transporter with demonstrated activity for alanine, serine, cysteine and threonine.  2-aminobutyrate is structurally similar to these amino acids.","pubmed_id":"07896285"}],"gene_id":"ENSG00000115902","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":65220910},"locus_GRCh38":{"chromosome":"2","position":64993776},"rsid":"rs2160387"},"trait_info":{"ontology":["HMDB0000161","HMDB0000883"],"reported_trait_name":"Metabolite levels (Ala, Val)","standard_trait_name":"L-Alanine / L-Valine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001391","neg_log_pval":16.699,"otg_id":"GCST001391_10","pubmed_id":"22286219"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TAT encodes tyrosine aminotransferase which converts tyrosine to 4-hydroxyphenylpyruvate.  Enzyme deficiency in this enzyme causes tyrosine build up.","pubmed_id":"01973834"}],"gene_id":"ENSG00000198650","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":71634811},"locus_GRCh38":{"chromosome":"16","position":71600908},"rsid":"rs4788815"},"trait_info":{"ontology":["HMDB0000159","HMDB0000158"],"reported_trait_name":"Metabolite levels (Phe, Tyr)","standard_trait_name":"L-Phenylalanine / L-Tyrosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001392","neg_log_pval":11.097,"otg_id":"GCST001392_5","pubmed_id":"22286219"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CPT1A encodes a carnitine O-palmitoyltransferase which acts the CoA version of the free fatty acid metabolite detected here","pubmed_id":"01865762"}],"gene_id":"ENSG00000110090","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":68562328},"locus_GRCh38":{"chromosome":"11","position":68794860},"rsid":"rs2229738"},"trait_info":{"ontology":["HMDB0000673"],"reported_trait_name":"Lipid metabolism phenotypes (LA/PUFA)","standard_trait_name":"Linoleic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001414","neg_log_pval":9.097,"otg_id":"GCST001414_2","pubmed_id":"22359512"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGPAT1 encodes 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha, an enzyme which produces phosphatidic acid.","pubmed_id":"17707131"}],"gene_id":"ENSG00000204310","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":32136547},"locus_GRCh38":{"chromosome":"6","position":32168770},"rsid":"rs1061808"},"trait_info":{"ontology":["HMDB0008031","HMDB0008003"],"reported_trait_name":"Phospholipid levels (plasma) (proportions (PC 32∶0/PC 34∶1))","standard_trait_name":"similar to Phosphatidylcholine(18:0/14:0)|Phosphatidylcholine(16:1/18:0)"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001413","neg_log_pval":18.699,"otg_id":"GCST001413","pubmed_id":"22359512"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ATP10D encodes a phospholipid flippase.  Closely related gene family members have demonstrated activity versus phosphatidylcholine.","pubmed_id":"25947375"}],"gene_id":"ENSG00000145246","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":47551863},"locus_GRCh38":{"chromosome":"4","position":47549846},"rsid":"rs13106975"},"trait_info":{"ontology":["EFO_0004622 "],"reported_trait_name":"Sphingolipid levels (levels)","standard_trait_name":"sphingolipid measurement"}}
{"association_info":{"ancestry":["SAS"],"gwas_catalog_id":"GCST001421","neg_log_pval":8.523,"otg_id":"GCST001421","pubmed_id":"22383894"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AS3MT encodes arsenite methyltransferase which acts on methylarsonite to produce dimethylarsinate (also known as cacodylate)","pubmed_id":"20621156"}],"gene_id":"ENSG00000214435","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":104623578},"locus_GRCh38":{"chromosome":"10","position":102863821},"rsid":"rs9527"},"trait_info":{"ontology":["HMDB0011625"],"reported_trait_name":"Arsenic metabolism  (DMA%)","standard_trait_name":"Dimethylarsinate"}}
{"association_info":{"ancestry":["EAS"],"gwas_catalog_id":"GCST001608","neg_log_pval":62.523,"otg_id":"GCST001608","pubmed_id":"22797727"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter.  The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea.","pubmed_id":"12024214"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter.  The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea.","pubmed_id":"27105641"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":64464085},"locus_GRCh38":{"chromosome":"11","position":64696613},"rsid":"rs504915"},"trait_info":{"ontology":["HMDB0000294"],"reported_trait_name":"Renal function-related traits (urea)","standard_trait_name":"Urea"}}
{"association_info":{"ancestry":["EAS"],"gwas_catalog_id":"GCST001608","neg_log_pval":17.155,"otg_id":"GCST001608","pubmed_id":"22797727"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC14A2 encodes a urea transporter expressed in kidney.","pubmed_id":"11502588"}],"gene_id":"ENSG00000132874","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":43187130},"locus_GRCh38":{"chromosome":"18","position":45607165},"rsid":"rs7227483"},"trait_info":{"ontology":["HMDB0000294"],"reported_trait_name":"Renal function-related traits (BUN)","standard_trait_name":"Urea"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":17.068,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC2A2 encodes a glucose transporter (GLUT2)","pubmed_id":"02479026"}],"gene_id":"ENSG00000163581","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":170713290},"locus_GRCh38":{"chromosome":"3","position":170995501},"rsid":"rs1280"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":7.757,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"IGF2BP2 encodes a protein which binds insulin-like growth factor 2 mRNA.  ","pubmed_id":"09891060"}],"gene_id":"ENSG00000073792","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":185513392},"locus_GRCh38":{"chromosome":"3","position":185795604},"rsid":"rs7651090"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":14.991,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PCSK1 encodes a protease which is involved in maturation of insulin","pubmed_id":"01843283"}],"gene_id":"ENSG00000175426","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":95539448},"locus_GRCh38":{"chromosome":"5","position":96203744},"rsid":"rs4869272"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":98.541,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GCK encodes glucokinase which directly phosphorylates glucose and thus contributes to glucose homeostasis","pubmed_id":"01871135"}],"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44231886},"locus_GRCh38":{"chromosome":"7","position":44192287},"rsid":"rs6975024"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":214.971,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MTNR1B encodes a melatonin receptor.  Melatonin stimulates glucose uptake.","pubmed_id":"16842543"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544},"rsid":"rs10830963"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":14.876,"pubmed_id":"22885924"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2)  which each influence glucose levels","pubmed_id":"07901001"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2)  which each influence glucose levels","pubmed_id":"08923459"}],"gene_id":"ENSG00000139515","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":28487599},"locus_GRCh38":{"chromosome":"13","position":27913462},"rsid":"rs11619319"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"MAGIC Fasting Glucose GWAS/Metabochip 2012","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001791","neg_log_pval":29.0,"otg_id":"GCST001791","pubmed_id":"23263486"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PDZK1 encodes a protein that binds to and regulates the activity of URAT1 (encoded by SLC22A12), which is a urate transporter.","pubmed_id":"15304510"}],"gene_id":"ENSG00000174827","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":145723739},"locus_GRCh38":{"chromosome":"1","position":145711327},"rsid":"rs1471633"},"trait_info":{"ontology":["HMDB0000289"],"reported_trait_name":"Urate levels","standard_trait_name":"Uric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001791","neg_log_pval":700.0,"otg_id":"GCST001791","pubmed_id":"23263486"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC2A9 encodes a urate transporter.","pubmed_id":"18327257"}],"gene_id":"ENSG00000109667","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":9944052},"locus_GRCh38":{"chromosome":"4","position":9942428},"rsid":"rs12498742"},"trait_info":{"ontology":["HMDB0000289"],"reported_trait_name":"Urate levels","standard_trait_name":"Uric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001791","neg_log_pval":134.0,"otg_id":"GCST001791","pubmed_id":"23263486"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ABCG2 encodes a urate transporter.","pubmed_id":"19506252"}],"gene_id":"ENSG00000118777","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":89052323},"locus_GRCh38":{"chromosome":"4","position":88131171},"rsid":"rs2231142"},"trait_info":{"ontology":["HMDB0000289"],"reported_trait_name":"Urate levels","standard_trait_name":"Uric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001840","neg_log_pval":8.523,"otg_id":"GCST001840","pubmed_id":"23362303"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LPGAT1 encodes a lysophosphatidylglycerol acyltransferase which transfers long-chain acyl-CoAs to lysophosphatidylglycerol with a demonstrated preference for stearoyl-CoA.","pubmed_id":"15485873"}],"gene_id":"ENSG00000123684","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":211918244},"locus_GRCh38":{"chromosome":"1","position":211744902},"rsid":"rs11119805"},"trait_info":{"ontology":["HMDB0000827"],"reported_trait_name":"Stearic acid (18:0) plasma levels","standard_trait_name":"Stearic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001856","neg_log_pval":31.097,"otg_id":"GCST001856_4","pubmed_id":"23408906"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DIO1 encodes an iodothyronine deiodinase which deiodinates of thyroxine (T4) to produce the biologically active hormone T3","pubmed_id":"01400883"}],"gene_id":"ENSG00000211452","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":54375570},"locus_GRCh38":{"chromosome":"1","position":53909897},"rsid":"rs2235544"},"trait_info":{"ontology":["HMDB0000248"],"reported_trait_name":"Thyroid hormone levels (FT4: free thyroxine)","standard_trait_name":"Thyroxine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001856","neg_log_pval":10.699,"otg_id":"GCST001856_4","pubmed_id":"23408906"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FOXE1 encodes a transcription factor expressed specifically in thyroid gland, the source of the thyroxine (FT4 thyroid hormone)","pubmed_id":"09214635"}],"gene_id":"ENSG00000178919","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":100591463},"locus_GRCh38":{"chromosome":"9","position":97829181},"rsid":"rs7045138"},"trait_info":{"ontology":["HMDB0000248"],"reported_trait_name":"Thyroid hormone levels (FT4: free thyroxine)","standard_trait_name":"Thyroxine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST001856","neg_log_pval":13.699,"otg_id":"GCST001856_4","pubmed_id":"23408906"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LHX3 encodes pituitary-specific transcription factor which is critical for pituitary gland development.  The pituitary gland produces thyroid stimulating hormone which directs the thyroid gland to produce thyroxine (T4).","pubmed_id":"08638120"}],"gene_id":"ENSG00000107187","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":139089679},"locus_GRCh38":{"chromosome":"9","position":136197833},"rsid":"rs7860634"},"trait_info":{"ontology":["HMDB0000248"],"reported_trait_name":"Thyroid hormone levels (FT4: free thyroxine)","standard_trait_name":"Thyroxine"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","ZZ1"],"gwas_catalog_id":"GCST001914","neg_log_pval":7.523,"otg_id":"GCST001914","pubmed_id":"23518928"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TSPYL5 induces CYP19A1 expression, which in turn encodes a key enzyme involved in the biosynthesis of estradiol.","pubmed_id":"23518928"}],"gene_id":"ENSG00000180543","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":98282189},"locus_GRCh38":{"chromosome":"8","position":97269961},"rsid":"rs1864729"},"trait_info":{"ontology":["HMDB0000151"],"reported_trait_name":"Estradiol plasma levels (breast cancer)","standard_trait_name":"Estradiol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002041","neg_log_pval":19.523,"otg_id":"GCST002041","pubmed_id":"23720494"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SELENBP1 encodes a selenium-binding protein.  The Arabidopsis ortholog (61% identity) has been shown to bind copper.","pubmed_id":"25274629"}],"gene_id":"ENSG00000143416","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":151344741},"locus_GRCh38":{"chromosome":"1","position":151372265},"rsid":"rs2769264"},"trait_info":{"ontology":["HMDB0000657"],"reported_trait_name":"Blood trace element (Cu levels)","standard_trait_name":"Copper"}}
{"association_info":{"ancestry":["ASW"],"gwas_catalog_id":"GCST002043","neg_log_pval":9.222,"otg_id":"GCST002043","pubmed_id":"23726366"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CD36 encodes a platelet glycoprotein which binds HDL","pubmed_id":"09867808"}],"gene_id":"ENSG00000135218","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":80340622},"locus_GRCh38":{"chromosome":"7","position":80711306},"rsid":"rs2366858"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL cholesterol (AA)","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":32.18,"pubmed_id":"23823483"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DMGDH encodes dimethylglycine dehydrogenase which takes dimethlyglycine as a substrate.  Enzyme deficiency results in excess dimethlyglycine.","pubmed_id":"10102904"}],"gene_id":"ENSG00000132837","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":78330227},"locus_GRCh38":{"chromosome":"5","position":79034404},"rsid":"rs248386"},"trait_info":{"ontology":["HMDB0000092"],"reported_trait_name":"Dimethlyglycine","standard_trait_name":"Dimethlyglycine"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":9.854,"pubmed_id":"23823483"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGA encodes the enzyme aspartylglucosaminidase which generates asparagine from N-acetylglucosamines.  Deficiency results in an accumulation of asparagine-linked glycopeptides.","pubmed_id":"01281977"}],"gene_id":"ENSG00000038002","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":178361051},"locus_GRCh38":{"chromosome":"4","position":177439897},"rsid":"rs4690522"},"trait_info":{"ontology":["HMDB0000168"],"reported_trait_name":"Asparagine","standard_trait_name":"L-Asparagine"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":9.119,"pubmed_id":"23823483"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"UMPS encodes uridine monophosphate synthetase, the enzyme which converts orotic acid to uridine.  Enzyme deficiency results in accumulation of orotic acid.","pubmed_id":"06893554"}],"gene_id":"ENSG00000114491","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":124451064},"locus_GRCh38":{"chromosome":"3","position":124732217},"rsid":"rs9844948"},"trait_info":{"ontology":["HMDB0000226"],"reported_trait_name":"Orotic acid","standard_trait_name":"Orotic acid"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":19.886,"pubmed_id":"23823483"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SERPINA7 encodes the thyroxine-binding globulin protein.","pubmed_id":"03094014"}],"gene_id":"ENSG00000123561","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"X","position":105276609},"locus_GRCh38":{"chromosome":"X","position":106032618},"rsid":"rs7883218"},"trait_info":{"ontology":["HMDB0000248"],"reported_trait_name":"Thyroxine","standard_trait_name":"Thyroxine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":103.398,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MTHFR encodes methylenetetrahydrolate reductase, an enzyme that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the methyl donor in the conversion of homocysteine to methionine.  Defects in MTHFR lead to homocysteinuria.","pubmed_id":"05057914"}],"gene_id":"ENSG00000177000","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":11856378},"locus_GRCh38":{"chromosome":"1","position":11796321},"rsid":"rs1801133"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":8.699,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MMACHC encodes a cobalamin-binding protein.  Defects in MMACHC are a known cause of homocystinuria.","pubmed_id":"16311595"}],"gene_id":"ENSG00000132763","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":45978675},"locus_GRCh38":{"chromosome":"1","position":45513003},"rsid":"rs4660306"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":9.699,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MTR encodes 5-methyltetrahydrofolate-homocysteine methyltransferase.  The enzyme acts on homocysteine to produce methionine","pubmed_id":"02407589"}],"gene_id":"ENSG00000116984","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":237048676},"locus_GRCh38":{"chromosome":"1","position":236885376},"rsid":"rs2275565"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":9.699,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MUT is a cobalamin-dependent enzyme.  Cobalamin is also needed in a reaction taking the homocysteine as a substrate","pubmed_id":"07901104"}],"gene_id":"ENSG00000146085","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":49382193},"locus_GRCh38":{"chromosome":"6","position":49414480},"rsid":"rs9369898"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":19.699,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FOLH1B encodes a liver-enriched polyglutamylfolate hydrolase which will influence folate availability for the conversion of homocysteine to methionine","pubmed_id":"09816319"}],"gene_id":"ENSG00000134612","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":89148372},"locus_GRCh38":{"chromosome":"11","position":89415204},"rsid":"rs7130284"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002087","neg_log_pval":42.699,"otg_id":"GCST002087","pubmed_id":"23824729"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DPEP1 encodes a dipeptidase that acts on glutathione, which is a downstream product of homocysteine metabolism. Glutathione and homocysteine levels have been shown to be negatively correlated.","pubmed_id":"06122685"}],"gene_id":"ENSG00000015413","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89708096},"locus_GRCh38":{"chromosome":"16","position":89641688},"rsid":"rs154657"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Homocysteine levels","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002196","neg_log_pval":45.0,"otg_id":"GCST002196","pubmed_id":"24047826"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GATM encodes glycine amidinotransferase.  This enzyme produces the Homoarginine when using lysine as a substrate.","pubmed_id":"23010440"}],"gene_id":"ENSG00000171766","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":45652703},"locus_GRCh38":{"chromosome":"15","position":45360505},"rsid":"rs1153858"},"trait_info":{"ontology":["HMDB0000670"],"reported_trait_name":"Homoarginine levels","standard_trait_name":"Homo-L-arginine"}}
{"association_info":{"ancestry":["EAS"],"gwas_catalog_id":"GCST002195","neg_log_pval":30.155,"otg_id":"GCST002195_2","pubmed_id":"24049095"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP19A1 encodes aromatase which produces estradiol (the measured analyte) from testosterone.","pubmed_id":"04153532"}],"gene_id":"ENSG00000137869","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":51524292},"locus_GRCh38":{"chromosome":"15","position":51232095},"rsid":"rs2414095"},"trait_info":{"ontology":["HMDB0000151"],"reported_trait_name":"Hormone measurements (Oestradiol)","standard_trait_name":"Estradiol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002201","neg_log_pval":10.097,"otg_id":"GCST002201","pubmed_id":"24068962"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TRPM8 encodes a calcium-permeable channel activated by menthol and cold.","pubmed_id":"11882888"}],"gene_id":"ENSG00000144481","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":234264848},"locus_GRCh38":{"chromosome":"2","position":233356202},"rsid":"rs1550532"},"trait_info":{"ontology":["HMDB0000464"],"reported_trait_name":"Calcium levels","standard_trait_name":"Calcium"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002201","neg_log_pval":85.046,"otg_id":"GCST002201","pubmed_id":"24068962"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CASR encodes the calcium sensing receptor, a GPCR which binds calcium and regulates parathyroid hormone secretion which in turn regulates circulating levels of calcium.","pubmed_id":"11013439"}],"gene_id":"ENSG00000036828","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":122003757},"locus_GRCh38":{"chromosome":"3","position":122284910},"rsid":"rs1801725"},"trait_info":{"ontology":["HMDB0000464"],"reported_trait_name":"Calcium levels","standard_trait_name":"Calcium"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002201","neg_log_pval":8.097,"otg_id":"GCST002201","pubmed_id":"24068962"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GUSB encodes a glucuronidase which induces the opening of the calcium-specific kidney-specific channel, TRPV5.","pubmed_id":"18495742"}],"gene_id":"ENSG00000169919","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":65271197},"locus_GRCh38":{"chromosome":"7","position":65806210},"rsid":"rs17711722"},"trait_info":{"ontology":["HMDB0000464"],"reported_trait_name":"Calcium levels","standard_trait_name":"Calcium"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002201","neg_log_pval":11.046,"otg_id":"GCST002201","pubmed_id":"24068962"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP24A1 encodes the 1,25-dihydroxyvitamin D(3) 24-hydroxylase which produces the biologically active form of vitamin D, which regulates calcium levels.","pubmed_id":"09333115"}],"gene_id":"ENSG00000019186","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":52774427},"locus_GRCh38":{"chromosome":"20","position":54157888},"rsid":"rs1570669"},"trait_info":{"ontology":["HMDB0000464"],"reported_trait_name":"Calcium levels","standard_trait_name":"Calcium"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":27.153,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"IRF2BP2 encodes a protein which binds to the interferon regulatory factor 2 transcription factor.  This transcription factor is essential for the activation of the ABCA1 cholesterol transporter.","pubmed_id":"26195219"}],"gene_id":"ENSG00000168264","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":234853406},"locus_GRCh38":{"chromosome":"1","position":234717659},"rsid":"rs558971"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002221","neg_log_pval":11.398,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ABCB11 encodes a transporter for taurocholate, a bile acid derived from cholesterol","pubmed_id":"01862084"}],"gene_id":"ENSG00000073734","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":169830155},"locus_GRCh38":{"chromosome":"2","position":168973645},"rsid":"rs2287623"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Cholesterol, total","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":16.075,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PPARG encodes a transcription factor that upreguates ABCA1 among other proteins involved in lipid metabolism.","pubmed_id":"11135616"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":12267648},"locus_GRCh38":{"chromosome":"3","position":12226148},"rsid":"rs7616006"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":16.141,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LPA encodes the lipoprotein(a) protein, a constituent of the lipoprotein(a) particle, a carrier of cholesterol.","pubmed_id":"24977982"}],"gene_id":"ENSG00000198670","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086},"rsid":"rs10455872"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":22.952,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids.  CYP7A1 deficiency results in excess cholesterol.","pubmed_id":"02993784"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids.  CYP7A1 deficiency results in excess cholesterol.","pubmed_id":"12093894"}],"gene_id":"ENSG00000167910","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":59393273},"locus_GRCh38":{"chromosome":"8","position":58480714},"rsid":"rs4738684"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":9.176,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"VLDLR encodes the very low density lipoprotein receptor ","pubmed_id":"08294473"}],"gene_id":"ENSG00000147852","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":2640759},"locus_GRCh38":{"chromosome":"9","position":2640759},"rsid":"rs3780181"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002221","neg_log_pval":8.006,"otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PPARA encodes a transcription factor which regulates expression of HDL apolipoproteins","pubmed_id":"09808609"}],"gene_id":"ENSG00000186951","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":46627603},"locus_GRCh38":{"chromosome":"22","position":46231706},"rsid":"rs4253772"},"trait_info":{"ontology":["HMDB0000067"],"reported_trait_name":"Total Cholesterol","standard_trait_name":"Cholesterol"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":7.744,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NAXE (formerly APOA1BP) encodes an APOA1 binding protein which promotes cholesterol efflux into high density lipoprotein (HDL) particles.","pubmed_id":"23719382"}],"gene_id":"ENSG00000163382","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":156700651},"locus_GRCh38":{"chromosome":"1","position":156730859},"rsid":"rs12145743"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":40.454,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GALNT2 encodes an acetylgalactosaminyltransferase which glycosylates the APOC3 protein, which in turn inhibits the lipoprotein lipase (LPL) enzyme which hydrolyzes triglycerides from triglyceride-containing lipoproteins, leading to the generation of HDL","pubmed_id":"22152306"}],"gene_id":"ENSG00000143641","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":230295691},"locus_GRCh38":{"chromosome":"1","position":230159944},"rsid":"rs4846914"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":8.663,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GPIHBP1 encodes the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1, a receptor for the HDL.","pubmed_id":"12496272"}],"gene_id":"ENSG00000182851","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":144303418},"locus_GRCh38":{"chromosome":"8","position":143221248},"rsid":"rs10087900"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":64.825,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ABCA1 encodes a cholesterol transporter.  Deficiency results in reduced HDL.","pubmed_id":"10431237"}],"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":107664301},"locus_GRCh38":{"chromosome":"9","position":104902020},"rsid":"rs1883025"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":37.481,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NR1H3 encodes the LXR-alpha nuclear hormone receptor.  This transcription factor upreguates ABCA1, a cholesterol transporter with a direct impact on HDL levels.","pubmed_id":"11090131"}],"gene_id":"ENSG00000025434","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":47333685},"locus_GRCh38":{"chromosome":"11","position":47312134},"rsid":"rs3847502"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":7.951,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DGAT2 encodes a diacylglycerol O-acyltransferase which produces triglycerides from diaglycerides.","pubmed_id":"11481335"}],"gene_id":"ENSG00000062282","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":75455021},"locus_GRCh38":{"chromosome":"11","position":75743976},"rsid":"rs499974"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":19.604,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MVK encodes mevalonate kinase which synthesizes a precursor to cholesterol.","pubmed_id":"02153681"}],"gene_id":"ENSG00000110921","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":109950144},"locus_GRCh38":{"chromosome":"12","position":109512339},"rsid":"rs2241210"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":32.135,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SCARB1 encodes a scavanger receptor which can act as an HDL receptor.","pubmed_id":"08560269"}],"gene_id":"ENSG00000073060","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":125259888},"locus_GRCh38":{"chromosome":"12","position":124775342},"rsid":"rs838876"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":8.019,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AKT1 encodes a protein kinase which activates SREBP which induces transcription of enzymes involved in cholesterol biosynthesis.","pubmed_id":"16007182"}],"gene_id":"ENSG00000142208","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":105277209},"locus_GRCh38":{"chromosome":"14","position":104810872},"rsid":"rs4983559"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002223","neg_log_pval":188.0,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LIPC encodes hepatic triglyceride lipase which hydrolyses triglycerides.  The enzyme plays a key role in regulating levels of HDL.","pubmed_id":"07417375"}],"gene_id":"ENSG00000166035","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":58683366},"locus_GRCh38":{"chromosome":"15","position":58391167},"rsid":"rs1532085"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":801.939,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CETP encodes the cholesterol ester transfer protein which acts on high density lipoprotein (HDL).  Deficiency of this enzyme results in increased HDL. ","pubmed_id":"02586614"}],"gene_id":"ENSG00000087237","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56989590},"locus_GRCh38":{"chromosome":"16","position":56955678},"rsid":"rs247616"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002223","neg_log_pval":53.097,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LCAT encodes lecithin-cholesterol acyltransferase which travels with HDL, esterifying cholesterol to cholesterol ester for incorporation into the HDL particles for transport back to the liver.","pubmed_id":"04868699"}],"gene_id":"ENSG00000213398","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":67928042},"locus_GRCh38":{"chromosome":"16","position":67894139},"rsid":"rs16942887"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":19.264,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"STARD3 encodes the StAR-related lipid transfer protein 3 which promotes export of cholesterol to HDL","pubmed_id":"25014273"}],"gene_id":"ENSG00000131748","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":37821435},"locus_GRCh38":{"chromosome":"17","position":39665182},"rsid":"rs113612868"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":65.746,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LIPG encodes endothelial lipase which acts on HDL.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo","pubmed_id":"12569161"}],"gene_id":"ENSG00000101670","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":47167214},"locus_GRCh38":{"chromosome":"18","position":49640844},"rsid":"rs4939883"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002223","neg_log_pval":33.785,"otg_id":"GCST002223","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HNF4A drives expression of many cholesterol related genes including HMGCR","pubmed_id":"21071704"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":43042364},"locus_GRCh38":{"chromosome":"20","position":44413724},"rsid":"rs1800961"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"HDL Cholesterol","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":16.519,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LDLRAP1 encodes an adapter protein which binds to the LDL receptor.  Mutations in this gene cause a form of familial hypercholesterolemia.","pubmed_id":"15166224"}],"gene_id":"ENSG00000157978","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":25768937},"locus_GRCh38":{"chromosome":"1","position":25442446},"rsid":"rs10903129"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":142.067,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PCSK9 encodes a protein that binds to the LDLR receptor, promoting its degradation and thus influencing circulating LDL cholesterol levels.  Rare gain of function mutations result in greatly elevated LDL cholesterol levels.","pubmed_id":"12730697"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974},"rsid":"rs11591147"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":271.788,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SORT1 encodes sortilin, a receptor with a role in VLDL secretion from the liver","pubmed_id":"20686566"}],"gene_id":"ENSG00000134243","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":109818530},"locus_GRCh38":{"chromosome":"1","position":109275908},"rsid":"rs646776"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":182.023,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"APOB encodes apolipoprotein B, a major component of LDL particles.  Defects in APOB can lead to familial hypercholesterolemia.","pubmed_id":"00052771"}],"gene_id":"ENSG00000084674","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":21263900},"locus_GRCh38":{"chromosome":"2","position":21041028},"rsid":"rs1367117"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":11.77,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"INSIG2 encodes a protein that plays a key role in regulating the SREBP cleavage-activating protein (SCAP), thus providing a means for feedback regulation of cholesterol synthesis over a wide range of sterol concentrations.","pubmed_id":"12242332"}],"gene_id":"ENSG00000125629","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":118835841},"locus_GRCh38":{"chromosome":"2","position":118078265},"rsid":"rs10490626"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":77.108,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HMGCR encodes HMG-CoA reductase, the rate-limiting enzyme for cholesterol biosynthesis","pubmed_id":"01967820"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74656539},"locus_GRCh38":{"chromosome":"5","position":75360714},"rsid":"rs12916"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":16.68,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MYLIP encodes an E3 ubiquitin ligase which ubiquitinates the low density lipoprotein receptor (LDLR), which promotes the degradation of LDLR, influencing the circulating levels of LDL-cholesterol.","pubmed_id":"19520913"}],"gene_id":"ENSG00000007944","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":16127407},"locus_GRCh38":{"chromosome":"6","position":16127176},"rsid":"rs3757354"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":20.716,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NPC1L1 encodes a transporter for cholesterol in the intestine.","pubmed_id":"14976318"}],"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":44582331},"locus_GRCh38":{"chromosome":"7","position":44542732},"rsid":"rs2073547"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002222","neg_log_pval":40.398,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HP encodes haptoglobin which binds to ApoA-I, the primary protein component of HDL.","pubmed_id":"23420675"}],"gene_id":"ENSG00000257017","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":72108093},"locus_GRCh38":{"chromosome":"16","position":72074194},"rsid":"rs2000999"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":11.008,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ApoH increases the enzymic activity of lipoprotein lipase (LPL) in the presence of apoC-II by 45.7 percent [ 7417307].  a small molecule inhibitor of PKC alpha, HBDDE, show minimal inhibition of cholesterol accumulation while a small molecule inhibitor of PKC beta, LY333513, could completely account for the inhibition of cholesterol accumulation by the classical group PKC isoenzyme [16930534]","pubmed_id":"07417307"}],"gene_id":"ENSG00000091583","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":64210580},"locus_GRCh38":{"chromosome":"17","position":66214462},"rsid":"rs1801689"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["AFR","EAS","EUR","SAS"],"gwas_catalog_id":"GCST002222","neg_log_pval":261.415,"otg_id":"GCST002222","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LDLR encodes the LDL receptor.","pubmed_id":"00226968"}],"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11202306},"locus_GRCh38":{"chromosome":"19","position":11091630},"rsid":"rs6511720"},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"LDL Cholesterol","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["Caucasian"],"gwas_catalog_id":"GCST002219","neg_log_pval":81.456,"otg_id":"GCST002219","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ANGPTL3 encodes a protein that regulates triglyceride clearance by reducing the activity of lipoprotein lipase (LPL).","pubmed_id":"22063269"}],"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":63133930},"locus_GRCh38":{"chromosome":"1","position":62668259},"rsid":"rs4587594"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["Caucasian"],"gwas_catalog_id":"GCST002219","neg_log_pval":11.795,"otg_id":"GCST002219","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LRPAP1 encodes a protein which binds the LDL-receptor-related protein and the VLDL receptor affecting distribution of lipoprotein particles.","pubmed_id":"07538675"}],"gene_id":"ENSG00000163956","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":3473139},"locus_GRCh38":{"chromosome":"4","position":3471412},"rsid":"rs6831256"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["Caucasian"],"gwas_catalog_id":"GCST002219","neg_log_pval":7.676,"otg_id":"GCST002219","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CAV1 encodes caveolin-1, a scaffolding protein.  Very rare CAV1 frameshift mutations appear to be associated with atypical lipodystrophy and hypertriglyceridemia.","pubmed_id":"18237401"}],"gene_id":"ENSG00000105974","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":116358044},"locus_GRCh38":{"chromosome":"7","position":116717990},"rsid":"rs38855"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["Caucasian"],"gwas_catalog_id":"GCST002219","neg_log_pval":198.74,"otg_id":"GCST002219","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LPL encodes the lipoprotein lipase which hydrolyzes triglycerides.  LPL deficiency results in accumulation of triglycerides.","pubmed_id":"13712364"}],"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":19844222},"locus_GRCh38":{"chromosome":"8","position":19986711},"rsid":"rs12678919"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["Caucasian"],"gwas_catalog_id":"GCST002219","neg_log_pval":112.652,"otg_id":"GCST002219","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TRIB1 regulates hepatic lipogenesis.","pubmed_id":"26517927"}],"gene_id":"ENSG00000173334","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":126482621},"locus_GRCh38":{"chromosome":"8","position":125470379},"rsid":"rs2954022"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002242","neg_log_pval":40.0,"otg_id":"GCST002242","pubmed_id":"24159190"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DDAH1 encodes dimethylarginine dimethylaminohydrolase which acts directly on dimethylarginine.","pubmed_id":"07608105"}],"gene_id":"ENSG00000153904","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":85797110},"locus_GRCh38":{"chromosome":"1","position":85331427},"rsid":"rs28489187"},"trait_info":{"ontology":["HMDB0001539"],"reported_trait_name":"Serum dimethylarginine levels (asymmetric)","standard_trait_name":"Asymmetric dimethylarginine"}}
{"association_info":{"ancestry":["EUR"],"neg_log_pval":36.538,"pubmed_id":"24507774"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ANGPTL4 regulates TG clearance by reducing the activity of LPL","pubmed_id":"16081640"}],"gene_id":"ENSG00000167772","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":8429323},"locus_GRCh38":{"chromosome":"19","position":8364439},"rsid":"rs116843064"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002549","neg_log_pval":15.699,"otg_id":"GCST002549_7","pubmed_id":"24528284"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP2C19 encodes a cytochrome P450 which acts on xenobiotics including the selective serotonin reuptake inhibitor citalopram.","pubmed_id":"08451774"}],"gene_id":"ENSG00000165841","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":96681846},"locus_GRCh38":{"chromosome":"10","position":94922089},"rsid":"rs1074145"},"trait_info":{"ontology":["HMDB0060576","HMDB0005038"],"reported_trait_name":"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DCT/S-CT ratio)","standard_trait_name":"Desmethylcitalopram / Citalopram"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002549","neg_log_pval":15.699,"otg_id":"GCST002549_8","pubmed_id":"24528284"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP2D6 encodes a cytochrome P450 which acts on many xenobiotics including the conversion of desmethylcitalopram to didesmethylcitalopram (DDCT)","pubmed_id":"08451774"}],"gene_id":"ENSG00000100197","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":42526694},"locus_GRCh38":{"chromosome":"22","position":42130692},"rsid":"rs1065852"},"trait_info":{"ontology":["HMDB0060472"],"reported_trait_name":"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DDCT concentration)","standard_trait_name":"Didemethylcitalopram"}}
{"association_info":{"ancestry":["AMR","EUR"],"gwas_catalog_id":"GCST002364","neg_log_pval":35.523,"otg_id":"GCST002364_35","pubmed_id":"24586186"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FUT2 encodes a galactoside 2-alpha-L-fucosyltransferase, which adds fucose moeities to various proteins.","pubmed_id":"07876235"}],"gene_id":"ENSG00000176920","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":49228272},"locus_GRCh38":{"chromosome":"19","position":48725015},"rsid":"rs2287921"},"trait_info":{"ontology":["HMDB0000174"],"reported_trait_name":"Urinary metabolites (H-NMR features) (5.2125, Fucose)","standard_trait_name":"L-Fucose"}}
{"association_info":{"ancestry":["AMR","EUR"],"gwas_catalog_id":"GCST002364","neg_log_pval":33.0,"otg_id":"GCST002364_9","pubmed_id":"24586186"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC7A9 encodes an amino acid transporter which can transport a range of amino acids including lysine","pubmed_id":"24107421"}],"gene_id":"ENSG00000021488","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":33364628},"locus_GRCh38":{"chromosome":"19","position":32873722},"rsid":"rs8101881"},"trait_info":{"ontology":["HMDB0000182"],"reported_trait_name":"Urinary metabolites (H-NMR features) (1.7325, Lysine)","standard_trait_name":"L-Lysine"}}
{"association_info":{"ancestry":["ASW"],"gwas_catalog_id":"GCST002388","neg_log_pval":15.046,"otg_id":"GCST002388_14","pubmed_id":"24625756"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACY3 encodes an aminoacylase which preferentially deacetylates N-acetylaromatic amino acids including N-acetyl-L-phenylalanine.","pubmed_id":"14656720"}],"gene_id":"ENSG00000132744","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":67421341},"locus_GRCh38":{"chromosome":"11","position":67653870},"rsid":"rs12288023"},"trait_info":{"ontology":["HMDB0000512"],"reported_trait_name":"Serum metabolite levels (N-acetylphenylalanine)","standard_trait_name":"N-Acetyl-L-phenylalanine"}}
{"association_info":{"ancestry":["ASW"],"gwas_catalog_id":"GCST002388","neg_log_pval":29.523,"otg_id":"GCST002388_18","pubmed_id":"24625756"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TREH encodes trehalase which hydrolyses the disaccharide trehalose.","pubmed_id":"09427547"}],"gene_id":"ENSG00000118094","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118549582},"locus_GRCh38":{"chromosome":"11","position":118678873},"rsid":"rs507080"},"trait_info":{"ontology":["HMDB0000975"],"reported_trait_name":"Serum metabolite levels (Trehalose)","standard_trait_name":"Trehalose"}}
{"association_info":{"ancestry":["AFR","EUR"],"gwas_catalog_id":"GCST002391","neg_log_pval":12.155,"otg_id":"GCST002391","pubmed_id":"24651765"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALDH1L1 encodes a multifunctional enzyme which includes 10-formyltetrahydrofolate dehydrogenase activity.  The gene thus plays a key role in one carbon metabolism.","pubmed_id":"07702556"}],"gene_id":"ENSG00000144908","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":125906179},"locus_GRCh38":{"chromosome":"3","position":126187336},"rsid":"rs10934753"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Plasma homocysteine levels (post-methionine load test)","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["AFR","EUR"],"gwas_catalog_id":"GCST002391","neg_log_pval":62.699,"otg_id":"GCST002391","pubmed_id":"24651765"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GNMT encodes an enzyme which produces S-adenosylhomocysteine.  S-adenosylhomocysteine can be converted to homocysteine by the enzyme S-adenosylhomocysteine hydrolase","pubmed_id":"10843803"}],"gene_id":"ENSG00000124713","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":42925803},"locus_GRCh38":{"chromosome":"6","position":42958065},"rsid":"rs9296404"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Plasma homocysteine levels (post-methionine load test)","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["AFR","EUR"],"gwas_catalog_id":"GCST002391","neg_log_pval":25.523,"otg_id":"GCST002391","pubmed_id":"24651765"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CBS encodes the cystathionine beta-synthase which acts on homocysteine to produce cystathionine","pubmed_id":"16545978"}],"gene_id":"ENSG00000160200","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"21","position":44488033},"locus_GRCh38":{"chromosome":"21","position":43067923},"rsid":"rs234714"},"trait_info":{"ontology":["HMDB0000742"],"reported_trait_name":"Plasma homocysteine levels (post-methionine load test)","standard_trait_name":"Homocysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.0,"otg_id":"GCST002443_34","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ADHFE1 encodes the hydroxyacid-oxoacid transhydrogenase which catalyzes the oxidation of 4-hydroxybutanoic acid to 4-oxobutanoic acid, while reducing 2-oxoglutarate to 2-hydroxyglutarate.","pubmed_id":"16616524"}],"gene_id":"ENSG00000147576","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":67360725},"locus_GRCh38":{"chromosome":"8","position":66448490},"rsid":"rs1030420"},"trait_info":{"ontology":["HMDB0000337"],"reported_trait_name":"Blood metabolite levels (X-04499--3,4-dihydroxybutyrate)","standard_trait_name":"(S)-3,4-Dihydroxybutyric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":25.222,"otg_id":"GCST002442_19","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"F12 encodes coagulation factor XII, a protease which activates kallikrein which releases bradykinin from kininogen.","pubmed_id":"03521732"}],"gene_id":"ENSG00000131187","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":176842474},"locus_GRCh38":{"chromosome":"5","position":177415473},"rsid":"rs2731672"},"trait_info":{"ontology":["HMDB0004246"],"reported_trait_name":"Blood metabolite ratios (X-12038/bradykinin, des-arg(9))","standard_trait_name":"/ Bradykinin"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":60.0,"otg_id":"GCST002443_9","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NAT2 encodes an N-acetyltransferase which can produce methylxanthine as a downstream metabolite of caffeine.","pubmed_id":"10744128"}],"gene_id":"ENSG00000156006","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":18272438},"locus_GRCh38":{"chromosome":"8","position":18414928},"rsid":"rs4921914"},"trait_info":{"ontology":["HMDB0010738"],"reported_trait_name":"Blood metabolite levels (1-methylxanthine)","standard_trait_name":"1-methylxanthine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":22.699,"otg_id":"GCST002443_71","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE).  12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE.","pubmed_id":"04215079"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE).  12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE.","pubmed_id":"02377602"}],"gene_id":"ENSG00000108839","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":6915401},"locus_GRCh38":{"chromosome":"17","position":7012082},"rsid":"rs2271316"},"trait_info":{"ontology":["HMDB0006111"],"reported_trait_name":"Blood metabolite levels (X-12441--12-hydroxyeicosatetraenoate (12-HETE))","standard_trait_name":"12-HETE"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":7.77,"otg_id":"GCST002443_2","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PEMT encodes the phosphatidylethanolamine N-methyltransferase which converts phosphatidylethanolamine to phosphatidylcholine.","pubmed_id":"09370326"}],"gene_id":"ENSG00000133027","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":17422768},"locus_GRCh38":{"chromosome":"17","position":17519454},"rsid":"rs748196"},"trait_info":{"ontology":["HMDB0061699"],"reported_trait_name":"1-arachidonoylglycerophosphocholine - M33228","standard_trait_name":"2-Arachidonoylglycerophosphocholine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.751,"otg_id":"GCST002443_99","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HAO2 encodes a 2-hydroxyacid oxidase which catalyzes the oxidation of L-alpha-hydroxy acids; alpha-hydroxyisovalerate or a related metabolite may be a potential substrate","pubmed_id":"10777549"}],"gene_id":"ENSG00000116882","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":119952776},"locus_GRCh38":{"chromosome":"1","position":119410153},"rsid":"rs12141041"},"trait_info":{"ontology":["HMDB0000407"],"reported_trait_name":"alpha-hydroxyisovalerate - M33937","standard_trait_name":"2-Hydroxy-3-methylbutyric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":30.0,"otg_id":"GCST002443_99","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LDHA encodes lactate dehydrogenase.  In addition to producing pyruvate from lactate, this enzyme can produce the observed metabolite from the keto acid 3-methyl-2-oxobutanoate","pubmed_id":"26014429"}],"gene_id":"ENSG00000134333","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":18325146},"locus_GRCh38":{"chromosome":"11","position":18303599},"rsid":"rs2403254"},"trait_info":{"ontology":["HMDB0000407"],"reported_trait_name":"Blood metabolite levels (alpha-hydroxyisovalerate)","standard_trait_name":"2-Hydroxy-3-methylbutyric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":10.155,"otg_id":"GCST002443_69","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"IDO1 and IDO2 encode the two indoleamine 2,3-dioxygenase isozymes.  Both enzymes take tryptophan and tryptophan-related metabolites as substrates, but IDO1 is more active [18282734].  IDO1 has known activity against 5-hydroxy-tryptophan [10833386].  Common polymorphisms in IDO2 ablate activity but have no effect on this endpoint [17671174]","pubmed_id":"10833386"}],"gene_id":"ENSG00000131203","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":39823145},"locus_GRCh38":{"chromosome":"8","position":39965626},"rsid":"rs2160860"},"trait_info":{"ontology":["HMDB0000472"],"reported_trait_name":"Blood metabolite levels (X-12100--hydroxytryptophan)","standard_trait_name":"5-Hydroxy-L-tryptophan"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":10.699,"otg_id":"GCST002443_49","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"UGT3A1 encodes a UDP glycosyltransferase.  This enzyme has demonstrated activity against the bile acid ursodeoxycholic acid.  The metabolite detected here is structurally related to the bile acids.","pubmed_id":"18981171"}],"gene_id":"ENSG00000145626","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":35968000},"locus_GRCh38":{"chromosome":"5","position":35967898},"rsid":"rs10491431"},"trait_info":{"ontology":["HMDB0094650"],"reported_trait_name":"Blood metabolite levels (X-11445--5-alpha-pregnan-3beta,20alpha-disulfate)","standard_trait_name":"5alpha-pregnan-3beta,20alpha-diol disulfate"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":37.398,"otg_id":"GCST002443_83","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ECI2 encodes the enoyl-CoA delta isomerase 2, which is known to act on octenoyl-CoA and could possibly act on decenoyl-CoA as well.","pubmed_id":"10419495"}],"gene_id":"ENSG00000198721","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":4146198},"locus_GRCh38":{"chromosome":"6","position":4145964},"rsid":"rs9392556"},"trait_info":{"ontology":["HMDB0013205"],"reported_trait_name":"Blood metabolite levels (X-13435, a 10:1 acylcarnitine)","standard_trait_name":"9-Decenoylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":20.097,"otg_id":"GCST002443_70","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GADL1 encodes the glutamate decarboxylase-like protein 1 which produces beta-alanine, a component of the dipeptide carnosine","pubmed_id":"23038267"}],"gene_id":"ENSG00000144644","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":30753573},"locus_GRCh38":{"chromosome":"3","position":30712081},"rsid":"rs6804368"},"trait_info":{"ontology":["HMDB0012881"],"reported_trait_name":"Blood metabolite levels (X-12244--N-acetylcarnosine)","standard_trait_name":"Acetylcarnosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":37.523,"otg_id":"GCST002443_100","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AKR1C4 encodes a 3 alpha-hydroxysteroid dehydrogenase (HSD) isoform, which is expressed in the liver and acts on androsterone.   The nearby paralogous gene AKR1C3 is expressed in prostate and mammary gland and the encoded enzyme does not act on androsterone. ","pubmed_id":"15026176"}],"gene_id":"ENSG00000198610","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":5256272},"locus_GRCh38":{"chromosome":"10","position":5214309},"rsid":"rs17134585"},"trait_info":{"ontology":["HMDB0002759","HMDB0062657"],"reported_trait_name":"Blood metabolite ratios (androsterone sulfate/epiandrosterone sulfate)","standard_trait_name":"Androsterone sulfate / Epiandrosterone Sulfate"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":360.699,"otg_id":"GCST002442_26","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FADS1 encodes a delta-5 desaturase, which converts dihomo-linolenate (20:3n6) to arachidonate (20:4n6).","pubmed_id":"10601301"}],"gene_id":"ENSG00000149485","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":61571348},"locus_GRCh38":{"chromosome":"11","position":61803876},"rsid":"rs174548"},"trait_info":{"ontology":["HMDB0060102","HMDB0002925"],"reported_trait_name":"Blood metabolite ratios (arachidonate (20:4n6)/dihomo-linolenate (20:3n3 or n6))","standard_trait_name":"Arachidonate / 8,11,14-Eicosatrienoic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":28.699,"otg_id":"GCST002442_26","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MBOAT7 encodes a lysophosphatidylinositol acyltransferase that has specificity for arachidonoyl-CoA as an acyl donor. Arachidonate is readily converted to arachidonoyl-CoA. Thus the associated ratio is closely linked to the substrate/product pair for this enzyme. The associated ratio is closely linked to the substrate/product pair for this enzyme.","pubmed_id":"18094042"}],"gene_id":"ENSG00000125505","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":54676433},"locus_GRCh38":{"chromosome":"19","position":54172738},"rsid":"rs2576452"},"trait_info":{"ontology":["HMDB0060102","HMDB0061690"],"reported_trait_name":"Blood metabolite ratios (arachidonate (20:4n6)/1-arachidonoylglycerophosphoinositol)","standard_trait_name":"Arachidonate|1-Arachidonoylglycerophosphoinositol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":37.0,"otg_id":"GCST002442_28","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACE encodes an angiotensin-converting enzyme.  This carboxypeptidase can generate aspartylphenylalanine from cholecystokinin-8.","pubmed_id":"02554881"}],"gene_id":"ENSG00000159640","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":61566031},"locus_GRCh38":{"chromosome":"17","position":63488670},"rsid":"rs4343"},"trait_info":{"ontology":["HMDB0000706"],"reported_trait_name":"Blood metabolite ratios (aspartylphenylalanine/X-14450--phenylalanylleucine)","standard_trait_name":"Aspartylphenylalanine / "}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":19.0,"otg_id":"GCST002443_104","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine.  Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine.","pubmed_id":"06746658"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine.  Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine.","pubmed_id":"18230605"}],"gene_id":"ENSG00000145692","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":78346769},"locus_GRCh38":{"chromosome":"5","position":79050946},"rsid":"rs16876394"},"trait_info":{"ontology":["HMDB0000043"],"reported_trait_name":"Blood metabolite levels (betaine)","standard_trait_name":"Betaine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.097,"otg_id":"GCST002443_104","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC6A12 encodes a sodium- and chloride-dependent betaine transporter.","pubmed_id":"08198549"}],"gene_id":"ENSG00000111181","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":320920},"locus_GRCh38":{"chromosome":"12","position":211754},"rsid":"rs499368"},"trait_info":{"ontology":["HMDB0000043"],"reported_trait_name":"Blood metabolite levels (betaine)","standard_trait_name":"Betaine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.222,"otg_id":"GCST002443_109","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"KNG1 includes the coding sequence for the bradykinin peptide.","pubmed_id":"02989293"}],"gene_id":"ENSG00000113889","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":186454180},"locus_GRCh38":{"chromosome":"3","position":186736391},"rsid":"rs5030062"},"trait_info":{"ontology":["HMDB0004246"],"reported_trait_name":"Blood metabolite levels (bradykinin, des-arg(9))","standard_trait_name":"Bradykinin"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":47.398,"otg_id":"GCST002443_109","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"KLKB1 encodes kallikrein, a serine protease which releases bradykinin from kininogen.","pubmed_id":"08662673"}],"gene_id":"ENSG00000164344","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":187174683},"locus_GRCh38":{"chromosome":"4","position":186253529},"rsid":"rs4253311"},"trait_info":{"ontology":["HMDB0004246"],"reported_trait_name":"Blood metabolite levels (bradykinin, des-arg(9))","standard_trait_name":"Bradykinin"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":629.523,"otg_id":"GCST002443_110","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACADS encodes the short chain acyl-CoA dehydrogenase which takes butyrl-CoA as a substrate.   Butyryl-CoA and butyrylcarnitine readily interconvert.  ","pubmed_id":"03597357"}],"gene_id":"ENSG00000122971","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":121160615},"locus_GRCh38":{"chromosome":"12","position":120722812},"rsid":"rs2066938"},"trait_info":{"ontology":["HMDB0002013"],"reported_trait_name":"Blood metabolite levels (butyrylcarnitine)","standard_trait_name":"Butyrylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":7.657,"otg_id":"GCST002443_25","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CFH encodes complement factor H which binds complement factor 3.  The detected analyte is a peptide fragment of complement factor 3.","pubmed_id":"06219696"}],"gene_id":"ENSG00000000971","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":196682346},"locus_GRCh38":{"chromosome":"1","position":196713216},"rsid":"rs7535263"},"trait_info":{"ontology":["EFO_0004983"],"reported_trait_name":"HWESASXX - M32836","standard_trait_name":"C3f, complement C3 derived peptide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.752,"otg_id":"GCST002443_25","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase.  HWESASXX, a peptide derived from C3 complement is a possible substrate.","pubmed_id":"07957888"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase.  HWESASXX, a peptide derived from C3 complement is a possible substrate.","pubmed_id":"09647737"}],"gene_id":"ENSG00000166825","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":90345335},"locus_GRCh38":{"chromosome":"15","position":89802104},"rsid":"rs2007084"},"trait_info":{"ontology":["EFO_0004983"],"reported_trait_name":"HWESASXX - M32836","standard_trait_name":"C3f, complement C3 derived peptide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":10.097,"otg_id":"GCST002443_115","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALDH18A1 encodes delta-1-pyrroline-5-carboxylate synthetase which catalyzes a step in the de novo production of ornithine which is subsequently converted to citrulline.  Mutations in ALDH18A1 cause hypocitrullinemia.","pubmed_id":"11092761"}],"gene_id":"ENSG00000059573","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":97395962},"locus_GRCh38":{"chromosome":"10","position":95636205},"rsid":"rs56322409"},"trait_info":{"ontology":["HMDB0000904"],"reported_trait_name":"Blood metabolite levels (citrulline)","standard_trait_name":"Citrulline"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":44.0,"otg_id":"GCST002442_17","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SRD5A2 encodes the type II steroid 5 alpha-reductase enzyme best known for converting testosterone to dihydrotestosterone.  The metabolites represented by the ratio detected here are also steroid molecules differing in reduction at carbon 5.  The enzyme has known activity against corticosterone.","pubmed_id":"07734398"}],"gene_id":"ENSG00000049319","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":31810974},"locus_GRCh38":{"chromosome":"2","position":31585905},"rsid":"rs559555"},"trait_info":{"ontology":["HMDB0010320"],"reported_trait_name":"Blood metabolite ratios (X-11444/X-12844) (X-11444 is tentatively identified by Metabolon as urocortisol glucuronide or cortolone glucuronide and X-12844 is tentatively identified as tetrahydrocortisone glucuronide)","standard_trait_name":"cortolone glucuronide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.699,"otg_id":"GCST002443_117","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GGT1 encodes gamma-glutamyltransferase 1 which catalyzes the transfer of the glutamyl moiety of glutathione to a number of different amino acids and can take the analyte reported here (the cysteine-glutathione mixed disulfide) as a substrate. ","pubmed_id":"06130452"}],"gene_id":"ENSG00000100031","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":25002081},"locus_GRCh38":{"chromosome":"22","position":24606114},"rsid":"rs2330809"},"trait_info":{"ontology":["HMDB0000656"],"reported_trait_name":"Blood metabolite levels (cysteine-glutathione disulfide)","standard_trait_name":"Cysteineglutathione disulfide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":37.061,"otg_id":"GCST002443_118","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ETFDH encodes a mitochondrial electron transfer flavoprotein dehydrogenase which is essential for electron transfer from the short-, medium- and long-chain acyl-CoA dehydrogenases.  Mutations in ETFDH lead to multiple acyl-CoA dehydrogenase deficiency, which is characterized by elevated short-, medium- and long-chain acyl carnitines.","pubmed_id":"17412732"}],"gene_id":"ENSG00000171503","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":159630817},"locus_GRCh38":{"chromosome":"4","position":158709665},"rsid":"rs8396"},"trait_info":{"ontology":["HMDB0000651"],"reported_trait_name":"decanoylcarnitine - M33941","standard_trait_name":"Decanoylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.699,"otg_id":"GCST002443_124","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AKR1A1 encodes an aldehyde reductase which can catalyze the production of erythritol","pubmed_id":"04402936"}],"gene_id":"ENSG00000117448","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":46990681},"locus_GRCh38":{"chromosome":"1","position":46525009},"rsid":"rs7542172"},"trait_info":{"ontology":["HMDB0002994"],"reported_trait_name":"Blood metabolite levels (erythritol)","standard_trait_name":"erythritol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":13.398,"otg_id":"GCST002442","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC27A2 encodes a very-long-chain acyl-CoA synthetase which activates fatty acids by forming their coenzyme A derivatives.","pubmed_id":"10198260"}],"gene_id":"ENSG00000140284","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":50477138},"locus_GRCh38":{"chromosome":"15","position":50184941},"rsid":"rs1365505"},"trait_info":{"ontology":["HMDB0034286"],"reported_trait_name":"Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438)","standard_trait_name":"Ethyl 10-undecenoate / "}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":36.046,"otg_id":"GCST002442_4","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ABO encodes a glycosyltransferase that determines the blood group.  ABO blood group contributes to von Willebrand Factor levels perhaps by protecting it from susceptibility to ADAMTS13-mediated proteolysis.  As part of the coagulation cascade, von Willebrand Factor effects rates of fibrinogen cleavage.","pubmed_id":"17894864"}],"gene_id":"ENSG00000175164","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":136154304},"locus_GRCh38":{"chromosome":"9","position":133278860},"rsid":"rs649129"},"trait_info":{"ontology":["EFO_0004623"],"reported_trait_name":"Blood metabolite ratios (ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR)","standard_trait_name":"Fibrinopeptide A"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":27.553,"otg_id":"GCST002443_128","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CPT2 encodes carnitine palmitoyltransferase II, which catalyzes the transfer of palmitate and related metabolites from carnitine to coenzyme A in the mitochondrial inner membrane.","pubmed_id":"09654057"}],"gene_id":"ENSG00000157184","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":53695882},"locus_GRCh38":{"chromosome":"1","position":53230210},"rsid":"rs13375749"},"trait_info":{"ontology":["HMDB13130"],"reported_trait_name":"Blood metabolite levels (glutaroyl carnitine)","standard_trait_name":"Glutarylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":44.222,"otg_id":"GCST002443_128","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GCDH encodes a glutaryl-CoA dehydrogenase which catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA.","pubmed_id":"03081514"}],"gene_id":"ENSG00000105607","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":13010520},"locus_GRCh38":{"chromosome":"19","position":12899706},"rsid":"rs8012"},"trait_info":{"ontology":["HMDB13130"],"reported_trait_name":"Blood metabolite levels (glutaroyl carnitine)","standard_trait_name":"Glutarylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":16.0,"otg_id":"GCST002443_135","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MCCC1 encodes methylcrotonoyl-CoA carboxylase 1 which catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in the breakdown of leucine.  An alternate fate of 3-methylcrotonyl-CoA is 3-hydroxyisovaleryl-CoA.  3-Methylcrotonyl-CoA carboxylase deficiency has been associated with elevated urinary 3-hydroxyisovalerylcarnitine levels.","pubmed_id":"19339287"}],"gene_id":"ENSG00000078070","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":182755209},"locus_GRCh38":{"chromosome":"3","position":183037421},"rsid":"rs2270968"},"trait_info":{"ontology":["HMDB0062555"],"reported_trait_name":"Blood metabolite levels (hydroxyisovaleroyl carnitine)","standard_trait_name":"hydroxyisovaleroyl carnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":15.699,"otg_id":"GCST002443_136","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GMPR encodes guanosine monophosphate reducatase which converts guanosine monophosphate to inosine monophosphate which can subsequently be converted to hypoxanthine by the enzyme purine-nucleoside phosphorylase.","pubmed_id":"00218932"}],"gene_id":"ENSG00000137198","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":16288192},"locus_GRCh38":{"chromosome":"6","position":16287961},"rsid":"rs6459467"},"trait_info":{"ontology":["HMDB0000157"],"reported_trait_name":"Blood metabolite levels (hypoxanthine)","standard_trait_name":"Hypoxanthine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":9.795,"otg_id":"GCST002443_137","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DDC encodes dopa decarboxylase which converts tryptophan to tryptamine, which can be further metabolized to indoleacetic acid.","pubmed_id":"13610897"}],"gene_id":"ENSG00000132437","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":50610379},"locus_GRCh38":{"chromosome":"7","position":50542681},"rsid":"rs7809234"},"trait_info":{"ontology":["HMDB0000197"],"reported_trait_name":"indoleacetate - M27513","standard_trait_name":"Indoleacetic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.0,"otg_id":"GCST002443_137","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CCBL1 encodes a kyneurenine aminotransferase, also known as hKAT-1, which can convert tryptophan to indolepyruvate.  Indolepyruvate is then converted to indolelactate. ","pubmed_id":"15606768"}],"gene_id":"ENSG00000171097","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":131572027},"locus_GRCh38":{"chromosome":"9","position":128809748},"rsid":"rs15676"},"trait_info":{"ontology":["HMDB0000671"],"reported_trait_name":"Blood metabolite levels (indolelactate)","standard_trait_name":"Indolelactic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":48.303,"otg_id":"GCST002443_140","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC22A1 encodes OCT1, an organic cation transporter with activity towards acylcarnitine.","pubmed_id":"28942964"}],"gene_id":"ENSG00000175003","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":160564476},"locus_GRCh38":{"chromosome":"6","position":160143444},"rsid":"rs662138"},"trait_info":{"ontology":["HMDB0062556"],"reported_trait_name":"isobutyrylcarnitine - M33441","standard_trait_name":"isobutyrylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.449,"otg_id":"GCST002443_140","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ETFA encodes a mitochondrial-specific electron transfer flavoprotein.  Enzyme deficiency results in urinary excretion of isobutyric acid and isobutyrylglycine; the urinary levels of these metabolites should reflect plasma levels of the analyte reported here, isobutyrylcarnitine.","pubmed_id":"07360517"}],"gene_id":"ENSG00000140374","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":77030792},"locus_GRCh38":{"chromosome":"15","position":76738451},"rsid":"rs2404602"},"trait_info":{"ontology":["HMDB0062556"],"reported_trait_name":"isobutyrylcarnitine - M33441","standard_trait_name":"isobutyrylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":7.343,"otg_id":"GCST002443_17","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SUCLA2 encodes a subunit of succinyl-CoA synthetase a key enzyme in the Krebs cycle.  SUCLA2 deficiency results in elevated urinary excretion of leucine degradation products downstream of the analyte detected here (specifically 3-hydroxyisovaleric acid and 3-methylglutaconic acid).","pubmed_id":"19666145"}],"gene_id":"ENSG00000136143","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"13","position":48459901},"locus_GRCh38":{"chromosome":"13","position":47885766},"rsid":"rs4941615"},"trait_info":{"ontology":["HMDB0000695"],"reported_trait_name":"4-methyl-2-oxopentanoate - M22116","standard_trait_name":"Ketoleucine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":171.699,"otg_id":"GCST002442_23","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACADM encodes an acyl-CoA dehydrogenase with a preference for medium chain length acyl-CoAs.  Acyl-CoAs are converted to acyl-carnitines for circulation which are then detected in the plasma.","pubmed_id":"03597357"}],"gene_id":"ENSG00000117054","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":76161889},"locus_GRCh38":{"chromosome":"1","position":75696204},"rsid":"rs4949874"},"trait_info":{"ontology":["HMDB0000201","HMDB0000705"],"reported_trait_name":"Blood metabolite ratios (acetylcarnitine/hexanoylcarnitine)","standard_trait_name":"L-Acetylcarnitine|Hexanoylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":8.831,"otg_id":"GCST002443_102","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ASRGL1 encodes an asparaginase which hydrolyzes asparagine to produce aspartate.","pubmed_id":"24768817"}],"gene_id":"ENSG00000162174","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":62176943},"locus_GRCh38":{"chromosome":"11","position":62409471},"rsid":"rs3017098"},"trait_info":{"ontology":["HMDB0000168"],"reported_trait_name":"asparagine - M34283","standard_trait_name":"L-Asparagine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":40.806,"otg_id":"GCST002443_102","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ASPG encodes an asparaginase homolog which which can hydrolyse asparagine to form aspartic acid","pubmed_id":"09575212"}],"gene_id":"ENSG00000166183","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"14","position":104608068},"locus_GRCh38":{"chromosome":"14","position":104141731},"rsid":"rs2011069"},"trait_info":{"ontology":["HMDB0000168"],"reported_trait_name":"asparagine - M34283","standard_trait_name":"L-Asparagine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":25.046,"otg_id":"GCST002443_142","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC7A5 encodes LAT1 which mediates tryptophan/kynurenine exchange.","pubmed_id":"17896864"}],"gene_id":"ENSG00000103257","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":87878822},"locus_GRCh38":{"chromosome":"16","position":87845216},"rsid":"rs8051149"},"trait_info":{"ontology":["HMDB0000684"],"reported_trait_name":"Blood metabolite levels (kynurenine)","standard_trait_name":"L-Kynurenine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":26.155,"otg_id":"GCST002443_161","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PHGDH encodes a phosphoglycerate dehydrogenase which catalyses the first and rate-limiting step in serine biosynthesis.","pubmed_id":"16589713"}],"gene_id":"ENSG00000092621","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":120209755},"locus_GRCh38":{"chromosome":"1","position":119667132},"rsid":"rs1163251"},"trait_info":{"ontology":["HMDB0000187"],"reported_trait_name":"Blood metabolite levels (serine)","standard_trait_name":"L-Serine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.046,"otg_id":"GCST002443_167","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TDO2 encodes tryptophan 2,3-dioxygenase which acts on tryptophan.","pubmed_id":"08666386"}],"gene_id":"ENSG00000151790","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156808288},"locus_GRCh38":{"chromosome":"4","position":155887136},"rsid":"rs13122250"},"trait_info":{"ontology":["HMDB0000929"],"reported_trait_name":"Blood metabolite levels (tryptophan)","standard_trait_name":"L-Tryptophan"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":50.523,"otg_id":"GCST002442_46","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC22A5 encodes the OCTN2 protein, which is the primary transporter reponsible for carnitine homeostasis.","pubmed_id":"20648231"}],"gene_id":"ENSG00000197375","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131665378},"locus_GRCh38":{"chromosome":"5","position":132329685},"rsid":"rs272889"},"trait_info":{"ontology":["HMDB0000883","HMDB0000688"],"reported_trait_name":"Blood metabolite ratios (valine/isovalerylcarnitine)","standard_trait_name":"L-Valine / Isovalerylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":37.398,"otg_id":"GCST002442_37","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"THEM4 is a broad range acyl-CoA thioesterase with a preference for medium and long chain acyl-CoAs. [19453107].  X-12442 has been identified as 5,8-tetradecadienoate.","pubmed_id":"19453107"}],"gene_id":"ENSG00000159445","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":151930645},"locus_GRCh38":{"chromosome":"1","position":151958169},"rsid":"rs6693388"},"trait_info":{"ontology":["HMDB0000673","HMDB0000560"],"reported_trait_name":"Blood metabolite ratios (linoleate (18:2n6)/X-12442--5,8-tetradecadienoate)","standard_trait_name":"Linoleic acid / 5,8-Tetradecadienoic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":13.097,"otg_id":"GCST002443_59","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FMO3 encodes a flavin containing monooxygenase which can act on S-allyl-cysteine and methionine. Methylcysteine is a plausible substrate.  This isozyme prefers smaller substrates and shows highest expression in liver.","pubmed_id":"18775983"}],"gene_id":"ENSG00000007933","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":171080615},"locus_GRCh38":{"chromosome":"1","position":171111474},"rsid":"rs7061710"},"trait_info":{"ontology":["HMDB0002108"],"reported_trait_name":"Blood metabolite levels (X-11786--methylcysteine)","standard_trait_name":"Methylcysteine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":13.301,"otg_id":"GCST002443_148","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ISYNA1 encodes an inositol-3-phosphate synthase, which converts d-glucose 6-phosphate to 1-d-myo-inositol 3-phosphate.","pubmed_id":"15024000"}],"gene_id":"ENSG00000105655","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":18618867},"locus_GRCh38":{"chromosome":"19","position":18508057},"rsid":"rs4808136"},"trait_info":{"ontology":["HMDB0000211"],"reported_trait_name":"Blood metabolite levels (myo-inositol)","standard_trait_name":"myo-Inositol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":115.0,"otg_id":"GCST002442_40","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SCD encodes a stearyl-CoA desaturase which acts on medium chain-length acyl-CoAs to bring about the delta 9 desaturation of various fatty acids, such as the conversion of myristate (14:0) to myristoleate (14:1n5).","pubmed_id":"00008453"}],"gene_id":"ENSG00000099194","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":102075479},"locus_GRCh38":{"chromosome":"10","position":100315722},"rsid":"rs603424"},"trait_info":{"ontology":["HMDB0000806","HMDB0002000"],"reported_trait_name":"Blood metabolite ratios (myristate (14:0)/myristoleate (14:1n5))","standard_trait_name":"Myristic acid / Myristoleic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":13.523,"otg_id":"GCST002443_31","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AOC1 encodes an amine oxidase which deaminates N1-acetylspermidine to produce N-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide (also known as acisoga).  ","pubmed_id":"12072962"}],"gene_id":"ENSG00000002726","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":150543721},"locus_GRCh38":{"chromosome":"7","position":150846633},"rsid":"rs1005390"},"trait_info":{"ontology":["HMDB0061384"],"reported_trait_name":"Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide)","standard_trait_name":"N-(3-acetamidopropyl)pyrrolidin-2-one"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":12.523,"otg_id":"GCST002443_32","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PAOX encodes an N1-acetylspermidine oxidase.  The detected analyte is a downstream metabolite of N1-acetylspermidine.  ","pubmed_id":"12660232"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PAOX encodes an N1-acetylspermidine oxidase.  The detected analyte is a downstream metabolite of N1-acetylspermidine.  ","pubmed_id":"03558558"}],"gene_id":"ENSG00000148832","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":135197336},"locus_GRCh38":{"chromosome":"10","position":133383832},"rsid":"rs11101730"},"trait_info":{"ontology":["HMDB0061384"],"reported_trait_name":"Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide)","standard_trait_name":"N-(3-acetamidopropyl)pyrrolidin-2-one"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":497.301,"otg_id":"GCST002442_10","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"NAT8 shows sequence similarity to N-acetyltransferases.  N-acetylornithine may be a product or related to a product.  Ornithine itself is part of the urea cycle and myoinositol levels are altered in patients with urea cycle disorders.","pubmed_id":"18662894"}],"gene_id":"ENSG00000144035","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":73868328},"locus_GRCh38":{"chromosome":"2","position":73641201},"rsid":"rs13538"},"trait_info":{"ontology":["HMDB0003357","HMDB0000211"],"reported_trait_name":"Blood metabolite ratios (N-acetylornithine/myo-inositol)","standard_trait_name":"N-Acetylornithine / myo-Inositol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":11.222,"otg_id":"GCST002443_68","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan.  The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation.","pubmed_id":"16807375"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan.  The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation.","pubmed_id":"12694300"}],"gene_id":"ENSG00000153086","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":135631400},"locus_GRCh38":{"chromosome":"2","position":134873830},"rsid":"rs6430553"},"trait_info":{"ontology":["HMDB0004194"],"reported_trait_name":"Blood metabolite levels (X-12095--N1-methyl-3-pyridone-4-carboxamide)","standard_trait_name":"N1-Methyl-4-pyridone-3-carboxamide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":134.0,"otg_id":"GCST002443_82","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACADL encodes Long-chain acyl-CoA dehydrogenase which has activity against a variety of medium and long chain acyl-CoAs .  Intracellular acyl-CoAs are converted to acyl-carnitines for circulation.","pubmed_id":"10832093"}],"gene_id":"ENSG00000115361","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":210874246},"locus_GRCh38":{"chromosome":"2","position":210009522},"rsid":"rs3738934"},"trait_info":{"ontology":["HMDB0013288"],"reported_trait_name":"Blood metabolite levels (X-13431--nonanoylcarnitine)","standard_trait_name":"Nonanoylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":177.301,"otg_id":"GCST002443_58","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"COMT encodes the catechol-O-methyltransferase which can methylate ascorbate to produce O-methylascorbate.","pubmed_id":"07129800"}],"gene_id":"ENSG00000093010","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":19951271},"locus_GRCh38":{"chromosome":"22","position":19963748},"rsid":"rs4680"},"trait_info":{"ontology":["HMDB0000044"],"reported_trait_name":"Blood metabolite levels (X-11593--O-methylascorbate)","standard_trait_name":"O-methylascorbate"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":17.155,"otg_id":"GCST002443_44","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ARSA encodes the arylsulfatase A, which can act on L-tyrosine O-sulfate.","pubmed_id":"00033715"}],"gene_id":"ENSG00000100299","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"22","position":51063477},"locus_GRCh38":{"chromosome":"22","position":50625049},"rsid":"rs6151429"},"trait_info":{"ontology":["HMDB0000158"],"reported_trait_name":"Blood metabolite levels (X-11423--O-sulfo-L-tyrosine)","standard_trait_name":"O-Sulfotyrosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":10.097,"otg_id":"GCST002443_154","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC5A6 encodes a solute transporter with demonstrated activity for pantothenate","pubmed_id":"09516450"}],"gene_id":"ENSG00000138074","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":27424636},"locus_GRCh38":{"chromosome":"2","position":27201768},"rsid":"rs1395"},"trait_info":{"ontology":["HMDB0000210"],"reported_trait_name":"Blood metabolite levels (pantothenate)","standard_trait_name":"Pantothenic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":23.523,"otg_id":"GCST002442_42","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GOT2 encodes the enzyme aspartate aminotransferase which can take each of the aromatic amino acids as substrates. In particular, GOT2 catalyzes the conversion of phenylalanine to phenylpyruvate which is then converted to phenyllactate.","pubmed_id":"04623131"}],"gene_id":"ENSG00000125166","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":58829790},"locus_GRCh38":{"chromosome":"16","position":58795886},"rsid":"rs12709013"},"trait_info":{"ontology":["HMDB0000779","HMDB0000159"],"reported_trait_name":"Blood metabolite ratios (phenyllactate (PLA)/phenylalanine)","standard_trait_name":"Phenyllactic acid / L-Phenylalanine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":22.046,"otg_id":"GCST002442_43","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TKT encodes transkelolase, an enzyme with a prefererence for D-erythrose 4-phosphate as a substrate.","pubmed_id":"09924800"}],"gene_id":"ENSG00000163931","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":53282188},"locus_GRCh38":{"chromosome":"3","position":53248172},"rsid":"rs4687717"},"trait_info":{"ontology":["HMDB0001429","HMDB0000613"],"reported_trait_name":"Blood metabolite ratios (phosphate/erythronate)","standard_trait_name":"Phosphate / Erythronic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":42.046,"otg_id":"GCST002442_44","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"IVD encodes isovaleryl-CoA dehydrogenase which acts on isovaleryl-CoA in the third step of leucine catabolism.  Isovaleryl-CoA is converted to isovalerylcarnitine for circulation.","pubmed_id":"03597357"}],"gene_id":"ENSG00000128928","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":40703211},"locus_GRCh38":{"chromosome":"15","position":40411012},"rsid":"rs9635324"},"trait_info":{"ontology":["HMDB0000824","HMDB0000688"],"reported_trait_name":"Blood metabolite ratios (propionylcarnitine/isovalerylcarnitine)","standard_trait_name":"Propionylcarnitine / Isovalerylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":109.222,"otg_id":"GCST002443_22","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"OPLAH encodes 5-oxoprolinase which catalyzes the ATP-dependent hydrolysis of 5-oxoproline to glutamic acid","pubmed_id":"09233839"}],"gene_id":"ENSG00000178814","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":145155408},"locus_GRCh38":{"chromosome":"8","position":144100505},"rsid":"rs12550729"},"trait_info":{"ontology":["HMDB0000267"],"reported_trait_name":"Blood metabolite levels (5-oxoproline)","standard_trait_name":"Pyroglutamic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":190.523,"otg_id":"GCST002442_15","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SULT2A1 encodes a bile salt sulfotransferase which can catalyze the sulfation of steroids and bile acids.","pubmed_id":"08575776"}],"gene_id":"ENSG00000105398","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":48385057},"locus_GRCh38":{"chromosome":"19","position":47881800},"rsid":"rs2547231"},"trait_info":{"ontology":["HMDB03818"],"reported_trait_name":"Blood metabolite ratios (X-11440/4-androsten-3beta,17beta-diol disulfate 2)","standard_trait_name":"similar to 5-Androstenediol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":10.155,"otg_id":"GCST002443_164","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SUCLG2 encodes the beta subunit of succinate-CoA ligase which acts on succinate-CoA.  Acyl-CoAs and acyl-carnitines are readily interconverted.","pubmed_id":"18392745"}],"gene_id":"ENSG00000172340","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":67416322},"locus_GRCh38":{"chromosome":"3","position":67365898},"rsid":"rs17806888"},"trait_info":{"ontology":["HMDB0061717"],"reported_trait_name":"Blood metabolite levels (succinylcarnitine)","standard_trait_name":"Succinylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":85.097,"otg_id":"GCST002442","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP4A11 encodes a fatty acid omega-hydroxylase.  X-11438 may be a hydroxylated tridecenoic acid (C13:1(OH)) so may represent a product.","pubmed_id":"10860550"}],"gene_id":"ENSG00000187048","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":47331966},"locus_GRCh38":{"chromosome":"1","position":46866294},"rsid":"rs6678639"},"trait_info":{"ontology":["HMDB33724","HMDB0035881"],"reported_trait_name":"Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438)","standard_trait_name":"Undecylenic acid / 11-Hydroxy-9-tridecenoic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":7.467,"otg_id":"GCST002443_170","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CDA encodes cytidine deaminase which deaminates cytidine, producing uridine.","pubmed_id":"08422236"}],"gene_id":"ENSG00000158825","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":20915172},"locus_GRCh38":{"chromosome":"1","position":20588679},"rsid":"rs532545"},"trait_info":{"ontology":["HMDB0000296"],"reported_trait_name":"uridine - M00606","standard_trait_name":"Uridine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":7.724,"otg_id":"GCST002443_170","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"UPP1 encodes uridine phosphorylase which catalyzes the interconversion of uridine and uracil.","pubmed_id":"07488099"}],"gene_id":"ENSG00000183696","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":48102911},"locus_GRCh38":{"chromosome":"7","position":48063314},"rsid":"rs2686796"},"trait_info":{"ontology":["HMDB0000296"],"reported_trait_name":"uridine - M00606","standard_trait_name":"Uridine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002443","neg_log_pval":15.398,"otg_id":"GCST002443_170","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TYMP encodes thymidine phosphorylase, which catalyzes the phosphorolysis of thymidine and deoxyuridine.   These pyrimidines are metabolically linked to uridine.","pubmed_id":"07284378"}],"gene_id":"ENSG00000025708","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":50971752},"locus_GRCh38":{"chromosome":"22","position":50533323},"rsid":"rs131794"},"trait_info":{"ontology":["HMDB0000296"],"reported_trait_name":"Blood metabolite levels (uridine)","standard_trait_name":"Uridine"}}
{"association_info":{"ancestry":["AFR","EUR"],"gwas_catalog_id":"GCST002559","neg_log_pval":12.699,"otg_id":"GCST002559_2","pubmed_id":"25147783"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CUBN encodes cubilin, a protein involved in the uptake of vitamin B12 (cobalamin).  CUBN deficiency results in reduced levels of cobalamin.","pubmed_id":"09478979"}],"gene_id":"ENSG00000107611","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":17156151},"locus_GRCh38":{"chromosome":"10","position":17114152},"rsid":"rs1801222"},"trait_info":{"ontology":["HMDB0002174"],"reported_trait_name":"Vitamin B levels in ischemic stroke (Vitamin B12)","standard_trait_name":"Cobalamin"}}
{"association_info":{"ancestry":["EAS"],"gwas_catalog_id":"GCST002586","neg_log_pval":11.719,"otg_id":"GCST002586","pubmed_id":"25187374"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FOXA2 encodes a transcription factor that impacts the expression of many genes (i.e., GCK, SLC2A2) previously related to the glucose levels.","pubmed_id":"11875061"}],"gene_id":"ENSG00000125798","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":22581268},"locus_GRCh38":{"chromosome":"20","position":22600630},"rsid":"rs6048216"},"trait_info":{"ontology":["HMDB0000122"],"reported_trait_name":"Fasting plasma glucose (East Asian)","standard_trait_name":"D-Glucose"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002623","neg_log_pval":18.398,"otg_id":"GCST002623","pubmed_id":"25245031"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ARG1 encodes an arginase which hydrolyzes arginine.  Enzyme deficiency causes argininemia.","pubmed_id":"03540966"}],"gene_id":"ENSG00000118520","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":131924689},"locus_GRCh38":{"chromosome":"6","position":131603549},"rsid":"rs2248551"},"trait_info":{"ontology":["HMDB0000517"],"reported_trait_name":"L-arginine levels","standard_trait_name":"L-Arginine"}}
{"association_info":{"ancestry":["AMR","ASW","EUR","JPT","ZZ2"],"gwas_catalog_id":"GCST002652","neg_log_pval":154.699,"otg_id":"GCST002652","pubmed_id":"25293881"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"UGT2B10 encodes a UDP glucuronosyltransferase which glucuronidates cotinine to produce cotinine glucuronide","pubmed_id":"17576790"}],"gene_id":"ENSG00000109181","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":69673553},"locus_GRCh38":{"chromosome":"4","position":68807835},"rsid":"rs34100980"},"trait_info":{"ontology":["HMDB0001013"],"reported_trait_name":"Cotinine glucuronidation","standard_trait_name":"Cotinine glucuronide"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002679","neg_log_pval":19.177,"otg_id":"GCST002679","pubmed_id":"25352340"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TF encodes transferrin, a key transporter for iron.","pubmed_id":"01809186"}],"gene_id":"ENSG00000091513","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":133477701},"locus_GRCh38":{"chromosome":"3","position":133758857},"rsid":"rs8177240"},"trait_info":{"ontology":["HMDB0015531"],"reported_trait_name":"Iron|serum","standard_trait_name":"Iron"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002679","neg_log_pval":96.565,"otg_id":"GCST002679","pubmed_id":"25352340"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HFE encodes the hereditary hemochromatosis protein which binds transferrin receptor which binds transferrin which binds iron","pubmed_id":"09465039"}],"gene_id":"ENSG00000010704","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":26093141},"locus_GRCh38":{"chromosome":"6","position":26092913},"rsid":"rs1800562"},"trait_info":{"ontology":["HMDB0015531"],"reported_trait_name":"Iron|serum","standard_trait_name":"Iron"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002679","neg_log_pval":18.0,"otg_id":"GCST002679","pubmed_id":"25352340"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TFR2 encodes a receptor for transferrin which binds iron","pubmed_id":"10409623"}],"gene_id":"ENSG00000106327","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":100235970},"locus_GRCh38":{"chromosome":"7","position":100638347},"rsid":"rs7385804"},"trait_info":{"ontology":["HMDB0015531"],"reported_trait_name":"Iron status biomarkers (iron levels)","standard_trait_name":"Iron"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002679","neg_log_pval":139.0,"otg_id":"GCST002679","pubmed_id":"25352340"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TMPRSS6 encodes a protease which regulates levels of hepcidin which regulates iron levels","pubmed_id":"25588876"}],"gene_id":"ENSG00000187045","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":37462936},"locus_GRCh38":{"chromosome":"22","position":37066896},"rsid":"rs855791"},"trait_info":{"ontology":["HMDB0015531"],"reported_trait_name":"Iron status biomarkers (iron levels)","standard_trait_name":"Iron"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002690","neg_log_pval":39.577,"otg_id":"GCST002690","pubmed_id":"25378659"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CERS4 encodes a ceramide synthase which produces ceramides from sphingosine and a long chain acyl CoA, derived from long chain free fatty acids.","pubmed_id":"12912983"}],"gene_id":"ENSG00000090661","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":8281635},"locus_GRCh38":{"chromosome":"19","position":8216751},"rsid":"rs2100944"},"trait_info":{"ontology":["HMDB0002212"],"reported_trait_name":"FA 20:0|plasma","standard_trait_name":"Arachidic acid"}}
{"association_info":{"ancestry":["unknown"],"gwas_catalog_id":"GCST002712","neg_log_pval":48.523,"otg_id":"GCST002712_9","pubmed_id":"25500335"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LPCAT3 encodes a lysophosphatidylcholine acyltransferase which takes the CoA version of oleic acid to convert lysophosphatidylcholine to phosphatidylcholine.","pubmed_id":"18781350"}],"gene_id":"ENSG00000111684","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":7075882},"locus_GRCh38":{"chromosome":"12","position":6966719},"rsid":"rs2110073"},"trait_info":{"ontology":["HMDB0000207"],"reported_trait_name":"Red blood cell fatty acid levels (OA)","standard_trait_name":"Oleic Acid"}}
{"association_info":{"ancestry":["unknown"],"gwas_catalog_id":"GCST002831","neg_log_pval":13.398,"otg_id":"GCST002831","pubmed_id":"25820613"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALAD encodes aminolevulinate dehydratase, an enzyme which binds to lead.","pubmed_id":"01713045"}],"gene_id":"ENSG00000148218","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":116151191},"locus_GRCh38":{"chromosome":"9","position":113388911},"rsid":"rs1805313"},"trait_info":{"ontology":["HMDB0004628"],"reported_trait_name":"Lead levels in blood","standard_trait_name":"Lead"}}
{"association_info":{"ancestry":["unknown"],"gwas_catalog_id":"GCST002932","neg_log_pval":13.658,"otg_id":"GCST002932","pubmed_id":"26025379"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC30A10 encodes a transporter with specificity for manganese.","pubmed_id":"25319704"}],"gene_id":"ENSG00000196660","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":220080028},"locus_GRCh38":{"chromosome":"1","position":219906686},"rsid":"rs1776029"},"trait_info":{"ontology":["HMDB0001333"],"reported_trait_name":"Manganese|plasma","standard_trait_name":"Manganese"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002964","neg_log_pval":31.699,"otg_id":"GCST002964_2","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SPTLC3 encodes a subunit of serine palmitoyltransferase, which catalyzes the first step in de novo sphingolipid biosynthesis.","pubmed_id":"17023427"}],"gene_id":"ENSG00000172296","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":12959398},"locus_GRCh38":{"chromosome":"20","position":12978750},"rsid":"rs4814176"},"trait_info":{"ontology":["HMDB0013469"],"reported_trait_name":"Sphingolipid levels (Hydroxysphingomyeline C24:1)","standard_trait_name":"Hydroxysphingomyeline C24:1"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002961","neg_log_pval":80.82,"otg_id":"GCST002961_2","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC16A9 encodes a carnitine efflux transporter.","pubmed_id":"21886157"}],"gene_id":"ENSG00000165449","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":61469538},"locus_GRCh38":{"chromosome":"10","position":59709780},"rsid":"rs1171614"},"trait_info":{"ontology":["HMDB0000062"],"reported_trait_name":"C0","standard_trait_name":"L-Carnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":58.523,"otg_id":"GCST002966_4","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PRODH encodes proline dehydrogenase which catalyzes the first step in proline degradation","pubmed_id":"16874462"}],"gene_id":"ENSG00000100033","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":18959684},"locus_GRCh38":{"chromosome":"22","position":18972171},"rsid":"rs2540641"},"trait_info":{"ontology":["HMDB0000162"],"reported_trait_name":"Blood metabolite levels (proline)","standard_trait_name":"L-Proline"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":17.353,"otg_id":"GCST002966_5","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PSPH encodes phosphoserine phosphatase which produces serine","pubmed_id":"16589713"}],"gene_id":"ENSG00000146733","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":56079094},"locus_GRCh38":{"chromosome":"7","position":56011401},"rsid":"rs4947534"},"trait_info":{"ontology":["HMDB0000187"],"reported_trait_name":"Ser","standard_trait_name":"L-Serine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":12.552,"otg_id":"GCST002965_33","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MFSD2A encodes a lysophosphotidylcholine transporter.","pubmed_id":"24828044"}],"gene_id":"ENSG00000168389","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":40403370},"locus_GRCh38":{"chromosome":"1","position":39937698},"rsid":"rs7529794"},"trait_info":{"ontology":["HMDB0010382"],"reported_trait_name":"lysoPC a C16:0","standard_trait_name":"LysoPC(16:0)"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":9.39,"otg_id":"GCST002965_13","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGPS encodes the alkylglycerone phosphate synthase which generates ether phospholipids such as the metabolite detected here.","pubmed_id":"10215861"}],"gene_id":"ENSG00000018510","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":178370631},"locus_GRCh38":{"chromosome":"2","position":177505903},"rsid":"rs7582179"},"trait_info":{"ontology":["HMDB0013456"],"reported_trait_name":"PC ae C44:5","standard_trait_name":"PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":10.475,"otg_id":"GCST002965_13","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ACSL1 encodes a long-chain fatty-acid-coenzyme A ligase which produces acyl-CoAs.  These in turn can be used in the synthesis of plasmalogens, e.g., via LPCAT4","pubmed_id":"08584017"}],"gene_id":"ENSG00000151726","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":185773811},"locus_GRCh38":{"chromosome":"4","position":184852657},"rsid":"rs7700133"},"trait_info":{"ontology":["HMDB0013456"],"reported_trait_name":"PC ae C44:5","standard_trait_name":"PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST002966","neg_log_pval":10.419,"otg_id":"GCST002965_2","pubmed_id":"26068415"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ABHD3 encodes a phospholipase with demonstrated activity against PC(32:2), specifically the PC(14:0/18:2) stereoisomer.","pubmed_id":"21926997"}],"gene_id":"ENSG00000158201","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":19263128},"locus_GRCh38":{"chromosome":"18","position":21683167},"rsid":"rs7343008"},"trait_info":{"ontology":["HMDB0007874"],"reported_trait_name":"PC aa C32:2","standard_trait_name":"Phosphatidyl choline PC(14:0/18:2(9Z,12Z)) is a specific example  "}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":251.625,"otg_id":"GCST003119_11","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate.","pubmed_id":"08427875"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate.","pubmed_id":"05773299"}],"gene_id":"ENSG00000113492","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":35037115},"locus_GRCh38":{"chromosome":"5","position":35037010},"rsid":"rs37369"},"trait_info":{"ontology":["HMDB0003911"],"reported_trait_name":"3-aminoisobutyrate|urine","standard_trait_name":"3-Aminoisobutanoic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":17.159,"pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AGXT encodes alanine-glyoxylate aminotransferase.  When acting on valine, rather than alanine, as a substrate, the enzyme will produce alpha-ketoisovaleric acid as a product (see EC code EC 2.6.1.66).  The mouse and rat orthologs have demonstrated activity on valine.","pubmed_id":"00629740"}],"gene_id":"ENSG00000172482","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":241837452},"locus_GRCh38":{"chromosome":"2","position":240898035},"rsid":"rs6748734"},"trait_info":{"ontology":["HMDB0000019"],"reported_trait_name":"alpha-ketoisovalerate|urine","standard_trait_name":"alpha-Ketoisovaleric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":59.074,"otg_id":"GCST003119_14","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC6A20 encodes a transporter for N-methylglycine, proline and other specific amino acids.","pubmed_id":"15632147"}],"gene_id":"ENSG00000163817","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":45814094},"locus_GRCh38":{"chromosome":"3","position":45772602},"rsid":"rs17279437"},"trait_info":{"ontology":["HMDB0000092","HMDB0000161"],"reported_trait_name":"N,N-dimethylglycine/alanine|urine","standard_trait_name":"Dimethylglycine / L-Alanine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":27.146,"pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ETNPPL encodes the ethanolamine-phosphate phospho-lyase which acts on the phosphorylated form of ethanolamine.  AGXT2L1 is a common synonym for this gene.","pubmed_id":"22241472"}],"gene_id":"ENSG00000164089","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":109705967},"locus_GRCh38":{"chromosome":"4","position":108784811},"rsid":"rs56043887"},"trait_info":{"ontology":["HMDB0000149"],"reported_trait_name":"ethanolamine|urine","standard_trait_name":"Ethanolamine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":14.68,"otg_id":"GCST003119_16","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC36A2 encodes the a proton-coupled amino acid transporter, which is specific for glycine and proline.","pubmed_id":"19033659"}],"gene_id":"ENSG00000186335","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":150698806},"locus_GRCh38":{"chromosome":"5","position":151319245},"rsid":"rs3846710"},"trait_info":{"ontology":["HMDB0000123","HMDB0000094"],"reported_trait_name":"glycine/citrate|urine","standard_trait_name":"Glycine / Citric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":13.53,"otg_id":"GCST003119_17","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"XYLB encodes a xylulokinase homolog which phosphorylates D-xylulose, a precursor of glycolate","pubmed_id":"09783918"}],"gene_id":"ENSG00000093217","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38395562},"locus_GRCh38":{"chromosome":"3","position":38354071},"rsid":"rs3132440"},"trait_info":{"ontology":["HMDB0000115"],"reported_trait_name":"glycolate|urine","standard_trait_name":"Glycolic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":261.126,"otg_id":"GCST002443_168","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine.  The nearby paralog, SLC6A18, is specific for glycine.","pubmed_id":"15044460"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine.  The nearby paralog, SLC6A18, is specific for glycine.","pubmed_id":"15804236"}],"gene_id":"ENSG00000174358","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1183560},"locus_GRCh38":{"chromosome":"5","position":1183445},"rsid":"rs11750211"},"trait_info":{"ontology":["HMDB0000158"],"reported_trait_name":"tyrosine|urine","standard_trait_name":"L-Tyrosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":65.034,"otg_id":"GCST002443_148","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC5A11 encodes a sodium/myo-inositol transporter (SMIT2) which can also transport scyllo-inostiol.","pubmed_id":"21887366"}],"gene_id":"ENSG00000158865","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":25002600},"locus_GRCh38":{"chromosome":"16","position":24991279},"rsid":"rs17702912"},"trait_info":{"ontology":["HMDB0000211"],"reported_trait_name":"myo-inositol|urine","standard_trait_name":"myo-Inositol"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003119","neg_log_pval":15.845,"otg_id":"GCST003666_3","pubmed_id":"26352407"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC13A3 encodes a high affinity succinate transporter enriched in kidney tissue.","pubmed_id":"10794676"}],"gene_id":"ENSG00000158296","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":45261041},"locus_GRCh38":{"chromosome":"20","position":46632402},"rsid":"rs941206"},"trait_info":{"ontology":["HMDB0000254","HMDB0000094"],"reported_trait_name":"sucinate/citrate|urine","standard_trait_name":"Succinic acid / Citric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST006879","neg_log_pval":36.131,"otg_id":"GCST006879_4","pubmed_id":"26401656"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC22A16 encodes transporter specific for carnitine","pubmed_id":"12089149"}],"gene_id":"ENSG00000004809","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":110760008},"locus_GRCh38":{"chromosome":"6","position":110438805},"rsid":"rs12210538"},"trait_info":{"ontology":["EFO_0005059 "],"reported_trait_name":"total acylcarnitine","standard_trait_name":"acylcarnitine measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST006879","neg_log_pval":11.622,"otg_id":"GCST006879_5","pubmed_id":"26401656"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GPT encodes alanine aminotransferase which takes alanine as a substrate and produces glutamate which is one step removed from aspartate.","pubmed_id":"09119391"}],"gene_id":"ENSG00000167701","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":145701453},"locus_GRCh38":{"chromosome":"8","position":144476070},"rsid":"rs750472"},"trait_info":{"ontology":["HMDB0000161","HMDB0000168"],"reported_trait_name":"metabolite ratio (Ala/Asp)","standard_trait_name":"L-Alanine / L-Asparagine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST006879","neg_log_pval":82.375,"otg_id":"GCST006879_17","pubmed_id":"26401656"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CRAT encodes carnitine O-acetyltransferase, which catalyzes the interconversion of short chain acylcarnitines and acyl-coenzyme A derivatives. ","pubmed_id":"02351134"}],"gene_id":"ENSG00000095321","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":131865027},"locus_GRCh38":{"chromosome":"9","position":129102748},"rsid":"rs746872"},"trait_info":{"ontology":["HMDB0013133"],"reported_trait_name":"Methylmalonylcarnitine","standard_trait_name":"Methylmalonylcarnitine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST006879","neg_log_pval":7.269,"otg_id":"GCST006879_2","pubmed_id":"26401656"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HLCS encodes a biotin apo-protein ligase which attaches biotin to four biotin-dependent enymes, including enzymes involved in branched chain amino acid catabolism.  Holocarboxylase synthetase deficiency results in increased levels of 3-Hydroxyisovalerylcarnitine.","pubmed_id":"19201116"}],"gene_id":"ENSG00000159267","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"21","position":38336834},"locus_GRCh38":{"chromosome":"21","position":36964534},"rsid":"rs1571700"},"trait_info":{"ontology":["HMDB0061189"],"reported_trait_name":"2-Hydroxyisovalerylcarnitine","standard_trait_name":"Similar to 3-Hydroxyisovalerylcarnitine"}}
{"association_info":{"ancestry":["FIN"],"neg_log_pval":85.239,"pubmed_id":"26407342"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CYP2A6 encodes a cytochrome P450 which is the primary enzyme responsible for the conversion of nicotine to cotinine.","pubmed_id":"08937855"}],"gene_id":"ENSG00000255974","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":41353107},"locus_GRCh38":{"chromosome":"19","position":40847202},"rsid":"rs56113850"},"trait_info":{"ontology":["HMDB0001390","HMDB0001046"],"reported_trait_name":"Nicotine Metabolite Ratio","standard_trait_name":"ratio of Hydroxycotinine to Cotinine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":17.319,"otg_id":"GCST003666_3","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC13A5 encodes NaCT, a sodium-coupled citrate transporter.","pubmed_id":"16973915"}],"gene_id":"ENSG00000141485","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":6595398},"locus_GRCh38":{"chromosome":"17","position":6692079},"rsid":"rs172642"},"trait_info":{"ontology":["HMDB0000094"],"reported_trait_name":"Citrate","standard_trait_name":"Citric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":21.886,"otg_id":"GCST003666_3","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC25A1 encodes the mitochondrial-localized tricarboxylate transporter of citrate.","pubmed_id":"02804096"}],"gene_id":"ENSG00000100075","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":19161935},"locus_GRCh38":{"chromosome":"22","position":19174422},"rsid":"rs2040771"},"trait_info":{"ontology":["HMDB0000094"],"reported_trait_name":"Citrate","standard_trait_name":"Citric acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":300.0,"otg_id":"GCST003666_7","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CPS1 encodes a mitochondrial carbamoyl phosphate synthetase which takes ammonia as a substrate.   Glycine and ammonia are interconverted via the glycine cleavage complex.","pubmed_id":"18941301"}],"gene_id":"ENSG00000021826","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":211540507},"locus_GRCh38":{"chromosome":"2","position":210675783},"rsid":"rs1047891"},"trait_info":{"ontology":["HMDB0000123"],"reported_trait_name":"Glycine","standard_trait_name":"Glycine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":39.432,"otg_id":"GCST003666_7","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GLDC encodes glycine dehydrogenase which takes glycine as a substrate.  GLDC deficiency causes excess of glycine.","pubmed_id":"04585091"}],"gene_id":"ENSG00000178445","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"TA","reference":"T"},"locus_GRCh37":{"chromosome":"9","position":5877295},"locus_GRCh38":{"chromosome":"9","position":5877295},"rsid":"rs140348140"},"trait_info":{"ontology":["HMDB0000123"],"reported_trait_name":"Glycine","standard_trait_name":"Glycine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":12.523,"otg_id":"GCST003666_7","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GCSH encodes the glycine cleavage system H protein which is involved in the degradation of glycine.  GCSH deficiency leads to excess plasma glycine.","pubmed_id":"18941301"}],"gene_id":"ENSG00000140905","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":81065282},"locus_GRCh38":{"chromosome":"16","position":81031677},"rsid":"rs10083777"},"trait_info":{"ontology":["HMDB0000123"],"reported_trait_name":"Glycine","standard_trait_name":"Glycine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003665","neg_log_pval":10.495,"otg_id":"GCST003665_10","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"APOA2 encodes apolipoprotein A-II, a major component of HDL particles","pubmed_id":"24089247"}],"gene_id":"ENSG00000158874","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":161190250},"locus_GRCh38":{"chromosome":"1","position":161220460},"rsid":"rs4503368"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"XL.HDL.PL","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003665","neg_log_pval":54.585,"otg_id":"GCST003665","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PLTP encodes phospholipid transfer protein which acts directly on HDL particles.","pubmed_id":"08664337"}],"gene_id":"ENSG00000100979","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44551855},"locus_GRCh38":{"chromosome":"20","position":45923216},"rsid":"rs6073958"},"trait_info":{"ontology":["EFO_0004612"],"reported_trait_name":"S.HDL.P","standard_trait_name":"high density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":12.215,"otg_id":"GCST003666","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine.","pubmed_id":"11342143"},{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine.","pubmed_id":"11118514"}],"gene_id":"ENSG00000139209","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":47201814},"locus_GRCh38":{"chromosome":"12","position":46808031},"rsid":"rs4554975"},"trait_info":{"ontology":["HMDB0000161"],"reported_trait_name":"Alanine","standard_trait_name":"L-Alanine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":69.481,"otg_id":"GCST003666_6","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GLS2 encodes the mitochondrial phosphate-activated glutaminase which catalyzes the hydrolysis of glutamine to glutamate and ammonia.","pubmed_id":"10620514"}],"gene_id":"ENSG00000135423","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56865338},"locus_GRCh38":{"chromosome":"12","position":56471554},"rsid":"rs2657879"},"trait_info":{"ontology":["HMDB0000641"],"reported_trait_name":"Glutamine","standard_trait_name":"L-Glutamine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":14.137,"otg_id":"GCST003666_10","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HAL encodes histidine ammonia-lyase which catalyzes the first step in the degradation of histidine to glutamate.","pubmed_id":"13018112"}],"gene_id":"ENSG00000084110","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":96314795},"locus_GRCh38":{"chromosome":"12","position":95921017},"rsid":"rs7954638"},"trait_info":{"ontology":["HMDB0000177"],"reported_trait_name":"Metabolite levels (small molecules and protein measures) (Histidine)","standard_trait_name":"L-Histidine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":14.602,"otg_id":"GCST003666_11","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PAH encodes the enzyme phenylalanine hydroxylase which is the rate-limiting step in phenylalanine catabolism.","pubmed_id":"04150152"}],"gene_id":"ENSG00000171759","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":103242396},"locus_GRCh38":{"chromosome":"12","position":102848618},"rsid":"rs1718309"},"trait_info":{"ontology":["HMDB0000159"],"reported_trait_name":"Phenylalanine","standard_trait_name":"L-Phenylalanine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":23.854,"otg_id":"GCST003666_13","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC16A10 encodes the T?type amino acid transporter?1 (TAT1); this transporter transports tryptophan, tyrosine and phenylalanine","pubmed_id":"11827462"}],"gene_id":"ENSG00000112394","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":111543944},"locus_GRCh38":{"chromosome":"6","position":111222741},"rsid":"rs14399"},"trait_info":{"ontology":["HMDB0000158"],"reported_trait_name":"Tyrosine","standard_trait_name":"L-Tyrosine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":34.77,"otg_id":"GCST003666_15","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PPM1K encodes a phosphatase called PP2Cm for the branched-chain keto acid dehydrogenase (BCKD) complex.  BCKD catalyzes an essential step in the catabolism of valine and the other branched chain amino acids.","pubmed_id":"19411760"}],"gene_id":"ENSG00000163644","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":89206230},"locus_GRCh38":{"chromosome":"4","position":88285078},"rsid":"rs9637599"},"trait_info":{"ontology":["HMDB0000883"],"reported_trait_name":"Valine","standard_trait_name":"L-Valine"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003666","neg_log_pval":10.678,"otg_id":"GCST003666_12","pubmed_id":"27005778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PDPR encodes a component of the pyruvate dehydrogenase complex (PDC) which converts pyruvate into acetyl-CoA.","pubmed_id":"09395502"}],"gene_id":"ENSG00000090857","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":69979271},"locus_GRCh38":{"chromosome":"16","position":69945368},"rsid":"rs74249229"},"trait_info":{"ontology":["HMDB0000243"],"reported_trait_name":"Pyruvate","standard_trait_name":"Pyruvic acid"}}
{"association_info":{"ancestry":["EUR"],"gwas_catalog_id":"GCST003665","neg_log_pval":99.866,"otg_id":"GCST003217","pubmed_id":"28334899"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MLXIPL encodes the carbohydrate-responsive element-binding protein, a transcription factor for multiple lipogenic enzymes.","pubmed_id":"16890538"}],"gene_id":"ENSG00000009950","highest_confidence":"High"},"metadata":{"date_added":"2019-05-17","reviewed_by":"Ed Mountjoy","set_label":"ProGeM","submitted_by":"Eric Fauman","tags":["metabolite","mQTL"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":72863249},"locus_GRCh38":{"chromosome":"7","position":73448919},"rsid":"rs17145738"},"trait_info":{"ontology":["EFO_0004530"],"reported_trait_name":"Triglycerides","standard_trait_name":"triglyceride measurement"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":10.221848749616356,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000171608 at this locus (355116bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171608","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":9356676},"locus_GRCh38":{"chromosome":"1","position":9296617}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European, Other=1157"],"gwas_catalog_id":"GCST001476","neg_log_pval":7.301029995663981,"otg_id":"GCST001476_7","pubmed_id":"22491018"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000171608 at this locus (302833bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171608","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":9408959},"locus_GRCh38":{"chromosome":"1","position":9348900}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Response to tocilizumab in rheumatoid arthritis [CSJC , EA, RF-]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=488","African American or Afro-Caribbean=111","Hispanic or Latin American=60","Other=56"],"gwas_catalog_id":"GCST004250","neg_log_pval":8.0,"otg_id":"GCST004250_2","pubmed_id":"28090653"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"CAMPATH-1 antigen inhibitor drug ALEMTUZUMAB is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000169442 at this locus (491379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169442","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":27138393},"locus_GRCh38":{"chromosome":"1","position":26811902}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) [AA]","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":8.522878745280337,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (419487bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":44037685},"locus_GRCh38":{"chromosome":"1","position":43572014}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":12.0,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":44097530},"locus_GRCh38":{"chromosome":"1","position":43631859}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":8.397940008672037,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":44097530},"locus_GRCh38":{"chromosome":"1","position":43631859}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.0,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":44097530},"locus_GRCh38":{"chromosome":"1","position":43631859}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":44097530},"locus_GRCh38":{"chromosome":"1","position":43631859}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":9.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":44100084},"locus_GRCh38":{"chromosome":"1","position":43634413}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":9.397940008672037,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196517","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":44100084},"locus_GRCh38":{"chromosome":"1","position":43634413}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":7.530472520812986,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Anandamide amidohydrolase inhibitor drug ACETAMINOPHEN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000117480 at this locus (259073bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117480","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":46600917},"locus_GRCh38":{"chromosome":"1","position":46135245}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.214189147749966,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55487346},"locus_GRCh38":{"chromosome":"1","position":55021673}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.214189147749966,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55487346},"locus_GRCh38":{"chromosome":"1","position":55021673}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.214189147749966,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55487346},"locus_GRCh38":{"chromosome":"1","position":55021673}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.88941028970075,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.71669877129645,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.88941028970075,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.71669877129645,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=408878"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.79860287567955,"otg_id":"SAIGE_272_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["EFO_0003774"],"reported_trait_name":"Hyperlipidemia","standard_trait_name":"hyperlipidemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.88941028970075,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":55489542},"locus_GRCh38":{"chromosome":"1","position":55023869}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":7.698970004336019,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (9183bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":55496039},"locus_GRCh38":{"chromosome":"1","position":55030366}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408878"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":23.57186520597121,"otg_id":"SAIGE_272_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0003774"],"reported_trait_name":"Hyperlipidemia","standard_trait_name":"hyperlipidemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.25103713874384,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":24.69897000433602,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.844663962534938,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.25103713874384,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.25103713874384,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":11.0,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":64.89219328560758,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":9.522878745280337,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":64.89219328560758,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":21.731656086048936,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":17.82390874094432,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":23.614393726401687,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":23.614393726401687,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":64.89219328560758,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":11.0,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":14.0,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55521313},"locus_GRCh38":{"chromosome":"1","position":55055640}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":14.0,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55521313},"locus_GRCh38":{"chromosome":"1","position":55055640}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":14.0,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169174","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55521313},"locus_GRCh38":{"chromosome":"1","position":55055640}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.812479279163537,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (14882bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132855","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":63048277},"locus_GRCh38":{"chromosome":"1","position":62582606}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":24.119709018294724,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (49271bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132855","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TC","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":63121101},"locus_GRCh38":{"chromosome":"1","position":62655430}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=6889"],"gwas_catalog_id":"GCST001957","neg_log_pval":8.698970004336019,"otg_id":"GCST001957","pubmed_id":"23563609"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Leptin receptor agonist drug METRELEPTIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000116678 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000116678","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":65979280},"locus_GRCh38":{"chromosome":"1","position":65513597}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity (early onset extreme)","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=26621"],"gwas_catalog_id":"GCST001198","neg_log_pval":9.426548177964515,"otg_id":"GCST001198","pubmed_id":"21833088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sphingosine 1-phosphate receptor Edg-1 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000170989","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":101407519},"locus_GRCh38":{"chromosome":"1","position":100941963}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=26621"],"gwas_catalog_id":"GCST001198","neg_log_pval":9.426548177964515,"otg_id":"GCST001198","pubmed_id":"21833088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sphingosine 1-phosphate receptor Edg-1 agonist drug PONESIMOD is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000170989","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":101407519},"locus_GRCh38":{"chromosome":"1","position":100941963}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":14.221848749616356,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-cell surface antigen CD2 inhibitor drug SIPLIZUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000116824","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":117287354},"locus_GRCh38":{"chromosome":"1","position":116744732}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":14.221848749616356,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"T-cell surface antigen CD2 inhibitor drug ALEFACEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000116824","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":117287354},"locus_GRCh38":{"chromosome":"1","position":116744732}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.397940008672037,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"HG1287_PATCH","position":150745909},"locus_GRCh38":{"chromosome":"1","position":150059494}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":9.154901959985743,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"HG1287_PATCH","position":150745909},"locus_GRCh38":{"chromosome":"1","position":150059494}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":9.397940008672037,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"HG1287_PATCH","position":150745909},"locus_GRCh38":{"chromosome":"1","position":150059494}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":10.301029995663981,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (225954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":150115974},"locus_GRCh38":{"chromosome":"1","position":150143798}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":10.301029995663981,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000159164 at this locus (225954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":150115974},"locus_GRCh38":{"chromosome":"1","position":150143798}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":11.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000143387","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":150658287},"locus_GRCh38":{"chromosome":"1","position":150685811}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":10.221848749616356,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000143387","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":150658287},"locus_GRCh38":{"chromosome":"1","position":150685811}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":8.522878745280337,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000143387","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":150658287},"locus_GRCh38":{"chromosome":"1","position":150685811}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":9.096910013008056,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169418 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169418","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":153662423},"locus_GRCh38":{"chromosome":"1","position":153689947}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":10.209025579976215,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169418 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169418","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":153662423},"locus_GRCh38":{"chromosome":"1","position":153689947}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":14.698970004336019,"otg_id":"GCST005529_3","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [EA]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":17.045757490560675,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":12.522878745280337,"otg_id":"GCST005529","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":14.698970004336019,"otg_id":"GCST005529_3","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [EA]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":17.045757490560675,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":12.522878745280337,"otg_id":"GCST005529","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":154426264},"locus_GRCh38":{"chromosome":"1","position":154453788}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":8.397940008672037,"otg_id":"GCST002318","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":154426970},"locus_GRCh38":{"chromosome":"1","position":154454494}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=47580"],"gwas_catalog_id":"GCST005569","neg_log_pval":7.8807441107220635,"otg_id":"GCST005569","pubmed_id":"23143596"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":154426970},"locus_GRCh38":{"chromosome":"1","position":154454494}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":8.522878745280337,"otg_id":"GCST006959","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160712","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":154426970},"locus_GRCh38":{"chromosome":"1","position":154454494}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160752","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":154834183},"locus_GRCh38":{"chromosome":"1","position":154861707}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":7.698970004336019,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160752","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":154834183},"locus_GRCh38":{"chromosome":"1","position":154861707}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":9.522878745280337,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Farnesyl diphosphate synthase inhibitor drug PAMIDRONIC ACID is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000160752 at this locus (150834bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160752","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":155130391},"locus_GRCh38":{"chromosome":"1","position":155157915}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":10.316502682320188,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160752","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":155148781},"locus_GRCh38":{"chromosome":"1","position":155176305}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":10.316502682320188,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Farnesyl diphosphate synthase inhibitor drug ALENDRONIC ACID is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160752","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":155148781},"locus_GRCh38":{"chromosome":"1","position":155176305}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":10.316502682320188,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mucin-1 other drug HUHMFG1 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000185499 at this locus (9520bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000185499","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":155148781},"locus_GRCh38":{"chromosome":"1","position":155176305}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":33.801755413771765,"otg_id":"NEALE2_6152_7","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198734","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":169467654},"locus_GRCh38":{"chromosome":"1","position":169498416}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":34.79160702064111,"otg_id":"NEALE2_20002_1093","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198734","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":169467654},"locus_GRCh38":{"chromosome":"1","position":169498416}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Pulmonary embolism +/- dvt | non-cancer illness code, self-reported","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":136.39794000867204,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198734","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":169519049},"locus_GRCh38":{"chromosome":"1","position":169549811}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Thrombosis","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":7.340779989063745,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (452003bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117586","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":172700868},"locus_GRCh38":{"chromosome":"1","position":172731728}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":11.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (21377bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117586","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":173131493},"locus_GRCh38":{"chromosome":"1","position":173162354}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":7.522878745280337,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (834bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117586","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":173152036},"locus_GRCh38":{"chromosome":"1","position":173182897}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.202546175019036,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117586","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":173170618},"locus_GRCh38":{"chromosome":"1","position":173201479}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":8.11264155329629,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117586","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":173170618},"locus_GRCh38":{"chromosome":"1","position":173201479}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=455221"],"gwas_catalog_id":"GCST007093","neg_log_pval":8.0,"otg_id":"GCST007093","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Antithrombin-III activator drug HEPARIN SODIUM is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000117601 at this locus (305887bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000117601","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TAAAAAAAAAAAAAAAAA"},"locus_GRCh37":{"chromosome":"1","position":174192402},"locus_GRCh38":{"chromosome":"1","position":174223264}},"trait_info":{"ontology":["EFO_0002506"],"reported_trait_name":"Osteoarthritis","standard_trait_name":"osteoarthritis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":8.37190434327122,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cyclooxygenase-2 inhibitor drug CELECOXIB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000073756 at this locus (225905bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000073756","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":186875459},"locus_GRCh38":{"chromosome":"1","position":186906327}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":19.006828394969236,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":203026214},"locus_GRCh38":{"chromosome":"1","position":203057086}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":24.221848749616356,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":203026214},"locus_GRCh38":{"chromosome":"1","position":203057086}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["East Asian=36792"],"gwas_catalog_id":"GCST004373","neg_log_pval":10.045757490560675,"otg_id":"GCST004373","pubmed_id":"28416822"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33191bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":203026591},"locus_GRCh38":{"chromosome":"1","position":203057463}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.97061622231479,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":203028711},"locus_GRCh38":{"chromosome":"1","position":203059583}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":18.0,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":203028711},"locus_GRCh38":{"chromosome":"1","position":203059583}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["East Asian=4372"],"gwas_catalog_id":"GCST004352","neg_log_pval":8.698970004336019,"otg_id":"GCST004352","pubmed_id":"28460022"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (24876bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":203034906},"locus_GRCh38":{"chromosome":"1","position":203065778}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Early onset atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":9.949848472659069,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":203091274},"locus_GRCh38":{"chromosome":"1","position":203122146}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":10.045757490560675,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":203093201},"locus_GRCh38":{"chromosome":"1","position":203124073}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":8.0,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":203100504},"locus_GRCh38":{"chromosome":"1","position":203131376}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":9.000392345087638,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163485","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TA","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":203103205},"locus_GRCh38":{"chromosome":"1","position":203134077}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.172660456455034,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 2 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000082482 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082482","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TATA"},"locus_GRCh37":{"chromosome":"1","position":215304685},"locus_GRCh38":{"chromosome":"1","position":215131342}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":8.408601448718752,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen-related receptor gamma antagonist drug AFIMOXIFENE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000196482 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196482","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":217220574},"locus_GRCh38":{"chromosome":"1","position":217047232}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":8.154901959985743,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M3 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000133019","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":239901006},"locus_GRCh38":{"chromosome":"1","position":239737706}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":8.154901959985743,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M3 antagonist drug AZD8683 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000133019","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":239901006},"locus_GRCh38":{"chromosome":"1","position":239737706}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":7.698970004336019,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000134460 at this locus (268502bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":5784151},"locus_GRCh38":{"chromosome":"10","position":5742188}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":12.095825631715837,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6081230},"locus_GRCh38":{"chromosome":"10","position":6039267}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=4421"],"gwas_catalog_id":"GCST004290","neg_log_pval":9.0,"otg_id":"GCST004290","pubmed_id":"28445677"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6092346},"locus_GRCh38":{"chromosome":"10","position":6050383}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":14.096910013008056,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6093139},"locus_GRCh38":{"chromosome":"10","position":6051176}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":17.69897000433602,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6093139},"locus_GRCh38":{"chromosome":"10","position":6051176}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.749579997691106,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6093139},"locus_GRCh38":{"chromosome":"10","position":6051176}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":13.823908740944319,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6093139},"locus_GRCh38":{"chromosome":"10","position":6051176}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":15.0,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=16179"],"gwas_catalog_id":"GCST001394","neg_log_pval":8.301029995663981,"otg_id":"GCST001394","pubmed_id":"22293688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":7.702896349850744,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":15.0,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":38.54606892809315,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16179"],"gwas_catalog_id":"GCST001394","neg_log_pval":8.301029995663981,"otg_id":"GCST001394","pubmed_id":"22293688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=102453"],"gwas_catalog_id":"GCST007563","neg_log_pval":11.397940008672037,"otg_id":"GCST007563","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":38.54606892809315,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":12.496209316942819,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":10.698970004336019,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6094697},"locus_GRCh38":{"chromosome":"10","position":6052734}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=19102"],"gwas_catalog_id":"GCST001191","neg_log_pval":38.0,"otg_id":"GCST001191","pubmed_id":"21829393"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6097283},"locus_GRCh38":{"chromosome":"10","position":6055320}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=19102"],"gwas_catalog_id":"GCST001191","neg_log_pval":38.0,"otg_id":"GCST001191","pubmed_id":"21829393"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6097283},"locus_GRCh38":{"chromosome":"10","position":6055320}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.221848749616356,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6098949},"locus_GRCh38":{"chromosome":"10","position":6056986}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.221848749616356,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6098949},"locus_GRCh38":{"chromosome":"10","position":6056986}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.221848749616356,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6098949},"locus_GRCh38":{"chromosome":"10","position":6056986}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.221848749616356,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6098949},"locus_GRCh38":{"chromosome":"10","position":6056986}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.221848749616356,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6098949},"locus_GRCh38":{"chromosome":"10","position":6056986}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":22.11861534322943,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6099045},"locus_GRCh38":{"chromosome":"10","position":6057082}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=26621"],"gwas_catalog_id":"GCST001198","neg_log_pval":8.68909437062386,"otg_id":"GCST001198","pubmed_id":"21833088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6101713},"locus_GRCh38":{"chromosome":"10","position":6059750}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=21389"],"gwas_catalog_id":"GCST000879","neg_log_pval":8.522878745280337,"otg_id":"GCST000879","pubmed_id":"21102463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6102012},"locus_GRCh38":{"chromosome":"10","position":6060049}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=5224"],"gwas_catalog_id":"GCST000062","neg_log_pval":7.522878745280337,"otg_id":"GCST000062","pubmed_id":"17660530"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6102012},"locus_GRCh38":{"chromosome":"10","position":6060049}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=17698"],"gwas_catalog_id":"GCST001341","neg_log_pval":7.3979400086720375,"otg_id":"GCST001341","pubmed_id":"22190364"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6102012},"locus_GRCh38":{"chromosome":"10","position":6060049}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":22.81702340982209,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6106552},"locus_GRCh38":{"chromosome":"10","position":6064589}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":22.81702340982209,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6106552},"locus_GRCh38":{"chromosome":"10","position":6064589}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":20.443697499232712,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (16953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6121286},"locus_GRCh38":{"chromosome":"10","position":6079323}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=15283"],"gwas_catalog_id":"GCST003566","neg_log_pval":8.397940008672037,"otg_id":"GCST003566","pubmed_id":"27386562"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (18336bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":6122669},"locus_GRCh38":{"chromosome":"10","position":6080706}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":13.0,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6123495},"locus_GRCh38":{"chromosome":"10","position":6081532}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":13.0,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6123495},"locus_GRCh38":{"chromosome":"10","position":6081532}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":17.190440285364733,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (19925bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6124257},"locus_GRCh38":{"chromosome":"10","position":6082294}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":8.257205214388867,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6129643},"locus_GRCh38":{"chromosome":"10","position":6087680}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":8.257205214388867,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6129643},"locus_GRCh38":{"chromosome":"10","position":6087680}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":8.018482423811946,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (71834bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":6176166},"locus_GRCh38":{"chromosome":"10","position":6134203}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=8207"],"gwas_catalog_id":"GCST000258","neg_log_pval":8.397940008672037,"otg_id":"GCST000258","pubmed_id":"18978792"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":6390450},"locus_GRCh38":{"chromosome":"10","position":6348488}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=8207"],"gwas_catalog_id":"GCST000258","neg_log_pval":8.397940008672037,"otg_id":"GCST000258","pubmed_id":"18978792"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000134460","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":6390450},"locus_GRCh38":{"chromosome":"10","position":6348488}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=18264","African American or Afro-Caribbean=5422","Hispanic or Latin American=3888"],"gwas_catalog_id":"GCST005752","neg_log_pval":9.154901959985743,"otg_id":"GCST005752","pubmed_id":"28714469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (327251bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":49974656},"locus_GRCh38":{"chromosome":"10","position":48766611}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=5420"],"gwas_catalog_id":"GCST003599","neg_log_pval":8.698970004336019,"otg_id":"GCST003599","pubmed_id":"26663301"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":50025396},"locus_GRCh38":{"chromosome":"10","position":48817351}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=14267"],"gwas_catalog_id":"GCST003155","neg_log_pval":10.065299598284575,"otg_id":"GCST003155","pubmed_id":"26502338"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":50025396},"locus_GRCh38":{"chromosome":"10","position":48817351}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=5057","European=10995"],"gwas_catalog_id":"GCST003622","neg_log_pval":10.045757490560675,"otg_id":"GCST003622_3","pubmed_id":"27399966"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":50025396},"locus_GRCh38":{"chromosome":"10","position":48817351}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus [EA]","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=14267"],"gwas_catalog_id":"GCST003156","neg_log_pval":10.065299598284575,"otg_id":"GCST003156","pubmed_id":"26502338"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":50025396},"locus_GRCh38":{"chromosome":"10","position":48817351}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=1798"],"gwas_catalog_id":"GCST000592","neg_log_pval":11.096910013008056,"otg_id":"GCST000592","pubmed_id":"20169177"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":50025396},"locus_GRCh38":{"chromosome":"10","position":48817351}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=5050"],"gwas_catalog_id":"GCST001795","neg_log_pval":8.096910013008056,"otg_id":"GCST001795","pubmed_id":"23273568"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (395547bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":50042951},"locus_GRCh38":{"chromosome":"10","position":48834906}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=18264"],"gwas_catalog_id":"GCST007400","neg_log_pval":8.0,"otg_id":"GCST007400","pubmed_id":"28714469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (454572bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":50101977},"locus_GRCh38":{"chromosome":"10","position":48893932}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=2252"],"gwas_catalog_id":"GCST000507","neg_log_pval":11.154901959985743,"otg_id":"GCST000507","pubmed_id":"19838193"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (471650bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000107643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":50119054},"locus_GRCh38":{"chromosome":"10","position":48911009}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":10.522878745280337,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Cytochrome P450 26A1 inhibitor drug TALAROZOLE is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000095596 at this locus (401233bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000095596","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":94432000},"locus_GRCh38":{"chromosome":"10","position":92672243}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":9.301029995663981,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000148795","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":104414221},"locus_GRCh38":{"chromosome":"10","position":102654464}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":9.301029995663981,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000148795","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":104414221},"locus_GRCh38":{"chromosome":"10","position":102654464}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":15.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000148795","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":104414221},"locus_GRCh38":{"chromosome":"10","position":102654464}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":15.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000148795","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":104414221},"locus_GRCh38":{"chromosome":"10","position":102654464}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.399595651036623,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug NADOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (80138bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":115723678},"locus_GRCh38":{"chromosome":"10","position":113963919}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":8.698970004336019,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug ACEBUTOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (61988bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":115741828},"locus_GRCh38":{"chromosome":"10","position":113982069}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=91102","African American or Afro-Caribbean=21417","Asian unspecified=12365","Hispanic or Latin American=8471"],"gwas_catalog_id":"GCST006434","neg_log_pval":19.69897000433602,"otg_id":"GCST006434_9","pubmed_id":"29912962"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11754bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115792062},"locus_GRCh38":{"chromosome":"10","position":114032303}},"trait_info":{"ontology":["EFO_0004329"],"reported_trait_name":"Systolic blood pressure x alcohol consumption interaction (2df test) [EA]","standard_trait_name":"alcohol drinking"}}
{"association_info":{"ancestry":["European=91110","African American or Afro-Caribbean=21416","Asian unspecified=12365","Hispanic or Latin American=8470"],"gwas_catalog_id":"GCST006167","neg_log_pval":9.698970004336019,"otg_id":"GCST006167_9","pubmed_id":"29912962"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115792787},"locus_GRCh38":{"chromosome":"10","position":114033028}},"trait_info":{"ontology":["EFO_0004329"],"reported_trait_name":"Mean arterial pressure x alcohol consumption interaction (2df test) [EA]","standard_trait_name":"alcohol drinking"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":21.73008330295326,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug METOPROLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (11029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115792787},"locus_GRCh38":{"chromosome":"10","position":114033028}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=91099","African American or Afro-Caribbean=21416","Asian unspecified=12365","Hispanic or Latin American=8471"],"gwas_catalog_id":"GCST006166","neg_log_pval":22.096910013008056,"otg_id":"GCST006166_8","pubmed_id":"29912962"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115792787},"locus_GRCh38":{"chromosome":"10","position":114033028}},"trait_info":{"ontology":["EFO_0004329"],"reported_trait_name":"Diastolic blood pressure x alcohol consumption interaction (2df test) [EA]","standard_trait_name":"alcohol drinking"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.522878745280337,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115805056},"locus_GRCh38":{"chromosome":"10","position":114045297}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.397940008672037,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115805056},"locus_GRCh38":{"chromosome":"10","position":114045297}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":23.221848749616356,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Beta-1 adrenergic receptor agonist drug DOPAMINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000043591 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000043591","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":115805056},"locus_GRCh38":{"chromosome":"10","position":114045297}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":7.698970004336019,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123093901},"locus_GRCh38":{"chromosome":"10","position":121334387}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":8.096910013008056,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123093901},"locus_GRCh38":{"chromosome":"10","position":121334387}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":11.680685695909489,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143858bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"GT","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123093991},"locus_GRCh38":{"chromosome":"10","position":121334477}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":43.678815972697684,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123331467},"locus_GRCh38":{"chromosome":"10","position":121571953}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":190.37059040089727,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123331690},"locus_GRCh38":{"chromosome":"10","position":121572176}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":34.096910013008056,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123334930},"locus_GRCh38":{"chromosome":"10","position":121575416}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":34.096910013008056,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123334930},"locus_GRCh38":{"chromosome":"10","position":121575416}},"trait_info":{"ontology":["EFO_0005842"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"colorectal cancer"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":34.096910013008056,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123334930},"locus_GRCh38":{"chromosome":"10","position":121575416}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["European=8556"],"gwas_catalog_id":"GCST000678","neg_log_pval":30.397940008672037,"otg_id":"GCST000678","pubmed_id":"20453838"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123337335},"locus_GRCh38":{"chromosome":"10","position":121577821}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=2287"],"gwas_catalog_id":"GCST000365","neg_log_pval":9.698970004336019,"otg_id":"GCST000365","pubmed_id":"19330030"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123337335},"locus_GRCh38":{"chromosome":"10","position":121577821}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":169.69897000433602,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123337335},"locus_GRCh38":{"chromosome":"10","position":121577821}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":10.522878745280337,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123337335},"locus_GRCh38":{"chromosome":"10","position":121577821}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":163.22184874961636,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123337335},"locus_GRCh38":{"chromosome":"10","position":121577821}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=330828"],"neg_log_pval":30.844827992822484,"otg_id":"NEALE2_20110_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123338975},"locus_GRCh38":{"chromosome":"10","position":121579461}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer | illnesses of mother","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=4741"],"gwas_catalog_id":"GCST002234","neg_log_pval":12.0,"otg_id":"GCST002234","pubmed_id":"24143190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123340311},"locus_GRCh38":{"chromosome":"10","position":121580797}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=4741"],"gwas_catalog_id":"GCST002234","neg_log_pval":12.0,"otg_id":"GCST002234","pubmed_id":"24143190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123340311},"locus_GRCh38":{"chromosome":"10","position":121580797}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":321.65300282934044,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GC"},"locus_GRCh37":{"chromosome":"10","position":123340431},"locus_GRCh38":{"chromosome":"10","position":121580917}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=279478"],"neg_log_pval":14.096910013008056,"otg_id":"NEALE2_20111_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":123343909},"locus_GRCh38":{"chromosome":"10","position":121584395}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer | illnesses of siblings","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=1703"],"gwas_catalog_id":"GCST000846","neg_log_pval":8.0,"otg_id":"GCST000846","pubmed_id":"21060860"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123346116},"locus_GRCh38":{"chromosome":"10","position":121586602}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer in BRCA2 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":71.26440110030182,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":123346116},"locus_GRCh38":{"chromosome":"10","position":121586602}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=6346"],"gwas_catalog_id":"GCST000952","neg_log_pval":30.0,"otg_id":"GCST000952","pubmed_id":"21263130"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123346190},"locus_GRCh38":{"chromosome":"10","position":121586676}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":8.221848749616356,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123346190},"locus_GRCh38":{"chromosome":"10","position":121586676}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=8428"],"gwas_catalog_id":"GCST000811","neg_log_pval":12.698970004336019,"otg_id":"GCST000811","pubmed_id":"20872241"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123346190},"locus_GRCh38":{"chromosome":"10","position":121586676}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=2287"],"gwas_catalog_id":"GCST000036","neg_log_pval":10.0,"otg_id":"GCST000036","pubmed_id":"17529973"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123346190},"locus_GRCh38":{"chromosome":"10","position":121586676}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=6225"],"gwas_catalog_id":"GCST002346","neg_log_pval":26.522878745280337,"otg_id":"GCST002346","pubmed_id":"24493630"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":123348662},"locus_GRCh38":{"chromosome":"10","position":121589148}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer (early onset)","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":36.13804762507855,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123349324},"locus_GRCh38":{"chromosome":"10","position":121589810}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=359981"],"neg_log_pval":13.229147988357855,"otg_id":"NEALE2_2453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123350216},"locus_GRCh38":{"chromosome":"10","position":121590702}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Cancer diagnosed by doctor","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=8211"],"gwas_catalog_id":"GCST007302","neg_log_pval":13.698970004336019,"otg_id":"GCST007302","pubmed_id":"23544012"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":123351324},"locus_GRCh38":{"chromosome":"10","position":121591810}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer in BRCA2 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=5452"],"gwas_catalog_id":"GCST003823","neg_log_pval":10.301029995663981,"otg_id":"GCST003823","pubmed_id":"27764800"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123352220},"locus_GRCh38":{"chromosome":"10","position":121592706}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Estrogen receptor status in HER2 negative breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=754"],"gwas_catalog_id":"GCST000035","neg_log_pval":75.69897000433602,"otg_id":"GCST000035","pubmed_id":"17529967"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123352317},"locus_GRCh38":{"chromosome":"10","position":121592803}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":7.698970004336019,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":123352317},"locus_GRCh38":{"chromosome":"10","position":121592803}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=8727"],"gwas_catalog_id":"GCST003821","neg_log_pval":11.221848749616356,"otg_id":"GCST003821","pubmed_id":"27764800"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123353869},"locus_GRCh38":{"chromosome":"10","position":121594355}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Estrogen receptor status in breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":13.173925197299173,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000066468","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":123357561},"locus_GRCh38":{"chromosome":"10","position":121598047}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.0,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":1873232},"locus_GRCh38":{"chromosome":"11","position":1852002}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.0,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":1873232},"locus_GRCh38":{"chromosome":"11","position":1852002}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":16.29810490633703,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (308214bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":1876945},"locus_GRCh38":{"chromosome":"11","position":1855715}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":8.0,"otg_id":"GCST007707_2","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (298091bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1887068},"locus_GRCh38":{"chromosome":"11","position":1865838}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [Japanese]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":26.22452645095722,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":1888614},"locus_GRCh38":{"chromosome":"11","position":1867384}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.518557371497696,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":1888614},"locus_GRCh38":{"chromosome":"11","position":1867384}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.619788758288394,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":1888614},"locus_GRCh38":{"chromosome":"11","position":1867384}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":15.397940008672037,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (286496bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180176","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1898664},"locus_GRCh38":{"chromosome":"11","position":1877434}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":37.01300446027562,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (251679bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1898664},"locus_GRCh38":{"chromosome":"11","position":1877434}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":8.045757490560675,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (248245bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":1902097},"locus_GRCh38":{"chromosome":"11","position":1880867}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":12.698970004336019,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1909006},"locus_GRCh38":{"chromosome":"11","position":1887776}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":10.698970004336019,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1909006},"locus_GRCh38":{"chromosome":"11","position":1887776}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=754"],"gwas_catalog_id":"GCST000035","neg_log_pval":8.522878745280337,"otg_id":"GCST000035","pubmed_id":"17529967"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":1909006},"locus_GRCh38":{"chromosome":"11","position":1887776}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.896196279044043,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408404},"locus_GRCh38":{"chromosome":"11","position":17386857}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":10.494850021680094,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":10.522878745280337,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":19.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.096910013008056,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":20.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":21.30102999566398,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":16.397940008672037,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000025","neg_log_pval":10.301029995663981,"otg_id":"GCST000025_2","pubmed_id":"17463249"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":21.69897000433602,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2931"],"gwas_catalog_id":"GCST000028","neg_log_pval":10.154901959985743,"otg_id":"GCST000028","pubmed_id":"17463246"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000277","neg_log_pval":9.0,"otg_id":"GCST000277","pubmed_id":"19056611"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [non-obese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2335"],"gwas_catalog_id":"GCST000024","neg_log_pval":10.154901959985743,"otg_id":"GCST000024_2","pubmed_id":"17463248"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":21.221848749616356,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (943bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187486","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17411821},"locus_GRCh38":{"chromosome":"11","position":17390274}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":13.853871964321762,"otg_id":"NEALE2_20002_1093","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (34991bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":46705739},"locus_GRCh38":{"chromosome":"11","position":46684189}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Pulmonary embolism +/- dvt | non-cancer illness code, self-reported","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=120158"],"gwas_catalog_id":"GCST004256","neg_log_pval":8.096910013008056,"otg_id":"GCST004256_2","pubmed_id":"28373160"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46760756},"locus_GRCh38":{"chromosome":"11","position":46739206}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism [Conditioned on rs1799963]","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=120158"],"gwas_catalog_id":"GCST004256","neg_log_pval":8.096910013008056,"otg_id":"GCST004256_2","pubmed_id":"28373160"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46760756},"locus_GRCh38":{"chromosome":"11","position":46739206}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism [Conditioned on rs1799963]","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=404271"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.829738284605043,"otg_id":"SAIGE_459_9"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Circulatory disease nec","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Thrombosis","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=120158"],"gwas_catalog_id":"GCST004256","neg_log_pval":12.301029995663981,"otg_id":"GCST004256","pubmed_id":"28373160"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=404449"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.882728704344236,"otg_id":"SAIGE_459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Other disorders of circulatory system","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=404449"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.882728704344236,"otg_id":"SAIGE_459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Other disorders of circulatory system","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug ARGATROBAN is Phase III for the indiciation HP_0002140 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["HP_0002140"],"reported_trait_name":"Thrombosis","standard_trait_name":"Ischemic stroke"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":19.56919957537582,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg (dvt) | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=60139"],"gwas_catalog_id":"GCST002808","neg_log_pval":8.698970004336019,"otg_id":"GCST002808","pubmed_id":"25772935"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Thrombosis","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=120158"],"gwas_catalog_id":"GCST004256","neg_log_pval":12.301029995663981,"otg_id":"GCST004256","pubmed_id":"28373160"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Thrombosis","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=404271"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.829738284605043,"otg_id":"SAIGE_459_9"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Circulatory disease nec","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=60139"],"gwas_catalog_id":"GCST002808","neg_log_pval":8.698970004336019,"otg_id":"GCST002808","pubmed_id":"25772935"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Venous thromboembolism","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Thrombosis","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":20.081541349622885,"otg_id":"NEALE2_20002_1094","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Deep venous thrombosis (dvt) | non-cancer illness code, self-reported","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":12.362510270487489,"otg_id":"NEALE2_6152_7","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":24.0,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180210","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Thrombosis","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":8.413929430513312,"otg_id":"NEALE2_6152_9","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"G protein-coupled receptor 44 antagonist drug SETIPIPRANT is Phase III for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183134","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":60793648},"locus_GRCh38":{"chromosome":"11","position":61026176}},"trait_info":{"ontology":["EFO_0003956"],"reported_trait_name":"Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"seasonal allergic rhinitis"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":8.413929430513312,"otg_id":"NEALE2_6152_9","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"G protein-coupled receptor 44 antagonist drug QAV680 is Phase II for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183134","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":60793648},"locus_GRCh38":{"chromosome":"11","position":61026176}},"trait_info":{"ontology":["EFO_0003956"],"reported_trait_name":"Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"seasonal allergic rhinitis"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":26.0,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":62186542},"locus_GRCh38":{"chromosome":"11","position":62419070}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":26.0,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":62186542},"locus_GRCh38":{"chromosome":"11","position":62419070}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":13.698970004336019,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":62197427},"locus_GRCh38":{"chromosome":"11","position":62429955}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":13.698970004336019,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":62197427},"locus_GRCh38":{"chromosome":"11","position":62429955}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":9.0,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":62199817},"locus_GRCh38":{"chromosome":"11","position":62432345}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":9.0,"otg_id":"GCST001737_2","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168539","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":62199817},"locus_GRCh38":{"chromosome":"11","position":62432345}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [CC16]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=408393"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.543633966870957,"otg_id":"SAIGE_274_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64334114},"locus_GRCh38":{"chromosome":"11","position":64566642}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=408393"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.543633966870957,"otg_id":"SAIGE_274_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64334114},"locus_GRCh38":{"chromosome":"11","position":64566642}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=408393"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.543633966870957,"otg_id":"SAIGE_274_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64334114},"locus_GRCh38":{"chromosome":"11","position":64566642}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":15.066630665946775,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (9456bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":64349802},"locus_GRCh38":{"chromosome":"11","position":64582330}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":15.066630665946775,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":64349802},"locus_GRCh38":{"chromosome":"11","position":64582330}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":15.066630665946775,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug SULFINPYRAZONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":64349802},"locus_GRCh38":{"chromosome":"11","position":64582330}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":23.07433525192862,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":64352063},"locus_GRCh38":{"chromosome":"11","position":64584591}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":23.07433525192862,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":64352063},"locus_GRCh38":{"chromosome":"11","position":64584591}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":23.07433525192862,"otg_id":"NEALE2_20002_1466","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (11717bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":64352063},"locus_GRCh38":{"chromosome":"11","position":64584591}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout | non-cancer illness code, self-reported","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=2158"],"gwas_catalog_id":"GCST003925","neg_log_pval":10.301029995663981,"otg_id":"GCST003925_2","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout [Japanese]","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=1832"],"gwas_catalog_id":"GCST003926","neg_log_pval":9.045757490560675,"otg_id":"GCST003926","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Renal underexcretion gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=1832"],"gwas_catalog_id":"GCST003926","neg_log_pval":9.045757490560675,"otg_id":"GCST003926","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168065","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Renal underexcretion gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=2158"],"gwas_catalog_id":"GCST003925","neg_log_pval":10.301029995663981,"otg_id":"GCST003925_2","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout [Japanese]","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=1832"],"gwas_catalog_id":"GCST003926","neg_log_pval":9.045757490560675,"otg_id":"GCST003926","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Renal underexcretion gout","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["East Asian=2158"],"gwas_catalog_id":"GCST003925","neg_log_pval":10.301029995663981,"otg_id":"GCST003925_2","pubmed_id":"27899376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197891","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":64435906},"locus_GRCh38":{"chromosome":"11","position":64668434}},"trait_info":{"ontology":["EFO_0004274"],"reported_trait_name":"Gout [Japanese]","standard_trait_name":"gout"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":9.0,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168959","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":88695846},"locus_GRCh38":{"chromosome":"11","position":88962678}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":24.522878745280337,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168959","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":88744425},"locus_GRCh38":{"chromosome":"11","position":89011257}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=322580"],"gwas_catalog_id":"GCST005902","neg_log_pval":10.171997842193115,"otg_id":"GCST005902","pubmed_id":"29662059"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000168959","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":88748162},"locus_GRCh38":{"chromosome":"11","position":89014994}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression (broad)","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":12.0,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (318127bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100582228},"locus_GRCh38":{"chromosome":"11","position":100711497}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":9.301029995663981,"otg_id":"GCST007707_2","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100593538},"locus_GRCh38":{"chromosome":"11","position":100722807}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [Japanese]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":46.69897000433602,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug MEGESTROL ACETATE is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000082175 at this locus (306817bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100593538},"locus_GRCh38":{"chromosome":"11","position":100722807}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=69395"],"gwas_catalog_id":"GCST001238","neg_log_pval":10.301029995663981,"otg_id":"GCST001238","pubmed_id":"21909115"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100593538},"locus_GRCh38":{"chromosome":"11","position":100722807}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":46.69897000433602,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100593538},"locus_GRCh38":{"chromosome":"11","position":100722807}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.14206473528057,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (306817bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":100593538},"locus_GRCh38":{"chromosome":"11","position":100722807}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":39.096910013008056,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000082175 at this locus (289809bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":100610546},"locus_GRCh38":{"chromosome":"11","position":100739815}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":9.55284196865778,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (289809bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":100610546},"locus_GRCh38":{"chromosome":"11","position":100739815}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.34008379993015,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":100610546},"locus_GRCh38":{"chromosome":"11","position":100739815}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.27490547891853,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":100610546},"locus_GRCh38":{"chromosome":"11","position":100739815}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":38.813874644838485,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":100610546},"locus_GRCh38":{"chromosome":"11","position":100739815}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":8.522878745280337,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (275756bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":100624599},"locus_GRCh38":{"chromosome":"11","position":100753868}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":10.168322150808534,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (268448bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000082175","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":100631908},"locus_GRCh38":{"chromosome":"11","position":100761177}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=574"],"gwas_catalog_id":"GCST002665","neg_log_pval":43.69897000433602,"otg_id":"GCST002665_5","pubmed_id":"25340798"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137745 at this locus (96747bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137745","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102716980},"locus_GRCh38":{"chromosome":"11","position":102846249}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["NR=574"],"gwas_catalog_id":"GCST002665","neg_log_pval":43.69897000433602,"otg_id":"GCST002665_5","pubmed_id":"25340798"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000118113 at this locus (119199bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000118113","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102716980},"locus_GRCh38":{"chromosome":"11","position":102846249}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["NR=574"],"gwas_catalog_id":"GCST002665","neg_log_pval":43.69897000433602,"otg_id":"GCST002665_5","pubmed_id":"25340798"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000196611 at this locus (48090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196611","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102716980},"locus_GRCh38":{"chromosome":"11","position":102846249}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["NR=574"],"gwas_catalog_id":"GCST002665","neg_log_pval":43.69897000433602,"otg_id":"GCST002665_5","pubmed_id":"25340798"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137673 at this locus (315500bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137673","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102716980},"locus_GRCh38":{"chromosome":"11","position":102846249}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["European=7100","African American or Afro-Caribbean=2570"],"gwas_catalog_id":"GCST002350","neg_log_pval":8.522878745280337,"otg_id":"GCST002350","pubmed_id":"24621683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137673 at this locus (319465bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137673","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":102720945},"locus_GRCh38":{"chromosome":"11","position":102850214}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease (severe)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=7100","African American or Afro-Caribbean=2570"],"gwas_catalog_id":"GCST002350","neg_log_pval":8.522878745280337,"otg_id":"GCST002350","pubmed_id":"24621683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000196611 at this locus (52055bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196611","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":102720945},"locus_GRCh38":{"chromosome":"11","position":102850214}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease (severe)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=7100","African American or Afro-Caribbean=2570"],"gwas_catalog_id":"GCST002350","neg_log_pval":8.522878745280337,"otg_id":"GCST002350","pubmed_id":"24621683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137745 at this locus (92782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137745","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":102720945},"locus_GRCh38":{"chromosome":"11","position":102850214}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease (severe)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=7100","African American or Afro-Caribbean=2570"],"gwas_catalog_id":"GCST002350","neg_log_pval":8.522878745280337,"otg_id":"GCST002350","pubmed_id":"24621683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000118113 at this locus (123164bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000118113","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":102720945},"locus_GRCh38":{"chromosome":"11","position":102850214}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease (severe)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.522878745280337,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196611 at this locus (284087bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196611","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102952976},"locus_GRCh38":{"chromosome":"11","position":103082247}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.522878745280337,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000118113 at this locus (355197bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000118113","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102952976},"locus_GRCh38":{"chromosome":"11","position":103082247}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.522878745280337,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000137745 at this locus (126515bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137745","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":102952976},"locus_GRCh38":{"chromosome":"11","position":103082247}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=348219"],"gwas_catalog_id":"GCST006478","neg_log_pval":9.0,"otg_id":"GCST006478","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug PALIPERIDONE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":112827715},"locus_GRCh38":{"chromosome":"11","position":112956992}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worry","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=348219"],"gwas_catalog_id":"GCST006478","neg_log_pval":9.0,"otg_id":"GCST006478","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug QUETIAPINE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":112827715},"locus_GRCh38":{"chromosome":"11","position":112956992}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worry","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":8.487182241435127,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CLOZAPINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":112849719},"locus_GRCh38":{"chromosome":"11","position":112978997}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":8.487182241435127,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug ILOPERIDONE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":112849719},"locus_GRCh38":{"chromosome":"11","position":112978997}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":8.487182241435127,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":112849719},"locus_GRCh38":{"chromosome":"11","position":112978997}},"trait_info":{"ontology":["EFO_0004247"],"reported_trait_name":"Depressed affect","standard_trait_name":"mood disorder"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":8.487182241435127,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":112849719},"locus_GRCh38":{"chromosome":"11","position":112978997}},"trait_info":{"ontology":["EFO_0004247"],"reported_trait_name":"Depressed affect","standard_trait_name":"mood disorder"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":7.698970004336019,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":113215923},"locus_GRCh38":{"chromosome":"11","position":113345201}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":7.698970004336019,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor modulator drug CARIPRAZINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":113215923},"locus_GRCh38":{"chromosome":"11","position":113345201}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":7.698970004336019,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug TRIMIPRAMINE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"HG305_PATCH","position":113215923},"locus_GRCh38":{"chromosome":"11","position":113345201}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=348219"],"gwas_catalog_id":"GCST006478","neg_log_pval":9.0,"otg_id":"GCST006478","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113364647},"locus_GRCh38":{"chromosome":"11","position":113493925}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worry","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=348219"],"gwas_catalog_id":"GCST006478","neg_log_pval":9.0,"otg_id":"GCST006478","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug BROMPERIDOL is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113364647},"locus_GRCh38":{"chromosome":"11","position":113493925}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worry","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":38.39794000867204,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (474846bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113370758},"locus_GRCh38":{"chromosome":"11","position":113500036}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":38.39794000867204,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113370758},"locus_GRCh38":{"chromosome":"11","position":113500036}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":38.39794000867204,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor modulator drug CARIPRAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113370758},"locus_GRCh38":{"chromosome":"11","position":113500036}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":12.761953896871205,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (459256bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":113386347},"locus_GRCh38":{"chromosome":"11","position":113515625}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":12.761953896871205,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":113386347},"locus_GRCh38":{"chromosome":"11","position":113515625}},"trait_info":{"ontology":["EFO_0004247"],"reported_trait_name":"Depressed affect","standard_trait_name":"mood disorder"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":12.761953896871205,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug PERPHENAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":113386347},"locus_GRCh38":{"chromosome":"11","position":113515625}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":12.761953896871205,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":113386347},"locus_GRCh38":{"chromosome":"11","position":113515625}},"trait_info":{"ontology":["EFO_0004247"],"reported_trait_name":"Depressed affect","standard_trait_name":"mood disorder"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":12.761953896871205,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":113386347},"locus_GRCh38":{"chromosome":"11","position":113515625}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":10.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":10.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":10.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.301029995663981,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.301029995663981,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":10.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.301029995663981,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.301029995663981,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":10.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.301029995663981,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003756 and targets the gene ENSG00000149295 at this locus (66031bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0003756"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"autism spectrum disorder"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug ASENAPINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor partial agonist drug BIFEPRUNOX is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.301029995663981,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":113412443},"locus_GRCh38":{"chromosome":"11","position":113541721}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.522878745280337,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.301029995663981,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":14.397940008672037,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000149295","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.522878745280337,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":14.397940008672037,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.301029995663981,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":113807181},"locus_GRCh38":{"chromosome":"11","position":113936459}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=9799"],"gwas_catalog_id":"GCST003227","neg_log_pval":10.221848749616356,"otg_id":"GCST003227","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":114030799},"locus_GRCh38":{"chromosome":"11","position":114160077}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=24009"],"gwas_catalog_id":"GCST004348","neg_log_pval":11.301029995663981,"otg_id":"GCST004348","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":114030799},"locus_GRCh38":{"chromosome":"11","position":114160077}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=5548"],"gwas_catalog_id":"GCST000439","neg_log_pval":8.0,"otg_id":"GCST000439","pubmed_id":"19578367"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":118477367},"locus_GRCh38":{"chromosome":"11","position":118606652}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST001058","neg_log_pval":10.301029995663981,"otg_id":"GCST001058","pubmed_id":"21531791"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":118477367},"locus_GRCh38":{"chromosome":"11","position":118606652}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=9799"],"gwas_catalog_id":"GCST003227","neg_log_pval":24.397940008672037,"otg_id":"GCST003227","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118480115},"locus_GRCh38":{"chromosome":"11","position":118609400}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=24009"],"gwas_catalog_id":"GCST004348","neg_log_pval":42.221848749616356,"otg_id":"GCST004348","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118480115},"locus_GRCh38":{"chromosome":"11","position":118609400}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST003228","neg_log_pval":15.698970004336019,"otg_id":"GCST003228","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118480115},"locus_GRCh38":{"chromosome":"11","position":118609400}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=30659"],"gwas_catalog_id":"GCST004347","neg_log_pval":15.0,"otg_id":"GCST004347","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118480115},"locus_GRCh38":{"chromosome":"11","position":118609400}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=38053"],"gwas_catalog_id":"GCST000987","neg_log_pval":12.0,"otg_id":"GCST000987","pubmed_id":"21383967"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000198851 at this locus (424897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198851","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":118611781},"locus_GRCh38":{"chromosome":"11","position":118741072}},"trait_info":{"ontology":["EFO_0000540"],"reported_trait_name":"Celiac disease or Rheumatoid arthritis","standard_trait_name":"immune system disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":12.096910013008056,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug MILRINONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (361012bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":20161168},"locus_GRCh38":{"chromosome":"12","position":20008234}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":13.096910013008056,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":20220033},"locus_GRCh38":{"chromosome":"12","position":20067099}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":8.2839966563652,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":20220033},"locus_GRCh38":{"chromosome":"12","position":20067099}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":13.537602002101044,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":20220033},"locus_GRCh38":{"chromosome":"12","position":20067099}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":8.698970004336019,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (161851bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":20360328},"locus_GRCh38":{"chromosome":"12","position":20207394}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=440328","East Asian=45564","South Asian=9144","African American or Afro-Caribbean=20687","Asian unspecified=555","Hispanic or Latin American=1247"],"gwas_catalog_id":"GCST005843","neg_log_pval":7.301029995663981,"otg_id":"GCST005843","pubmed_id":"29531354"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":20577593},"locus_GRCh38":{"chromosome":"12","position":20424659}},"trait_info":{"ontology":["HP_0002140"],"reported_trait_name":"Ischemic stroke","standard_trait_name":"Ischemic stroke"}}
{"association_info":{"ancestry":["European=440328","East Asian=45564","South Asian=9144","African American or Afro-Caribbean=20687","Asian unspecified=555","Hispanic or Latin American=1247"],"gwas_catalog_id":"GCST005843","neg_log_pval":7.301029995663981,"otg_id":"GCST005843","pubmed_id":"29531354"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":20577593},"locus_GRCh38":{"chromosome":"12","position":20424659}},"trait_info":{"ontology":["HP_0002140"],"reported_trait_name":"Ischemic stroke","standard_trait_name":"Ischemic stroke"}}
{"association_info":{"ancestry":["European=17565","African American or Afro-Caribbean=375","South Asian=4710"],"gwas_catalog_id":"GCST003322","neg_log_pval":7.522878745280337,"otg_id":"GCST003322_2","pubmed_id":"26732560"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (486296bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172572","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":21323611},"locus_GRCh38":{"chromosome":"12","position":21170677}},"trait_info":{"ontology":["HP_0002140"],"reported_trait_name":"Ischemic stroke (large artery atherosclerosis) [EA]","standard_trait_name":"Ischemic stroke"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.267891037697892,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48186563},"locus_GRCh38":{"chromosome":"12","position":47792780}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.267891037697892,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48186563},"locus_GRCh38":{"chromosome":"12","position":47792780}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=360838"],"gwas_catalog_id":"GCST005038","neg_log_pval":10.941953769604718,"otg_id":"GCST005038","pubmed_id":"29083406"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase II for the indiciation EFO_0003785 and targets the gene ENSG00000111424 at this locus (39448bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":48195873},"locus_GRCh38":{"chromosome":"12","position":47802090}},"trait_info":{"ontology":["EFO_0003785"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"allergy"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":10.154901959985743,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":48204499},"locus_GRCh38":{"chromosome":"12","position":47810716}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":10.154901959985743,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000111424 at this locus (30821bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":48204499},"locus_GRCh38":{"chromosome":"12","position":47810716}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":10.154901959985743,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":48204499},"locus_GRCh38":{"chromosome":"12","position":47810716}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug PEFCALCITOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48208368},"locus_GRCh38":{"chromosome":"12","position":47814585}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug DOXERCALCIFEROL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48208368},"locus_GRCh38":{"chromosome":"12","position":47814585}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000111424 at this locus (26953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48208368},"locus_GRCh38":{"chromosome":"12","position":47814585}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CALCITRIOL is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48208368},"locus_GRCh38":{"chromosome":"12","position":47814585}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000111424 at this locus (26953bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48208368},"locus_GRCh38":{"chromosome":"12","position":47814585}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":12.517126416391246,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48254353},"locus_GRCh38":{"chromosome":"12","position":47860570}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":9.301029995663981,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48254353},"locus_GRCh38":{"chromosome":"12","position":47860570}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":12.517126416391246,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":48254353},"locus_GRCh38":{"chromosome":"12","position":47860570}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=2062"],"gwas_catalog_id":"GCST007843","neg_log_pval":11.522878745280337,"otg_id":"GCST007843","pubmed_id":"30891314"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000111424 at this locus (78926bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":48415757},"locus_GRCh38":{"chromosome":"12","position":48021974}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":8.698970004336019,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":10.698970004336019,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":10.698970004336019,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.3979400086720375,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":8.698970004336019,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.3979400086720375,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48419618},"locus_GRCh38":{"chromosome":"12","position":48025835}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":9.301029995663981,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (260223bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48597053},"locus_GRCh38":{"chromosome":"12","position":48203270}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":9.53863955699212,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48615283},"locus_GRCh38":{"chromosome":"12","position":48221500}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":9.53863955699212,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111424","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":48615283},"locus_GRCh38":{"chromosome":"12","position":48221500}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":10.0,"otg_id":"GCST002318","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56394954},"locus_GRCh38":{"chromosome":"12","position":56001170}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":7.698970004336019,"otg_id":"GCST002318_2","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56394954},"locus_GRCh38":{"chromosome":"12","position":56001170}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":9.0,"otg_id":"GCST006959","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56394954},"locus_GRCh38":{"chromosome":"12","position":56001170}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.397940008672037,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56396768},"locus_GRCh38":{"chromosome":"12","position":56002984}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.397940008672037,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000110944 at this locus (331190bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56396768},"locus_GRCh38":{"chromosome":"12","position":56002984}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.397940008672037,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56396768},"locus_GRCh38":{"chromosome":"12","position":56002984}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.397940008672037,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56396768},"locus_GRCh38":{"chromosome":"12","position":56002984}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.397940008672037,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug BRAZIKUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56396768},"locus_GRCh38":{"chromosome":"12","position":56002984}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":9.0,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56737973},"locus_GRCh38":{"chromosome":"12","position":56344189}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=12244"],"gwas_catalog_id":"GCST002738","neg_log_pval":9.221848749616356,"otg_id":"GCST002738","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56737973},"locus_GRCh38":{"chromosome":"12","position":56344189}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=12244"],"gwas_catalog_id":"GCST002738","neg_log_pval":9.221848749616356,"otg_id":"GCST002738","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56737973},"locus_GRCh38":{"chromosome":"12","position":56344189}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":9.0,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":56737973},"locus_GRCh38":{"chromosome":"12","position":56344189}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":11.301029995663981,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56740682},"locus_GRCh38":{"chromosome":"12","position":56346898}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":10.0,"otg_id":"GCST002874_8","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56740682},"locus_GRCh38":{"chromosome":"12","position":56346898}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":11.301029995663981,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56740682},"locus_GRCh38":{"chromosome":"12","position":56346898}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":10.0,"otg_id":"GCST002874_8","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56740682},"locus_GRCh38":{"chromosome":"12","position":56346898}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":24.397940008672037,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56741228},"locus_GRCh38":{"chromosome":"12","position":56347444}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":24.397940008672037,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":56741228},"locus_GRCh38":{"chromosome":"12","position":56347444}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":11.698970004336019,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56744276},"locus_GRCh38":{"chromosome":"12","position":56350492}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":11.698970004336019,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56744276},"locus_GRCh38":{"chromosome":"12","position":56350492}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=8941"],"gwas_catalog_id":"GCST003268","neg_log_pval":14.397940008672037,"otg_id":"GCST003268","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000110944 at this locus (16011bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000110944","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":56750204},"locus_GRCh38":{"chromosome":"12","position":56356420}},"trait_info":{"ontology":["EFO_1001494"],"reported_trait_name":"Psoriasis vulgaris","standard_trait_name":"psoriasis vulgaris"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":8.154901959985743,"otg_id":"GCST002318_2","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"MAP kinase-activated protein kinase 5 inhibitor drug GLPG-0259 is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000089022 at this locus (446244bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000089022","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":111833788},"locus_GRCh38":{"chromosome":"12","position":111395984}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=314"],"gwas_catalog_id":"GCST002293","neg_log_pval":7.301029995663981,"otg_id":"GCST002293","pubmed_id":"24277619"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Aldehyde dehydrogenase inhibitor drug DISULFIRAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000111275 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000111275","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":112241766},"locus_GRCh38":{"chromosome":"12","position":111803962}},"trait_info":{"ontology":["EFO_0003829"],"reported_trait_name":"Alcohol dependence","standard_trait_name":"alcohol dependence"}}
{"association_info":{"ancestry":["NR=7046","European=7320","NR, Hispanic or Latin American, African unspecified, Asian unspecified=636"],"gwas_catalog_id":"GCST002991","neg_log_pval":10.045757490560675,"otg_id":"GCST002991","pubmed_id":"26098869"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"13","position":28476978},"locus_GRCh38":{"chromosome":"13","position":27902841}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["NR=7046","European=7320","NR, Hispanic or Latin American, African unspecified, Asian unspecified=636"],"gwas_catalog_id":"GCST002991","neg_log_pval":10.045757490560675,"otg_id":"GCST002991","pubmed_id":"26098869"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"13","position":28476978},"locus_GRCh38":{"chromosome":"13","position":27902841}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["European=21536"],"gwas_catalog_id":"GCST005434","neg_log_pval":13.301029995663981,"otg_id":"GCST005434","pubmed_id":"29422604"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"13","position":28493997},"locus_GRCh38":{"chromosome":"13","position":27919860}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["European=21536"],"gwas_catalog_id":"GCST005434","neg_log_pval":13.301029995663981,"otg_id":"GCST005434","pubmed_id":"29422604"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"13","position":28493997},"locus_GRCh38":{"chromosome":"13","position":27919860}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["European=6785"],"gwas_catalog_id":"GCST002553","neg_log_pval":8.698970004336019,"otg_id":"GCST002553","pubmed_id":"25086665"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"13","position":28493997},"locus_GRCh38":{"chromosome":"13","position":27919860}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["European=6785"],"gwas_catalog_id":"GCST002553","neg_log_pval":8.698970004336019,"otg_id":"GCST002553","pubmed_id":"25086665"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122025","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"13","position":28493997},"locus_GRCh38":{"chromosome":"13","position":27919860}},"trait_info":{"ontology":["EFO_0002618"],"reported_trait_name":"Pancreatic cancer","standard_trait_name":"pancreatic carcinoma"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":11.698970004336019,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Relaxin receptor 2 activator drug SERELAXIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000133105 at this locus (67851bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000133105","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"13","position":32245813},"locus_GRCh38":{"chromosome":"13","position":31671676}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":11.549904924128398,"otg_id":"NEALE2_20002_1309","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 11 inhibitor drug DENOSUMAB is Phase IV for the indiciation EFO_0003882 and targets the gene ENSG00000120659 at this locus (184727bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000120659","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"13","position":42952145},"locus_GRCh38":{"chromosome":"13","position":42378009}},"trait_info":{"ontology":["EFO_0003882"],"reported_trait_name":"Osteoporosis | non-cancer illness code, self-reported","standard_trait_name":"osteoporosis"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":11.096910013008056,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":113631780},"locus_GRCh38":{"chromosome":"13","position":112977466}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":11.085445301482366,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":113631780},"locus_GRCh38":{"chromosome":"13","position":112977466}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":11.096910013008056,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":113631780},"locus_GRCh38":{"chromosome":"13","position":112977466}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":11.085445301482366,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":113631780},"locus_GRCh38":{"chromosome":"13","position":112977466}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=8071"],"gwas_catalog_id":"GCST001209","neg_log_pval":7.698970004336019,"otg_id":"GCST001209","pubmed_id":"21871595"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000126218 at this locus (82619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":113694509},"locus_GRCh38":{"chromosome":"13","position":113040195}},"trait_info":{"ontology":["EFO_0002506"],"reported_trait_name":"Osteoarthritis","standard_trait_name":"osteoarthritis"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":7.860750782428393,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug BETRIXABAN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"13","position":113872712},"locus_GRCh38":{"chromosome":"13","position":113218398}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":7.860750782428393,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"13","position":113872712},"locus_GRCh38":{"chromosome":"13","position":113218398}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":7.860750782428393,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Coagulation factor X inhibitor drug IDRAPARINUX is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000126218","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"13","position":113872712},"locus_GRCh38":{"chromosome":"13","position":113218398}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":7.698970004336019,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug CARFILZOMIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000100804 at this locus (180104bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":23305649},"locus_GRCh38":{"chromosome":"14","position":22836440}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":7.698970004336019,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000258643 at this locus (470396bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258643","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":23305649},"locus_GRCh38":{"chromosome":"14","position":22836440}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":7.698970004336019,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000129473 at this locus (462350bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000129473","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":23305649},"locus_GRCh38":{"chromosome":"14","position":22836440}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1452","European=2358","Hispanic or Latin American=1313"],"gwas_catalog_id":"GCST001912","neg_log_pval":11.045757490560675,"otg_id":"GCST001912","pubmed_id":"23512250"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (80894bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"14","position":23585333},"locus_GRCh38":{"chromosome":"14","position":23116124}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood)","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=4735","Hispanic or Latin American=10533","African American or Afro-Caribbean=3972"],"gwas_catalog_id":"GCST005315","neg_log_pval":12.154901959985743,"otg_id":"GCST005315","pubmed_id":"29348612"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":23589057},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood)","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=893"],"gwas_catalog_id":"GCST001320","neg_log_pval":7.698970004336019,"otg_id":"GCST001320_3","pubmed_id":"22076464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":23589057},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood) [ETV6-RUNX1 positive]","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=6381"],"gwas_catalog_id":"GCST002158","neg_log_pval":16.0,"otg_id":"GCST002158","pubmed_id":"23996088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":23589057},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0000094"],"reported_trait_name":"Acute lymphoblastic leukemia (B-cell precursor)","standard_trait_name":"B-cell acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=893"],"gwas_catalog_id":"GCST001320","neg_log_pval":9.397940008672037,"otg_id":"GCST001320","pubmed_id":"22076464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":23589057},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood)","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=17051"],"gwas_catalog_id":"GCST005832","neg_log_pval":13.301029995663981,"otg_id":"GCST005832","pubmed_id":"29632299"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100804","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"14","position":23589057},"locus_GRCh38":{"chromosome":"14","position":23119848}},"trait_info":{"ontology":["EFO_0000094"],"reported_trait_name":"Acute lymphoblastic leukemia in childhood (B cell precursor)","standard_trait_name":"B-cell acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=480359"],"gwas_catalog_id":"GCST005839","neg_log_pval":9.096910013008056,"otg_id":"GCST005839","pubmed_id":"29700475"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000140009","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"14","position":64686207},"locus_GRCh38":{"chromosome":"14","position":64219489}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["East Asian=7394"],"gwas_catalog_id":"GCST003148","neg_log_pval":9.221848749616356,"otg_id":"GCST003148","pubmed_id":"26443449"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor beta modulator drug ESTRAMUSTINE PHOSPHATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000140009 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000140009","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"14","position":64693912},"locus_GRCh38":{"chromosome":"14","position":64227194}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":11.397940008672037,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000140009","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":64697037},"locus_GRCh38":{"chromosome":"14","position":64230319}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.172630726946174,"otg_id":"SAIGE_366"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0001059 and targets the gene ENSG00000182256 at this locus (443188bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000182256","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":28230318},"locus_GRCh38":{"chromosome":"15","position":27985172}},"trait_info":{"ontology":["EFO_0001059"],"reported_trait_name":"Cataract","standard_trait_name":"cataract"}}
{"association_info":{"ancestry":["European=11756"],"gwas_catalog_id":"GCST003524","neg_log_pval":12.301029995663981,"otg_id":"GCST003524","pubmed_id":"27135401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137869","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":51537806},"locus_GRCh38":{"chromosome":"15","position":51245609}},"trait_info":{"ontology":["EFO_1001512"],"reported_trait_name":"Endometrial cancer","standard_trait_name":"endometrial carcinoma"}}
{"association_info":{"ancestry":["European=121885"],"gwas_catalog_id":"GCST006464","neg_log_pval":13.522878745280337,"otg_id":"GCST006464","pubmed_id":"30093612"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137869","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":51553909},"locus_GRCh38":{"chromosome":"15","position":51261712}},"trait_info":{"ontology":["EFO_1001512"],"reported_trait_name":"Endometrial cancer","standard_trait_name":"endometrial carcinoma"}}
{"association_info":{"ancestry":["European=54884"],"gwas_catalog_id":"GCST006465","neg_log_pval":9.698970004336019,"otg_id":"GCST006465","pubmed_id":"30093612"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137869","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":51553909},"locus_GRCh38":{"chromosome":"15","position":51261712}},"trait_info":{"ontology":["EFO_1001512"],"reported_trait_name":"Endometrial cancer (endometrioid histology)","standard_trait_name":"endometrial carcinoma"}}
{"association_info":{"ancestry":["European=20926","African American or Afro-Caribbean=2895"],"gwas_catalog_id":"GCST000675","neg_log_pval":8.0,"otg_id":"GCST000675_2","pubmed_id":"20445134"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000074410 at this locus (63881bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000074410","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":63737925},"locus_GRCh38":{"chromosome":"15","position":63445726}},"trait_info":{"ontology":["EFO_0003144"],"reported_trait_name":"Heart failure [EA]","standard_trait_name":"heart failure"}}
{"association_info":{"ancestry":["European, NR=58918","European=458969"],"gwas_catalog_id":"GCST007656","neg_log_pval":12.0,"otg_id":"GCST007656","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000074410 at this locus (314720bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000074410","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":63988765},"locus_GRCh38":{"chromosome":"15","position":63696566}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=59133"],"gwas_catalog_id":"GCST001499","neg_log_pval":16.522878745280337,"otg_id":"GCST001499","pubmed_id":"22544366"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":73652174},"locus_GRCh38":{"chromosome":"15","position":73359833}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=59133"],"gwas_catalog_id":"GCST001499","neg_log_pval":16.522878745280337,"otg_id":"GCST001499","pubmed_id":"22544366"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":73652174},"locus_GRCh38":{"chromosome":"15","position":73359833}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":35.32039042822024,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73667255},"locus_GRCh38":{"chromosome":"15","position":73374914}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":35.32039042822024,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73667255},"locus_GRCh38":{"chromosome":"15","position":73374914}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":26.69897000433602,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73667255},"locus_GRCh38":{"chromosome":"15","position":73374914}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":26.69897000433602,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73667255},"locus_GRCh38":{"chromosome":"15","position":73374914}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.522878745280337,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73668046},"locus_GRCh38":{"chromosome":"15","position":73375705}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.522878745280337,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":73668046},"locus_GRCh38":{"chromosome":"15","position":73375705}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=118755"],"gwas_catalog_id":"GCST004297","neg_log_pval":11.096910013008056,"otg_id":"GCST004297","pubmed_id":"28416818"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":73669006},"locus_GRCh38":{"chromosome":"15","position":73376665}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=118755"],"gwas_catalog_id":"GCST004297","neg_log_pval":11.096910013008056,"otg_id":"GCST004297","pubmed_id":"28416818"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":73669006},"locus_GRCh38":{"chromosome":"15","position":73376665}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":27.0,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":73677264},"locus_GRCh38":{"chromosome":"15","position":73384923}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":27.0,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138622","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":73677264},"locus_GRCh38":{"chromosome":"15","position":73384923}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.698970004336019,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":9900057},"locus_GRCh38":{"chromosome":"16","position":9806200}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":8.698970004336019,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0003756 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":9900057},"locus_GRCh38":{"chromosome":"16","position":9806200}},"trait_info":{"ontology":["EFO_0003756"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"autism spectrum disorder"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":8.221848749616356,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":9900057},"locus_GRCh38":{"chromosome":"16","position":9806200}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":7.698970004336019,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":9946319},"locus_GRCh38":{"chromosome":"16","position":9852462}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":8.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":9946319},"locus_GRCh38":{"chromosome":"16","position":9852462}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":8.221848749616356,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":9946319},"locus_GRCh38":{"chromosome":"16","position":9852462}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":8.0,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":9946319},"locus_GRCh38":{"chromosome":"16","position":9852462}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":8.522878745280337,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183454","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":9946319},"locus_GRCh38":{"chromosome":"16","position":9852462}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":8.301029995663981,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":27349168},"locus_GRCh38":{"chromosome":"16","position":27337847}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":11.676747899828312,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":27349168},"locus_GRCh38":{"chromosome":"16","position":27337847}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007076","neg_log_pval":15.301029995663981,"otg_id":"GCST007076","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase II for the indiciation EFO_0000684 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":27349168},"locus_GRCh38":{"chromosome":"16","position":27337847}},"trait_info":{"ontology":["EFO_0000684"],"reported_trait_name":"Respiratory diseases","standard_trait_name":"respiratory system disease"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":12.204815410317575,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":27349168},"locus_GRCh38":{"chromosome":"16","position":27337847}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.97061622231479,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":27349438},"locus_GRCh38":{"chromosome":"16","position":27338117}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.866461091629782,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":27355849},"locus_GRCh38":{"chromosome":"16","position":27344528}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":19.397940008672037,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":27369502},"locus_GRCh38":{"chromosome":"16","position":27358181}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":12.795880017344075,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":27371424},"locus_GRCh38":{"chromosome":"16","position":27360103}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":13.721246399047171,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":27371424},"locus_GRCh38":{"chromosome":"16","position":27360103}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007075","neg_log_pval":8.096910013008056,"otg_id":"GCST007075","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase IV for the indiciation HP_0000964 and targets the gene ENSG00000077238 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000077238","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":27371539},"locus_GRCh38":{"chromosome":"16","position":27360218}},"trait_info":{"ontology":["HP_0000964"],"reported_trait_name":"Eczema","standard_trait_name":"Eczema"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":29.397940008672037,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (312964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GT"},"locus_GRCh37":{"chromosome":"16","position":30171015},"locus_GRCh38":{"chromosome":"16","position":30159694}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2252"],"gwas_catalog_id":"GCST000507","neg_log_pval":7.522878745280337,"otg_id":"GCST000507","pubmed_id":"19838193"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000005844 at this locus (108362bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":30642867},"locus_GRCh38":{"chromosome":"16","position":30631546}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":7.607581136972331,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (269751bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":30804257},"locus_GRCh38":{"chromosome":"16","position":30792936}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["NR=4377"],"gwas_catalog_id":"GCST000834","neg_log_pval":9.045757490560675,"otg_id":"GCST000834","pubmed_id":"20953189"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (408120bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":30942625},"locus_GRCh38":{"chromosome":"16","position":30931304}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":10.0,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (436435bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":30970941},"locus_GRCh38":{"chromosome":"16","position":30959620}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":7.698970004336019,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (466304bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":31000809},"locus_GRCh38":{"chromosome":"16","position":30989488}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":15.0,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (486572bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000005844","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":31021078},"locus_GRCh38":{"chromosome":"16","position":31009757}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":9.289274371510311,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium/glucose cotransporter 2 inhibitor drug DAPAGLIFLOZIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000140675 at this locus (345181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000140675","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":31149142},"locus_GRCh38":{"chromosome":"16","position":31137821}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":12.0,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium/glucose cotransporter 2 inhibitor drug EMPAGLIFLOZIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000140675 at this locus (345181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000140675","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":31149142},"locus_GRCh38":{"chromosome":"16","position":31137821}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=22161"],"gwas_catalog_id":"GCST001003","neg_log_pval":8.045757490560675,"otg_id":"GCST001003","pubmed_id":"21386085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56988044},"locus_GRCh38":{"chromosome":"16","position":56954132}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=22161"],"gwas_catalog_id":"GCST001007","neg_log_pval":16.0,"otg_id":"GCST001007_4","pubmed_id":"21386085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56988044},"locus_GRCh38":{"chromosome":"16","position":56954132}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome (bivariate traits) [HDLC-WC]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":149.0,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cholesteryl ester transfer protein inhibitor drug ANACETRAPIB is Phase III for the indiciation EFO_0001645 and targets the gene ENSG00000087237 at this locus (5120bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087237","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56990716},"locus_GRCh38":{"chromosome":"16","position":56956804}},"trait_info":{"ontology":["EFO_0001645"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"coronary heart disease"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":149.0,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000070915 at this locus (40954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56990716},"locus_GRCh38":{"chromosome":"16","position":56956804}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":149.0,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000070915 at this locus (40954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56990716},"locus_GRCh38":{"chromosome":"16","position":56956804}},"trait_info":{"ontology":["EFO_0003144"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"heart failure"}}
{"association_info":{"ancestry":["European=10564"],"gwas_catalog_id":"GCST001436","neg_log_pval":59.045757490560675,"otg_id":"GCST001436_2","pubmed_id":"22399527"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (40954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56990716},"locus_GRCh38":{"chromosome":"16","position":56956804}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [HDL]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=22161"],"gwas_catalog_id":"GCST001007","neg_log_pval":12.522878745280337,"otg_id":"GCST001007_2","pubmed_id":"21386085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56993324},"locus_GRCh38":{"chromosome":"16","position":56959412}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome (bivariate traits) [BP-HDLC]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["South Asian=2554"],"gwas_catalog_id":"GCST000753","neg_log_pval":48.0,"otg_id":"GCST000753_3","pubmed_id":"20694148"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":56993324},"locus_GRCh38":{"chromosome":"16","position":56959412}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [HDL]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=22161"],"gwas_catalog_id":"GCST001007","neg_log_pval":11.154901959985743,"otg_id":"GCST001007_3","pubmed_id":"21386085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (52971bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000070915","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":57002732},"locus_GRCh38":{"chromosome":"16","position":56968820}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome (bivariate traits) [HDLC-GLUC]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.522878745280337,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dihydroorotate dehydrogenase inhibitor drug LEFLUNOMIDE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000102967 at this locus (351162bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000102967","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":71691329},"locus_GRCh38":{"chromosome":"16","position":71657426}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=455221"],"gwas_catalog_id":"GCST007093","neg_log_pval":9.698970004336019,"otg_id":"GCST007093","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0002506 and targets the gene ENSG00000258947 at this locus (283436bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89704365},"locus_GRCh38":{"chromosome":"16","position":89637957}},"trait_info":{"ontology":["EFO_0002506"],"reported_trait_name":"Osteoarthritis","standard_trait_name":"osteoarthritis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":33.803837637410474,"otg_id":"NEALE2_20001_1059","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89736157},"locus_GRCh38":{"chromosome":"16","position":89669749}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Malignant melanoma | cancer code, self-reported","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=61457"],"gwas_catalog_id":"GCST003327","neg_log_pval":20.0,"otg_id":"GCST003327_3","pubmed_id":"26829030"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89736157},"locus_GRCh38":{"chromosome":"16","position":89669749}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma [adjusted for rs4268748]","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":33.803837637410474,"otg_id":"NEALE2_20001_1059","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89736157},"locus_GRCh38":{"chromosome":"16","position":89669749}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Malignant melanoma | cancer code, self-reported","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=61457"],"gwas_catalog_id":"GCST003327","neg_log_pval":20.0,"otg_id":"GCST003327_3","pubmed_id":"26829030"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89736157},"locus_GRCh38":{"chromosome":"16","position":89669749}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma [adjusted for rs4268748]","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=10422"],"gwas_catalog_id":"GCST001267","neg_log_pval":26.522878745280337,"otg_id":"GCST001267","pubmed_id":"21983787"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":26.522878745280337,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":26.522878745280337,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=6122"],"gwas_catalog_id":"GCST002514","neg_log_pval":8.698970004336019,"otg_id":"GCST002514","pubmed_id":"24980573"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=5456"],"gwas_catalog_id":"GCST000437","neg_log_pval":26.522878745280337,"otg_id":"GCST000437","pubmed_id":"19578364"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=5456"],"gwas_catalog_id":"GCST000437","neg_log_pval":26.522878745280337,"otg_id":"GCST000437","pubmed_id":"19578364"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=10422"],"gwas_catalog_id":"GCST001267","neg_log_pval":26.522878745280337,"otg_id":"GCST001267","pubmed_id":"21983787"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=6122"],"gwas_catalog_id":"GCST002514","neg_log_pval":8.698970004336019,"otg_id":"GCST002514","pubmed_id":"24980573"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":89755903},"locus_GRCh38":{"chromosome":"16","position":89689495}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=58607"],"neg_log_pval":11.396639075651619,"otg_id":"NEALE2_40009","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89846677},"locus_GRCh38":{"chromosome":"16","position":89780269}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Reported occurrences of cancer","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":44.69897000433602,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89846677},"locus_GRCh38":{"chromosome":"16","position":89780269}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=58607"],"neg_log_pval":11.396639075651619,"otg_id":"NEALE2_40009","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89846677},"locus_GRCh38":{"chromosome":"16","position":89780269}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Reported occurrences of cancer","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":44.69897000433602,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89846677},"locus_GRCh38":{"chromosome":"16","position":89780269}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=58607"],"neg_log_pval":11.396639075651619,"otg_id":"NEALE2_40009","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89846677},"locus_GRCh38":{"chromosome":"16","position":89780269}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Reported occurrences of cancer","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":12.303643611266669,"otg_id":"NEALE2_20001_1059","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":89951527},"locus_GRCh38":{"chromosome":"16","position":89885119}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Malignant melanoma | cancer code, self-reported","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":12.303643611266669,"otg_id":"NEALE2_20001_1059","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":89951527},"locus_GRCh38":{"chromosome":"16","position":89885119}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Malignant melanoma | cancer code, self-reported","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=406033"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.698970004336019,"otg_id":"SAIGE_702_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0002496 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0002496"],"reported_trait_name":"Actinic keratosis","standard_trait_name":"actinic keratosis"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":28.661543506395397,"otg_id":"SAIGE_172_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":36.39794000867204,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":36.39794000867204,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=287137"],"gwas_catalog_id":"GCST003655","neg_log_pval":38.045757490560675,"otg_id":"GCST003655","pubmed_id":"27424798"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_1001927 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_1001927"],"reported_trait_name":"Cutaneous squamous cell carcinoma","standard_trait_name":"cutaneous squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":28.661543506395397,"otg_id":"SAIGE_172_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":28.661543506395397,"otg_id":"SAIGE_172_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin, dx or hx","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":28.661543506395397,"otg_id":"SAIGE_172_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89986117},"locus_GRCh38":{"chromosome":"16","position":89919709}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin, dx or hx","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.339134521996131,"otg_id":"SAIGE_172_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89990843},"locus_GRCh38":{"chromosome":"16","position":89924435}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.339134521996131,"otg_id":"SAIGE_172_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89990843},"locus_GRCh38":{"chromosome":"16","position":89924435}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.339134521996131,"otg_id":"SAIGE_172_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89990843},"locus_GRCh38":{"chromosome":"16","position":89924435}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin, dx or hx","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=397762"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.339134521996131,"otg_id":"SAIGE_172_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89990843},"locus_GRCh38":{"chromosome":"16","position":89924435}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Melanomas of skin, dx or hx","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=359981"],"neg_log_pval":12.515700160653214,"otg_id":"NEALE2_2453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90024206},"locus_GRCh38":{"chromosome":"16","position":89957798}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Cancer diagnosed by doctor","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=359981"],"neg_log_pval":12.515700160653214,"otg_id":"NEALE2_2453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90024206},"locus_GRCh38":{"chromosome":"16","position":89957798}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Cancer diagnosed by doctor","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=359981"],"neg_log_pval":12.515700160653214,"otg_id":"NEALE2_2453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90024206},"locus_GRCh38":{"chromosome":"16","position":89957798}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Cancer diagnosed by doctor","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=61457"],"gwas_catalog_id":"GCST003327","neg_log_pval":43.69897000433602,"otg_id":"GCST003327","pubmed_id":"26829030"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":90026512},"locus_GRCh38":{"chromosome":"16","position":89960104}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=61457"],"gwas_catalog_id":"GCST003327","neg_log_pval":43.69897000433602,"otg_id":"GCST003327","pubmed_id":"26829030"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":90026512},"locus_GRCh38":{"chromosome":"16","position":89960104}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=13550"],"gwas_catalog_id":"GCST003422","neg_log_pval":8.698970004336019,"otg_id":"GCST003422","pubmed_id":"26908436"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90027626},"locus_GRCh38":{"chromosome":"16","position":89961218}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=13550"],"gwas_catalog_id":"GCST003422","neg_log_pval":8.698970004336019,"otg_id":"GCST003422","pubmed_id":"26908436"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90027626},"locus_GRCh38":{"chromosome":"16","position":89961218}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Squamous cell carcinoma","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":21.221848749616356,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90066936},"locus_GRCh38":{"chromosome":"16","position":90000528}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=5456"],"gwas_catalog_id":"GCST000437","neg_log_pval":21.221848749616356,"otg_id":"GCST000437","pubmed_id":"19578364"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90066936},"locus_GRCh38":{"chromosome":"16","position":90000528}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":21.221848749616356,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90066936},"locus_GRCh38":{"chromosome":"16","position":90000528}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=5456"],"gwas_catalog_id":"GCST000437","neg_log_pval":21.221848749616356,"otg_id":"GCST000437","pubmed_id":"19578364"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000258947","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":90066936},"locus_GRCh38":{"chromosome":"16","position":90000528}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":10.096910013008056,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":3947644},"locus_GRCh38":{"chromosome":"17","position":4044350}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":10.096910013008056,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":3947644},"locus_GRCh38":{"chromosome":"17","position":4044350}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":10.045757490560675,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":3953102},"locus_GRCh38":{"chromosome":"17","position":4049808}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":8.096910013008056,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":3953102},"locus_GRCh38":{"chromosome":"17","position":4049808}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":8.096910013008056,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":3953102},"locus_GRCh38":{"chromosome":"17","position":4049808}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":10.045757490560675,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":3953102},"locus_GRCh38":{"chromosome":"17","position":4049808}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.644381843915278,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000196689 at this locus (467788bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":3980493},"locus_GRCh38":{"chromosome":"17","position":4077199}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":13.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":3985864},"locus_GRCh38":{"chromosome":"17","position":4082570}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":13.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196689","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":3985864},"locus_GRCh38":{"chromosome":"17","position":4082570}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=5704"],"gwas_catalog_id":"GCST001364","neg_log_pval":10.045757490560675,"otg_id":"GCST001364","pubmed_id":"22197929"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000161955","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":7462969},"locus_GRCh38":{"chromosome":"17","position":7559652}},"trait_info":{"ontology":["EFO_0004194"],"reported_trait_name":"IgA nephropathy","standard_trait_name":"IGA glomerulonephritis"}}
{"association_info":{"ancestry":["East Asian=5704"],"gwas_catalog_id":"GCST001364","neg_log_pval":9.397940008672037,"otg_id":"GCST001364","pubmed_id":"22197929"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (26251bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000161955","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":7491177},"locus_GRCh38":{"chromosome":"17","position":7587859}},"trait_info":{"ontology":["EFO_0004194"],"reported_trait_name":"IgA nephropathy","standard_trait_name":"IGA glomerulonephritis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":20.30102999566398,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Eotaxin inhibitor drug BERTILIMUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000172156 at this locus (42141bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000172156","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":32570547},"locus_GRCh38":{"chromosome":"17","position":34243528}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["East Asian=4392"],"gwas_catalog_id":"GCST002082","neg_log_pval":9.045757490560675,"otg_id":"GCST002082","pubmed_id":"23817570"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA topoisomerase II alpha inhibitor drug DOXORUBICIN is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000131747 at this locus (493430bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000131747","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":38051348},"locus_GRCh38":{"chromosome":"17","position":39895095}},"trait_info":{"ontology":["EFO_0001061"],"reported_trait_name":"Cervical cancer [Matched]","standard_trait_name":"cervical carcinoma"}}
{"association_info":{"ancestry":["East Asian=4392"],"gwas_catalog_id":"GCST002082","neg_log_pval":9.045757490560675,"otg_id":"GCST002082","pubmed_id":"23817570"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Receptor protein-tyrosine kinase erbB-2 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000141736 at this locus (164669bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000141736","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"17","position":38051348},"locus_GRCh38":{"chromosome":"17","position":39895095}},"trait_info":{"ontology":["EFO_0001061"],"reported_trait_name":"Cervical cancer [Matched]","standard_trait_name":"cervical carcinoma"}}
{"association_info":{"ancestry":["European=4735","Hispanic or Latin American=10533","African American or Afro-Caribbean=3972"],"gwas_catalog_id":"GCST005315","neg_log_pval":9.0,"otg_id":"GCST005315","pubmed_id":"29348612"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA topoisomerase II alpha inhibitor drug ETOPOSIDE PHOSPHATE is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000131747","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":38066240},"locus_GRCh38":{"chromosome":"17","position":39909987}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood)","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=4735","Hispanic or Latin American=10533","African American or Afro-Caribbean=3972"],"gwas_catalog_id":"GCST005315","neg_log_pval":9.0,"otg_id":"GCST005315","pubmed_id":"29348612"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA topoisomerase II alpha inhibitor drug DAUNORUBICIN is Phase IV for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000131747","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":38066240},"locus_GRCh38":{"chromosome":"17","position":39909987}},"trait_info":{"ontology":["EFO_0000220"],"reported_trait_name":"Acute lymphoblastic leukemia (childhood)","standard_trait_name":"acute lymphoblastic leukemia"}}
{"association_info":{"ancestry":["European=359241"],"neg_log_pval":12.11747546204512,"otg_id":"NEALE2_2463","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (37925bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167941","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CT"},"locus_GRCh37":{"chromosome":"17","position":41793182},"locus_GRCh38":{"chromosome":"17","position":43715814}},"trait_info":{"ontology":["EFO_0003931"],"reported_trait_name":"Fractured/broken bones in last 5 years","standard_trait_name":"bone fracture"}}
{"association_info":{"ancestry":["European=426795"],"gwas_catalog_id":"GCST006980","neg_log_pval":40.30102999566398,"otg_id":"GCST006980","pubmed_id":"30598549"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (32252bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167941","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":41798855},"locus_GRCh38":{"chromosome":"17","position":43721487}},"trait_info":{"ontology":["EFO_0003931"],"reported_trait_name":"Fractures","standard_trait_name":"bone fracture"}}
{"association_info":{"ancestry":["East Asian=800","European=264173"],"gwas_catalog_id":"GCST006423","neg_log_pval":24.522878745280337,"otg_id":"GCST006423","pubmed_id":"30158200"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (4268bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167941","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":41826839},"locus_GRCh38":{"chromosome":"17","position":43749471}},"trait_info":{"ontology":["EFO_0003931"],"reported_trait_name":"Fractures","standard_trait_name":"bone fracture"}}
{"association_info":{"ancestry":["NR=171776"],"gwas_catalog_id":"GCST005835","neg_log_pval":10.522878745280337,"otg_id":"GCST005835","pubmed_id":"29559929"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (297425bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000120088","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":43564222},"locus_GRCh38":{"chromosome":"17","position":45486856}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Remission after SSRI treatment in MDD or neuroticism","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":21.624885315307775,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (5007bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000120088","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":43856639},"locus_GRCh38":{"chromosome":"17","position":45779273}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":15.265200170411154,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Carbonic anhydrase IV inhibitor drug TOPIRAMATE is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000167434 at this locus (410546bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167434","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":57816757},"locus_GRCh38":{"chromosome":"17","position":59739396}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":24.154901959985743,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug FOSINOPRIL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000159640 at this locus (5504bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61548918},"locus_GRCh38":{"chromosome":"17","position":63471557}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":24.154901959985743,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000007314 at this locus (466997bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61548918},"locus_GRCh38":{"chromosome":"17","position":63471557}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":19.50811606596098,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug CAPTOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61548948},"locus_GRCh38":{"chromosome":"17","position":63471587}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":19.50811606596098,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61548948},"locus_GRCh38":{"chromosome":"17","position":63471587}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":19.50811606596098,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug BUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (466967bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61548948},"locus_GRCh38":{"chromosome":"17","position":63471587}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.26440110030182,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.26440110030182,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.26440110030182,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.172630726946174,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.172630726946174,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.172630726946174,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61556298},"locus_GRCh38":{"chromosome":"17","position":63478937}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.3979400086720375,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61687600},"locus_GRCh38":{"chromosome":"17","position":63610240}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.3979400086720375,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Angiotensin-converting enzyme inhibitor drug PERINDOPRIL is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000159640","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61687600},"locus_GRCh38":{"chromosome":"17","position":63610240}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.3979400086720375,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000007314 at this locus (328315bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":61687600},"locus_GRCh38":{"chromosome":"17","position":63610240}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.096910013008056,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (336814bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":62387091},"locus_GRCh38":{"chromosome":"17","position":64309731}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":10.20210951694165,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (351688bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000007314","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":62401965},"locus_GRCh38":{"chromosome":"17","position":64324605}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":10.0,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (160996bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000123700","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":68337185},"locus_GRCh38":{"chromosome":"17","position":70341044}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":8.522878745280337,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000123700","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":68347338},"locus_GRCh38":{"chromosome":"17","position":70351197}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":8.522878745280337,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000123700","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":68347338},"locus_GRCh38":{"chromosome":"17","position":70351197}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["East Asian=9299","European=45790"],"gwas_catalog_id":"GCST006048","neg_log_pval":7.522878745280337,"otg_id":"GCST006048","pubmed_id":"24532676"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000176014","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":12797694},"locus_GRCh38":{"chromosome":"18","position":12797695}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-positive)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=20965"],"gwas_catalog_id":"GCST001454","neg_log_pval":7.698970004336019,"otg_id":"GCST001454","pubmed_id":"22446963"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000176014","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":12797694},"locus_GRCh38":{"chromosome":"18","position":12797695}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=4075"],"gwas_catalog_id":"GCST001674","neg_log_pval":10.698970004336019,"otg_id":"GCST001674","pubmed_id":"22960999"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000176014","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":12821593},"locus_GRCh38":{"chromosome":"18","position":12821594}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Esophageal cancer (squamous cell)","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["East Asian=4075"],"gwas_catalog_id":"GCST001674","neg_log_pval":10.698970004336019,"otg_id":"GCST001674","pubmed_id":"22960999"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000176014","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":12821593},"locus_GRCh38":{"chromosome":"18","position":12821594}},"trait_info":{"ontology":["EFO_0000707"],"reported_trait_name":"Esophageal cancer (squamous cell)","standard_trait_name":"squamous cell carcinoma"}}
{"association_info":{"ancestry":["East Asian=4075"],"gwas_catalog_id":"GCST001674","neg_log_pval":10.698970004336019,"otg_id":"GCST001674","pubmed_id":"22960999"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0002916 and targets the gene ENSG00000176014 at this locus (477275bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000176014","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":12821593},"locus_GRCh38":{"chromosome":"18","position":12821594}},"trait_info":{"ontology":["EFO_0002916"],"reported_trait_name":"Esophageal cancer (squamous cell)","standard_trait_name":"esophageal carcinoma"}}
{"association_info":{"ancestry":["European=2258"],"gwas_catalog_id":"GCST000663","neg_log_pval":10.221848749616356,"otg_id":"GCST000663","pubmed_id":"20421936"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (226313bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57811982},"locus_GRCh38":{"chromosome":"18","position":60144750}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity (early onset extreme)","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":35.69897000433602,"otg_id":"GCST001953_4","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187873bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57850422},"locus_GRCh38":{"chromosome":"18","position":60183189}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Obesity class I]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=2796"],"gwas_catalog_id":"GCST000317","neg_log_pval":7.698970004336019,"otg_id":"GCST000317_3","pubmed_id":"19151714"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57851097},"locus_GRCh38":{"chromosome":"18","position":60183864}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [children]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=2796"],"gwas_catalog_id":"GCST000317","neg_log_pval":14.301029995663981,"otg_id":"GCST000317","pubmed_id":"19151714"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57851097},"locus_GRCh38":{"chromosome":"18","position":60183864}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=2796"],"gwas_catalog_id":"GCST000317","neg_log_pval":8.397940008672037,"otg_id":"GCST000317_2","pubmed_id":"19151714"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57851097},"locus_GRCh38":{"chromosome":"18","position":60183864}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [adults]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":26.69897000433602,"otg_id":"GCST001953_5","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (186533bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":57851763},"locus_GRCh38":{"chromosome":"18","position":60184530}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Overweight]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=408792"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.251037138743838,"otg_id":"SAIGE_278_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57852587},"locus_GRCh38":{"chromosome":"18","position":60185354}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=6889"],"gwas_catalog_id":"GCST001957","neg_log_pval":13.045757490560675,"otg_id":"GCST001957","pubmed_id":"23563609"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57852587},"locus_GRCh38":{"chromosome":"18","position":60185354}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity (early onset extreme)","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.126098402135538,"otg_id":"SAIGE_278"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":57852587},"locus_GRCh38":{"chromosome":"18","position":60185354}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Overweight, obesity and other hyperalimentation","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":21.522878745280337,"otg_id":"GCST001953_3","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185347bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000166603","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":57852948},"locus_GRCh38":{"chromosome":"18","position":60185715}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Obesity class II]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=10486"],"gwas_catalog_id":"GCST002643","neg_log_pval":9.096910013008056,"otg_id":"GCST002643","pubmed_id":"25279986"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase II for the indiciation EFO_0000096 and targets the gene ENSG00000171791 at this locus (7369bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":60783211},"locus_GRCh38":{"chromosome":"18","position":63115978}},"trait_info":{"ontology":["EFO_0000096"],"reported_trait_name":"Follicular lymphoma","standard_trait_name":"neoplasm of mature B-cells"}}
{"association_info":{"ancestry":["European=17691"],"gwas_catalog_id":"GCST004146","neg_log_pval":10.698970004336019,"otg_id":"GCST004146","pubmed_id":"28165464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":60788745},"locus_GRCh38":{"chromosome":"18","position":63121512}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=17691"],"gwas_catalog_id":"GCST004146","neg_log_pval":10.698970004336019,"otg_id":"GCST004146","pubmed_id":"28165464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":60788745},"locus_GRCh38":{"chromosome":"18","position":63121512}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=10767"],"gwas_catalog_id":"GCST003468","neg_log_pval":10.397940008672037,"otg_id":"GCST003468","pubmed_id":"26956414"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"18","position":60793494},"locus_GRCh38":{"chromosome":"18","position":63126261}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=10767"],"gwas_catalog_id":"GCST003468","neg_log_pval":10.397940008672037,"otg_id":"GCST003468","pubmed_id":"26956414"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"18","position":60793494},"locus_GRCh38":{"chromosome":"18","position":63126261}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=8400"],"gwas_catalog_id":"GCST002073","neg_log_pval":11.522878745280337,"otg_id":"GCST002073","pubmed_id":"23770605"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"18","position":60793549},"locus_GRCh38":{"chromosome":"18","position":63126316}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=8400"],"gwas_catalog_id":"GCST002073","neg_log_pval":11.522878745280337,"otg_id":"GCST002073","pubmed_id":"23770605"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"18","position":60793549},"locus_GRCh38":{"chromosome":"18","position":63126316}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=8400"],"gwas_catalog_id":"GCST002073","neg_log_pval":10.096910013008056,"otg_id":"GCST002073","pubmed_id":"23770605"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":60793921},"locus_GRCh38":{"chromosome":"18","position":63126688}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=8400"],"gwas_catalog_id":"GCST002073","neg_log_pval":10.096910013008056,"otg_id":"GCST002073","pubmed_id":"23770605"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"18","position":60793921},"locus_GRCh38":{"chromosome":"18","position":63126688}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"CT","reference":"C"},"locus_GRCh37":{"chromosome":"18","position":60961193},"locus_GRCh38":{"chromosome":"18","position":63293960}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CT"},"locus_GRCh37":{"chromosome":"18","position":60961193},"locus_GRCh38":{"chromosome":"18","position":63293960}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=33976"],"gwas_catalog_id":"GCST003219","neg_log_pval":7.522878745280337,"otg_id":"GCST003219_2","pubmed_id":"26691988"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Complement factor D inhibitor drug LAMPALIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000197766 at this locus (167810bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197766","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":1031438},"locus_GRCh38":{"chromosome":"19","position":1031439}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Advanced age-related macular degeneration [EA]","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=17691"],"gwas_catalog_id":"GCST004146","neg_log_pval":7.301029995663981,"otg_id":"GCST004146","pubmed_id":"28165464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Elongation factor 2 inhibitor drug DENILEUKIN DIFTITOX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000167658 at this locus (83658bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167658","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":4069119},"locus_GRCh38":{"chromosome":"19","position":4069121}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=1043"],"gwas_catalog_id":"GCST005934","neg_log_pval":8.522878745280337,"otg_id":"GCST005934","pubmed_id":"29884837"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Insulin receptor inhibitor drug LINSITINIB is Phase II for the indiciation EFO_0006859 and targets the gene ENSG00000171105 at this locus (340047bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171105","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":7699347},"locus_GRCh38":{"chromosome":"19","position":7634461}},"trait_info":{"ontology":["EFO_0006859"],"reported_trait_name":"Neuropathic pain in head and neck cancer","standard_trait_name":"head and neck malignant neoplasia"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":21.69897000433602,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (169080bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":10427721},"locus_GRCh38":{"chromosome":"19","position":10317045}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":42.52287874528034,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":10463118},"locus_GRCh38":{"chromosome":"19","position":10352442}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":11.517984423549288,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":10463118},"locus_GRCh38":{"chromosome":"19","position":10352442}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":13.045757490560675,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":10463118},"locus_GRCh38":{"chromosome":"19","position":10352442}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":10.397940008672037,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (126826bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":10469975},"locus_GRCh38":{"chromosome":"19","position":10359299}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":8.397940008672037,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (123868bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":10472933},"locus_GRCh38":{"chromosome":"19","position":10362257}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":13.522878745280337,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (18959bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":10577843},"locus_GRCh38":{"chromosome":"19","position":10467167}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":9.019088062223156,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase IV for the indiciation EFO_0003885 and targets the gene ENSG00000079999 at this locus (127936bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":10742170},"locus_GRCh38":{"chromosome":"19","position":10631494}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":9.019088062223156,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sphingosine 1-phosphate receptor Edg-8 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000180739 at this locus (113564bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180739","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":10742170},"locus_GRCh38":{"chromosome":"19","position":10631494}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":9.378437388797577,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (203859bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":10818092},"locus_GRCh38":{"chromosome":"19","position":10707416}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":9.698970004336019,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (271972bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000079999","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":10886206},"locus_GRCh38":{"chromosome":"19","position":10775530}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6042"],"gwas_catalog_id":"GCST000340","neg_log_pval":8.698970004336019,"otg_id":"GCST000340","pubmed_id":"19198609"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11163601},"locus_GRCh38":{"chromosome":"19","position":11052925}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction (early onset)","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=123388"],"gwas_catalog_id":"GCST002287","neg_log_pval":11.522878745280337,"otg_id":"GCST002287","pubmed_id":"24262325"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (324283bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11163601},"locus_GRCh38":{"chromosome":"19","position":11052925}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Coronary artery disease or ischemic stroke","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=6042"],"gwas_catalog_id":"GCST000340","neg_log_pval":8.698970004336019,"otg_id":"GCST000340","pubmed_id":"19198609"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11163601},"locus_GRCh38":{"chromosome":"19","position":11052925}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction (early onset)","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=446696","East Asian=45564","South Asian=9144","African American or Afro-Caribbean=20695","Asian unspecified=698","Hispanic or Latin American=1557"],"gwas_catalog_id":"GCST005838","neg_log_pval":7.522878745280337,"otg_id":"GCST005838","pubmed_id":"29531354"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (312949bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":11174935},"locus_GRCh38":{"chromosome":"19","position":11064259}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Stroke","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":7.522878745280337,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":11188153},"locus_GRCh38":{"chromosome":"19","position":11077477}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":7.522878745280337,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":11188153},"locus_GRCh38":{"chromosome":"19","position":11077477}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.777283528852417,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":11188164},"locus_GRCh38":{"chromosome":"19","position":11077488}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.777283528852417,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":11188164},"locus_GRCh38":{"chromosome":"19","position":11077488}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":35.71175077442801,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11188247},"locus_GRCh38":{"chromosome":"19","position":11077571}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.602059991327963,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11188247},"locus_GRCh38":{"chromosome":"19","position":11077571}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":14.397940008672037,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11188247},"locus_GRCh38":{"chromosome":"19","position":11077571}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":40.30102999566398,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11202306},"locus_GRCh38":{"chromosome":"19","position":11091630}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":21.096910013008056,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11202306},"locus_GRCh38":{"chromosome":"19","position":11091630}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":23.4089353929735,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":11202306},"locus_GRCh38":{"chromosome":"19","position":11091630}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":7.705313375720557,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (263618bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":11224265},"locus_GRCh38":{"chromosome":"19","position":11113589}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":7.698970004336019,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (184329bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":11303554},"locus_GRCh38":{"chromosome":"19","position":11192878}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=87827"],"gwas_catalog_id":"GCST005077","neg_log_pval":8.154901959985743,"otg_id":"GCST005077","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000187266 at this locus (64180bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":11423703},"locus_GRCh38":{"chromosome":"19","position":11313027}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":8.2518119729938,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (1963bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000187266","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":11496981},"locus_GRCh38":{"chromosome":"19","position":11386305}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=66756"],"gwas_catalog_id":"GCST004744","neg_log_pval":9.045757490560675,"otg_id":"GCST004744","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase receptor UFO inhibitor drug R428 is Phase II for the indiciation EFO_0000571 and targets the gene ENSG00000167601 at this locus (372022bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000167601","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":41353107},"locus_GRCh38":{"chromosome":"19","position":40847202}},"trait_info":{"ontology":["EFO_0000571"],"reported_trait_name":"Lung adenocarcinoma","standard_trait_name":"lung adenocarcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.045757490560675,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium/potassium-transporting ATPase inhibitor drug DIGOXIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000105409 at this locus (199298bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000105409","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":42700947},"locus_GRCh38":{"chromosome":"19","position":42196795}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":7.522878745280337,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (462229bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115758","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":10117868},"locus_GRCh38":{"chromosome":"2","position":9977740}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.698970004336019,"otg_id":"GCST002606_3","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115758","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":10710730},"locus_GRCh38":{"chromosome":"2","position":10570604}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer [EA]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":16.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115758","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":10710730},"locus_GRCh38":{"chromosome":"2","position":10570604}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=67543","Sub-Saharan African, African American or Afro-Caribbean=10463","East Asian=6954","Hispanic or Latin American=2080"],"gwas_catalog_id":"GCST002606","neg_log_pval":7.522878745280337,"otg_id":"GCST002606","pubmed_id":"25217961"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115758","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":10710730},"locus_GRCh38":{"chromosome":"2","position":10570604}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=241704"],"gwas_catalog_id":"GCST004483","neg_log_pval":16.0,"otg_id":"GCST004483","pubmed_id":"27363682"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (47687bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000119772","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":25613146},"locus_GRCh38":{"chromosome":"2","position":25390277}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=14421"],"gwas_catalog_id":"GCST004099","neg_log_pval":9.221848749616356,"otg_id":"GCST004099","pubmed_id":"28112199"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (63979bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000119772","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":25629438},"locus_GRCh38":{"chromosome":"2","position":25406569}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=14421"],"gwas_catalog_id":"GCST004099","neg_log_pval":9.221848749616356,"otg_id":"GCST004099","pubmed_id":"28112199"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000119772 at this locus (63979bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000119772","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":25629438},"locus_GRCh38":{"chromosome":"2","position":25406569}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":35.59516628338006,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171303","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":26914364},"locus_GRCh38":{"chromosome":"2","position":26691496}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":39.522019692388156,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171303","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":26914364},"locus_GRCh38":{"chromosome":"2","position":26691496}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":13.301029995663981,"otg_id":"GCST007707_2","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171303","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":26920025},"locus_GRCh38":{"chromosome":"2","position":26697157}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [Japanese]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":35.37263414340727,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171303","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":26923568},"locus_GRCh38":{"chromosome":"2","position":26700700}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":17.69897000433602,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171303","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":26930411},"locus_GRCh38":{"chromosome":"2","position":26707543}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=17500"],"gwas_catalog_id":"GCST003983","neg_log_pval":14.698970004336019,"otg_id":"GCST003983","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000277893","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":31805826},"locus_GRCh38":{"chromosome":"2","position":31580756}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["European=43590"],"gwas_catalog_id":"GCST005116","neg_log_pval":25.69897000433602,"otg_id":"GCST005116","pubmed_id":"29146897"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (375418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000277893","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":32181424},"locus_GRCh38":{"chromosome":"2","position":31956355}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":8.397940008672037,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=1639"],"gwas_catalog_id":"GCST000914","neg_log_pval":20.096910013008056,"otg_id":"GCST000914","pubmed_id":"21151128"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":8.397940008672037,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000170820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":8.397940008672037,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=1639"],"gwas_catalog_id":"GCST000914","neg_log_pval":20.096910013008056,"otg_id":"GCST000914","pubmed_id":"21151128"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=1639"],"gwas_catalog_id":"GCST000914","neg_log_pval":20.096910013008056,"otg_id":"GCST000914","pubmed_id":"21151128"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000170820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":48978159},"locus_GRCh38":{"chromosome":"2","position":48751020}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":12.0,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug LH (MENOTROPINS) is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":49201612},"locus_GRCh38":{"chromosome":"2","position":48974473}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":12.0,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138039","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":49201612},"locus_GRCh38":{"chromosome":"2","position":48974473}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["East Asian=5255"],"gwas_catalog_id":"GCST001634","neg_log_pval":12.0,"otg_id":"GCST001634","pubmed_id":"22885925"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Follicle stimulating hormone receptor agonist drug HUMAN FSH is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000170820","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":49201612},"locus_GRCh38":{"chromosome":"2","position":48974473}},"trait_info":{"ontology":["EFO_0000660"],"reported_trait_name":"Polycystic ovary syndrome","standard_trait_name":"polycystic ovary syndrome"}}
{"association_info":{"ancestry":["European=407052"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.52432881167557,"otg_id":"SAIGE_420_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-1 beta inhibitor drug RILONACEPT is Phase III for the indiciation EFO_0007427 and targets the gene ENSG00000125538 at this locus (15088bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000125538","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":113609568},"locus_GRCh38":{"chromosome":"2","position":112851991}},"trait_info":{"ontology":["EFO_0007427"],"reported_trait_name":"Pericarditis","standard_trait_name":"pericarditis"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":7.698970004336019,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000115159 at this locus (278767bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115159","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":157013035},"locus_GRCh38":{"chromosome":"2","position":156156523}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":17.522878745280337,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115159","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":157111313},"locus_GRCh38":{"chromosome":"2","position":156254801}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=480359"],"gwas_catalog_id":"GCST005839","neg_log_pval":7.698970004336019,"otg_id":"GCST005839","pubmed_id":"29700475"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115159","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":157111313},"locus_GRCh38":{"chromosome":"2","position":156254801}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=357957"],"gwas_catalog_id":"GCST006475","neg_log_pval":7.4889191544608815,"otg_id":"GCST006475","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (134654bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115159","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":157157148},"locus_GRCh38":{"chromosome":"2","position":156300636}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depressed affect","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.54284051026846,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (367302bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":162481453},"locus_GRCh38":{"chromosome":"2","position":161624943}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.732828271596986,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":162583504},"locus_GRCh38":{"chromosome":"2","position":161726994}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.580044251510242,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":162583504},"locus_GRCh38":{"chromosome":"2","position":161726994}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":7.301029995663981,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug LINAGLIPTIN is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000197635 at this locus (2901bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":162845855},"locus_GRCh38":{"chromosome":"2","position":161989345}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":12.522878745280337,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":163110536},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":11.698970004336019,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":163110536},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":17.418639958543828,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":163110536},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":17.418639958543828,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":163110536},"locus_GRCh38":{"chromosome":"2","position":162254026}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":7.709543459425466,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=19102"],"gwas_catalog_id":"GCST001191","neg_log_pval":13.698970004336019,"otg_id":"GCST001191","pubmed_id":"21829393"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":8.0,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=5000"],"gwas_catalog_id":"GCST000038","neg_log_pval":10.698970004336019,"otg_id":"GCST000038","pubmed_id":"17554260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":8.154901959985743,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":8.154901959985743,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=5000"],"gwas_catalog_id":"GCST000038","neg_log_pval":10.698970004336019,"otg_id":"GCST000038","pubmed_id":"17554260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=19102"],"gwas_catalog_id":"GCST001191","neg_log_pval":13.698970004336019,"otg_id":"GCST001191","pubmed_id":"21829393"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163124051},"locus_GRCh38":{"chromosome":"2","position":162267541}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":10.522878745280337,"otg_id":"GCST002874_5","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":163128824},"locus_GRCh38":{"chromosome":"2","position":162272314}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA, conditional on rs1990760]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":18.0,"otg_id":"GCST002874_9","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":163128824},"locus_GRCh38":{"chromosome":"2","position":162272314}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [conditional on rs1990760]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":24.0,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (237021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":163167746},"locus_GRCh38":{"chromosome":"2","position":162311236}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=12244"],"gwas_catalog_id":"GCST002738","neg_log_pval":8.522878745280337,"otg_id":"GCST002738","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":163260691},"locus_GRCh38":{"chromosome":"2","position":162404181}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":13.0,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000197635","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":163260691},"locus_GRCh38":{"chromosome":"2","position":162404181}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":10.012333735073724,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Integrin alpha-4/beta-1 inhibitor drug NATALIZUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000115232 at this locus (13578bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000115232","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":182308352},"locus_GRCh38":{"chromosome":"2","position":181443625}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["East Asian=4325"],"gwas_catalog_id":"GCST001457","neg_log_pval":13.045757490560675,"otg_id":"GCST001457","pubmed_id":"22452962"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Receptor protein-tyrosine kinase erbB-4 inhibitor drug BMS-690514 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000178568 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000178568","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":213296863},"locus_GRCh38":{"chromosome":"2","position":212432139}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European, NR=58918","European=458969"],"gwas_catalog_id":"GCST007656","neg_log_pval":8.698970004336019,"otg_id":"GCST007656","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (360196bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163464","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":218667372},"locus_GRCh38":{"chromosome":"2","position":217802649}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458969"],"gwas_catalog_id":"GCST007656","neg_log_pval":8.698970004336019,"otg_id":"GCST007656","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (322641bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":218667372},"locus_GRCh38":{"chromosome":"2","position":217802649}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":11.522878745280337,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (344415bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163464","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":218683154},"locus_GRCh38":{"chromosome":"2","position":217818431}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":11.522878745280337,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug DANIRIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (306858bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":218683154},"locus_GRCh38":{"chromosome":"2","position":217818431}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":9.466355021201236,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor A modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000163464 at this locus (304113bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163464","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":218723455},"locus_GRCh38":{"chromosome":"2","position":217858732}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":9.466355021201236,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000180871 at this locus (266557bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":218723455},"locus_GRCh38":{"chromosome":"2","position":217858732}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":8.682610761959468,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":219010146},"locus_GRCh38":{"chromosome":"2","position":218145423}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":10.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":219010146},"locus_GRCh38":{"chromosome":"2","position":218145423}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=26405"],"gwas_catalog_id":"GCST000964","neg_log_pval":8.056505484093897,"otg_id":"GCST000964","pubmed_id":"21297633"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":219010146},"locus_GRCh38":{"chromosome":"2","position":218145423}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":10.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000180871 at this locus (8173bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000180871","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":219010146},"locus_GRCh38":{"chromosome":"2","position":218145423}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":10.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000163464 at this locus (17422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163464","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":219010146},"locus_GRCh38":{"chromosome":"2","position":218145423}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=17691"],"gwas_catalog_id":"GCST004146","neg_log_pval":11.045757490560675,"otg_id":"GCST004146","pubmed_id":"28165464"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Programmed cell death protein 1 inhibitor drug NIVOLUMAB is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000188389 at this locus (494386bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000188389","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":242294913},"locus_GRCh38":{"chromosome":"2","position":241355498}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":14.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000188389","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":242382864},"locus_GRCh38":{"chromosome":"2","position":241443449}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":8.301029995663981,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000188389","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":242382864},"locus_GRCh38":{"chromosome":"2","position":241443449}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":11.0,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":1610551},"locus_GRCh38":{"chromosome":"20","position":1629905}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16559"],"gwas_catalog_id":"GCST000392","neg_log_pval":11.0,"otg_id":"GCST000392","pubmed_id":"19430480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":1610551},"locus_GRCh38":{"chromosome":"20","position":1629905}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":9.526299949462304,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":1616206},"locus_GRCh38":{"chromosome":"20","position":1635560}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":9.526299949462304,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":1616206},"locus_GRCh38":{"chromosome":"20","position":1635560}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":54.01739783478714,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":1682037},"locus_GRCh38":{"chromosome":"20","position":1701391}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":41.87573133737034,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000088832 at this locus (308219bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":1682037},"locus_GRCh38":{"chromosome":"20","position":1701391}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":54.01739783478714,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000088832","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":1682037},"locus_GRCh38":{"chromosome":"20","position":1701391}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.4634655452861525,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (408100bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":44229447},"locus_GRCh38":{"chromosome":"20","position":45600808}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":10.576918041702768,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (2636bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":44634912},"locus_GRCh38":{"chromosome":"20","position":46006273}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.402641632544848,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (48698bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":44693897},"locus_GRCh38":{"chromosome":"20","position":46065258}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=43327"],"gwas_catalog_id":"GCST005568","neg_log_pval":9.0,"otg_id":"GCST005568","pubmed_id":"23143596"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (89110bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":44734310},"locus_GRCh38":{"chromosome":"20","position":46105671}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-positive)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":11.569280112136719,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (94996bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":44740196},"locus_GRCh38":{"chromosome":"20","position":46111557}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":11.397940008672037,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000100985 at this locus (101782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44746982},"locus_GRCh38":{"chromosome":"20","position":46118343}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":11.397940008672037,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (101782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44746982},"locus_GRCh38":{"chromosome":"20","position":46118343}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["East Asian=9299","European=45790"],"gwas_catalog_id":"GCST006048","neg_log_pval":12.698970004336019,"otg_id":"GCST006048","pubmed_id":"24532676"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (101782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44746982},"locus_GRCh38":{"chromosome":"20","position":46118343}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-positive)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=25708"],"gwas_catalog_id":"GCST000679","neg_log_pval":8.244874758392445,"otg_id":"GCST000679","pubmed_id":"20453842"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44747947},"locus_GRCh38":{"chromosome":"20","position":46119308}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=15853"],"gwas_catalog_id":"GCST000232","neg_log_pval":8.096910013008056,"otg_id":"GCST000232","pubmed_id":"18794853"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44747947},"locus_GRCh38":{"chromosome":"20","position":46119308}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=43327"],"gwas_catalog_id":"GCST005568","neg_log_pval":10.045757490560675,"otg_id":"GCST005568","pubmed_id":"23143596"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44747947},"locus_GRCh38":{"chromosome":"20","position":46119308}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-positive)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":13.522878745280337,"otg_id":"GCST006959","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44749251},"locus_GRCh38":{"chromosome":"20","position":46120612}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":17.397940008672037,"otg_id":"GCST002318","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44749251},"locus_GRCh38":{"chromosome":"20","position":46120612}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":13.397940008672037,"otg_id":"GCST006959_3","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44749251},"locus_GRCh38":{"chromosome":"20","position":46120612}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":16.0,"otg_id":"GCST002318_2","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":44749251},"locus_GRCh38":{"chromosome":"20","position":46120612}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.61253898367965,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (229958bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":44875157},"locus_GRCh38":{"chromosome":"20","position":46246518}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.818633826857316,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (391013bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100985","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":45036213},"locus_GRCh38":{"chromosome":"20","position":46407574}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":8.34338536184194,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug TRASTUZUMAB EMTANSINE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57367899},"locus_GRCh38":{"chromosome":"20","position":58792844}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":8.34338536184194,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57367899},"locus_GRCh38":{"chromosome":"20","position":58792844}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=70506"],"gwas_catalog_id":"GCST007552","neg_log_pval":7.698970004336019,"otg_id":"GCST007552","pubmed_id":"30529582"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000101162 at this locus (119118bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57475191},"locus_GRCh38":{"chromosome":"20","position":58900136}},"trait_info":{"ontology":["EFO_0005842"],"reported_trait_name":"Colorectal cancer","standard_trait_name":"colorectal cancer"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.5130894413060085,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57659124},"locus_GRCh38":{"chromosome":"20","position":59084069}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.5130894413060085,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57659124},"locus_GRCh38":{"chromosome":"20","position":59084069}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":9.099086932262331,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000101162 at this locus (112317bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":57714025},"locus_GRCh38":{"chromosome":"20","position":59138970}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":11.397940008672037,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000101162 at this locus (222600bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":57824309},"locus_GRCh38":{"chromosome":"20","position":59249254}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.339507340775082,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":57971104},"locus_GRCh38":{"chromosome":"20","position":59396049}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=89677"],"gwas_catalog_id":"GCST007236","neg_log_pval":7.339507340775082,"otg_id":"GCST007236","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101162","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":57971104},"locus_GRCh38":{"chromosome":"20","position":59396049}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":17.522878745280337,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101213","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":62362563},"locus_GRCh38":{"chromosome":"20","position":63731211}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=22548"],"gwas_catalog_id":"GCST001942","neg_log_pval":15.397940008672037,"otg_id":"GCST001942","pubmed_id":"23535732"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000101213","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":62362563},"locus_GRCh38":{"chromosome":"20","position":63731211}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":7.522878745280337,"otg_id":"GCST002318_2","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interferon-alpha/beta receptor alpha chain antagonist drug ANIFROLUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000142166 at this locus (32118bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142166","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"21","position":34764288},"locus_GRCh38":{"chromosome":"21","position":33391982}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":9.154901959985743,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000128271","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":24658858},"locus_GRCh38":{"chromosome":"22","position":24262890}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":9.698970004336019,"otg_id":"GCST003116_2","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000128271","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":24658858},"locus_GRCh38":{"chromosome":"22","position":24262890}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease [additive model]","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":9.045757490560675,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (151677bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000128271","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"22","position":24662171},"locus_GRCh38":{"chromosome":"22","position":24266203}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":8.428291168191313,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (141129bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000128271","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":24672718},"locus_GRCh38":{"chromosome":"22","position":24276750}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":7.7544873321858505,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100385 at this locus (263382bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100385","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"22","position":37258503},"locus_GRCh38":{"chromosome":"22","position":36862461}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=29652"],"gwas_catalog_id":"GCST005536","neg_log_pval":7.748198311221298,"otg_id":"GCST005536","pubmed_id":"25751624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (16018bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100385","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":37587111},"locus_GRCh38":{"chromosome":"22","position":37191071}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=8207"],"gwas_catalog_id":"GCST000258","neg_log_pval":7.698970004336019,"otg_id":"GCST000258","pubmed_id":"18978792"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (20224bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000100385","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":37591318},"locus_GRCh38":{"chromosome":"22","position":37195278}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["NR=237"],"gwas_catalog_id":"GCST004105","neg_log_pval":7.3979400086720375,"otg_id":"GCST004105","pubmed_id":"28044437"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-5 receptor subunit alpha inhibitor drug BENRALIZUMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000091181 at this locus (122868bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091181","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":2985142},"locus_GRCh38":{"chromosome":"3","position":2943458}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Body mass index (change over time) in chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":10.0,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Histamine H1 receptor agonist drug TOLAZOLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196639 at this locus (203935bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196639","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":11508965},"locus_GRCh38":{"chromosome":"3","position":11467491}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":7.301029995663981,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Histamine H1 receptor antagonist drug HYDROXYZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196639","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":11590751},"locus_GRCh38":{"chromosome":"3","position":11549277}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":7.301029995663981,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Histamine H1 receptor agonist drug BETAHISTINE is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196639","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":11590751},"locus_GRCh38":{"chromosome":"3","position":11549277}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":7.301029995663981,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Histamine H1 receptor antagonist drug DIBENZEPIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196639","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":11590751},"locus_GRCh38":{"chromosome":"3","position":11549277}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=360192"],"neg_log_pval":7.5486127463375,"otg_id":"NEALE2_2443","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug PIOGLITAZONE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Diabetes diagnosed by doctor","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=360192"],"neg_log_pval":7.5486127463375,"otg_id":"NEALE2_2443","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Diabetes diagnosed by doctor","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.795880017344075,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12392272},"locus_GRCh38":{"chromosome":"3","position":12350773}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.795880017344075,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12392272},"locus_GRCh38":{"chromosome":"3","position":12350773}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.795880017344075,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12392272},"locus_GRCh38":{"chromosome":"3","position":12350773}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":18.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":16.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.221848749616356,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":18.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":18.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.221848749616356,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.221848749616356,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":17.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":18.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":17.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":18.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":16.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":18.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":16.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":17.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":23.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12394840},"locus_GRCh38":{"chromosome":"3","position":12353341}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":23.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12394840},"locus_GRCh38":{"chromosome":"3","position":12353341}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":23.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12394840},"locus_GRCh38":{"chromosome":"3","position":12353341}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":15.357832365595055,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":12396913},"locus_GRCh38":{"chromosome":"3","position":12355414}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":15.357832365595055,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":12396913},"locus_GRCh38":{"chromosome":"3","position":12355414}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":15.357832365595055,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000132170","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":12396913},"locus_GRCh38":{"chromosome":"3","position":12355414}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":7.698970004336019,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38634142},"locus_GRCh38":{"chromosome":"3","position":38592651}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":7.698970004336019,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38634142},"locus_GRCh38":{"chromosome":"3","position":38592651}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":7.698970004336019,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38634142},"locus_GRCh38":{"chromosome":"3","position":38592651}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":15.12010167566999,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":15.12010167566999,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":13.154901959985743,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":13.154901959985743,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":13.154901959985743,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":15.12010167566999,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":38710315},"locus_GRCh38":{"chromosome":"3","position":38668824}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.87942606879415,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":38766675},"locus_GRCh38":{"chromosome":"3","position":38725184}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.87942606879415,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":38766675},"locus_GRCh38":{"chromosome":"3","position":38725184}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=395739"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.87942606879415,"otg_id":"SAIGE_427_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":38766675},"locus_GRCh38":{"chromosome":"3","position":38725184}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation and flutter","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":17.397940008672037,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":14.221848749616356,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":19.619607839942972,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":19.619607839942972,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":14.221848749616356,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":17.397940008672037,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":14.221848749616356,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":19.619607839942972,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":17.397940008672037,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000183873","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":38771925},"locus_GRCh38":{"chromosome":"3","position":38730434}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":10.553695886048077,"otg_id":"NEALE2_20002_1456","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (247604bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":46192270},"locus_GRCh38":{"chromosome":"3","position":46150778}},"trait_info":{"ontology":["EFO_0001060"],"reported_trait_name":"Malabsorption/coeliac disease | non-cancer illness code, self-reported","standard_trait_name":"celiac disease"}}
{"association_info":{"ancestry":["European=23649","South Asian=620"],"gwas_catalog_id":"GCST005523","neg_log_pval":8.045757490560675,"otg_id":"GCST005523_7","pubmed_id":"22057235"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (261019bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":46205686},"locus_GRCh38":{"chromosome":"3","position":46164194}},"trait_info":{"ontology":["EFO_0001060"],"reported_trait_name":"Celiac disease [conditioned on rs2097282]","standard_trait_name":"celiac disease"}}
{"association_info":{"ancestry":["European=15283"],"gwas_catalog_id":"GCST000612","neg_log_pval":10.597222930389652,"otg_id":"GCST000612","pubmed_id":"20190752"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (290535bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":46235201},"locus_GRCh38":{"chromosome":"3","position":46193709}},"trait_info":{"ontology":["EFO_0001060"],"reported_trait_name":"Celiac disease","standard_trait_name":"celiac disease"}}
{"association_info":{"ancestry":["European=4634"],"gwas_catalog_id":"GCST002520","neg_log_pval":7.3979400086720375,"otg_id":"GCST002520","pubmed_id":"24999842"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (337078bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":46281744},"locus_GRCh38":{"chromosome":"3","position":46240253}},"trait_info":{"ontology":["EFO_0001060"],"reported_trait_name":"Celiac disease","standard_trait_name":"celiac disease"}}
{"association_info":{"ancestry":["European=23649","South Asian=620"],"gwas_catalog_id":"GCST005523","neg_log_pval":20.0,"otg_id":"GCST005523","pubmed_id":"22057235"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (433359bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":46378025},"locus_GRCh38":{"chromosome":"3","position":46336534}},"trait_info":{"ontology":["EFO_0001060"],"reported_trait_name":"Celiac disease","standard_trait_name":"celiac disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":7.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000121807 at this locus (26239bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121807","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46428658},"locus_GRCh38":{"chromosome":"3","position":46387167}},"trait_info":{"ontology":["EFO_0004268"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"sclerosing cholangitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":7.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000160791 at this locus (10962bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46428658},"locus_GRCh38":{"chromosome":"3","position":46387167}},"trait_info":{"ontology":["EFO_0004268"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"sclerosing cholangitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":7.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000173585 at this locus (483992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46428658},"locus_GRCh38":{"chromosome":"3","position":46387167}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":7.698970004336019,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000173585 at this locus (483992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000173585","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46428658},"locus_GRCh38":{"chromosome":"3","position":46387167}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=6315"],"gwas_catalog_id":"GCST003183","neg_log_pval":18.69897000433602,"otg_id":"GCST003183","pubmed_id":"26553974"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000121807 at this locus (49262bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121807","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46451680},"locus_GRCh38":{"chromosome":"3","position":46410189}},"trait_info":{"ontology":["EFO_0000180"],"reported_trait_name":"Setpoint viral load in HIV-1 infection","standard_trait_name":"HIV-1 infection"}}
{"association_info":{"ancestry":["European=6315"],"gwas_catalog_id":"GCST003183","neg_log_pval":18.69897000433602,"otg_id":"GCST003183","pubmed_id":"26553974"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160791","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46451680},"locus_GRCh38":{"chromosome":"3","position":46410189}},"trait_info":{"ontology":["EFO_0000180"],"reported_trait_name":"Setpoint viral load in HIV-1 infection","standard_trait_name":"HIV-1 infection"}}
{"association_info":{"ancestry":["European=6315"],"gwas_catalog_id":"GCST003183","neg_log_pval":18.69897000433602,"otg_id":"GCST003183","pubmed_id":"26553974"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"C-C chemokine receptor type 5 antagonist drug MARAVIROC is Phase IV for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000160791","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":46451680},"locus_GRCh38":{"chromosome":"3","position":46410189}},"trait_info":{"ontology":["EFO_0000180"],"reported_trait_name":"Setpoint viral load in HIV-1 infection","standard_trait_name":"HIV-1 infection"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":7.3979400086720375,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (220268bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":52268866},"locus_GRCh38":{"chromosome":"3","position":52234850}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":8.522878745280337,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (201667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":52287468},"locus_GRCh38":{"chromosome":"3","position":52253452}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=398213"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.847711655616943,"otg_id":"SAIGE_740_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (196795bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000239732","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":52456973},"locus_GRCh38":{"chromosome":"3","position":52422957}},"trait_info":{"ontology":["EFO_0002506"],"reported_trait_name":"Osteoarthritis; localized","standard_trait_name":"osteoarthritis"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":12.698970004336019,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52628056},"locus_GRCh38":{"chromosome":"3","position":52594040}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":12.301029995663981,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52628056},"locus_GRCh38":{"chromosome":"3","position":52594040}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=18419"],"gwas_catalog_id":"GCST001592","neg_log_pval":8.301029995663981,"otg_id":"GCST001592","pubmed_id":"22763110"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (461126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000239732","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":52721305},"locus_GRCh38":{"chromosome":"3","position":52687289}},"trait_info":{"ontology":["EFO_0002506"],"reported_trait_name":"Osteoarthritis","standard_trait_name":"osteoarthritis"}}
{"association_info":{"ancestry":["European=417596"],"gwas_catalog_id":"GCST007092","neg_log_pval":9.698970004336019,"otg_id":"GCST007092","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase II for the indiciation EFO_0004616 and targets the gene ENSG00000239732 at this locus (468625bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000239732","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52728804},"locus_GRCh38":{"chromosome":"3","position":52694788}},"trait_info":{"ontology":["EFO_0004616"],"reported_trait_name":"Osteoarthritis of the hip or knee","standard_trait_name":"osteoarthritis, knee"}}
{"association_info":{"ancestry":["NR, African American or Afro-Caribbean, European, African unspecified, Asian unspecified, Other=48070"],"gwas_catalog_id":"GCST002254","neg_log_pval":7.522878745280337,"otg_id":"GCST002254","pubmed_id":"24166486"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (288821bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":52815905},"locus_GRCh38":{"chromosome":"3","position":52781889}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia, schizoaffective disorder or bipolar disorder","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=61220"],"gwas_catalog_id":"GCST001877","neg_log_pval":11.522878745280337,"otg_id":"GCST001877","pubmed_id":"23453885"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":52833219},"locus_GRCh38":{"chromosome":"3","position":52799203}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":10.698970004336019,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":52833219},"locus_GRCh38":{"chromosome":"3","position":52799203}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.0,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52833805},"locus_GRCh38":{"chromosome":"3","position":52799789}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":11.522878745280337,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52833805},"locus_GRCh38":{"chromosome":"3","position":52799789}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":10.0,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":52833805},"locus_GRCh38":{"chromosome":"3","position":52799789}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=11244","NR=20899"],"gwas_catalog_id":"GCST002149","neg_log_pval":8.0,"otg_id":"GCST002149","pubmed_id":"23974872"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (311318bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":52838402},"locus_GRCh38":{"chromosome":"3","position":52804386}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":10.397940008672037,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":52845105},"locus_GRCh38":{"chromosome":"3","position":52811089}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":10.698970004336019,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000010322","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":52845105},"locus_GRCh38":{"chromosome":"3","position":52811089}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=5158"],"gwas_catalog_id":"GCST004302","neg_log_pval":12.522878745280337,"otg_id":"GCST004302","pubmed_id":"28425483"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (93052bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":119150089},"locus_GRCh38":{"chromosome":"3","position":119431242}},"trait_info":{"ontology":["EFO_1001486"],"reported_trait_name":"Primary biliary cholangitis","standard_trait_name":"primary biliary cirrhosis"}}
{"association_info":{"ancestry":["European=18264","African American or Afro-Caribbean=5422","Hispanic or Latin American=3888"],"gwas_catalog_id":"GCST005752","neg_log_pval":11.0,"otg_id":"GCST005752","pubmed_id":"28714469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (68758bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":119174383},"locus_GRCh38":{"chromosome":"3","position":119455536}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=13239"],"gwas_catalog_id":"GCST003129","neg_log_pval":14.397940008672037,"otg_id":"GCST003129","pubmed_id":"26394269"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119219934},"locus_GRCh38":{"chromosome":"3","position":119501087}},"trait_info":{"ontology":["EFO_1001486"],"reported_trait_name":"Primary biliary cholangitis","standard_trait_name":"primary biliary cirrhosis"}}
{"association_info":{"ancestry":["European=26621"],"gwas_catalog_id":"GCST001198","neg_log_pval":8.96738123914928,"otg_id":"GCST001198","pubmed_id":"21833088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (23206bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119219934},"locus_GRCh38":{"chromosome":"3","position":119501087}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=11375"],"gwas_catalog_id":"GCST005581","neg_log_pval":15.16526148109616,"otg_id":"GCST005581","pubmed_id":"22961000"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119219934},"locus_GRCh38":{"chromosome":"3","position":119501087}},"trait_info":{"ontology":["EFO_1001486"],"reported_trait_name":"Primary biliary cirrhosis","standard_trait_name":"primary biliary cirrhosis"}}
{"association_info":{"ancestry":["East Asian=3574"],"gwas_catalog_id":"GCST007036","neg_log_pval":8.221848749616356,"otg_id":"GCST007036","pubmed_id":"30643196"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119219934},"locus_GRCh38":{"chromosome":"3","position":119501087}},"trait_info":{"ontology":["EFO_1001486"],"reported_trait_name":"Primary biliary cholangitis","standard_trait_name":"primary biliary cirrhosis"}}
{"association_info":{"ancestry":["European=18264"],"gwas_catalog_id":"GCST007400","neg_log_pval":9.0,"otg_id":"GCST007400","pubmed_id":"28714469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (20684bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119222456},"locus_GRCh38":{"chromosome":"3","position":119503609}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":14.397940008672037,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119244593},"locus_GRCh38":{"chromosome":"3","position":119525746}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["East Asian=5050"],"gwas_catalog_id":"GCST001795","neg_log_pval":15.522878745280337,"otg_id":"GCST001795","pubmed_id":"23273568"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":119260944},"locus_GRCh38":{"chromosome":"3","position":119542097}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=5050"],"gwas_catalog_id":"GCST002845","neg_log_pval":7.301029995663981,"otg_id":"GCST002845","pubmed_id":"25862617"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000121594","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":119272391},"locus_GRCh38":{"chromosome":"3","position":119553544}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":14.154901959985743,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (230632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":121543577},"locus_GRCh38":{"chromosome":"3","position":121824730}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["NR=215725"],"gwas_catalog_id":"GCST007124","neg_log_pval":7.3979400086720375,"otg_id":"GCST007124","pubmed_id":"26920376"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (113546bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"3","position":121660664},"locus_GRCh38":{"chromosome":"3","position":121941817}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis and HDL levels (pleiotropy)","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":8.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000114013 at this locus (58039bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":121716171},"locus_GRCh38":{"chromosome":"3","position":121997324}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=15283"],"gwas_catalog_id":"GCST003566","neg_log_pval":9.0,"otg_id":"GCST003566","pubmed_id":"27386562"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (4687bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"3","position":121769522},"locus_GRCh38":{"chromosome":"3","position":122050675}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["NR=3599","Hispanic or Latin American=1956","European=17698"],"gwas_catalog_id":"GCST003340","neg_log_pval":7.301029995663981,"otg_id":"GCST003340","pubmed_id":"26819262"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":121770539},"locus_GRCh38":{"chromosome":"3","position":122051692}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=38582"],"gwas_catalog_id":"GCST005531","neg_log_pval":12.273272790973428,"otg_id":"GCST005531","pubmed_id":"24076602"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":121770539},"locus_GRCh38":{"chromosome":"3","position":122051692}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=26621"],"gwas_catalog_id":"GCST001198","neg_log_pval":8.811915626285062,"otg_id":"GCST001198","pubmed_id":"21833088"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000114013","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":121796768},"locus_GRCh38":{"chromosome":"3","position":122077921}},"trait_info":{"ontology":["EFO_0003885"],"reported_trait_name":"Multiple sclerosis","standard_trait_name":"multiple sclerosis"}}
{"association_info":{"ancestry":["European=41199"],"gwas_catalog_id":"GCST000639","neg_log_pval":11.0,"otg_id":"GCST000639","pubmed_id":"20348956"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000068078","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":1734239},"locus_GRCh38":{"chromosome":"4","position":1732512}},"trait_info":{"ontology":["EFO_0000292"],"reported_trait_name":"Urinary bladder cancer","standard_trait_name":"bladder carcinoma"}}
{"association_info":{"ancestry":["European=6206"],"gwas_catalog_id":"GCST002240","neg_log_pval":24.154901959985743,"otg_id":"GCST002240","pubmed_id":"24163127"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000068078","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":1734239},"locus_GRCh38":{"chromosome":"4","position":1732512}},"trait_info":{"ontology":["EFO_0000292"],"reported_trait_name":"Bladder cancer","standard_trait_name":"bladder carcinoma"}}
{"association_info":{"ancestry":["European=8652"],"gwas_catalog_id":"GCST000842","neg_log_pval":12.397940008672037,"otg_id":"GCST000842","pubmed_id":"20972438"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000068078","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":1734239},"locus_GRCh38":{"chromosome":"4","position":1732512}},"trait_info":{"ontology":["EFO_0000292"],"reported_trait_name":"Bladder cancer","standard_trait_name":"bladder carcinoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":7.692944898477948,"otg_id":"NEALE2_20001_1035","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (25584bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000068078","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":1769436},"locus_GRCh38":{"chromosome":"4","position":1767709}},"trait_info":{"ontology":["EFO_0000292"],"reported_trait_name":"Bladder cancer | cancer code, self-reported","standard_trait_name":"bladder carcinoma"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1541","European=1436"],"gwas_catalog_id":"GCST004955","neg_log_pval":7.522878745280337,"otg_id":"GCST004955","pubmed_id":"28990359"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug LORAZEPAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":45547068},"locus_GRCh38":{"chromosome":"4","position":45545051}},"trait_info":{"ontology":["EFO_0003829"],"reported_trait_name":"Risky sexual behaviors in alcohol dependence [AA]","standard_trait_name":"alcohol dependence"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1541","European=1436"],"gwas_catalog_id":"GCST004955","neg_log_pval":7.522878745280337,"otg_id":"GCST004955","pubmed_id":"28990359"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel allosteric antagonist drug FLUMAZENIL is Phase II for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":45547068},"locus_GRCh38":{"chromosome":"4","position":45545051}},"trait_info":{"ontology":["EFO_0003829"],"reported_trait_name":"Risky sexual behaviors in alcohol dependence [AA]","standard_trait_name":"alcohol dependence"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1541","European=1436"],"gwas_catalog_id":"GCST004955","neg_log_pval":7.522878745280337,"otg_id":"GCST004955","pubmed_id":"28990359"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug CHLORDIAZEPOXIDE is Phase III for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":45547068},"locus_GRCh38":{"chromosome":"4","position":45545051}},"trait_info":{"ontology":["EFO_0003829"],"reported_trait_name":"Risky sexual behaviors in alcohol dependence [AA]","standard_trait_name":"alcohol dependence"}}
{"association_info":{"ancestry":["European=3524"],"gwas_catalog_id":"GCST003427","neg_log_pval":9.0,"otg_id":"GCST003427","pubmed_id":"26830138"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000163285 at this locus (288042bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":46414112},"locus_GRCh38":{"chromosome":"4","position":46412095}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Alzheimer disease and age of onset [between families]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["European=3524"],"gwas_catalog_id":"GCST003427","neg_log_pval":9.0,"otg_id":"GCST003427","pubmed_id":"26830138"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151834","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":46414112},"locus_GRCh38":{"chromosome":"4","position":46412095}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Alzheimer disease and age of onset [between families]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["European=26405"],"gwas_catalog_id":"GCST000964","neg_log_pval":8.872895201635192,"otg_id":"GCST000964","pubmed_id":"21297633"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000151834 at this locus (66059bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151834","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":46543306},"locus_GRCh38":{"chromosome":"4","position":46541289}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=26405"],"gwas_catalog_id":"GCST000964","neg_log_pval":8.872895201635192,"otg_id":"GCST000964","pubmed_id":"21297633"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000163285 at this locus (417235bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000163285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":46543306},"locus_GRCh38":{"chromosome":"4","position":46541289}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=3524"],"gwas_catalog_id":"GCST003427","neg_log_pval":9.0,"otg_id":"GCST003427","pubmed_id":"26830138"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (213998bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151834","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":46691244},"locus_GRCh38":{"chromosome":"4","position":46689227}},"trait_info":{"ontology":["EFO_0000249"],"reported_trait_name":"Alzheimer disease and age of onset [between families]","standard_trait_name":"Alzheimer's disease"}}
{"association_info":{"ancestry":["East Asian=4275"],"gwas_catalog_id":"GCST001384","neg_log_pval":8.096910013008056,"otg_id":"GCST001384","pubmed_id":"22291604"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"c-Jun N-terminal kinase 3 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000109339 at this locus (442619bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000109339","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":87958395},"locus_GRCh38":{"chromosome":"4","position":87037243}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":9.056494107508188,"otg_id":"NEALE2_20002_1262","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (25518bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TA","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90619732},"locus_GRCh38":{"chromosome":"4","position":89698581}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinsons disease | non-cancer illness code, self-reported","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=334141"],"gwas_catalog_id":"GCST003984","neg_log_pval":56.0,"otg_id":"GCST003984","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90626111},"locus_GRCh38":{"chromosome":"4","position":89704960}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=108990"],"gwas_catalog_id":"GCST002544","neg_log_pval":72.39794000867204,"otg_id":"GCST002544","pubmed_id":"25064009"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90626111},"locus_GRCh38":{"chromosome":"4","position":89704960}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=417508"],"gwas_catalog_id":"GCST004902","neg_log_pval":122.30102999566398,"otg_id":"GCST004902","pubmed_id":"28892059"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90626111},"locus_GRCh38":{"chromosome":"4","position":89704960}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["NR=4258"],"gwas_catalog_id":"GCST001445","neg_log_pval":64.22184874961636,"otg_id":"GCST001445_2","pubmed_id":"22438815"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90637601},"locus_GRCh38":{"chromosome":"4","position":89716450}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease [EA]","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=17352"],"gwas_catalog_id":"GCST000959","neg_log_pval":46.69897000433602,"otg_id":"GCST000959","pubmed_id":"21292315"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90637601},"locus_GRCh38":{"chromosome":"4","position":89716450}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["East Asian=3509"],"gwas_catalog_id":"GCST000530","neg_log_pval":16.154901959985743,"otg_id":"GCST000530","pubmed_id":"19915576"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (5735bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90639515},"locus_GRCh38":{"chromosome":"4","position":89718364}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=33050"],"gwas_catalog_id":"GCST001126","neg_log_pval":18.69897000433602,"otg_id":"GCST001126","pubmed_id":"21738487"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=3986"],"gwas_catalog_id":"GCST002353","neg_log_pval":9.0,"otg_id":"GCST002353_3","pubmed_id":"24511991"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease [Sporadic]","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=8477"],"gwas_catalog_id":"GCST001430","neg_log_pval":34.096910013008056,"otg_id":"GCST001430","pubmed_id":"22451204"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=3986"],"gwas_catalog_id":"GCST000772","neg_log_pval":10.522878745280337,"otg_id":"GCST000772","pubmed_id":"20711177"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=6880"],"gwas_catalog_id":"GCST000855","neg_log_pval":15.045757490560675,"otg_id":"GCST000855","pubmed_id":"21044948"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=3023"],"gwas_catalog_id":"GCST000874","neg_log_pval":7.522878745280337,"otg_id":"GCST000874","pubmed_id":"21084426"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=3986"],"gwas_catalog_id":"GCST002353","neg_log_pval":10.522878745280337,"otg_id":"GCST002353","pubmed_id":"24511991"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":90641340},"locus_GRCh38":{"chromosome":"4","position":89720189}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["East Asian=14006"],"gwas_catalog_id":"GCST003922","neg_log_pval":32.0,"otg_id":"GCST003922","pubmed_id":"28011712"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (797bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":90644454},"locus_GRCh38":{"chromosome":"4","position":89723303}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["NR=17996"],"gwas_catalog_id":"GCST007780","neg_log_pval":11.698970004336019,"otg_id":"GCST007780","pubmed_id":"30957308"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":90666041},"locus_GRCh38":{"chromosome":"4","position":89744890}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease (age of onset)","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=5691"],"gwas_catalog_id":"GCST000528","neg_log_pval":15.698970004336019,"otg_id":"GCST000528","pubmed_id":"19915575"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90678541},"locus_GRCh38":{"chromosome":"4","position":89757390}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["NR=4258"],"gwas_catalog_id":"GCST001445","neg_log_pval":10.301029995663981,"otg_id":"GCST001445","pubmed_id":"22438815"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (21437bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145335","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":90780902},"locus_GRCh38":{"chromosome":"4","position":89859751}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease [Asian]","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":14.096910013008056,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Microsomal triglyceride transfer protein inhibitor drug LOMITAPIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000138823 at this locus (245600bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000138823","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":100239319},"locus_GRCh38":{"chromosome":"4","position":99318162}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["East Asian=4168"],"gwas_catalog_id":"GCST003154","neg_log_pval":8.301029995663981,"otg_id":"GCST003154","pubmed_id":"26488411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Endothelin receptor ET-A antagonist drug ZIBOTENTAN is Phase II for the indiciation EFO_0004265 and targets the gene ENSG00000151617 at this locus (1251bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151617","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":148400819},"locus_GRCh38":{"chromosome":"4","position":147479667}},"trait_info":{"ontology":["EFO_0004265"],"reported_trait_name":"Peripheral artery disease","standard_trait_name":"peripheral arterial disease"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":10.878440155812498,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":148937537},"locus_GRCh38":{"chromosome":"4","position":148016386}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":13.221848749616356,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":148937537},"locus_GRCh38":{"chromosome":"4","position":148016386}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":10.878440155812498,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":148937537},"locus_GRCh38":{"chromosome":"4","position":148016386}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":13.221848749616356,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":148937537},"locus_GRCh38":{"chromosome":"4","position":148016386}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":12.154901959985743,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug CANRENONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":148946690},"locus_GRCh38":{"chromosome":"4","position":148025539}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":12.154901959985743,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000151623","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":148946690},"locus_GRCh38":{"chromosome":"4","position":148025539}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":10.698970004336019,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (259540bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156420605},"locus_GRCh38":{"chromosome":"4","position":155499453}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.636910992288339,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156433308},"locus_GRCh38":{"chromosome":"4","position":155512156}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.636910992288339,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156433308},"locus_GRCh38":{"chromosome":"4","position":155512156}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":9.962972120244226,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156436507},"locus_GRCh38":{"chromosome":"4","position":155515355}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":9.962972120244226,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156436507},"locus_GRCh38":{"chromosome":"4","position":155515355}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":9.962972120244226,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156436507},"locus_GRCh38":{"chromosome":"4","position":155515355}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.0,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156436517},"locus_GRCh38":{"chromosome":"4","position":155515365}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.0,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156436517},"locus_GRCh38":{"chromosome":"4","position":155515365}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.0,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156436517},"locus_GRCh38":{"chromosome":"4","position":155515365}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":14.0,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156614184},"locus_GRCh38":{"chromosome":"4","position":155693032}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":14.0,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156614184},"locus_GRCh38":{"chromosome":"4","position":155693032}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":14.0,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156614184},"locus_GRCh38":{"chromosome":"4","position":155693032}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":22.476643793345207,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":21.397940008672037,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":21.397940008672037,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":21.397940008672037,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":22.476643793345207,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":22.476643793345207,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156635309},"locus_GRCh38":{"chromosome":"4","position":155714157}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":9.0,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156638573},"locus_GRCh38":{"chromosome":"4","position":155717421}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":9.0,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156638573},"locus_GRCh38":{"chromosome":"4","position":155717421}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":9.0,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156638573},"locus_GRCh38":{"chromosome":"4","position":155717421}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":8.221848749616356,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156639888},"locus_GRCh38":{"chromosome":"4","position":155718736}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":8.221848749616356,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156639888},"locus_GRCh38":{"chromosome":"4","position":155718736}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":8.221848749616356,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156639888},"locus_GRCh38":{"chromosome":"4","position":155718736}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":7.698970004336019,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000061918 at this locus (40257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":156639888},"locus_GRCh38":{"chromosome":"4","position":155718736}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.378823718224965,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156642884},"locus_GRCh38":{"chromosome":"4","position":155721732}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.32513885926219,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156642884},"locus_GRCh38":{"chromosome":"4","position":155721732}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408343"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.378823718224965,"otg_id":"SAIGE_401"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156642884},"locus_GRCh38":{"chromosome":"4","position":155721732}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408089"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.32513885926219,"otg_id":"SAIGE_401_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156642884},"locus_GRCh38":{"chromosome":"4","position":155721732}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Essential hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.669586226650809,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156645513},"locus_GRCh38":{"chromosome":"4","position":155724361}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.669586226650809,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156645513},"locus_GRCh38":{"chromosome":"4","position":155724361}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.669586226650809,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":156645513},"locus_GRCh38":{"chromosome":"4","position":155724361}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":19.69897000433602,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (33805bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":156646340},"locus_GRCh38":{"chromosome":"4","position":155725188}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":15.293624498063002,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":156646340},"locus_GRCh38":{"chromosome":"4","position":155725188}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":15.293624498063002,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":156646340},"locus_GRCh38":{"chromosome":"4","position":155725188}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":8.698970004336019,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156666991},"locus_GRCh38":{"chromosome":"4","position":155745839}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=50792"],"gwas_catalog_id":"GCST007707","neg_log_pval":8.698970004336019,"otg_id":"GCST007707","pubmed_id":"30487518"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000061918","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":156666991},"locus_GRCh38":{"chromosome":"4","position":155745839}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension [East Asian]","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=30659"],"gwas_catalog_id":"GCST004347","neg_log_pval":65.52287874528034,"otg_id":"GCST004347","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=3749","European=5388"],"gwas_catalog_id":"GCST001298","neg_log_pval":10.0,"otg_id":"GCST001298","pubmed_id":"22037553"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":8.0,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":73.09691001300806,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioblastoma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":73.09691001300806,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioblastoma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=24009"],"gwas_catalog_id":"GCST004348","neg_log_pval":16.0,"otg_id":"GCST004348","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":8.154901959985743,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=15566"],"gwas_catalog_id":"GCST005075","neg_log_pval":15.397940008672037,"otg_id":"GCST005075","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=24009"],"gwas_catalog_id":"GCST004348","neg_log_pval":16.0,"otg_id":"GCST004348","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=30659"],"gwas_catalog_id":"GCST004347","neg_log_pval":65.52287874528034,"otg_id":"GCST004347","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":16.10874138309586,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST003228","neg_log_pval":19.397940008672037,"otg_id":"GCST003228","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":8.154901959985743,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=63347"],"gwas_catalog_id":"GCST004415","neg_log_pval":7.522878745280337,"otg_id":"GCST004415","pubmed_id":"28346442"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Invasive epithelial ovarian cancer","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["European=39387"],"gwas_catalog_id":"GCST001930","neg_log_pval":11.301029995663981,"otg_id":"GCST001930","pubmed_id":"23535733"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=39387"],"gwas_catalog_id":"GCST001930","neg_log_pval":11.301029995663981,"otg_id":"GCST001930","pubmed_id":"23535733"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":16.10874138309586,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=15566"],"gwas_catalog_id":"GCST005075","neg_log_pval":15.397940008672037,"otg_id":"GCST005075","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST003228","neg_log_pval":19.397940008672037,"otg_id":"GCST003228","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":8.0,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=3749","European=5388"],"gwas_catalog_id":"GCST001298","neg_log_pval":10.0,"otg_id":"GCST001298","pubmed_id":"22037553"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1279790},"locus_GRCh38":{"chromosome":"5","position":1279675}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":51.39794000867204,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280028},"locus_GRCh38":{"chromosome":"5","position":1279913}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":27.096910013008056,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (112882bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280028},"locus_GRCh38":{"chromosome":"5","position":1279913}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":27.096910013008056,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280028},"locus_GRCh38":{"chromosome":"5","position":1279913}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":23.522878745280337,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280028},"locus_GRCh38":{"chromosome":"5","position":1279913}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=407770"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.411168274405792,"otg_id":"SAIGE_191_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280830},"locus_GRCh38":{"chromosome":"5","position":1280715}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Cancer of brain and nervous system","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=407770"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.411168274405792,"otg_id":"SAIGE_191_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1280830},"locus_GRCh38":{"chromosome":"5","position":1280715}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Cancer of brain and nervous system","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":7.522878745280337,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110590bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1282319},"locus_GRCh38":{"chromosome":"5","position":1282204}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":7.522878745280337,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1282319},"locus_GRCh38":{"chromosome":"5","position":1282204}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":9.698970004336019,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (110495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":9.698970004336019,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":9.698970004336019,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":9.698970004336019,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (110495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=123671"],"gwas_catalog_id":"GCST003588","neg_log_pval":9.698970004336019,"otg_id":"GCST003588_2","pubmed_id":"27197191"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Cancer (pleiotropy) [subset analysis]","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=7541"],"gwas_catalog_id":"GCST002890","neg_log_pval":10.522878745280337,"otg_id":"GCST002890","pubmed_id":"25939597"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1282414},"locus_GRCh38":{"chromosome":"5","position":1282299}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=291407"],"gwas_catalog_id":"GCST004142","neg_log_pval":11.154901959985743,"otg_id":"GCST004142","pubmed_id":"28212542"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (108257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1284653},"locus_GRCh38":{"chromosome":"5","position":1284538}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=63347"],"gwas_catalog_id":"GCST004415","neg_log_pval":9.154901959985743,"otg_id":"GCST004415","pubmed_id":"28346442"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (106936bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1285974},"locus_GRCh38":{"chromosome":"5","position":1285859}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Invasive epithelial ovarian cancer","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":7.383947958952672,"otg_id":"NEALE2_20002_1438","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000164362 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1285974},"locus_GRCh38":{"chromosome":"5","position":1285859}},"trait_info":{"ontology":["EFO_0002429"],"reported_trait_name":"Polycythaemia vera | non-cancer illness code, self-reported","standard_trait_name":"polycythemia vera"}}
{"association_info":{"ancestry":["East Asian=5408"],"gwas_catalog_id":"GCST001140","neg_log_pval":27.0,"otg_id":"GCST001140","pubmed_id":"21725308"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=4773"],"gwas_catalog_id":"GCST001194","neg_log_pval":8.154901959985743,"otg_id":"GCST001194","pubmed_id":"21827660"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST001058","neg_log_pval":14.0,"otg_id":"GCST001058","pubmed_id":"21531791"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=7608"],"gwas_catalog_id":"GCST002474","neg_log_pval":15.0,"otg_id":"GCST002474","pubmed_id":"24908248"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma (high-grade)","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=5548"],"gwas_catalog_id":"GCST000439","neg_log_pval":16.69897000433602,"otg_id":"GCST000439","pubmed_id":"19578367"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["East Asian=10054"],"gwas_catalog_id":"GCST001740","neg_log_pval":26.397940008672037,"otg_id":"GCST001740","pubmed_id":"23143601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=4773"],"gwas_catalog_id":"GCST001194","neg_log_pval":8.154901959985743,"otg_id":"GCST001194","pubmed_id":"21827660"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=6811"],"gwas_catalog_id":"GCST001633","neg_log_pval":8.397940008672037,"otg_id":"GCST001633","pubmed_id":"22886559"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=7608"],"gwas_catalog_id":"GCST002474","neg_log_pval":15.0,"otg_id":"GCST002474","pubmed_id":"24908248"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma (high-grade)","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=5548"],"gwas_catalog_id":"GCST000439","neg_log_pval":16.69897000433602,"otg_id":"GCST000439","pubmed_id":"19578367"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST001058","neg_log_pval":14.0,"otg_id":"GCST001058","pubmed_id":"21531791"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=6811"],"gwas_catalog_id":"GCST001633","neg_log_pval":8.397940008672037,"otg_id":"GCST001633","pubmed_id":"22886559"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1286516},"locus_GRCh38":{"chromosome":"5","position":1286401}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=5339"],"gwas_catalog_id":"GCST003775","neg_log_pval":8.522878745280337,"otg_id":"GCST003775","pubmed_id":"27393504"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (105715bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1287194},"locus_GRCh38":{"chromosome":"5","position":1287079}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=5548"],"gwas_catalog_id":"GCST000439","neg_log_pval":13.397940008672037,"otg_id":"GCST000439","pubmed_id":"19578367"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":1288547},"locus_GRCh38":{"chromosome":"5","position":1288432}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=5548"],"gwas_catalog_id":"GCST000439","neg_log_pval":13.397940008672037,"otg_id":"GCST000439","pubmed_id":"19578367"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":1288547},"locus_GRCh38":{"chromosome":"5","position":1288432}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":20.392866795608434,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (166bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":1295349},"locus_GRCh38":{"chromosome":"5","position":1295234}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":20.392866795608434,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (97561bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":1295349},"locus_GRCh38":{"chromosome":"5","position":1295234}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":13.522878745280337,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1297488},"locus_GRCh38":{"chromosome":"5","position":1297373}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":8.698970004336019,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1297488},"locus_GRCh38":{"chromosome":"5","position":1297373}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":8.698970004336019,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1297488},"locus_GRCh38":{"chromosome":"5","position":1297373}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":13.522878745280337,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164362","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1297488},"locus_GRCh38":{"chromosome":"5","position":1297373}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=3390"],"gwas_catalog_id":"GCST000459","neg_log_pval":8.522878745280337,"otg_id":"GCST000459","pubmed_id":"19654303"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (77250bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1315660},"locus_GRCh38":{"chromosome":"5","position":1315545}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=40187"],"gwas_catalog_id":"GCST004749","neg_log_pval":16.522878745280337,"otg_id":"GCST004749","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72773bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1320136},"locus_GRCh38":{"chromosome":"5","position":1320021}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer in ever smokers","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=85716"],"gwas_catalog_id":"GCST004748","neg_log_pval":31.69897000433602,"otg_id":"GCST004748","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72663bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":1320247},"locus_GRCh38":{"chromosome":"5","position":1320132}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=10422"],"gwas_catalog_id":"GCST001267","neg_log_pval":7.522878745280337,"otg_id":"GCST001267","pubmed_id":"21983787"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (70822bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1322087},"locus_GRCh38":{"chromosome":"5","position":1321972}},"trait_info":{"ontology":["EFO_0000756"],"reported_trait_name":"Melanoma","standard_trait_name":"melanoma"}}
{"association_info":{"ancestry":["European=10295"],"gwas_catalog_id":"GCST000257","neg_log_pval":8.096910013008056,"otg_id":"GCST000257","pubmed_id":"18978787"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (70822bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1322087},"locus_GRCh38":{"chromosome":"5","position":1321972}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=314072"],"neg_log_pval":10.406891232219362,"otg_id":"NEALE2_20107_3","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (53019bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":1339890},"locus_GRCh38":{"chromosome":"5","position":1339775}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer | illnesses of father","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=360738"],"neg_log_pval":7.9587810673873625,"otg_id":"NEALE2_1200","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug MODAFINIL is Phase IV for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1442979},"locus_GRCh38":{"chromosome":"5","position":1442864}},"trait_info":{"ontology":["EFO_0004698"],"reported_trait_name":"Sleeplessness / insomnia","standard_trait_name":"insomnia"}}
{"association_info":{"ancestry":["European=360738"],"neg_log_pval":7.9587810673873625,"otg_id":"NEALE2_1200","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1442979},"locus_GRCh38":{"chromosome":"5","position":1442864}},"trait_info":{"ontology":["EFO_0004698"],"reported_trait_name":"Sleeplessness / insomnia","standard_trait_name":"insomnia"}}
{"association_info":{"ancestry":["East Asian=4969"],"gwas_catalog_id":"GCST000750","neg_log_pval":17.397940008672037,"otg_id":"GCST000750","pubmed_id":"20676098"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1895829},"locus_GRCh38":{"chromosome":"5","position":1895715}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["East Asian=7394"],"gwas_catalog_id":"GCST003148","neg_log_pval":11.698970004336019,"otg_id":"GCST003148","pubmed_id":"26443449"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000142319","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":1895829},"locus_GRCh38":{"chromosome":"5","position":1895715}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European, NR=45975"],"gwas_catalog_id":"GCST004133","neg_log_pval":8.104080454689985,"otg_id":"GCST004133","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (332548bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171522","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":40347469},"locus_GRCh38":{"chromosome":"5","position":40347367}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":11.43486084803021,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265131bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171522","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":40414886},"locus_GRCh38":{"chromosome":"5","position":40414784}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":74.0,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171522","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":40414989},"locus_GRCh38":{"chromosome":"5","position":40414887}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":10.096910013008056,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (192747bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000171522","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":40487270},"locus_GRCh38":{"chromosome":"5","position":40487168}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=83129"],"gwas_catalog_id":"GCST006983","neg_log_pval":7.522878745280337,"otg_id":"GCST006983","pubmed_id":"30610198"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Growth hormone receptor agonist drug SOMATROPIN is Phase IV for the indiciation EFO_0003888 and targets the gene ENSG00000112964 at this locus (332768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112964","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":43054747},"locus_GRCh38":{"chromosome":"5","position":43054645}},"trait_info":{"ontology":["EFO_0003888"],"reported_trait_name":"Attention deficit hyperactivity disorder or cannabis use","standard_trait_name":"attention deficit hyperactivity disorder"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.3979400086720375,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serotonin 1a (5-HT1a) receptor agonist drug ERGOLOID is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000178394 at this locus (478140bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000178394","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":63736474},"locus_GRCh38":{"chromosome":"5","position":64440647}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=408878"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.436518914605589,"otg_id":"SAIGE_272_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000113161 at this locus (26934bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74605220},"locus_GRCh38":{"chromosome":"5","position":75309395}},"trait_info":{"ontology":["EFO_0003774"],"reported_trait_name":"Hyperlipidemia","standard_trait_name":"hyperlipidemia"}}
{"association_info":{"ancestry":["European=406276"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":14.154901959985743,"otg_id":"SAIGE_272_11"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (26934bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74605220},"locus_GRCh38":{"chromosome":"5","position":75309395}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"Hypercholesterolemia","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.410050398674292,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74605220},"locus_GRCh38":{"chromosome":"5","position":75309395}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=408961"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.410050398674292,"otg_id":"SAIGE_272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug LOVASTATIN is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74605220},"locus_GRCh38":{"chromosome":"5","position":75309395}},"trait_info":{"ontology":["Orphanet_309005"],"reported_trait_name":"Disorders of lipoid metabolism","standard_trait_name":"Disorder of lipid metabolism"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0003144"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"heart failure"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":11.045757490560675,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (6667bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":74625487},"locus_GRCh38":{"chromosome":"5","position":75329662}},"trait_info":{"ontology":["EFO_0001645"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"coronary heart disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":8.301029995663981,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000113161 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74656539},"locus_GRCh38":{"chromosome":"5","position":75360714}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":42.19124767849288,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74656539},"locus_GRCh38":{"chromosome":"5","position":75360714}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0001645"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"coronary heart disease"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0003144"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"heart failure"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.698970004336019,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (101258bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74759183},"locus_GRCh38":{"chromosome":"5","position":75463358}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0001645"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"coronary heart disease"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0003144"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"heart failure"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0000311"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"cancer"}}
{"association_info":{"ancestry":["European=9618"],"gwas_catalog_id":"GCST004045","neg_log_pval":7.522878745280337,"otg_id":"GCST004045","pubmed_id":"27790247"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (221964bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":74879890},"locus_GRCh38":{"chromosome":"5","position":75584065}},"trait_info":{"ontology":["EFO_0000400"],"reported_trait_name":"Age-related diseases, mortality and associated endophenotypes","standard_trait_name":"diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":14.698970004336019,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":11.522878745280337,"otg_id":"GCST001953_4","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (345752bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Obesity class I]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":8.397940008672037,"otg_id":"GCST001953_3","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75015242},"locus_GRCh38":{"chromosome":"5","position":75719417}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Obesity class II]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=204498"],"gwas_catalog_id":"GCST001953","neg_log_pval":8.0,"otg_id":"GCST001953_5","pubmed_id":"23563607"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113161","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75015242},"locus_GRCh38":{"chromosome":"5","position":75719417}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity [Overweight]","standard_trait_name":"obesity"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":19.0,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110142816},"locus_GRCh38":{"chromosome":"5","position":110807116}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":19.0,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110142816},"locus_GRCh38":{"chromosome":"5","position":110807116}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=102453"],"gwas_catalog_id":"GCST007563","neg_log_pval":19.69897000433602,"otg_id":"GCST007563","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110142816},"locus_GRCh38":{"chromosome":"5","position":110807116}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=102453"],"gwas_catalog_id":"GCST007563","neg_log_pval":19.69897000433602,"otg_id":"GCST007563","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110142816},"locus_GRCh38":{"chromosome":"5","position":110807116}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.835647144215563,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110158844},"locus_GRCh38":{"chromosome":"5","position":110823145}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.835647144215563,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110158844},"locus_GRCh38":{"chromosome":"5","position":110823145}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":7.755663492560309,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":7.755663492560309,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":17.72690377259096,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":17.72690377259096,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":19.160999247384563,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=72232"],"neg_log_pval":8.280520382028882,"otg_id":"NEALE2_3761_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Age hay fever, rhinitis or eczema diagnosed","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":19.160999247384563,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"CA","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110161473},"locus_GRCh38":{"chromosome":"5","position":110825774}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.097453220686008,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110198114},"locus_GRCh38":{"chromosome":"5","position":110862415}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.097453220686008,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110198114},"locus_GRCh38":{"chromosome":"5","position":110862415}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":7.8621333944441085,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":20.97469413473523,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":36.21098861481695,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":30.522878745280337,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":19.69897000433602,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":7.8621333944441085,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":19.69897000433602,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":30.522878745280337,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1612","European=2088","Hispanic or Latin American=1688"],"gwas_catalog_id":"GCST001182","neg_log_pval":14.0,"otg_id":"GCST001182","pubmed_id":"21804549"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":37.65559397059892,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=1612","European=2088","Hispanic or Latin American=1688"],"gwas_catalog_id":"GCST001182","neg_log_pval":14.0,"otg_id":"GCST001182","pubmed_id":"21804549"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":21.00267741002066,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":20.397940008672037,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":26.016373712875467,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":20.97469413473523,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":20.397940008672037,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":41.0,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=20776"],"gwas_catalog_id":"GCST002322","neg_log_pval":9.0,"otg_id":"GCST002322","pubmed_id":"24388013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma and hay fever","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":37.65559397059892,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":41.0,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":21.69897000433602,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=20776"],"gwas_catalog_id":"GCST002322","neg_log_pval":9.0,"otg_id":"GCST002322","pubmed_id":"24388013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma and hay fever","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["East Asian=4836"],"gwas_catalog_id":"GCST001183","neg_log_pval":16.0,"otg_id":"GCST001183","pubmed_id":"21804548"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":14.301029995663981,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["East Asian=4836"],"gwas_catalog_id":"GCST001183","neg_log_pval":16.0,"otg_id":"GCST001183","pubmed_id":"21804548"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":26.016373712875467,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":21.69897000433602,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":21.00267741002066,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":36.21098861481695,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":14.301029995663981,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":110401872},"locus_GRCh38":{"chromosome":"5","position":111066174}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":25.045757490560675,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110404999},"locus_GRCh38":{"chromosome":"5","position":111069301}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":25.045757490560675,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110404999},"locus_GRCh38":{"chromosome":"5","position":111069301}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":24.692503962086786,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110404999},"locus_GRCh38":{"chromosome":"5","position":111069301}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":24.692503962086786,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110404999},"locus_GRCh38":{"chromosome":"5","position":111069301}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":18.959010211096686,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110406742},"locus_GRCh38":{"chromosome":"5","position":111071044}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":18.959010211096686,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110406742},"locus_GRCh38":{"chromosome":"5","position":111071044}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":20.137288556960716,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110406742},"locus_GRCh38":{"chromosome":"5","position":111071044}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":20.137288556960716,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110406742},"locus_GRCh38":{"chromosome":"5","position":111071044}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=20776"],"gwas_catalog_id":"GCST002322","neg_log_pval":10.522878745280337,"otg_id":"GCST002322","pubmed_id":"24388013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma and hay fever","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":12.522878745280337,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":12.522878745280337,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=102453"],"gwas_catalog_id":"GCST007563","neg_log_pval":19.30102999566398,"otg_id":"GCST007563","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=102453"],"gwas_catalog_id":"GCST007563","neg_log_pval":19.30102999566398,"otg_id":"GCST007563","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Allergic disease (asthma, hay fever or eczema)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=20776"],"gwas_catalog_id":"GCST002322","neg_log_pval":10.522878745280337,"otg_id":"GCST002322","pubmed_id":"24388013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110467499},"locus_GRCh38":{"chromosome":"5","position":111131801}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma and hay fever","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":18.149353764816933,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110470137},"locus_GRCh38":{"chromosome":"5","position":111134439}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":18.149353764816933,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":110470137},"locus_GRCh38":{"chromosome":"5","position":111134439}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=72232"],"neg_log_pval":8.814540009081632,"otg_id":"NEALE2_3761_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (57494bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145777","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":110471218},"locus_GRCh38":{"chromosome":"5","position":111135520}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Age hay fever, rhinitis or eczema diagnosed","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["East Asian=20965"],"gwas_catalog_id":"GCST001454","neg_log_pval":9.522878745280337,"otg_id":"GCST001454","pubmed_id":"22446963"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000164400 at this locus (18255bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131430118},"locus_GRCh38":{"chromosome":"5","position":132094425}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":25.175982286576183,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (322795bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131669161},"locus_GRCh38":{"chromosome":"5","position":132333468}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":46.705144404319334,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (322795bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131669161},"locus_GRCh38":{"chromosome":"5","position":132333468}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=719047"],"gwas_catalog_id":"GCST007443","neg_log_pval":8.0,"otg_id":"GCST007443","pubmed_id":"30643255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (200819bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131676320},"locus_GRCh38":{"chromosome":"5","position":132340627}},"trait_info":{"ontology":["EFO_1000391"],"reported_trait_name":"Nasal polyps","standard_trait_name":"Nasal Cavity Polyp"}}
{"association_info":{"ancestry":["European=393356"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.707743928643524,"otg_id":"SAIGE_471"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (166739bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131710399},"locus_GRCh38":{"chromosome":"5","position":132374707}},"trait_info":{"ontology":["EFO_1000391"],"reported_trait_name":"Nasal polyps","standard_trait_name":"Nasal Cavity Polyp"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":25.162379159732975,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (259500bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131732456},"locus_GRCh38":{"chromosome":"5","position":132396764}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":35.25274360255786,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131770805},"locus_GRCh38":{"chromosome":"5","position":132435113}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=9541"],"gwas_catalog_id":"GCST000207","neg_log_pval":17.69897000433602,"otg_id":"GCST000207","pubmed_id":"18587394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131770805},"locus_GRCh38":{"chromosome":"5","position":132435113}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":54.69897000433602,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (213503bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131778452},"locus_GRCh38":{"chromosome":"5","position":132442760}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":54.69897000433602,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (213503bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131778452},"locus_GRCh38":{"chromosome":"5","position":132442760}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":54.69897000433602,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (366590bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131778452},"locus_GRCh38":{"chromosome":"5","position":132442760}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":54.69897000433602,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (366590bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131778452},"locus_GRCh38":{"chromosome":"5","position":132442760}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=21389"],"gwas_catalog_id":"GCST000879","neg_log_pval":20.0,"otg_id":"GCST000879","pubmed_id":"21102463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131784393},"locus_GRCh38":{"chromosome":"5","position":132448701}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=34366"],"gwas_catalog_id":"GCST001729","neg_log_pval":19.496209316942817,"otg_id":"GCST001729","pubmed_id":"23128233"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131784393},"locus_GRCh38":{"chromosome":"5","position":132448701}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":10.237794241945119,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (195033bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131796922},"locus_GRCh38":{"chromosome":"5","position":132461230}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.667561540084394,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (79591bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131797547},"locus_GRCh38":{"chromosome":"5","position":132461855}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.667561540084394,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131797547},"locus_GRCh38":{"chromosome":"5","position":132461855}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.667561540084394,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131797547},"locus_GRCh38":{"chromosome":"5","position":132461855}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":10.667561540084394,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (212132bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131797547},"locus_GRCh38":{"chromosome":"5","position":132461855}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":7.620391669707774,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (387511bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131799373},"locus_GRCh38":{"chromosome":"5","position":132463681}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":13.221848749616356,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":26.061318695302564,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.563837352959244,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":26.061318695302564,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":13.221848749616356,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":26.061318695302564,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":13.221848749616356,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.563837352959244,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.563837352959244,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":27.398007329534234,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":27.398007329534234,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":27.398007329534234,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":13.221848749616356,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":27.398007329534234,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.563837352959244,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":26.061318695302564,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131799626},"locus_GRCh38":{"chromosome":"5","position":132463934}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.301029995663981,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (68469bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131808668},"locus_GRCh38":{"chromosome":"5","position":132472976}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.301029995663981,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (201010bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131808668},"locus_GRCh38":{"chromosome":"5","position":132472976}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.301029995663981,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131808668},"locus_GRCh38":{"chromosome":"5","position":132472976}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.301029995663981,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131808668},"locus_GRCh38":{"chromosome":"5","position":132472976}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (180773bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131811182},"locus_GRCh38":{"chromosome":"5","position":132475490}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (180773bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131811182},"locus_GRCh38":{"chromosome":"5","position":132475490}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (399320bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131811182},"locus_GRCh38":{"chromosome":"5","position":132475490}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (399320bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164400","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131811182},"locus_GRCh38":{"chromosome":"5","position":132475490}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":11.05858795962645,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (50815bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131826322},"locus_GRCh38":{"chromosome":"5","position":132490630}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":11.05858795962645,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131826322},"locus_GRCh38":{"chromosome":"5","position":132490630}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":11.05858795962645,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (183357bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131826322},"locus_GRCh38":{"chromosome":"5","position":132490630}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":11.05858795962645,"otg_id":"NEALE2_22127","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":131826322},"locus_GRCh38":{"chromosome":"5","position":132490630}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Doctor diagnosed asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":14.698970004336019,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131887986},"locus_GRCh38":{"chromosome":"5","position":132552294}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":14.698970004336019,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131887986},"locus_GRCh38":{"chromosome":"5","position":132552294}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":14.698970004336019,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131887986},"locus_GRCh38":{"chromosome":"5","position":132552294}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=30810"],"gwas_catalog_id":"GCST006911","neg_log_pval":14.698970004336019,"otg_id":"GCST006911","pubmed_id":"30552067"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (121692bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131887986},"locus_GRCh38":{"chromosome":"5","position":132552294}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma (moderate or severe)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":15.698970004336019,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131901225},"locus_GRCh38":{"chromosome":"5","position":132565533}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":15.698970004336019,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (8696bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131901225},"locus_GRCh38":{"chromosome":"5","position":132565533}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":15.698970004336019,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131901225},"locus_GRCh38":{"chromosome":"5","position":132565533}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":15.698970004336019,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (108454bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131901225},"locus_GRCh38":{"chromosome":"5","position":132565533}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":31.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":26.939774475605834,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":28.044273294785736,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":31.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":28.044273294785736,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":31.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":26.939774475605834,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":8.154901959985743,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":28.044273294785736,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":26.939774475605834,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":8.154901959985743,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":8.154901959985743,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=28835"],"gwas_catalog_id":"GCST007797","neg_log_pval":8.154901959985743,"otg_id":"GCST007797","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma onset (childhood vs adult)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":28.044273294785736,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":26.939774475605834,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":31.154901959985743,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131916940},"locus_GRCh38":{"chromosome":"5","position":132581248}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":11.0,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (84491bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131925187},"locus_GRCh38":{"chromosome":"5","position":132589495}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":11.0,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131925187},"locus_GRCh38":{"chromosome":"5","position":132589495}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":11.0,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (32657bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131925187},"locus_GRCh38":{"chromosome":"5","position":132589495}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=90853"],"gwas_catalog_id":"GCST007562","neg_log_pval":11.0,"otg_id":"GCST007562","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131925187},"locus_GRCh38":{"chromosome":"5","position":132589495}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":17.69897000433602,"otg_id":"GCST002740_3","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131952222},"locus_GRCh38":{"chromosome":"5","position":132616530}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Inflammatory skin disease [Opposed]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":17.69897000433602,"otg_id":"GCST002740_3","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131952222},"locus_GRCh38":{"chromosome":"5","position":132616530}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Inflammatory skin disease [Opposed]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["NR, European=212120"],"gwas_catalog_id":"GCST006409","neg_log_pval":8.698970004336019,"otg_id":"GCST006409","pubmed_id":"30013184"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131955577},"locus_GRCh38":{"chromosome":"5","position":132619885}},"trait_info":{"ontology":["EFO_0005854"],"reported_trait_name":"Allergic rhinitis","standard_trait_name":"allergic rhinitis"}}
{"association_info":{"ancestry":["NR, European=212120"],"gwas_catalog_id":"GCST006409","neg_log_pval":8.698970004336019,"otg_id":"GCST006409","pubmed_id":"30013184"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TATATATATATAG","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131955577},"locus_GRCh38":{"chromosome":"5","position":132619885}},"trait_info":{"ontology":["EFO_0005854"],"reported_trait_name":"Allergic rhinitis","standard_trait_name":"allergic rhinitis"}}
{"association_info":{"ancestry":["NR, European=212120"],"gwas_catalog_id":"GCST006409","neg_log_pval":8.698970004336019,"otg_id":"GCST006409","pubmed_id":"30013184"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TAGAG","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131955577},"locus_GRCh38":{"chromosome":"5","position":132619885}},"trait_info":{"ontology":["EFO_0005854"],"reported_trait_name":"Allergic rhinitis","standard_trait_name":"allergic rhinitis"}}
{"association_info":{"ancestry":["NR, European=212120"],"gwas_catalog_id":"GCST006409","neg_log_pval":8.698970004336019,"otg_id":"GCST006409","pubmed_id":"30013184"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TAG","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131955577},"locus_GRCh38":{"chromosome":"5","position":132619885}},"trait_info":{"ontology":["EFO_0005854"],"reported_trait_name":"Allergic rhinitis","standard_trait_name":"allergic rhinitis"}}
{"association_info":{"ancestry":["NR, European=212120"],"gwas_catalog_id":"GCST006409","neg_log_pval":8.698970004336019,"otg_id":"GCST006409","pubmed_id":"30013184"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"TAA","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131955577},"locus_GRCh38":{"chromosome":"5","position":132619885}},"trait_info":{"ontology":["EFO_0005854"],"reported_trait_name":"Allergic rhinitis","standard_trait_name":"allergic rhinitis"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":16.397940008672037,"otg_id":"GCST003184","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131991085},"locus_GRCh38":{"chromosome":"5","position":132655393}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [EA, fixed effects]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":16.397940008672037,"otg_id":"GCST003184","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131991085},"locus_GRCh38":{"chromosome":"5","position":132655393}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [EA, fixed effects]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.5654310959658,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131991881},"locus_GRCh38":{"chromosome":"5","position":132656189}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.5654310959658,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (99351bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131991881},"locus_GRCh38":{"chromosome":"5","position":132656189}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.5654310959658,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131991881},"locus_GRCh38":{"chromosome":"5","position":132656189}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=401837"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.5654310959658,"otg_id":"SAIGE_495"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (17797bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":131991881},"locus_GRCh38":{"chromosome":"5","position":132656189}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=5617"],"gwas_catalog_id":"GCST002100","neg_log_pval":16.69897000433602,"otg_id":"GCST002100","pubmed_id":"23886662"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131995843},"locus_GRCh38":{"chromosome":"5","position":132660151}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=5946"],"gwas_catalog_id":"GCST002737","neg_log_pval":8.301029995663981,"otg_id":"GCST002737","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131995843},"locus_GRCh38":{"chromosome":"5","position":132660151}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=5617"],"gwas_catalog_id":"GCST002100","neg_log_pval":16.69897000433602,"otg_id":"GCST002100","pubmed_id":"23886662"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131995843},"locus_GRCh38":{"chromosome":"5","position":132660151}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=5946"],"gwas_catalog_id":"GCST002737","neg_log_pval":8.301029995663981,"otg_id":"GCST002737","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":131995843},"locus_GRCh38":{"chromosome":"5","position":132660151}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":15.301029995663981,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":15.301029995663981,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":13.853871964321762,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":13.853871964321762,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":15.301029995663981,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":13.853871964321762,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":15.301029995663981,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=127669"],"gwas_catalog_id":"GCST006862","neg_log_pval":13.853871964321762,"otg_id":"GCST006862","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131995964},"locus_GRCh38":{"chromosome":"5","position":132660272}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=7565"],"gwas_catalog_id":"GCST004866","neg_log_pval":8.301029995663981,"otg_id":"GCST004866","pubmed_id":"25608926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase II for the indiciation EFO_0004192 and targets the gene ENSG00000169194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":131996500},"locus_GRCh38":{"chromosome":"5","position":132660808}},"trait_info":{"ontology":["EFO_0004192"],"reported_trait_name":"Alopecia areata","standard_trait_name":"alopecia areata"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":11.154901959985743,"otg_id":"GCST003184_2","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":132028858},"locus_GRCh38":{"chromosome":"5","position":132693166}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [conditional on rs6419573]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":11.154901959985743,"otg_id":"GCST003184_2","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":132028858},"locus_GRCh38":{"chromosome":"5","position":132693166}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [conditional on rs6419573]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=11181"],"gwas_catalog_id":"GCST003180","neg_log_pval":7.301029995663981,"otg_id":"GCST003180","pubmed_id":"26542096"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132030667},"locus_GRCh38":{"chromosome":"5","position":132694975}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic march","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=11181"],"gwas_catalog_id":"GCST003180","neg_log_pval":7.301029995663981,"otg_id":"GCST003180","pubmed_id":"26542096"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132030667},"locus_GRCh38":{"chromosome":"5","position":132694975}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic march","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":10.0,"otg_id":"GCST003184","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132049027},"locus_GRCh38":{"chromosome":"5","position":132713335}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [EA, fixed effects]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=26171"],"gwas_catalog_id":"GCST001363","neg_log_pval":7.3979400086720375,"otg_id":"GCST001363","pubmed_id":"22197932"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132049027},"locus_GRCh38":{"chromosome":"5","position":132713335}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=103066","Hispanic or Latin American=1892","African American or Afro-Caribbean=1266","East Asian=9438","NR=1201"],"gwas_catalog_id":"GCST003184","neg_log_pval":10.0,"otg_id":"GCST003184","pubmed_id":"26482879"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132049027},"locus_GRCh38":{"chromosome":"5","position":132713335}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis [EA, fixed effects]","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=26171"],"gwas_catalog_id":"GCST001363","neg_log_pval":7.3979400086720375,"otg_id":"GCST001363","pubmed_id":"22197932"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132049027},"locus_GRCh38":{"chromosome":"5","position":132713335}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic dermatitis","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":8.737359096244738,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":132056874},"locus_GRCh38":{"chromosome":"5","position":132721182}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":8.737359096244738,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":132056874},"locus_GRCh38":{"chromosome":"5","position":132721182}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":8.737359096244738,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (38505bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":132056874},"locus_GRCh38":{"chromosome":"5","position":132721182}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=36955"],"neg_log_pval":8.737359096244738,"otg_id":"NEALE2_3786_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (164345bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":132056874},"locus_GRCh38":{"chromosome":"5","position":132721182}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Age asthma diagnosed","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.698970004336019,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (168054bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113525","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132060583},"locus_GRCh38":{"chromosome":"5","position":132724891}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.698970004336019,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (42213bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132060583},"locus_GRCh38":{"chromosome":"5","position":132724891}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.698970004336019,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132060583},"locus_GRCh38":{"chromosome":"5","position":132724891}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":9.698970004336019,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":132060583},"locus_GRCh38":{"chromosome":"5","position":132724891}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":7.698970004336019,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":132439010},"locus_GRCh38":{"chromosome":"5","position":133103318}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":7.698970004336019,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":132439010},"locus_GRCh38":{"chromosome":"5","position":133103318}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":10.221848749616356,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":142650404},"locus_GRCh38":{"chromosome":"5","position":143270839}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":11.0,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":142650404},"locus_GRCh38":{"chromosome":"5","position":143270839}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":11.0,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":142650404},"locus_GRCh38":{"chromosome":"5","position":143270839}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":10.221848749616356,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":142650404},"locus_GRCh38":{"chromosome":"5","position":143270839}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":16.716472635138306,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug METHYLPREDNISOLONE HEMISUCCINATE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":142880532},"locus_GRCh38":{"chromosome":"5","position":143500967}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":16.716472635138306,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113580","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":142880532},"locus_GRCh38":{"chromosome":"5","position":143500967}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":32.52287874528034,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":147854970},"locus_GRCh38":{"chromosome":"5","position":148475407}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":32.52287874528034,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor partial agonist drug CELIPROLOL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":147854970},"locus_GRCh38":{"chromosome":"5","position":148475407}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":32.52287874528034,"otg_id":"GCST007692","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":147854970},"locus_GRCh38":{"chromosome":"5","position":148475407}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":13.0,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":13.0,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":13.0,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=3522","Hispanic or Latin American=600","European=47856","East Asian=6940"],"gwas_catalog_id":"GCST004147","neg_log_pval":25.30102999566398,"otg_id":"GCST004147","pubmed_id":"28166215"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=3522","Hispanic or Latin American=600","European=47856","East Asian=6940"],"gwas_catalog_id":"GCST004147","neg_log_pval":25.30102999566398,"otg_id":"GCST004147","pubmed_id":"28166215"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, NR=58918","European=458554"],"gwas_catalog_id":"GCST007611","neg_log_pval":13.0,"otg_id":"GCST007611","pubmed_id":"30940143"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor antagonist drug PROPRANOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=3522","Hispanic or Latin American=600","European=47856","East Asian=6940"],"gwas_catalog_id":"GCST004147","neg_log_pval":25.30102999566398,"otg_id":"GCST004147","pubmed_id":"28166215"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":147856333},"locus_GRCh38":{"chromosome":"5","position":148476770}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.715497077748008,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Beta-2 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (139293bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169252","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":148347543},"locus_GRCh38":{"chromosome":"5","position":148967980}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":8.698970004336019,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Macrophage colony stimulating factor receptor inhibitor drug VATALANIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000182578 at this locus (236621bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000182578","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":149196234},"locus_GRCh38":{"chromosome":"5","position":149816671}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":8.698970004336019,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Platelet-derived growth factor receptor beta inhibitor drug DASATINIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113721","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":149196234},"locus_GRCh38":{"chromosome":"5","position":149816671}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=88583"],"gwas_catalog_id":"GCST007505","neg_log_pval":8.698970004336019,"otg_id":"GCST007505","pubmed_id":"30429480"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Platelet-derived growth factor receptor beta inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113721","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":149196234},"locus_GRCh38":{"chromosome":"5","position":149816671}},"trait_info":{"ontology":["EFO_0000389"],"reported_trait_name":"Nevus count or cutaneous melanoma","standard_trait_name":"skin melanoma"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":10.388393510619363,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158669913},"locus_GRCh38":{"chromosome":"5","position":159242905}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":10.388393510619363,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158669913},"locus_GRCh38":{"chromosome":"5","position":159242905}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":27.69897000433602,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158717789},"locus_GRCh38":{"chromosome":"5","position":159290781}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6297"],"gwas_catalog_id":"GCST003269","neg_log_pval":13.0,"otg_id":"GCST003269","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158717789},"locus_GRCh38":{"chromosome":"5","position":159290781}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Cutaneous psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":27.69897000433602,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158717789},"locus_GRCh38":{"chromosome":"5","position":159290781}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6297"],"gwas_catalog_id":"GCST003269","neg_log_pval":13.0,"otg_id":"GCST003269","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158717789},"locus_GRCh38":{"chromosome":"5","position":159290781}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Cutaneous psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":9.301029995663981,"otg_id":"GCST002874_10","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158749088},"locus_GRCh38":{"chromosome":"5","position":159322080}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [conditional on rs7709212, rs4921493]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":9.301029995663981,"otg_id":"GCST002874_10","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158749088},"locus_GRCh38":{"chromosome":"5","position":159322080}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [conditional on rs7709212, rs4921493]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":7.698970004336019,"otg_id":"GCST002874_6","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158749088},"locus_GRCh38":{"chromosome":"5","position":159322080}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA, conditional on rs7709212, rs4921493]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":7.698970004336019,"otg_id":"GCST002874_6","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158749088},"locus_GRCh38":{"chromosome":"5","position":159322080}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA, conditional on rs7709212, rs4921493]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":10.301029995663981,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158750769},"locus_GRCh38":{"chromosome":"5","position":159323761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2271"],"gwas_catalog_id":"GCST000321","neg_log_pval":25.522878745280337,"otg_id":"GCST000321","pubmed_id":"19169255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158750769},"locus_GRCh38":{"chromosome":"5","position":159323761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":10.301029995663981,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158750769},"locus_GRCh38":{"chromosome":"5","position":159323761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2271"],"gwas_catalog_id":"GCST000321","neg_log_pval":25.522878745280337,"otg_id":"GCST000321","pubmed_id":"19169255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158750769},"locus_GRCh38":{"chromosome":"5","position":159323761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=398907"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.0268721464003,"otg_id":"SAIGE_696_42"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158755845},"locus_GRCh38":{"chromosome":"5","position":159328837}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthropathy","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":34.52287874528034,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158759900},"locus_GRCh38":{"chromosome":"5","position":159332892}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1618"],"gwas_catalog_id":"GCST000836","neg_log_pval":20.0,"otg_id":"GCST000836","pubmed_id":"20953188"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158759900},"locus_GRCh38":{"chromosome":"5","position":159332892}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1618"],"gwas_catalog_id":"GCST000836","neg_log_pval":20.0,"otg_id":"GCST000836","pubmed_id":"20953188"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158759900},"locus_GRCh38":{"chromosome":"5","position":159332892}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=18190"],"gwas_catalog_id":"GCST002740","neg_log_pval":34.52287874528034,"otg_id":"GCST002740_4","pubmed_id":"25574825"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158759900},"locus_GRCh38":{"chromosome":"5","position":159332892}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Inflammatory skin disease [Psoriasis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":19.522878745280337,"otg_id":"GCST002874_8","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":11.0,"otg_id":"GCST002874_3","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [Chinese]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":8.301029995663981,"otg_id":"GCST002874_2","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [Chinese, conditional on rs1990760]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":11.0,"otg_id":"GCST002874_3","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [Chinese]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":19.522878745280337,"otg_id":"GCST002874_8","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":29.69897000433602,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":8.301029995663981,"otg_id":"GCST002874_2","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [Chinese, conditional on rs1990760]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":29.69897000433602,"otg_id":"GCST002874","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764177},"locus_GRCh38":{"chromosome":"5","position":159337169}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6880"],"gwas_catalog_id":"GCST003270","neg_log_pval":24.0,"otg_id":"GCST003270","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (6584bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764478},"locus_GRCh38":{"chromosome":"5","position":159337470}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":22.400348322298537,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158766022},"locus_GRCh38":{"chromosome":"5","position":159339014}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":22.400348322298537,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158766022},"locus_GRCh38":{"chromosome":"5","position":159339014}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=2198"],"gwas_catalog_id":"GCST007043","neg_log_pval":9.045757490560675,"otg_id":"GCST007043","pubmed_id":"30552173"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (10470bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158768365},"locus_GRCh38":{"chromosome":"5","position":159341357}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":33.5271134750456,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158771337},"locus_GRCh38":{"chromosome":"5","position":159344329}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":33.5271134750456,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158771337},"locus_GRCh38":{"chromosome":"5","position":159344329}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":16.91802094893202,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158774965},"locus_GRCh38":{"chromosome":"5","position":159347957}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European, NR=45975"],"gwas_catalog_id":"GCST004133","neg_log_pval":19.67571754470231,"otg_id":"GCST004133","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158774965},"locus_GRCh38":{"chromosome":"5","position":159347957}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=21389"],"gwas_catalog_id":"GCST000879","neg_log_pval":13.301029995663981,"otg_id":"GCST000879","pubmed_id":"21102463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158787385},"locus_GRCh38":{"chromosome":"5","position":159360377}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=21389"],"gwas_catalog_id":"GCST000879","neg_log_pval":13.301029995663981,"otg_id":"GCST000879","pubmed_id":"21102463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158787385},"locus_GRCh38":{"chromosome":"5","position":159360377}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":19.061080187755227,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158798075},"locus_GRCh38":{"chromosome":"5","position":159371067}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":19.061080187755227,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158798075},"locus_GRCh38":{"chromosome":"5","position":159371067}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":20.03839715731701,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158810793},"locus_GRCh38":{"chromosome":"5","position":159383785}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":20.03839715731701,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158810793},"locus_GRCh38":{"chromosome":"5","position":159383785}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=9541"],"gwas_catalog_id":"GCST000207","neg_log_pval":12.397940008672037,"otg_id":"GCST000207","pubmed_id":"18587394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158814533},"locus_GRCh38":{"chromosome":"5","position":159387525}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=9541"],"gwas_catalog_id":"GCST000207","neg_log_pval":12.397940008672037,"otg_id":"GCST000207","pubmed_id":"18587394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158814533},"locus_GRCh38":{"chromosome":"5","position":159387525}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=11802"],"gwas_catalog_id":"GCST001149","neg_log_pval":7.698970004336019,"otg_id":"GCST001149","pubmed_id":"21743469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (60850bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158818745},"locus_GRCh38":{"chromosome":"5","position":159391737}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=400436"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":13.292429823902063,"otg_id":"SAIGE_696_4"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158820061},"locus_GRCh38":{"chromosome":"5","position":159393053}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=400436"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":13.292429823902063,"otg_id":"SAIGE_696_4"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158820061},"locus_GRCh38":{"chromosome":"5","position":159393053}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":13.017728766960431,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158821917},"locus_GRCh38":{"chromosome":"5","position":159394909}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":13.017728766960431,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158821917},"locus_GRCh38":{"chromosome":"5","position":159394909}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=400492"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.714442690992225,"otg_id":"SAIGE_696"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158826310},"locus_GRCh38":{"chromosome":"5","position":159399302}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis and related disorders","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=400492"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":20.714442690992225,"otg_id":"SAIGE_696"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":158826310},"locus_GRCh38":{"chromosome":"5","position":159399302}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis and related disorders","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":7.522878745280337,"otg_id":"GCST005529","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (68897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158826792},"locus_GRCh38":{"chromosome":"5","position":159399784}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European, NR=45975"],"gwas_catalog_id":"GCST004133","neg_log_pval":23.22951619056889,"otg_id":"GCST004133","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158826792},"locus_GRCh38":{"chromosome":"5","position":159399784}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=26405"],"gwas_catalog_id":"GCST000964","neg_log_pval":7.991399828238082,"otg_id":"GCST000964","pubmed_id":"21297633"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158826792},"locus_GRCh38":{"chromosome":"5","position":159399784}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=27432"],"gwas_catalog_id":"GCST003045","neg_log_pval":26.13838459401752,"otg_id":"GCST003045","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis [EA]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":40.64029045008325,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=20883"],"gwas_catalog_id":"GCST003044","neg_log_pval":40.64029045008325,"otg_id":"GCST003044","pubmed_id":"26192919"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease [EA]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.52287874528034,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158827769},"locus_GRCh38":{"chromosome":"5","position":159400761}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=400436"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.950781977329818,"otg_id":"SAIGE_696_4"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829289},"locus_GRCh38":{"chromosome":"5","position":159402281}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=400436"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.950781977329818,"otg_id":"SAIGE_696_4"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829289},"locus_GRCh38":{"chromosome":"5","position":159402281}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":28.860120913598763,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":9.698970004336019,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European, NR=40266"],"gwas_catalog_id":"GCST004132","neg_log_pval":28.860120913598763,"otg_id":"GCST004132","pubmed_id":"28067908"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158829294},"locus_GRCh38":{"chromosome":"5","position":159402286}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":32.77779353908738,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1460"],"gwas_catalog_id":"GCST000835","neg_log_pval":16.154901959985743,"otg_id":"GCST000835","pubmed_id":"20953186"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":32.77779353908738,"otg_id":"NEALE2_20002_1453","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis | non-cancer illness code, self-reported","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":83.52287874528034,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":12.669586226650809,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":12.669586226650809,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":11.735654492949907,"otg_id":"NEALE2_20002_1477","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthropathy | non-cancer illness code, self-reported","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":83.52287874528034,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=398907"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.665546248849068,"otg_id":"SAIGE_696_42"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158829527},"locus_GRCh38":{"chromosome":"5","position":159402519}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthropathy","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=7208"],"gwas_catalog_id":"GCST005538","neg_log_pval":8.698970004336019,"otg_id":"GCST005538","pubmed_id":"26051272"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000113302 at this locus (74382bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":158832277},"locus_GRCh38":{"chromosome":"5","position":159405269}},"trait_info":{"ontology":["Orphanet_797"],"reported_trait_name":"Sarcoidosis [EA]","standard_trait_name":"Sarcoidosis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":12.154901959985743,"otg_id":"GCST002874_11","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158836107},"locus_GRCh38":{"chromosome":"5","position":159409099}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [conditional on rs7709212]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":10.522878745280337,"otg_id":"GCST002874_7","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158836107},"locus_GRCh38":{"chromosome":"5","position":159409099}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA, conditional on rs7709212]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":12.154901959985743,"otg_id":"GCST002874_11","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158836107},"locus_GRCh38":{"chromosome":"5","position":159409099}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [conditional on rs7709212]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5134","European=8682"],"gwas_catalog_id":"GCST002874","neg_log_pval":10.522878745280337,"otg_id":"GCST002874_7","pubmed_id":"25903422"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113302","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158836107},"locus_GRCh38":{"chromosome":"5","position":159409099}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis [EA, conditional on rs7709212]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145863 at this locus (281691bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145863","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug ALPRAZOLAM is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000022355","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145864","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000022355","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113327","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug CLORAZEPIC ACID is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000113327","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=351833"],"neg_log_pval":8.322648589788734,"otg_id":"NEALE2_1980","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"GABA-A receptor; anion channel positive allosteric modulator drug CLOMETHIAZOLE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000145864","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CA"},"locus_GRCh37":{"chromosome":"5","position":161411289},"locus_GRCh38":{"chromosome":"5","position":161984283}},"trait_info":{"ontology":["EFO_0005230"],"reported_trait_name":"Worrier / anxious feelings","standard_trait_name":"anxiety"}}
{"association_info":{"ancestry":["European=10767"],"gwas_catalog_id":"GCST003468","neg_log_pval":7.698970004336019,"otg_id":"GCST003468","pubmed_id":"26956414"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137285 at this locus (255233bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":2969278},"locus_GRCh38":{"chromosome":"6","position":2969044}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["European=10767"],"gwas_catalog_id":"GCST003468","neg_log_pval":7.698970004336019,"otg_id":"GCST003468","pubmed_id":"26956414"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137267 at this locus (184622bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":2969278},"locus_GRCh38":{"chromosome":"6","position":2969044}},"trait_info":{"ontology":["EFO_0000095"],"reported_trait_name":"Chronic lymphocytic leukemia","standard_trait_name":"chronic lymphocytic leukemia"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":8.045757490560675,"otg_id":"GCST007728_9","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [serous]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137267","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["East Asian=7321"],"gwas_catalog_id":"GCST007728","neg_log_pval":7.3979400086720375,"otg_id":"GCST007728_2","pubmed_id":"30898391"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000137285","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":3581089},"locus_GRCh38":{"chromosome":"6","position":3580855}},"trait_info":{"ontology":["EFO_0001075"],"reported_trait_name":"Epithelial ovarian cancer [HGSOC]","standard_trait_name":"ovarian carcinoma"}}
{"association_info":{"ancestry":["European=40187"],"gwas_catalog_id":"GCST004749","neg_log_pval":12.154901959985743,"otg_id":"GCST004749","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":30342753},"locus_GRCh38":{"chromosome":"6","position":30374976}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer in ever smokers","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=40187"],"gwas_catalog_id":"GCST004749","neg_log_pval":12.154901959985743,"otg_id":"GCST004749","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":30342753},"locus_GRCh38":{"chromosome":"6","position":30374976}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer in ever smokers","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=63053"],"gwas_catalog_id":"GCST004750","neg_log_pval":13.522878745280337,"otg_id":"GCST004750","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":30351348},"locus_GRCh38":{"chromosome":"6","position":30383571}},"trait_info":{"ontology":["EFO_0000708"],"reported_trait_name":"Squamous cell lung carcinoma","standard_trait_name":"squamous cell lung carcinoma"}}
{"association_info":{"ancestry":["European=63053"],"gwas_catalog_id":"GCST004750","neg_log_pval":13.522878745280337,"otg_id":"GCST004750","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":30351348},"locus_GRCh38":{"chromosome":"6","position":30383571}},"trait_info":{"ontology":["EFO_0000708"],"reported_trait_name":"Squamous cell lung carcinoma","standard_trait_name":"squamous cell lung carcinoma"}}
{"association_info":{"ancestry":["European=85716"],"gwas_catalog_id":"GCST004748","neg_log_pval":17.397940008672037,"otg_id":"GCST004748","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30357294},"locus_GRCh38":{"chromosome":"6","position":30389517}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=85716"],"gwas_catalog_id":"GCST004748","neg_log_pval":17.397940008672037,"otg_id":"GCST004748","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30357294},"locus_GRCh38":{"chromosome":"6","position":30389517}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":30601232},"locus_GRCh38":{"chromosome":"6","position":30633455}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":30601232},"locus_GRCh38":{"chromosome":"6","position":30633455}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":8.221848749616356,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":30601232},"locus_GRCh38":{"chromosome":"6","position":30633455}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=85716"],"gwas_catalog_id":"GCST004748","neg_log_pval":18.154901959985743,"otg_id":"GCST004748","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30864279},"locus_GRCh38":{"chromosome":"6","position":30896502}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=85716"],"gwas_catalog_id":"GCST004748","neg_log_pval":18.154901959985743,"otg_id":"GCST004748","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30864279},"locus_GRCh38":{"chromosome":"6","position":30896502}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=63053"],"gwas_catalog_id":"GCST004750","neg_log_pval":15.522878745280337,"otg_id":"GCST004750","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30882415},"locus_GRCh38":{"chromosome":"6","position":30914638}},"trait_info":{"ontology":["EFO_0000708"],"reported_trait_name":"Squamous cell lung carcinoma","standard_trait_name":"squamous cell lung carcinoma"}}
{"association_info":{"ancestry":["European=63053"],"gwas_catalog_id":"GCST004750","neg_log_pval":15.522878745280337,"otg_id":"GCST004750","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":30882415},"locus_GRCh38":{"chromosome":"6","position":30914638}},"trait_info":{"ontology":["EFO_0000708"],"reported_trait_name":"Squamous cell lung carcinoma","standard_trait_name":"squamous cell lung carcinoma"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":324.22184874961636,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (223056bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":30916259},"locus_GRCh38":{"chromosome":"6","position":30948482}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=120184","East Asian=5294"],"gwas_catalog_id":"GCST007856","neg_log_pval":8.045757490560675,"otg_id":"GCST007856","pubmed_id":"30510241"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000196230 at this locus (316982bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31010185},"locus_GRCh38":{"chromosome":"6","position":31042408}},"trait_info":{"ontology":["EFO_0005842"],"reported_trait_name":"Colorectal cancer or advanced adenoma","standard_trait_name":"colorectal cancer"}}
{"association_info":{"ancestry":["European=1712","African American or Afro-Caribbean=1233","Hispanic or Latin American=677"],"gwas_catalog_id":"GCST000863","neg_log_pval":8.0,"otg_id":"GCST000863","pubmed_id":"21051598"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (331606bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31024808},"locus_GRCh38":{"chromosome":"6","position":31057031}},"trait_info":{"ontology":["EFO_0000180"],"reported_trait_name":"HIV-1 control [AA]","standard_trait_name":"HIV-1 infection"}}
{"association_info":{"ancestry":["East Asian=1098"],"gwas_catalog_id":"GCST001768","neg_log_pval":11.0,"otg_id":"GCST001768","pubmed_id":"23001997"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (364975bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31058178},"locus_GRCh38":{"chromosome":"6","position":31090401}},"trait_info":{"ontology":["EFO_0003780"],"reported_trait_name":"Behcet's disease","standard_trait_name":"Behcet's syndrome"}}
{"association_info":{"ancestry":["East Asian=1098"],"gwas_catalog_id":"GCST001768","neg_log_pval":11.0,"otg_id":"GCST001768","pubmed_id":"23001997"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (485164bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31058178},"locus_GRCh38":{"chromosome":"6","position":31090401}},"trait_info":{"ontology":["EFO_0003780"],"reported_trait_name":"Behcet's disease","standard_trait_name":"Behcet's syndrome"}}
{"association_info":{"ancestry":["European=781"],"gwas_catalog_id":"GCST000448","neg_log_pval":10.301029995663981,"otg_id":"GCST000448","pubmed_id":"19620980"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000096 and targets the gene ENSG00000196230 at this locus (380827bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31074030},"locus_GRCh38":{"chromosome":"6","position":31106253}},"trait_info":{"ontology":["EFO_0000096"],"reported_trait_name":"Follicular lymphoma","standard_trait_name":"neoplasm of mature B-cells"}}
{"association_info":{"ancestry":["European=1048"],"gwas_catalog_id":"GCST005541","neg_log_pval":26.096910013008056,"otg_id":"GCST005541","pubmed_id":"26651848"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31080016},"locus_GRCh38":{"chromosome":"6","position":31112239}},"trait_info":{"ontology":["Orphanet_797"],"reported_trait_name":"Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)","standard_trait_name":"Sarcoidosis"}}
{"association_info":{"ancestry":["European=1048"],"gwas_catalog_id":"GCST005541","neg_log_pval":26.096910013008056,"otg_id":"GCST005541","pubmed_id":"26651848"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31080016},"locus_GRCh38":{"chromosome":"6","position":31112239}},"trait_info":{"ontology":["Orphanet_797"],"reported_trait_name":"Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)","standard_trait_name":"Sarcoidosis"}}
{"association_info":{"ancestry":["European=40187"],"gwas_catalog_id":"GCST004749","neg_log_pval":15.301029995663981,"otg_id":"GCST004749","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31081205},"locus_GRCh38":{"chromosome":"6","position":31113428}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer in ever smokers","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=40187"],"gwas_catalog_id":"GCST004749","neg_log_pval":15.301029995663981,"otg_id":"GCST004749","pubmed_id":"28604730"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31081205},"locus_GRCh38":{"chromosome":"6","position":31113428}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer in ever smokers","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=8970","African American or Afro-Caribbean=2025"],"gwas_catalog_id":"GCST003833","neg_log_pval":10.698970004336019,"otg_id":"GCST003833","pubmed_id":"27611488"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (455197bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31088145},"locus_GRCh38":{"chromosome":"6","position":31120368}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Adult asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["Other=978","European=1112"],"gwas_catalog_id":"GCST006575","neg_log_pval":9.698970004336019,"otg_id":"GCST006575_3","pubmed_id":"25604533"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (453635bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31089708},"locus_GRCh38":{"chromosome":"6","position":31121931}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis [Turkish]","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["East Asian=1098"],"gwas_catalog_id":"GCST001768","neg_log_pval":19.69897000433602,"otg_id":"GCST001768","pubmed_id":"23001997"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (443766bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31099577},"locus_GRCh38":{"chromosome":"6","position":31131800}},"trait_info":{"ontology":["EFO_0003780"],"reported_trait_name":"Behcet's disease","standard_trait_name":"Behcet's syndrome"}}
{"association_info":{"ancestry":["East Asian=1098"],"gwas_catalog_id":"GCST001768","neg_log_pval":19.69897000433602,"otg_id":"GCST001768","pubmed_id":"23001997"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (406375bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31099577},"locus_GRCh38":{"chromosome":"6","position":31131800}},"trait_info":{"ontology":["EFO_0003780"],"reported_trait_name":"Behcet's disease","standard_trait_name":"Behcet's syndrome"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.0,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (440378bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31102964},"locus_GRCh38":{"chromosome":"6","position":31135187}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":9.698970004336019,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (437929bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31105413},"locus_GRCh38":{"chromosome":"6","position":31137636}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":9.698970004336019,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (437929bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31105413},"locus_GRCh38":{"chromosome":"6","position":31137636}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=9641"],"gwas_catalog_id":"GCST002140","neg_log_pval":10.0,"otg_id":"GCST002140","pubmed_id":"23955597"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31107258},"locus_GRCh38":{"chromosome":"6","position":31139481}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=9641"],"gwas_catalog_id":"GCST002140","neg_log_pval":10.0,"otg_id":"GCST002140","pubmed_id":"23955597"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31107258},"locus_GRCh38":{"chromosome":"6","position":31139481}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["East Asian=1310"],"gwas_catalog_id":"GCST000529","neg_log_pval":66.39794000867204,"otg_id":"GCST000529","pubmed_id":"19915573"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31111356},"locus_GRCh38":{"chromosome":"6","position":31143579}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["East Asian=1310"],"gwas_catalog_id":"GCST000529","neg_log_pval":66.39794000867204,"otg_id":"GCST000529","pubmed_id":"19915573"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31111356},"locus_GRCh38":{"chromosome":"6","position":31143579}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=241704"],"gwas_catalog_id":"GCST004483","neg_log_pval":16.522878745280337,"otg_id":"GCST004483","pubmed_id":"27363682"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31116526},"locus_GRCh38":{"chromosome":"6","position":31148749}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=241704"],"gwas_catalog_id":"GCST004483","neg_log_pval":16.522878745280337,"otg_id":"GCST004483","pubmed_id":"27363682"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31116526},"locus_GRCh38":{"chromosome":"6","position":31148749}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":7.522878745280337,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31118511},"locus_GRCh38":{"chromosome":"6","position":31150734}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":7.522878745280337,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31118511},"locus_GRCh38":{"chromosome":"6","position":31150734}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":7.522878745280337,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31118511},"locus_GRCh38":{"chromosome":"6","position":31150734}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":7.698970004336019,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (406890bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31136453},"locus_GRCh38":{"chromosome":"6","position":31168676}},"trait_info":{"ontology":["EFO_0004775"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"toxic epidermal necrolysis"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":7.698970004336019,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (406890bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31136453},"locus_GRCh38":{"chromosome":"6","position":31168676}},"trait_info":{"ontology":["EFO_0004276"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"Stevens-Johnson syndrome"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":7.522878745280337,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (401097bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31142245},"locus_GRCh38":{"chromosome":"6","position":31174468}},"trait_info":{"ontology":["EFO_0004276"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"Stevens-Johnson syndrome"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":7.522878745280337,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (401097bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31142245},"locus_GRCh38":{"chromosome":"6","position":31174468}},"trait_info":{"ontology":["EFO_0004775"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"toxic epidermal necrolysis"}}
{"association_info":{"ancestry":["European=1712","African American or Afro-Caribbean=1233","Hispanic or Latin American=677"],"gwas_catalog_id":"GCST000863","neg_log_pval":15.397940008672037,"otg_id":"GCST000863_2","pubmed_id":"21051598"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (450379bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31143582},"locus_GRCh38":{"chromosome":"6","position":31175805}},"trait_info":{"ontology":["EFO_0000180"],"reported_trait_name":"HIV-1 control [EA]","standard_trait_name":"HIV-1 infection"}}
{"association_info":{"ancestry":["East Asian=2271"],"gwas_catalog_id":"GCST000321","neg_log_pval":207.69897000433602,"otg_id":"GCST000321","pubmed_id":"19169255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31155785},"locus_GRCh38":{"chromosome":"6","position":31188008}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2271"],"gwas_catalog_id":"GCST000321","neg_log_pval":207.69897000433602,"otg_id":"GCST000321","pubmed_id":"19169255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31155785},"locus_GRCh38":{"chromosome":"6","position":31188008}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2271"],"gwas_catalog_id":"GCST000321","neg_log_pval":207.69897000433602,"otg_id":"GCST000321","pubmed_id":"19169255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (462582bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196230","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31155785},"locus_GRCh38":{"chromosome":"6","position":31188008}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":9.698970004336019,"otg_id":"GCST001737_7","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31240431},"locus_GRCh38":{"chromosome":"6","position":31272654}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [SP-D]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1951"],"gwas_catalog_id":"GCST001737","neg_log_pval":9.698970004336019,"otg_id":"GCST001737_7","pubmed_id":"23144326"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31240431},"locus_GRCh38":{"chromosome":"6","position":31272654}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease-related biomarkers [SP-D]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European=1460"],"gwas_catalog_id":"GCST000835","neg_log_pval":71.69897000433602,"otg_id":"GCST000835","pubmed_id":"20953186"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31241109},"locus_GRCh38":{"chromosome":"6","position":31273332}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=1460"],"gwas_catalog_id":"GCST000835","neg_log_pval":71.69897000433602,"otg_id":"GCST000835","pubmed_id":"20953186"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31241109},"locus_GRCh38":{"chromosome":"6","position":31273332}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["Other=978","European=1112"],"gwas_catalog_id":"GCST006575","neg_log_pval":9.0,"otg_id":"GCST006575_2","pubmed_id":"25604533"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (301152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31242191},"locus_GRCh38":{"chromosome":"6","position":31274414}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis [EA]","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":100.0,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6880"],"gwas_catalog_id":"GCST003270","neg_log_pval":98.69897000433602,"otg_id":"GCST003270","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=2759"],"gwas_catalog_id":"GCST000322","neg_log_pval":100.0,"otg_id":"GCST000322","pubmed_id":"19169254"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1618"],"gwas_catalog_id":"GCST000836","neg_log_pval":31.397940008672037,"otg_id":"GCST000836","pubmed_id":"20953188"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=1618"],"gwas_catalog_id":"GCST000836","neg_log_pval":31.397940008672037,"otg_id":"GCST000836","pubmed_id":"20953188"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6880"],"gwas_catalog_id":"GCST003270","neg_log_pval":98.69897000433602,"otg_id":"GCST003270","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31252925},"locus_GRCh38":{"chromosome":"6","position":31285148}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["East Asian=2546"],"gwas_catalog_id":"GCST000692","neg_log_pval":32.69897000433602,"otg_id":"GCST000692","pubmed_id":"20526339"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (284506bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31258837},"locus_GRCh38":{"chromosome":"6","position":31291060}},"trait_info":{"ontology":["EFO_0004208"],"reported_trait_name":"Vitiligo","standard_trait_name":"Vitiligo"}}
{"association_info":{"ancestry":["European=2198"],"gwas_catalog_id":"GCST007043","neg_log_pval":36.0,"otg_id":"GCST007043","pubmed_id":"30552173"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31265752},"locus_GRCh38":{"chromosome":"6","position":31297975}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=2198"],"gwas_catalog_id":"GCST007043","neg_log_pval":36.0,"otg_id":"GCST007043","pubmed_id":"30552173"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31265752},"locus_GRCh38":{"chromosome":"6","position":31297975}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=8941"],"gwas_catalog_id":"GCST003268","neg_log_pval":311.69897000433605,"otg_id":"GCST003268","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000232810 at this locus (277252bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31266090},"locus_GRCh38":{"chromosome":"6","position":31298313}},"trait_info":{"ontology":["EFO_1001494"],"reported_trait_name":"Psoriasis vulgaris","standard_trait_name":"psoriasis vulgaris"}}
{"association_info":{"ancestry":["East Asian=2644"],"gwas_catalog_id":"GCST003360","neg_log_pval":22.045757490560675,"otg_id":"GCST003360","pubmed_id":"26891255"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (273649bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31269693},"locus_GRCh38":{"chromosome":"6","position":31301916}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":213.39794000867204,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=7353"],"gwas_catalog_id":"GCST000833","neg_log_pval":213.39794000867204,"otg_id":"GCST000833","pubmed_id":"20953190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6297"],"gwas_catalog_id":"GCST003269","neg_log_pval":206.39794000867204,"otg_id":"GCST003269","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Cutaneous psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=737"],"gwas_catalog_id":"GCST000173","neg_log_pval":38.69897000433602,"otg_id":"GCST000173","pubmed_id":"18369459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=737"],"gwas_catalog_id":"GCST000173","neg_log_pval":38.69897000433602,"otg_id":"GCST000173","pubmed_id":"18369459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6297"],"gwas_catalog_id":"GCST003269","neg_log_pval":206.39794000867204,"otg_id":"GCST003269","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31274555},"locus_GRCh38":{"chromosome":"6","position":31306778}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Cutaneous psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=2569"],"gwas_catalog_id":"GCST006984","neg_log_pval":33.39794000867204,"otg_id":"GCST006984","pubmed_id":"30498034"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (263125bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31280218},"locus_GRCh38":{"chromosome":"6","position":31312441}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["European=606"],"gwas_catalog_id":"GCST000165","neg_log_pval":9.0,"otg_id":"GCST000165","pubmed_id":"18364390"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31312326},"locus_GRCh38":{"chromosome":"6","position":31344549}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=606"],"gwas_catalog_id":"GCST000165","neg_log_pval":9.0,"otg_id":"GCST000165","pubmed_id":"18364390"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31312326},"locus_GRCh38":{"chromosome":"6","position":31344549}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":19.096910013008056,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (222075bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31321267},"locus_GRCh38":{"chromosome":"6","position":31353490}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1828","Greater Middle Eastern (Middle Eastern / North African / Persian)=1176"],"gwas_catalog_id":"GCST007844","neg_log_pval":119.22184874961636,"otg_id":"GCST007844_4","pubmed_id":"30946743"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (221214bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31322129},"locus_GRCh38":{"chromosome":"6","position":31354352}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [Turkish]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=157242"],"gwas_catalog_id":"GCST003987","neg_log_pval":16.0,"otg_id":"GCST003987","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31322197},"locus_GRCh38":{"chromosome":"6","position":31354420}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=341215"],"gwas_catalog_id":"GCST007798","neg_log_pval":59.69897000433602,"otg_id":"GCST007798","pubmed_id":"30929738"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31322197},"locus_GRCh38":{"chromosome":"6","position":31354420}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["Other=1828","Greater Middle Eastern (Middle Eastern / North African / Persian)=1176"],"gwas_catalog_id":"GCST007844","neg_log_pval":90.04575749056067,"otg_id":"GCST007844_3","pubmed_id":"30946743"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (217409bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31325933},"locus_GRCh38":{"chromosome":"6","position":31358156}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [Iranian]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=4806"],"gwas_catalog_id":"GCST000961","neg_log_pval":8.0,"otg_id":"GCST000961","pubmed_id":"21254220"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000289 and targets the gene ENSG00000232810 at this locus (215641bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31327701},"locus_GRCh38":{"chromosome":"6","position":31359924}},"trait_info":{"ontology":["EFO_0000289"],"reported_trait_name":"Bipolar disorder [addtive]","standard_trait_name":"bipolar disorder"}}
{"association_info":{"ancestry":["European=7193"],"gwas_catalog_id":"GCST000563","neg_log_pval":303.30102999566395,"otg_id":"GCST000563","pubmed_id":"20062062"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (207242bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31336100},"locus_GRCh38":{"chromosome":"6","position":31368323}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["East Asian=1098"],"gwas_catalog_id":"GCST001768","neg_log_pval":9.698970004336019,"otg_id":"GCST001768","pubmed_id":"23001997"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (206925bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31336418},"locus_GRCh38":{"chromosome":"6","position":31368641}},"trait_info":{"ontology":["EFO_0003780"],"reported_trait_name":"Behcet's disease","standard_trait_name":"Behcet's syndrome"}}
{"association_info":{"ancestry":["European=22647","East Asian=3117"],"gwas_catalog_id":"GCST005529","neg_log_pval":100.0,"otg_id":"GCST005529_3","pubmed_id":"23749187"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (198427bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31344916},"locus_GRCh38":{"chromosome":"6","position":31377139}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [EA]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":15.698970004336019,"otg_id":"GCST007692_13","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31348519},"locus_GRCh38":{"chromosome":"6","position":31380742}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease [conditional on rs2284174]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"],"gwas_catalog_id":"GCST007692","neg_log_pval":15.698970004336019,"otg_id":"GCST007692_13","pubmed_id":"30804561"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31348519},"locus_GRCh38":{"chromosome":"6","position":31380742}},"trait_info":{"ontology":["EFO_0000341"],"reported_trait_name":"Chronic obstructive pulmonary disease [conditional on rs2284174]","standard_trait_name":"chronic obstructive pulmonary disease"}}
{"association_info":{"ancestry":["Other=978","European=1112"],"gwas_catalog_id":"GCST006575","neg_log_pval":7.698970004336019,"otg_id":"GCST006575_3","pubmed_id":"25604533"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (192130bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31351212},"locus_GRCh38":{"chromosome":"6","position":31383435}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis [Turkish]","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["European=7156"],"gwas_catalog_id":"GCST002357","neg_log_pval":8.045757490560675,"otg_id":"GCST002357","pubmed_id":"24532677"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (186502bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000226979","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31353329},"locus_GRCh38":{"chromosome":"6","position":31385552}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-negative)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=7156"],"gwas_catalog_id":"GCST002357","neg_log_pval":8.045757490560675,"otg_id":"GCST002357","pubmed_id":"24532677"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug PLACULUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31353329},"locus_GRCh38":{"chromosome":"6","position":31385552}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-negative)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=7156"],"gwas_catalog_id":"GCST002357","neg_log_pval":8.045757490560675,"otg_id":"GCST002357","pubmed_id":"24532677"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31353329},"locus_GRCh38":{"chromosome":"6","position":31385552}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis (ACPA-negative)","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["Other=788","European=659"],"gwas_catalog_id":"GCST006863","neg_log_pval":15.221848749616356,"otg_id":"GCST006863","pubmed_id":"23830517"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31354238},"locus_GRCh38":{"chromosome":"6","position":31386461}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["Other=978","European=1112"],"gwas_catalog_id":"GCST006575","neg_log_pval":14.522878745280337,"otg_id":"GCST006575_2","pubmed_id":"25604533"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31354238},"locus_GRCh38":{"chromosome":"6","position":31386461}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis [EA]","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["European=2930"],"gwas_catalog_id":"GCST007361","neg_log_pval":17.30102999566398,"otg_id":"GCST007361","pubmed_id":"25200001"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (183053bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31360289},"locus_GRCh38":{"chromosome":"6","position":31392512}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Acute anterior uveitis in ankylosing spondylitis","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":22.0,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31364707},"locus_GRCh38":{"chromosome":"6","position":31396930}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":22.0,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31364707},"locus_GRCh38":{"chromosome":"6","position":31396930}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=11802"],"gwas_catalog_id":"GCST001149","neg_log_pval":200.0,"otg_id":"GCST001149_2","pubmed_id":"21743469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (177556bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31365787},"locus_GRCh38":{"chromosome":"6","position":31398010}},"trait_info":{"ontology":["EFO_0003898"],"reported_trait_name":"Ankylosing spondylitis [less than]","standard_trait_name":"ankylosing spondylitis"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":8.698970004336019,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (135514bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31407828},"locus_GRCh38":{"chromosome":"6","position":31440051}},"trait_info":{"ontology":["EFO_0004775"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"toxic epidermal necrolysis"}}
{"association_info":{"ancestry":["European=2305"],"gwas_catalog_id":"GCST001181","neg_log_pval":8.698970004336019,"otg_id":"GCST001181","pubmed_id":"21801394"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (135514bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31407828},"locus_GRCh38":{"chromosome":"6","position":31440051}},"trait_info":{"ontology":["EFO_0004276"],"reported_trait_name":"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)","standard_trait_name":"Stevens-Johnson syndrome"}}
{"association_info":{"ancestry":["European=737"],"gwas_catalog_id":"GCST000173","neg_log_pval":25.69897000433602,"otg_id":"GCST000173","pubmed_id":"18369459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31431780},"locus_GRCh38":{"chromosome":"6","position":31464003}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=737"],"gwas_catalog_id":"GCST000173","neg_log_pval":25.69897000433602,"otg_id":"GCST000173","pubmed_id":"18369459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31431780},"locus_GRCh38":{"chromosome":"6","position":31464003}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":44.52287874528034,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (109011bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31434331},"locus_GRCh38":{"chromosome":"6","position":31466554}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["European=16582"],"gwas_catalog_id":"GCST006052","neg_log_pval":75.22184874961636,"otg_id":"GCST006052","pubmed_id":"26362759"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0003063 and targets the gene ENSG00000232810 at this locus (108976bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31434366},"locus_GRCh38":{"chromosome":"6","position":31466589}},"trait_info":{"ontology":["EFO_0003063"],"reported_trait_name":"Polymyositis","standard_trait_name":"polymyositis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":44.69897000433602,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108976bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31434366},"locus_GRCh38":{"chromosome":"6","position":31466589}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":44.69897000433602,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108721bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31434621},"locus_GRCh38":{"chromosome":"6","position":31466844}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":42.52287874528034,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (100560bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31442782},"locus_GRCh38":{"chromosome":"6","position":31475005}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["South Asian=1225"],"gwas_catalog_id":"GCST002453","neg_log_pval":14.698970004336019,"otg_id":"GCST002453","pubmed_id":"24837172"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31448862},"locus_GRCh38":{"chromosome":"6","position":31481085}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["South Asian=1225"],"gwas_catalog_id":"GCST002453","neg_log_pval":14.698970004336019,"otg_id":"GCST002453","pubmed_id":"24837172"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31448862},"locus_GRCh38":{"chromosome":"6","position":31481085}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":48.30102999566398,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (94366bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31448976},"locus_GRCh38":{"chromosome":"6","position":31481199}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["European=10564"],"gwas_catalog_id":"GCST001436","neg_log_pval":7.698970004336019,"otg_id":"GCST001436_2","pubmed_id":"22399527"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000195 and targets the gene ENSG00000232810 at this locus (94366bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31448976},"locus_GRCh38":{"chromosome":"6","position":31481199}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [HDL]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":49.0,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (91507bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31451836},"locus_GRCh38":{"chromosome":"6","position":31484059}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["African unspecified, African American or Afro-Caribbean=8204","European=127669","East Asian=5215","Hispanic or Latin American=1398"],"gwas_catalog_id":"GCST005212","neg_log_pval":11.045757490560675,"otg_id":"GCST005212","pubmed_id":"29273806"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (70622bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31472720},"locus_GRCh38":{"chromosome":"6","position":31504943}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":47.39794000867204,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (66885bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31476458},"locus_GRCh38":{"chromosome":"6","position":31508681}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["East Asian=1005"],"gwas_catalog_id":"GCST001239","neg_log_pval":7.698970004336019,"otg_id":"GCST001239","pubmed_id":"21912425"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (37863bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31505480},"locus_GRCh38":{"chromosome":"6","position":31537703}},"trait_info":{"ontology":["EFO_0004276"],"reported_trait_name":"Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)","standard_trait_name":"Stevens-Johnson syndrome"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":48.52287874528034,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (37863bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31505480},"locus_GRCh38":{"chromosome":"6","position":31537703}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["East Asian=1005"],"gwas_catalog_id":"GCST001239","neg_log_pval":7.698970004336019,"otg_id":"GCST001239","pubmed_id":"21912425"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (37863bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31505480},"locus_GRCh38":{"chromosome":"6","position":31537703}},"trait_info":{"ontology":["EFO_0004775"],"reported_trait_name":"Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)","standard_trait_name":"toxic epidermal necrolysis"}}
{"association_info":{"ancestry":["European=6434"],"gwas_catalog_id":"GCST003092","neg_log_pval":48.221848749616356,"otg_id":"GCST003092","pubmed_id":"26291516"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (29095bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31514247},"locus_GRCh38":{"chromosome":"6","position":31546470}},"trait_info":{"ontology":["EFO_0000783"],"reported_trait_name":"Myositis","standard_trait_name":"myositis"}}
{"association_info":{"ancestry":["European=21389"],"gwas_catalog_id":"GCST000879","neg_log_pval":10.397940008672037,"otg_id":"GCST000879","pubmed_id":"21102463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (1034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31542308},"locus_GRCh38":{"chromosome":"6","position":31574531}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":22.69897000433602,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31568469},"locus_GRCh38":{"chromosome":"6","position":31600692}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":22.69897000433602,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31568469},"locus_GRCh38":{"chromosome":"6","position":31600692}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["Other=978","European=1112"],"gwas_catalog_id":"GCST006575","neg_log_pval":9.0,"otg_id":"GCST006575_3","pubmed_id":"25604533"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (24557bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31570670},"locus_GRCh38":{"chromosome":"6","position":31602893}},"trait_info":{"ontology":["EFO_1001857"],"reported_trait_name":"Takayasu arteritis [Turkish]","standard_trait_name":"Takayasu arteritis"}}
{"association_info":{"ancestry":["European=69395"],"gwas_catalog_id":"GCST001238","neg_log_pval":10.0,"otg_id":"GCST001238","pubmed_id":"21909115"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (70254bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31616366},"locus_GRCh38":{"chromosome":"6","position":31648589}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["East Asian=700"],"gwas_catalog_id":"GCST001203","neg_log_pval":9.522878745280337,"otg_id":"GCST001203","pubmed_id":"21844665"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug OZORALIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31622606},"locus_GRCh38":{"chromosome":"6","position":31654829}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=700"],"gwas_catalog_id":"GCST001203","neg_log_pval":9.522878745280337,"otg_id":"GCST001203","pubmed_id":"21844665"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (80506bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000226979","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31622606},"locus_GRCh38":{"chromosome":"6","position":31654829}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=700"],"gwas_catalog_id":"GCST001203","neg_log_pval":9.522878745280337,"otg_id":"GCST001203","pubmed_id":"21844665"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31622606},"locus_GRCh38":{"chromosome":"6","position":31654829}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=3037"],"gwas_catalog_id":"GCST000142","neg_log_pval":51.69897000433602,"otg_id":"GCST000142","pubmed_id":"18204446"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (174921bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31721033},"locus_GRCh38":{"chromosome":"6","position":31753256}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=2734"],"gwas_catalog_id":"GCST004053","neg_log_pval":8.301029995663981,"otg_id":"GCST004053","pubmed_id":"28067912"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (187838bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"CAG"},"locus_GRCh37":{"chromosome":"6","position":31733950},"locus_GRCh38":{"chromosome":"6","position":31766173}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Poor prognosis in Crohn's disease","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=1048"],"gwas_catalog_id":"GCST005541","neg_log_pval":31.397940008672037,"otg_id":"GCST005541","pubmed_id":"26651848"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31749142},"locus_GRCh38":{"chromosome":"6","position":31781365}},"trait_info":{"ontology":["Orphanet_797"],"reported_trait_name":"Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)","standard_trait_name":"Sarcoidosis"}}
{"association_info":{"ancestry":["European=1048"],"gwas_catalog_id":"GCST005541","neg_log_pval":31.397940008672037,"otg_id":"GCST005541","pubmed_id":"26651848"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31749142},"locus_GRCh38":{"chromosome":"6","position":31781365}},"trait_info":{"ontology":["Orphanet_797"],"reported_trait_name":"Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)","standard_trait_name":"Sarcoidosis"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":19.30102999566398,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (241055bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31787167},"locus_GRCh38":{"chromosome":"6","position":31819390}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":18.154901959985743,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (280592bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31826705},"locus_GRCh38":{"chromosome":"6","position":31858928}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=2546"],"gwas_catalog_id":"GCST000692","neg_log_pval":48.0,"otg_id":"GCST000692","pubmed_id":"20526339"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (290954bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":31837066},"locus_GRCh38":{"chromosome":"6","position":31869289}},"trait_info":{"ontology":["EFO_0004208"],"reported_trait_name":"Vitiligo","standard_trait_name":"Vitiligo"}}
{"association_info":{"ancestry":["European=3163"],"gwas_catalog_id":"GCST002463","neg_log_pval":20.096910013008056,"otg_id":"GCST002463","pubmed_id":"24871463"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (324214bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31870326},"locus_GRCh38":{"chromosome":"6","position":31902549}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":15.698970004336019,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (335197bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31881309},"locus_GRCh38":{"chromosome":"6","position":31913532}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=3105"],"gwas_catalog_id":"GCST004873","neg_log_pval":7.698970004336019,"otg_id":"GCST004873","pubmed_id":"28881265"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001065 and targets the gene ENSG00000232810 at this locus (337844bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31883957},"locus_GRCh38":{"chromosome":"6","position":31916180}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["South Asian=1225"],"gwas_catalog_id":"GCST002453","neg_log_pval":13.301029995663981,"otg_id":"GCST002453","pubmed_id":"24837172"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31917540},"locus_GRCh38":{"chromosome":"6","position":31949763}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["South Asian=1225"],"gwas_catalog_id":"GCST002453","neg_log_pval":13.301029995663981,"otg_id":"GCST002453","pubmed_id":"24837172"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":31917540},"locus_GRCh38":{"chromosome":"6","position":31949763}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":24.30102999566398,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31918860},"locus_GRCh38":{"chromosome":"6","position":31951083}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=1073"],"gwas_catalog_id":"GCST002876","neg_log_pval":24.30102999566398,"otg_id":"GCST002876","pubmed_id":"25936594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":31918860},"locus_GRCh38":{"chromosome":"6","position":31951083}},"trait_info":{"ontology":["EFO_0001359"],"reported_trait_name":"Type 1 diabetes and autoimmune thyroid diseases","standard_trait_name":"insulin-dependent diabetes mellitus"}}
{"association_info":{"ancestry":["European=2198"],"gwas_catalog_id":"GCST007043","neg_log_pval":13.397940008672037,"otg_id":"GCST007043","pubmed_id":"30552173"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31936057},"locus_GRCh38":{"chromosome":"6","position":31968280}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=2198"],"gwas_catalog_id":"GCST007043","neg_log_pval":13.397940008672037,"otg_id":"GCST007043","pubmed_id":"30552173"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31936057},"locus_GRCh38":{"chromosome":"6","position":31968280}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"Psoriatic arthritis","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":12.0,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (401348bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31947460},"locus_GRCh38":{"chromosome":"6","position":31979683}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["NR=150064","European=70017"],"gwas_catalog_id":"GCST007257","neg_log_pval":12.0,"otg_id":"GCST007257","pubmed_id":"30626913"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (401348bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":31947460},"locus_GRCh38":{"chromosome":"6","position":31979683}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Broad depression or schizophrenia","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["East Asian=5057","European=10995"],"gwas_catalog_id":"GCST003622","neg_log_pval":100.69897000433602,"otg_id":"GCST003622_3","pubmed_id":"27399966"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (483092bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":32029205},"locus_GRCh38":{"chromosome":"6","position":32061428}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus [EA]","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=18264","African American or Afro-Caribbean=5422","Hispanic or Latin American=3888"],"gwas_catalog_id":"GCST005752","neg_log_pval":116.22184874961636,"otg_id":"GCST005752","pubmed_id":"28714469"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (492437bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":32038550},"locus_GRCh38":{"chromosome":"6","position":32070773}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=9469"],"gwas_catalog_id":"GCST002627","neg_log_pval":10.397940008672037,"otg_id":"GCST002627","pubmed_id":"25249183"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (498738bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000232810","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":32044851},"locus_GRCh38":{"chromosome":"6","position":32077074}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":7.3979400086720375,"otg_id":"GCST006959_3","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112062","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":36355654},"locus_GRCh38":{"chromosome":"6","position":36387877}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":8.698970004336019,"otg_id":"GCST006959","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112062","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":36355654},"locus_GRCh38":{"chromosome":"6","position":36387877}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"AAAAG","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"AAAAG","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"AG","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"AG","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":39039140},"locus_GRCh38":{"chromosome":"6","position":39071364}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":7.522878745280337,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000112164 at this locus (65370bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":39124448},"locus_GRCh38":{"chromosome":"6","position":39156672}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":7.698970004336019,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (75021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":39134099},"locus_GRCh38":{"chromosome":"6","position":39166323}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":11.117418546445549,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":39174922},"locus_GRCh38":{"chromosome":"6","position":39207146}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":11.522878745280337,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":39174922},"locus_GRCh38":{"chromosome":"6","position":39207146}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":9.0,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug LIXISENATIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":39282371},"locus_GRCh38":{"chromosome":"6","position":39314595}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":9.0,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":39282371},"locus_GRCh38":{"chromosome":"6","position":39314595}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=15000","South East Asian=2034","Asian unspecified=1783"],"gwas_catalog_id":"GCST001351","neg_log_pval":7.698970004336019,"otg_id":"GCST001351","pubmed_id":"22158537"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":39284050},"locus_GRCh38":{"chromosome":"6","position":39316274}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=15000","South East Asian=2034","Asian unspecified=1783"],"gwas_catalog_id":"GCST001351","neg_log_pval":7.698970004336019,"otg_id":"GCST001351","pubmed_id":"22158537"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Glucagon-like peptide 1 receptor agonist drug LIRAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112164","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":39284050},"locus_GRCh38":{"chromosome":"6","position":39316274}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":7.522878745280337,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000112715 at this locus (43324bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":43694598},"locus_GRCh38":{"chromosome":"6","position":43726861}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":11.39848321634999,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":43758873},"locus_GRCh38":{"chromosome":"6","position":43791136}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":11.698970004336019,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":43758873},"locus_GRCh38":{"chromosome":"6","position":43791136}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":8.3767507096021,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":43758873},"locus_GRCh38":{"chromosome":"6","position":43791136}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=33976"],"gwas_catalog_id":"GCST003219","neg_log_pval":14.0,"otg_id":"GCST003219_2","pubmed_id":"26691988"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Advanced age-related macular degeneration [EA]","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=55115","South Asian=229","East Asian=4150"],"gwas_catalog_id":"GCST001884","neg_log_pval":15.045757490560675,"otg_id":"GCST001884","pubmed_id":"23455636"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Age-related macular degeneration","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=33976"],"gwas_catalog_id":"GCST003219","neg_log_pval":14.0,"otg_id":"GCST003219_2","pubmed_id":"26691988"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0004683"],"reported_trait_name":"Advanced age-related macular degeneration [EA]","standard_trait_name":"wet macular degeneration"}}
{"association_info":{"ancestry":["European=33976"],"gwas_catalog_id":"GCST003219","neg_log_pval":14.0,"otg_id":"GCST003219_2","pubmed_id":"26691988"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0004683"],"reported_trait_name":"Advanced age-related macular degeneration [EA]","standard_trait_name":"wet macular degeneration"}}
{"association_info":{"ancestry":["European=33976"],"gwas_catalog_id":"GCST003219","neg_log_pval":14.0,"otg_id":"GCST003219_2","pubmed_id":"26691988"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Advanced age-related macular degeneration [EA]","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=55115","South Asian=229","East Asian=4150"],"gwas_catalog_id":"GCST001884","neg_log_pval":15.045757490560675,"otg_id":"GCST001884","pubmed_id":"23455636"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":43826627},"locus_GRCh38":{"chromosome":"6","position":43858890}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Age-related macular degeneration","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=6728"],"gwas_catalog_id":"GCST001100","neg_log_pval":8.045757490560675,"otg_id":"GCST001100","pubmed_id":"21665990"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":43828582},"locus_GRCh38":{"chromosome":"6","position":43860845}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Age-related macular degeneration","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["European=6728"],"gwas_catalog_id":"GCST001100","neg_log_pval":8.045757490560675,"otg_id":"GCST001100","pubmed_id":"21665990"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug CONBERCEPT is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":43828582},"locus_GRCh38":{"chromosome":"6","position":43860845}},"trait_info":{"ontology":["EFO_0001365"],"reported_trait_name":"Age-related macular degeneration","standard_trait_name":"age-related macular degeneration"}}
{"association_info":{"ancestry":["East Asian=7810"],"gwas_catalog_id":"GCST002766","neg_log_pval":17.221848749616356,"otg_id":"GCST002766","pubmed_id":"25629512"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":43970827},"locus_GRCh38":{"chromosome":"6","position":44003090}},"trait_info":{"ontology":["EFO_0004683"],"reported_trait_name":"Exudative age-related macular degeneration","standard_trait_name":"wet macular degeneration"}}
{"association_info":{"ancestry":["East Asian=7810"],"gwas_catalog_id":"GCST002766","neg_log_pval":17.221848749616356,"otg_id":"GCST002766","pubmed_id":"25629512"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Vascular endothelial growth factor A inhibitor drug AFLIBERCEPT is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112715","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":43970827},"locus_GRCh38":{"chromosome":"6","position":44003090}},"trait_info":{"ontology":["EFO_0004683"],"reported_trait_name":"Exudative age-related macular degeneration","standard_trait_name":"wet macular degeneration"}}
{"association_info":{"ancestry":["East Asian=5683"],"gwas_catalog_id":"GCST001681","neg_log_pval":15.0,"otg_id":"GCST001681","pubmed_id":"23028356"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":44232920},"locus_GRCh38":{"chromosome":"6","position":44265183}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["East Asian=20965"],"gwas_catalog_id":"GCST001454","neg_log_pval":18.221848749616356,"otg_id":"GCST001454","pubmed_id":"22446963"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":44232920},"locus_GRCh38":{"chromosome":"6","position":44265183}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":7.522878745280337,"otg_id":"GCST006959_3","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":18.69897000433602,"otg_id":"GCST006959","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":19.0,"otg_id":"GCST002318","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":12.698970004336019,"otg_id":"GCST002318_3","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [East Asian]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=58284","East Asian=22515"],"gwas_catalog_id":"GCST002318","neg_log_pval":7.522878745280337,"otg_id":"GCST002318_2","pubmed_id":"24390342"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [EA]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2308"],"gwas_catalog_id":"GCST006959","neg_log_pval":12.045757490560675,"otg_id":"GCST006959_4","pubmed_id":"30423114"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":44233921},"locus_GRCh38":{"chromosome":"6","position":44266184}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"Rheumatoid arthritis [East Asian]","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=2406"],"gwas_catalog_id":"GCST001659","neg_log_pval":7.301029995663981,"otg_id":"GCST001659","pubmed_id":"22941190"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000112759 at this locus (392271bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112759","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":44594159},"locus_GRCh38":{"chromosome":"6","position":44626422}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Stroke (ischemic) [LAA]","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=22156"],"gwas_catalog_id":"GCST004963","neg_log_pval":178.0,"otg_id":"GCST004963","pubmed_id":"28753643"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146070","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":46677098},"locus_GRCh38":{"chromosome":"6","position":46709361}},"trait_info":{"ontology":["EFO_0005672"],"reported_trait_name":"Lipoprotein phospholipase A2 activity in cardiovascular disease","standard_trait_name":"acute coronary syndrome"}}
{"association_info":{"ancestry":["European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=10874"],"gwas_catalog_id":"GCST004966","neg_log_pval":46.096910013008056,"otg_id":"GCST004966","pubmed_id":"28753643"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146070","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":46677098},"locus_GRCh38":{"chromosome":"6","position":46709361}},"trait_info":{"ontology":["EFO_0005672"],"reported_trait_name":"Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease","standard_trait_name":"acute coronary syndrome"}}
{"association_info":{"ancestry":["European=11181"],"gwas_catalog_id":"GCST003180","neg_log_pval":7.698970004336019,"otg_id":"GCST003180","pubmed_id":"26542096"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin 17A inhibitor drug SECUKINUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000112115 at this locus (236700bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112115","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":52292136},"locus_GRCh38":{"chromosome":"6","position":52427338}},"trait_info":{"ontology":["EFO_0000274"],"reported_trait_name":"Atopic march","standard_trait_name":"atopic eczema"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.3979400086720375,"otg_id":"GCST004549","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151816011},"locus_GRCh38":{"chromosome":"6","position":151494876}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.3979400086720375,"otg_id":"GCST004549","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151816011},"locus_GRCh38":{"chromosome":"6","position":151494876}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.287247628480976,"otg_id":"NEALE2_20002_1065","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000091831 at this locus (67422bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AAC"},"locus_GRCh37":{"chromosome":"6","position":151910404},"locus_GRCh38":{"chromosome":"6","position":151589269}},"trait_info":{"ontology":["EFO_0000537"],"reported_trait_name":"Hypertension | non-cancer illness code, self-reported","standard_trait_name":"hypertension"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":20.69897000433602,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151914113},"locus_GRCh38":{"chromosome":"6","position":151592978}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":20.69897000433602,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151914113},"locus_GRCh38":{"chromosome":"6","position":151592978}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=22627"],"gwas_catalog_id":"GCST001937","neg_log_pval":20.69897000433602,"otg_id":"GCST001937","pubmed_id":"23535729"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151914113},"locus_GRCh38":{"chromosome":"6","position":151592978}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":19.0,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":26.154901959985743,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":26.154901959985743,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":26.154901959985743,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":19.0,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":19.0,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151918856},"locus_GRCh38":{"chromosome":"6","position":151597721}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":9.154901959985743,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":151925507},"locus_GRCh38":{"chromosome":"6","position":151604372}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=688809"],"gwas_catalog_id":"GCST006477","neg_log_pval":9.154901959985743,"otg_id":"GCST006477","pubmed_id":"29942085"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":151925507},"locus_GRCh38":{"chromosome":"6","position":151604372}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=15566"],"gwas_catalog_id":"GCST005075","neg_log_pval":11.522878745280337,"otg_id":"GCST005075","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151942194},"locus_GRCh38":{"chromosome":"6","position":151621059}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=15566"],"gwas_catalog_id":"GCST005075","neg_log_pval":11.522878745280337,"otg_id":"GCST005075","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151942194},"locus_GRCh38":{"chromosome":"6","position":151621059}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=15566"],"gwas_catalog_id":"GCST005075","neg_log_pval":11.522878745280337,"otg_id":"GCST005075","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151942194},"locus_GRCh38":{"chromosome":"6","position":151621059}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":27.397940008672037,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151946152},"locus_GRCh38":{"chromosome":"6","position":151625017}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":27.397940008672037,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151946152},"locus_GRCh38":{"chromosome":"6","position":151625017}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=19291"],"gwas_catalog_id":"GCST003845","neg_log_pval":27.397940008672037,"otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":151946152},"locus_GRCh38":{"chromosome":"6","position":151625017}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=39387"],"gwas_catalog_id":"GCST001930","neg_log_pval":15.301029995663981,"otg_id":"GCST001930","pubmed_id":"23535733"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=39387"],"gwas_catalog_id":"GCST001930","neg_log_pval":15.301029995663981,"otg_id":"GCST001930","pubmed_id":"23535733"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":14.154901959985743,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":14.154901959985743,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=13905"],"gwas_catalog_id":"GCST003520","neg_log_pval":14.154901959985743,"otg_id":"GCST003520","pubmed_id":"27354352"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":23.221848749616356,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=2727"],"gwas_catalog_id":"GCST001916","neg_log_pval":8.301029995663981,"otg_id":"GCST001916","pubmed_id":"23544013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=39387"],"gwas_catalog_id":"GCST001930","neg_log_pval":15.301029995663981,"otg_id":"GCST001930","pubmed_id":"23535733"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":23.221848749616356,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=33864"],"gwas_catalog_id":"GCST004950","neg_log_pval":23.221848749616356,"otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=3027"],"gwas_catalog_id":"GCST000343","neg_log_pval":14.698970004336019,"otg_id":"GCST000343","pubmed_id":"19219042"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=3027"],"gwas_catalog_id":"GCST000343","neg_log_pval":14.698970004336019,"otg_id":"GCST000343","pubmed_id":"19219042"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=3027"],"gwas_catalog_id":"GCST000343","neg_log_pval":14.698970004336019,"otg_id":"GCST000343","pubmed_id":"19219042"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=2727"],"gwas_catalog_id":"GCST001916","neg_log_pval":8.301029995663981,"otg_id":"GCST001916","pubmed_id":"23544013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=2727"],"gwas_catalog_id":"GCST001916","neg_log_pval":8.301029995663981,"otg_id":"GCST001916","pubmed_id":"23544013"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151948366},"locus_GRCh38":{"chromosome":"6","position":151627231}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer in BRCA1 mutation carriers","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.344861565188618,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151949806},"locus_GRCh38":{"chromosome":"6","position":151628671}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.344861565188618,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151949806},"locus_GRCh38":{"chromosome":"6","position":151628671}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.344861565188618,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151949806},"locus_GRCh38":{"chromosome":"6","position":151628671}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=330828"],"neg_log_pval":12.785156151952302,"otg_id":"NEALE2_20110_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952332},"locus_GRCh38":{"chromosome":"6","position":151631197}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer | illnesses of mother","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=330828"],"neg_log_pval":12.785156151952302,"otg_id":"NEALE2_20110_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952332},"locus_GRCh38":{"chromosome":"6","position":151631197}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer | illnesses of mother","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=330828"],"neg_log_pval":12.785156151952302,"otg_id":"NEALE2_20110_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952332},"locus_GRCh38":{"chromosome":"6","position":151631197}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer | illnesses of mother","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":7.895171596346344,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952645},"locus_GRCh38":{"chromosome":"6","position":151631510}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":7.895171596346344,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952645},"locus_GRCh38":{"chromosome":"6","position":151631510}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":7.895171596346344,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151952645},"locus_GRCh38":{"chromosome":"6","position":151631510}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["Hispanic or Latin American=4710"],"gwas_catalog_id":"GCST002662","neg_log_pval":17.045757490560675,"otg_id":"GCST002662","pubmed_id":"25327703"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151954834},"locus_GRCh38":{"chromosome":"6","position":151633699}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["Hispanic or Latin American=4710"],"gwas_catalog_id":"GCST002662","neg_log_pval":17.045757490560675,"otg_id":"GCST002662","pubmed_id":"25327703"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151954834},"locus_GRCh38":{"chromosome":"6","position":151633699}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["Hispanic or Latin American=4710"],"gwas_catalog_id":"GCST002662","neg_log_pval":17.045757490560675,"otg_id":"GCST002662","pubmed_id":"25327703"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151954834},"locus_GRCh38":{"chromosome":"6","position":151633699}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":53.54668165995296,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151955914},"locus_GRCh38":{"chromosome":"6","position":151634779}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":53.54668165995296,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151955914},"locus_GRCh38":{"chromosome":"6","position":151634779}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":53.54668165995296,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151955914},"locus_GRCh38":{"chromosome":"6","position":151634779}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=32530","African American or Afro-Caribbean=3748"],"gwas_catalog_id":"GCST001683","neg_log_pval":9.698970004336019,"otg_id":"GCST001683","pubmed_id":"22976474"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151987357},"locus_GRCh38":{"chromosome":"6","position":151666222}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=32530","African American or Afro-Caribbean=3748"],"gwas_catalog_id":"GCST001683","neg_log_pval":9.698970004336019,"otg_id":"GCST001683","pubmed_id":"22976474"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151987357},"locus_GRCh38":{"chromosome":"6","position":151666222}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=32530","African American or Afro-Caribbean=3748"],"gwas_catalog_id":"GCST001683","neg_log_pval":9.698970004336019,"otg_id":"GCST001683","pubmed_id":"22976474"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":151987357},"locus_GRCh38":{"chromosome":"6","position":151666222}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":18.080451241031152,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":152020390},"locus_GRCh38":{"chromosome":"6","position":151699255}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":18.080451241031152,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":152020390},"locus_GRCh38":{"chromosome":"6","position":151699255}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":18.080451241031152,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":152020390},"locus_GRCh38":{"chromosome":"6","position":151699255}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.47755576649368,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152034820},"locus_GRCh38":{"chromosome":"6","position":151713685}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.47755576649368,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152034820},"locus_GRCh38":{"chromosome":"6","position":151713685}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.47755576649368,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152034820},"locus_GRCh38":{"chromosome":"6","position":151713685}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":25.84893674664625,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152432902},"locus_GRCh38":{"chromosome":"6","position":152111767}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":25.84893674664625,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152432902},"locus_GRCh38":{"chromosome":"6","position":152111767}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":25.84893674664625,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152432902},"locus_GRCh38":{"chromosome":"6","position":152111767}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.767003889607846,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152437016},"locus_GRCh38":{"chromosome":"6","position":152115881}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.767003889607846,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152437016},"locus_GRCh38":{"chromosome":"6","position":152115881}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=401447"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.767003889607846,"otg_id":"SAIGE_174"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":152437016},"locus_GRCh38":{"chromosome":"6","position":152115881}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.698970004336019,"otg_id":"GCST004549","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152554014},"locus_GRCh38":{"chromosome":"6","position":152232879}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.698970004336019,"otg_id":"GCST004549","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152554014},"locus_GRCh38":{"chromosome":"6","position":152232879}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.698970004336019,"otg_id":"GCST004549_2","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152554014},"locus_GRCh38":{"chromosome":"6","position":152232879}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis [EA]","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=204641","East Asian=4262"],"gwas_catalog_id":"GCST004549","neg_log_pval":7.698970004336019,"otg_id":"GCST004549_2","pubmed_id":"28537267"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152554014},"locus_GRCh38":{"chromosome":"6","position":152232879}},"trait_info":{"ontology":["EFO_0001065"],"reported_trait_name":"Endometriosis [EA]","standard_trait_name":"endometriosis"}}
{"association_info":{"ancestry":["European=539925"],"gwas_catalog_id":"GCST006462","neg_log_pval":23.045757490560675,"otg_id":"GCST006462","pubmed_id":"30194396"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000731 and targets the gene ENSG00000091831 at this locus (111518bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":152562271},"locus_GRCh38":{"chromosome":"6","position":152241136}},"trait_info":{"ontology":["EFO_0000731"],"reported_trait_name":"Uterine fibroids","standard_trait_name":"uterine fibroid"}}
{"association_info":{"ancestry":["European=33181"],"gwas_catalog_id":"GCST003962","neg_log_pval":7.3979400086720375,"otg_id":"GCST003962","pubmed_id":"28072414"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (263852bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":152714606},"locus_GRCh38":{"chromosome":"6","position":152393471}},"trait_info":{"ontology":["EFO_0000289"],"reported_trait_name":"Bipolar disorder","standard_trait_name":"bipolar disorder"}}
{"association_info":{"ancestry":["European=61220"],"gwas_catalog_id":"GCST001877","neg_log_pval":8.397940008672037,"otg_id":"GCST001877_3","pubmed_id":"23453885"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000091831 at this locus (339820bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":152790573},"locus_GRCh38":{"chromosome":"6","position":152469438}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=61220"],"gwas_catalog_id":"GCST001877","neg_log_pval":8.397940008672037,"otg_id":"GCST001877_3","pubmed_id":"23453885"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (339820bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":152790573},"locus_GRCh38":{"chromosome":"6","position":152469438}},"trait_info":{"ontology":["EFO_0000289"],"reported_trait_name":"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]","standard_trait_name":"bipolar disorder"}}
{"association_info":{"ancestry":["European=61220"],"gwas_catalog_id":"GCST001877","neg_log_pval":8.397940008672037,"otg_id":"GCST001877_3","pubmed_id":"23453885"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":152790573},"locus_GRCh38":{"chromosome":"6","position":152469438}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=61220"],"gwas_catalog_id":"GCST001877","neg_log_pval":8.397940008672037,"otg_id":"GCST001877_3","pubmed_id":"23453885"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000091831","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":152790573},"locus_GRCh38":{"chromosome":"6","position":152469438}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=1027","African American or Afro-Caribbean=383"],"gwas_catalog_id":"GCST004136","neg_log_pval":7.522878745280337,"otg_id":"GCST004136","pubmed_id":"28115739"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mu opioid receptor agonist drug MORPHINE is Phase IV for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112038","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":154025139},"locus_GRCh38":{"chromosome":"6","position":153704004}},"trait_info":{"ontology":["EFO_0005611"],"reported_trait_name":"Methadone dose in opioid dependence [AA]","standard_trait_name":"opioid dependence"}}
{"association_info":{"ancestry":["European=1027","African American or Afro-Caribbean=383"],"gwas_catalog_id":"GCST004136","neg_log_pval":7.522878745280337,"otg_id":"GCST004136","pubmed_id":"28115739"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mu opioid receptor agonist drug TRAMADOL is Phase III for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112038","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":154025139},"locus_GRCh38":{"chromosome":"6","position":153704004}},"trait_info":{"ontology":["EFO_0005611"],"reported_trait_name":"Methadone dose in opioid dependence [AA]","standard_trait_name":"opioid dependence"}}
{"association_info":{"ancestry":["European=1027","African American or Afro-Caribbean=383"],"gwas_catalog_id":"GCST004136","neg_log_pval":7.522878745280337,"otg_id":"GCST004136","pubmed_id":"28115739"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Mu opioid receptor antagonist drug NALDEMEDINE is Phase II for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000112038","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":154025139},"locus_GRCh38":{"chromosome":"6","position":153704004}},"trait_info":{"ontology":["EFO_0005611"],"reported_trait_name":"Methadone dose in opioid dependence [AA]","standard_trait_name":"opioid dependence"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":88.32422165832591,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (371740bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160751531},"locus_GRCh38":{"chromosome":"6","position":160330499}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":30.522878745280337,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.416801226031378,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.869666231504993,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.869666231504993,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":31.75870261289001,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":28.657577319177793,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":160911596},"locus_GRCh38":{"chromosome":"6","position":160490564}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=15666"],"gwas_catalog_id":"GCST006405","neg_log_pval":11.522878745280337,"otg_id":"GCST006405","pubmed_id":"30003307"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (126153bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":160997118},"locus_GRCh38":{"chromosome":"6","position":160576086}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease in diabetes","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.71524000401907,"otg_id":"NEALE2_20002_1075","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack/myocardial infarction | non-cancer illness code, self-reported","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":153.0096611452124,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":61.367542707815275,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.71524000401907,"otg_id":"NEALE2_20002_1075","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack/myocardial infarction | non-cancer illness code, self-reported","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":40.28149831113272,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":119.20065945054642,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":40.28149831113272,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":153.52287874528034,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":38.30102999566398,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161005610},"locus_GRCh38":{"chromosome":"6","position":160584578}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.522878745280337,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161006077},"locus_GRCh38":{"chromosome":"6","position":160585045}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":10.522878745280337,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161006077},"locus_GRCh38":{"chromosome":"6","position":160585045}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":26.045757490560675,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":26.045757490560675,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European, NR=63731"],"gwas_catalog_id":"GCST004787","neg_log_pval":48.69897000433602,"otg_id":"GCST004787","pubmed_id":"28714975"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=123388"],"gwas_catalog_id":"GCST002287","neg_log_pval":11.698970004336019,"otg_id":"GCST002287","pubmed_id":"24262325"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Coronary artery disease or ischemic stroke","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["European=360420"],"neg_log_pval":27.967377210462196,"otg_id":"NEALE2_6150_1","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack | vascular/heart problems diagnosed by doctor","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=360420"],"neg_log_pval":27.967377210462196,"otg_id":"NEALE2_6150_1","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack | vascular/heart problems diagnosed by doctor","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=123388"],"gwas_catalog_id":"GCST002287","neg_log_pval":11.698970004336019,"otg_id":"GCST002287","pubmed_id":"24262325"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug RETEPLASE is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Coronary artery disease or ischemic stroke","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["NR=123388"],"gwas_catalog_id":"GCST002287","neg_log_pval":11.698970004336019,"otg_id":"GCST002287","pubmed_id":"24262325"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug DESMOTEPLASE is Phase III for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":161010118},"locus_GRCh38":{"chromosome":"6","position":160589086}},"trait_info":{"ontology":["EFO_0000712"],"reported_trait_name":"Coronary artery disease or ischemic stroke","standard_trait_name":"cerebrovascular accident"}}
{"association_info":{"ancestry":["NR=547261"],"gwas_catalog_id":"GCST005195","neg_log_pval":76.85387196432177,"otg_id":"GCST005195","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":25.059981844992336,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":17.90926593057954,"otg_id":"NEALE2_20002_1075","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack/myocardial infarction | non-cancer illness code, self-reported","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":17.90926593057954,"otg_id":"NEALE2_20002_1075","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack/myocardial infarction | non-cancer illness code, self-reported","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=408458"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":42.36957212497498,"otg_id":"SAIGE_411"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Ischemic heart disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=388806"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":25.059981844992336,"otg_id":"SAIGE_411_2"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161013013},"locus_GRCh38":{"chromosome":"6","position":160591981}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":9.409046764812015,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (105907bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":161017363},"locus_GRCh38":{"chromosome":"6","position":160596331}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":7.698970004336019,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (35407bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161087863},"locus_GRCh38":{"chromosome":"6","position":160666831}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":23.69897000433602,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161108144},"locus_GRCh38":{"chromosome":"6","position":160687112}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=2908","Hispanic or Latin American=3615","South Asian=23156","Greater Middle Eastern (Middle Eastern / North African / Persian)=754","East Asian=9396","European=126630"],"gwas_catalog_id":"GCST003117","neg_log_pval":23.69897000433602,"otg_id":"GCST003117","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161108144},"locus_GRCh38":{"chromosome":"6","position":160687112}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=360420"],"neg_log_pval":17.657683931817257,"otg_id":"NEALE2_6150_1","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161111700},"locus_GRCh38":{"chromosome":"6","position":160690668}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack | vascular/heart problems diagnosed by doctor","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["European=360420"],"neg_log_pval":17.657683931817257,"otg_id":"NEALE2_6150_1","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161111700},"locus_GRCh38":{"chromosome":"6","position":160690668}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Heart attack | vascular/heart problems diagnosed by doctor","standard_trait_name":"myocardial infarction"}}
{"association_info":{"ancestry":["NR=250736"],"gwas_catalog_id":"GCST005196","neg_log_pval":91.30102999566398,"otg_id":"GCST005196","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161111700},"locus_GRCh38":{"chromosome":"6","position":160690668}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":96.70114692359029,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":161111700},"locus_GRCh38":{"chromosome":"6","position":160690668}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=141217","African American or Afro-Caribbean=3139","Hispanic or Latin American=4095","South Asian=25557","Greater Middle Eastern (Middle Eastern / North African / Persian)=2268","East Asian=11323"],"gwas_catalog_id":"GCST003116","neg_log_pval":31.69897000433602,"otg_id":"GCST003116","pubmed_id":"26343387"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000122194","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"6","position":161123451},"locus_GRCh38":{"chromosome":"6","position":160702419}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.507692295087963,"otg_id":"NEALE2_20002_1111","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000136244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AT"},"locus_GRCh37":{"chromosome":"7","position":22783490},"locus_GRCh38":{"chromosome":"7","position":22743871}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | non-cancer illness code, self-reported","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":9.229103089046006,"otg_id":"NEALE2_6152_8","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000136244","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"AT"},"locus_GRCh37":{"chromosome":"7","position":22783490},"locus_GRCh38":{"chromosome":"7","position":22743871}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.301029995663981,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (377278bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44174857},"locus_GRCh38":{"chromosome":"7","position":44135258}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European, NR=735838"],"gwas_catalog_id":"GCST007545","neg_log_pval":7.698970004336019,"otg_id":"GCST007545","pubmed_id":"30525989"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (335997bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":44216137},"locus_GRCh38":{"chromosome":"7","position":44176538}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease and triglyceride levels (multivariate analysis)","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["East Asian=7696"],"gwas_catalog_id":"GCST001965","neg_log_pval":9.522878745280337,"otg_id":"GCST001965_2","pubmed_id":"23575436"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":44229068},"locus_GRCh38":{"chromosome":"7","position":44189469}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Glycemic traits [2-hPG]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=7696"],"gwas_catalog_id":"GCST001965","neg_log_pval":17.30102999566398,"otg_id":"GCST001965_3","pubmed_id":"23575436"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":44229068},"locus_GRCh38":{"chromosome":"7","position":44189469}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Glycemic traits [FPG]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=7696"],"gwas_catalog_id":"GCST001965","neg_log_pval":8.522878745280337,"otg_id":"GCST001965","pubmed_id":"23575436"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":44229068},"locus_GRCh38":{"chromosome":"7","position":44189469}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Glycemic traits [1-hPG]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=10564"],"gwas_catalog_id":"GCST001436","neg_log_pval":12.397940008672037,"otg_id":"GCST001436","pubmed_id":"22399527"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (320918bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44231216},"locus_GRCh38":{"chromosome":"7","position":44191617}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [GLU]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (303306bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":44248828},"locus_GRCh38":{"chromosome":"7","position":44209229}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=10564"],"gwas_catalog_id":"GCST001436","neg_log_pval":10.045757490560675,"otg_id":"GCST001436","pubmed_id":"22399527"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":44259871},"locus_GRCh38":{"chromosome":"7","position":44220272}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [GLU]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=10564"],"gwas_catalog_id":"GCST001436","neg_log_pval":10.045757490560675,"otg_id":"GCST001436","pubmed_id":"22399527"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":44259871},"locus_GRCh38":{"chromosome":"7","position":44220272}},"trait_info":{"ontology":["EFO_0000195"],"reported_trait_name":"Metabolic syndrome [GLU]","standard_trait_name":"metabolic syndrome"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.301029995663981,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000015520 at this locus (1072bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44581986},"locus_GRCh38":{"chromosome":"7","position":44542387}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":7.301029995663981,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196262 at this locus (254293bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196262","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44581986},"locus_GRCh38":{"chromosome":"7","position":44542387}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":14.154901959985743,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000015520 at this locus (3637bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":44584551},"locus_GRCh38":{"chromosome":"7","position":44544952}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=26405"],"gwas_catalog_id":"GCST000964","neg_log_pval":9.097453220686008,"otg_id":"GCST000964","pubmed_id":"21297633"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000196262 at this locus (224051bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000196262","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":44612229},"locus_GRCh38":{"chromosome":"7","position":44572630}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Ulcerative colitis","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":7.438898616350944,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (497064bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000015520","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":45077978},"locus_GRCh38":{"chromosome":"7","position":45038379}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"Coronary artery disease","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":11.154901959985743,"otg_id":"GCST006480_2","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Below median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":15.397940008672037,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":33.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":11.154901959985743,"otg_id":"GCST006480_2","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Below median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=9218"],"gwas_catalog_id":"GCST003220","neg_log_pval":10.221848749616356,"otg_id":"GCST003220","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":33.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":11.698970004336019,"otg_id":"GCST006480_3","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":33.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioblastoma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=24009"],"gwas_catalog_id":"GCST004348","neg_log_pval":7.698970004336019,"otg_id":"GCST004348","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Non-glioblastoma glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":15.397940008672037,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":11.698970004336019,"otg_id":"GCST006480_3","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=11582"],"gwas_catalog_id":"GCST003228","neg_log_pval":10.698970004336019,"otg_id":"GCST003228","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=30659"],"gwas_catalog_id":"GCST004347","neg_log_pval":26.397940008672037,"otg_id":"GCST004347","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["European=9218"],"gwas_catalog_id":"GCST003220","neg_log_pval":10.221848749616356,"otg_id":"GCST003220","pubmed_id":"26424050"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":54916280},"locus_GRCh38":{"chromosome":"7","position":54848587}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":8.698970004336019,"otg_id":"GCST006480_3","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":22.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":22.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":10.698970004336019,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":10.698970004336019,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["European=24381"],"gwas_catalog_id":"GCST004349","neg_log_pval":22.30102999566398,"otg_id":"GCST004349","pubmed_id":"28346443"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000326"],"reported_trait_name":"Glioblastoma","standard_trait_name":"central nervous system cancer"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":8.698970004336019,"otg_id":"GCST006480_3","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55134872},"locus_GRCh38":{"chromosome":"7","position":55067179}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":9.698970004336019,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55159349},"locus_GRCh38":{"chromosome":"7","position":55091656}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=15094"],"gwas_catalog_id":"GCST006480","neg_log_pval":9.698970004336019,"otg_id":"GCST006480","pubmed_id":"30152087"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000146648","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":55159349},"locus_GRCh38":{"chromosome":"7","position":55091656}},"trait_info":{"ontology":["EFO_0000519"],"reported_trait_name":"Glioblastoma (age-stratified) [Above median age-at-diagnosis]","standard_trait_name":"glioblastoma multiforme"}}
{"association_info":{"ancestry":["NR=361315","European=446238"],"gwas_catalog_id":"GCST007342","neg_log_pval":13.045757490560675,"otg_id":"GCST007342","pubmed_id":"30718901"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (381311bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000153956","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":82454404},"locus_GRCh38":{"chromosome":"7","position":82825088}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Depression","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=6507"],"gwas_catalog_id":"GCST004486","neg_log_pval":7.522878745280337,"otg_id":"GCST004486","pubmed_id":"28540843"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000153956","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":82468374},"locus_GRCh38":{"chromosome":"7","position":82839058}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Major depressive disorder","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["European=6507"],"gwas_catalog_id":"GCST004486","neg_log_pval":7.522878745280337,"otg_id":"GCST004486","pubmed_id":"28540843"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000153956","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":82468374},"locus_GRCh38":{"chromosome":"7","position":82839058}},"trait_info":{"ontology":["EFO_0003761"],"reported_trait_name":"Major depressive disorder","standard_trait_name":"unipolar depression"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":10.154901959985743,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.397940008672037,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":9.522878745280337,"otg_id":"GCST007201_2","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia [EA]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":13.397940008672037,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=82315","East Asian=5219"],"gwas_catalog_id":"GCST002539","neg_log_pval":9.522878745280337,"otg_id":"GCST002539","pubmed_id":"25056061"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=13574","NR=2380"],"gwas_catalog_id":"GCST004521","neg_log_pval":10.0,"otg_id":"GCST004521","pubmed_id":"28540026"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Autism spectrum disorder or schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=26026","European=82315"],"gwas_catalog_id":"GCST004946","neg_log_pval":9.522878745280337,"otg_id":"GCST004946","pubmed_id":"28991256"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":86427626},"locus_GRCh38":{"chromosome":"7","position":86798310}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["East Asian=45528"],"gwas_catalog_id":"GCST007201","neg_log_pval":7.522878745280337,"otg_id":"GCST007201","pubmed_id":"30285260"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (305241bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000198822","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":86799441},"locus_GRCh38":{"chromosome":"7","position":87170125}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (200123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":100287495},"locus_GRCh38":{"chromosome":"7","position":100689872}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":100287495},"locus_GRCh38":{"chromosome":"7","position":100689872}},"trait_info":{"ontology":["EFO_0005411"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizoaffective disorder"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (200123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":100287495},"locus_GRCh38":{"chromosome":"7","position":100689872}},"trait_info":{"ontology":["EFO_0000289"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"bipolar disorder"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":100287495},"locus_GRCh38":{"chromosome":"7","position":100689872}},"trait_info":{"ontology":["EFO_0005411"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizoaffective disorder"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":100298984},"locus_GRCh38":{"chromosome":"7","position":100701361}},"trait_info":{"ontology":["EFO_0005411"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizoaffective disorder"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (188633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":100298984},"locus_GRCh38":{"chromosome":"7","position":100701361}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (188633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":100298984},"locus_GRCh38":{"chromosome":"7","position":100701361}},"trait_info":{"ontology":["EFO_0000289"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"bipolar disorder"}}
{"association_info":{"ancestry":["African unspecified=224","European=367"],"gwas_catalog_id":"GCST005028","neg_log_pval":8.0,"otg_id":"GCST005028_2","pubmed_id":"29064472"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000087085","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":100298984},"locus_GRCh38":{"chromosome":"7","position":100701361}},"trait_info":{"ontology":["EFO_0005411"],"reported_trait_name":"Pursuit maintenance gain in psychotic disorders [African]","standard_trait_name":"schizoaffective disorder"}}
{"association_info":{"ancestry":["European=139274"],"gwas_catalog_id":"GCST004988","neg_log_pval":15.979638717352293,"otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Serine/threonine-protein kinase B-raf inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000157764 at this locus (476824bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000157764","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":139942304},"locus_GRCh38":{"chromosome":"7","position":140242504}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":10.674484336636851,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":10.045757490560675,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":9.154901959985743,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":9.154901959985743,"otg_id":"GCST006061","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=1030836"],"gwas_catalog_id":"GCST006414","neg_log_pval":10.674484336636851,"otg_id":"GCST006414","pubmed_id":"30061737"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=537409","East Asian=36792","African American or Afro-Caribbean=8967","Hispanic or Latin American=5022"],"gwas_catalog_id":"GCST006061","neg_log_pval":10.045757490560675,"otg_id":"GCST006061_3","pubmed_id":"29892015"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150661409},"locus_GRCh38":{"chromosome":"7","position":150964321}},"trait_info":{"ontology":["EFO_0000275"],"reported_trait_name":"Atrial fibrillation [EA]","standard_trait_name":"atrial fibrillation"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007072","neg_log_pval":48.69897000433602,"otg_id":"GCST007072","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"HERG blocker drug SOTALOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000055118 at this locus (14774bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000055118","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":150690176},"locus_GRCh38":{"chromosome":"7","position":150993088}},"trait_info":{"ontology":["EFO_0000319"],"reported_trait_name":"Cardiovascular disease","standard_trait_name":"cardiovascular system disease"}}
{"association_info":{"ancestry":["European=241704"],"gwas_catalog_id":"GCST004483","neg_log_pval":8.0,"otg_id":"GCST004483","pubmed_id":"27363682"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Cyclin-dependent kinase 5 inhibitor drug DINACICLIB is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000164885 at this locus (195958bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000164885","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":150950940},"locus_GRCh38":{"chromosome":"7","position":151253854}},"trait_info":{"ontology":["EFO_0001378"],"reported_trait_name":"Multiple myeloma","standard_trait_name":"multiple myeloma"}}
{"association_info":{"ancestry":["European=33394"],"gwas_catalog_id":"GCST005527","neg_log_pval":7.481235531320022,"otg_id":"GCST005527","pubmed_id":"23143594"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (12463bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":4971927},"locus_GRCh38":{"chromosome":"9","position":4971927}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Psoriasis","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":42.30102999566398,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (2788bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":4981602},"locus_GRCh38":{"chromosome":"9","position":4981602}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["East Asian=5057","European=10995"],"gwas_catalog_id":"GCST003622","neg_log_pval":16.69897000433602,"otg_id":"GCST003622","pubmed_id":"27399966"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":4984530},"locus_GRCh38":{"chromosome":"9","position":4984530}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["East Asian=5057","European=10995"],"gwas_catalog_id":"GCST003622","neg_log_pval":13.397940008672037,"otg_id":"GCST003622_2","pubmed_id":"27399966"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":4984530},"locus_GRCh38":{"chromosome":"9","position":4984530}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Systemic lupus erythematosus [Chinese]","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=401535"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.707743928643524,"otg_id":"SAIGE_200_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5049092},"locus_GRCh38":{"chromosome":"9","position":5049092}},"trait_info":{"ontology":["EFO_0002429"],"reported_trait_name":"Polycythemia vera","standard_trait_name":"polycythemia vera"}}
{"association_info":{"ancestry":["European=401535"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.707743928643524,"otg_id":"SAIGE_200_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5049092},"locus_GRCh38":{"chromosome":"9","position":5049092}},"trait_info":{"ontology":["EFO_0002429"],"reported_trait_name":"Polycythemia vera","standard_trait_name":"polycythemia vera"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":19.559482903933304,"otg_id":"NEALE2_20002_1438","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5049092},"locus_GRCh38":{"chromosome":"9","position":5049092}},"trait_info":{"ontology":["EFO_0002429"],"reported_trait_name":"Polycythaemia vera | non-cancer illness code, self-reported","standard_trait_name":"polycythemia vera"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":19.559482903933304,"otg_id":"NEALE2_20002_1438","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5049092},"locus_GRCh38":{"chromosome":"9","position":5049092}},"trait_info":{"ontology":["EFO_0002429"],"reported_trait_name":"Polycythaemia vera | non-cancer illness code, self-reported","standard_trait_name":"polycythemia vera"}}
{"association_info":{"ancestry":["European=3198"],"gwas_catalog_id":"GCST002840","neg_log_pval":10.0,"otg_id":"GCST002840","pubmed_id":"25849990"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5063296},"locus_GRCh38":{"chromosome":"9","position":5063296}},"trait_info":{"ontology":["EFO_0004251"],"reported_trait_name":"Myeloproliferative neoplasms","standard_trait_name":"myeloproliferative disorder"}}
{"association_info":{"ancestry":["European=3198"],"gwas_catalog_id":"GCST002840","neg_log_pval":10.0,"otg_id":"GCST002840","pubmed_id":"25849990"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":5063296},"locus_GRCh38":{"chromosome":"9","position":5063296}},"trait_info":{"ontology":["EFO_0004251"],"reported_trait_name":"Myeloproliferative neoplasms","standard_trait_name":"myeloproliferative disorder"}}
{"association_info":{"ancestry":["European=3323"],"gwas_catalog_id":"GCST000357","neg_log_pval":19.397940008672037,"otg_id":"GCST000357","pubmed_id":"19287384"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":5070831},"locus_GRCh38":{"chromosome":"9","position":5070831}},"trait_info":{"ontology":["EFO_0004251"],"reported_trait_name":"Myeloproliferative neoplasms","standard_trait_name":"myeloproliferative disorder"}}
{"association_info":{"ancestry":["European=3323"],"gwas_catalog_id":"GCST000357","neg_log_pval":19.397940008672037,"otg_id":"GCST000357","pubmed_id":"19287384"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000096968","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":5070831},"locus_GRCh38":{"chromosome":"9","position":5070831}},"trait_info":{"ontology":["EFO_0004251"],"reported_trait_name":"Myeloproliferative neoplasms","standard_trait_name":"myeloproliferative disorder"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000147955 at this locus (72455bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000147955","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":34710260},"locus_GRCh38":{"chromosome":"9","position":34710263}},"trait_info":{"ontology":["EFO_0000729"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"ulcerative colitis"}}
{"association_info":{"ancestry":["European=86475"],"gwas_catalog_id":"GCST005537","neg_log_pval":8.221848749616356,"otg_id":"GCST005537","pubmed_id":"26974007"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000147955 at this locus (72455bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000147955","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":34710260},"locus_GRCh38":{"chromosome":"9","position":34710263}},"trait_info":{"ontology":["EFO_0000384"],"reported_trait_name":"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]","standard_trait_name":"Crohn's disease"}}
{"association_info":{"ancestry":["European=116538"],"gwas_catalog_id":"GCST007564","neg_log_pval":10.096910013008056,"otg_id":"GCST007564","pubmed_id":"29785011"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000147955 at this locus (251638bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000147955","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":34889444},"locus_GRCh38":{"chromosome":"9","position":34889447}},"trait_info":{"ontology":["EFO_0000270"],"reported_trait_name":"Asthma or allergic disease (pleiotropy)","standard_trait_name":"asthma"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":14.698970004336019,"otg_id":"NEALE2_20002_1473","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000165029 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":107664301},"locus_GRCh38":{"chromosome":"9","position":104902020}},"trait_info":{"ontology":["HP_0003124"],"reported_trait_name":"High cholesterol | non-cancer illness code, self-reported","standard_trait_name":"Hypercholesterolemia"}}
{"association_info":{"ancestry":["European=408878"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.73754891026957,"otg_id":"SAIGE_272_1"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000165029 at this locus (0bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000165029","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":107665978},"locus_GRCh38":{"chromosome":"9","position":104903697}},"trait_info":{"ontology":["EFO_0003774"],"reported_trait_name":"Hyperlipidemia","standard_trait_name":"hyperlipidemia"}}
{"association_info":{"ancestry":["European=38053"],"gwas_catalog_id":"GCST000987","neg_log_pval":10.397940008672037,"otg_id":"GCST000987","pubmed_id":"21383967"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Complement C5 inhibitor drug ECULIZUMAB is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000106804 at this locus (74113bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000106804","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"9","position":123640500},"locus_GRCh38":{"chromosome":"9","position":120878222}},"trait_info":{"ontology":["EFO_0000540"],"reported_trait_name":"Celiac disease or Rheumatoid arthritis","standard_trait_name":"immune system disease"}}
{"association_info":{"ancestry":["European=314072"],"neg_log_pval":7.955550400347374,"otg_id":"NEALE2_20107_3","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Tyrosine-protein kinase ABL inhibitor drug IMATINIB is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000097007 at this locus (238206bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000097007","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GT"},"locus_GRCh37":{"chromosome":"9","position":133351128},"locus_GRCh38":{"chromosome":"9","position":130475741}},"trait_info":{"ontology":["EFO_0001071"],"reported_trait_name":"Lung cancer | illnesses of father","standard_trait_name":"lung carcinoma"}}
{"association_info":{"ancestry":["European=1125"],"gwas_catalog_id":"GCST000250","neg_log_pval":10.301029995663981,"otg_id":"GCST000250","pubmed_id":"18849991"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (252890bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"X","position":66510984},"locus_GRCh38":{"chromosome":"X","position":67291142}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["European=1198"],"gwas_catalog_id":"GCST001297","neg_log_pval":21.522878745280337,"otg_id":"GCST001297","pubmed_id":"22032556"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"X","position":66563018},"locus_GRCh38":{"chromosome":"X","position":67343176}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["European=12806"],"gwas_catalog_id":"GCST001548","neg_log_pval":90.69897000433602,"otg_id":"GCST001548","pubmed_id":"22693459"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"X","position":66563018},"locus_GRCh38":{"chromosome":"X","position":67343176}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":8.0,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":8.0,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=13560"],"gwas_catalog_id":"GCST001148","neg_log_pval":8.0,"otg_id":"GCST001148","pubmed_id":"21743467"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":9.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"High","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_IV","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_IV"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":9.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=140254"],"gwas_catalog_id":"GCST006085","neg_log_pval":9.0,"otg_id":"GCST006085","pubmed_id":"29892016"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Medium","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_III","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_III"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":67021550},"locus_GRCh38":{"chromosome":"X","position":67801708}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate cancer","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"ancestry":["European=43590"],"gwas_catalog_id":"GCST005116","neg_log_pval":34.52287874528034,"otg_id":"GCST005116","pubmed_id":"29146897"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (413341bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000169083","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"X","position":67363801},"locus_GRCh38":{"chromosome":"X","position":68143959}},"trait_info":{"ontology":["EFO_0004191"],"reported_trait_name":"Male-pattern baldness","standard_trait_name":"androgenetic alopecia"}}
{"association_info":{"ancestry":["European=16753"],"gwas_catalog_id":"GCST003097","neg_log_pval":8.0,"otg_id":"GCST003097","pubmed_id":"26301688"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"CD40 ligand inhibitor drug DAPIROLIZUMAB PEGOL is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000102245 at this locus (64575bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000102245","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":135665778},"locus_GRCh38":{"chromosome":"X","position":136583619}},"trait_info":{"ontology":["EFO_0002690"],"reported_trait_name":"Pediatric autoimmune diseases","standard_trait_name":"systemic lupus erythematosus"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":12.154901959985743,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor VIII inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000185010 at this locus (23583bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000185010","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"X","position":154278797},"locus_GRCh38":{"chromosome":"X","position":155050522}},"trait_info":{"ontology":["EFO_0003827"],"reported_trait_name":"Thrombosis","standard_trait_name":"pulmonary embolism"}}
{"association_info":{"ancestry":["European=258962"],"gwas_catalog_id":"GCST003390","neg_log_pval":12.154901959985743,"otg_id":"GCST003390","pubmed_id":"26908601"},"gold_standard_info":{"evidence":[{"class":"drug","confidence":"Low","curated_by":"Ed Mountjoy","description":"Coagulation factor VIII inhibitor drug TB-402 is Phase II for the indiciation EFO_0004286 and targets the gene ENSG00000185010 at this locus (23583bp away).","source":"ChEMBL - Open Targets Evidence 19.06"}],"gene_id":"ENSG00000185010","highest_confidence":"Low"},"metadata":{"comments":"Gold-standard derived from drug-indication pairs in ChEMBL","date_added":"2019-07-29","reviewed_by":"Ed Mountjoy","set_label":"ChEMBL_II","submitted_by":"Ed Mountjoy","tags":["drug","ChEMBL","ChEMBL_II"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"X","position":154278797},"locus_GRCh38":{"chromosome":"X","position":155050522}},"trait_info":{"ontology":["EFO_0004286"],"reported_trait_name":"Thrombosis","standard_trait_name":"venous thromboembolism"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.20690839982342,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":12250620},"locus_GRCh38":{"chromosome":"10","position":12208621}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":26.096910013008056,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":12302607},"locus_GRCh38":{"chromosome":"10","position":12260608}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":16.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":9.42712839779952,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":13.397940008672037,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":12.0,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=3712"],"gwas_catalog_id":"GCST001666","neg_log_pval":8.154901959985743,"otg_id":"GCST001666","pubmed_id":"22961080"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":8.522878745280337,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":28.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.522878745280337,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":12307894},"locus_GRCh38":{"chromosome":"10","position":12265895}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=2729"],"gwas_catalog_id":"GCST000796","neg_log_pval":8.0,"otg_id":"GCST000796","pubmed_id":"20862305"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":12314997},"locus_GRCh38":{"chromosome":"10","position":12272998}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=10128"],"gwas_catalog_id":"GCST000167","neg_log_pval":10.0,"otg_id":"GCST000167","pubmed_id":"18372903"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000183049","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":12328010},"locus_GRCh38":{"chromosome":"10","position":12286011}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":8.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000122859","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":71273357},"locus_GRCh38":{"chromosome":"10","position":69513601}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":8.522878745280337,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000122859","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":71332301},"locus_GRCh38":{"chromosome":"10","position":69572545}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":8.073297505817354,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000122859","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":71465928},"locus_GRCh38":{"chromosome":"10","position":69706172}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.154901959985743,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000122859","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":71469514},"locus_GRCh38":{"chromosome":"10","position":69709758}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":10.522878745280337,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":80942631},"locus_GRCh38":{"chromosome":"10","position":79182874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.698970004336019,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":80942631},"locus_GRCh38":{"chromosome":"10","position":79182874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":19.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":80942631},"locus_GRCh38":{"chromosome":"10","position":79182874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":9.619788758288394,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"10","position":80942631},"locus_GRCh38":{"chromosome":"10","position":79182874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":7.522878745280337,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":80943841},"locus_GRCh38":{"chromosome":"10","position":79184084}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":14.221848749616356,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"10","position":80952826},"locus_GRCh38":{"chromosome":"10","position":79193069}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.025949097207123,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":80954785},"locus_GRCh38":{"chromosome":"10","position":79195028}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":10.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000108175","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":80964975},"locus_GRCh38":{"chromosome":"10","position":79205218}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":10.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114737777},"locus_GRCh38":{"chromosome":"10","position":112978018}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=455607"],"gwas_catalog_id":"GCST006868","neg_log_pval":10.397940008672037,"otg_id":"GCST006868","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114737777},"locus_GRCh38":{"chromosome":"10","position":112978018}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=56799","African American or Afro-Caribbean=3571","East Asian=4735","Hispanic or Latin American=6499"],"gwas_catalog_id":"GCST003619","neg_log_pval":52.221848749616356,"otg_id":"GCST003619","pubmed_id":"27189021"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754071},"locus_GRCh38":{"chromosome":"10","position":112994312}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":135.64397414280688,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754071},"locus_GRCh38":{"chromosome":"10","position":112994312}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":22.522878745280337,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754071},"locus_GRCh38":{"chromosome":"10","position":112994312}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000025","neg_log_pval":48.0,"otg_id":"GCST000025_2","pubmed_id":"17463249"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754088},"locus_GRCh38":{"chromosome":"10","position":112994329}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":48.52287874528034,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754088},"locus_GRCh38":{"chromosome":"10","position":112994329}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":28.732802449449522,"otg_id":"NEALE2_20002_1223","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114754784},"locus_GRCh38":{"chromosome":"10","position":112995025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes | non-cancer illness code, self-reported","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000277","neg_log_pval":15.221848749616356,"otg_id":"GCST000277_2","pubmed_id":"19056611"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [obese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["NR=60647"],"gwas_catalog_id":"GCST001550","neg_log_pval":39.69897000433602,"otg_id":"GCST001550","pubmed_id":"22693455"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Lean]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":202.52287874528034,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":74.10790539730952,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=1616"],"gwas_catalog_id":"GCST001809","neg_log_pval":74.04575749056067,"otg_id":"GCST001809_3","pubmed_id":"23300278"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [South Asian, East Asian, Europeans]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=997"],"gwas_catalog_id":"GCST000049","neg_log_pval":7.301029995663981,"otg_id":"GCST000049","pubmed_id":"17668382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=1616"],"gwas_catalog_id":"GCST001809","neg_log_pval":34.52287874528034,"otg_id":"GCST001809_5","pubmed_id":"23300278"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [South Asians]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=26805"],"gwas_catalog_id":"GCST002128","neg_log_pval":14.698970004336019,"otg_id":"GCST002128","pubmed_id":"23945395"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["Hispanic or Latin American=7746"],"gwas_catalog_id":"GCST004758","neg_log_pval":11.0,"otg_id":"GCST004758","pubmed_id":"28254843"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=2128"],"gwas_catalog_id":"GCST001759","neg_log_pval":35.0,"otg_id":"GCST001759_2","pubmed_id":"23209189"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Indo-European South Asians]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=23827"],"gwas_catalog_id":"GCST002560","neg_log_pval":93.39794000867204,"otg_id":"GCST002560","pubmed_id":"25102180"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=10128"],"gwas_catalog_id":"GCST000167","neg_log_pval":22.522878745280337,"otg_id":"GCST000167","pubmed_id":"18372903"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":347.0,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=1616"],"gwas_catalog_id":"GCST001809","neg_log_pval":21.221848749616356,"otg_id":"GCST001809","pubmed_id":"23300278"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [All Punjabi]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4805","African American or Afro-Caribbean=1683"],"gwas_catalog_id":"GCST001326","neg_log_pval":14.698970004336019,"otg_id":"GCST001326","pubmed_id":"22101970"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":93.92081875395237,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":183.69897000433602,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":74.09691001300806,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=1376"],"gwas_catalog_id":"GCST000478","neg_log_pval":30.0,"otg_id":"GCST000478","pubmed_id":"19734900"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["NR=60647"],"gwas_catalog_id":"GCST001550","neg_log_pval":20.397940008672037,"otg_id":"GCST001550_2","pubmed_id":"22693455"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Obese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["Hispanic or Latin American=8214"],"gwas_catalog_id":"GCST002317","neg_log_pval":14.0,"otg_id":"GCST002317","pubmed_id":"24390345"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=23827"],"gwas_catalog_id":"GCST002560","neg_log_pval":43.30102999566398,"otg_id":"GCST002560_2","pubmed_id":"25102180"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [AA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2931"],"gwas_catalog_id":"GCST000028","neg_log_pval":48.0,"otg_id":"GCST000028","pubmed_id":"17463246"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":50.69897000433602,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=1022"],"gwas_catalog_id":"GCST000383","neg_log_pval":11.096910013008056,"otg_id":"GCST000383","pubmed_id":"19401414"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000277","neg_log_pval":29.045757490560675,"otg_id":"GCST000277","pubmed_id":"19056611"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [non-obese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2335"],"gwas_catalog_id":"GCST000024","neg_log_pval":8.0,"otg_id":"GCST000024","pubmed_id":"17463248"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=1616"],"gwas_catalog_id":"GCST001809","neg_log_pval":18.522878745280337,"otg_id":"GCST001809_2","pubmed_id":"23300278"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Punjabi Sikhs]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=1947"],"gwas_catalog_id":"GCST007221","neg_log_pval":10.522878745280337,"otg_id":"GCST007221","pubmed_id":"30470734"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=8686"],"gwas_catalog_id":"GCST000027","neg_log_pval":9.698970004336019,"otg_id":"GCST000027","pubmed_id":"17460697"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=1616"],"gwas_catalog_id":"GCST001809","neg_log_pval":37.69897000433602,"otg_id":"GCST001809_4","pubmed_id":"23300278"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [South Asians, East Asians]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=1275"],"gwas_catalog_id":"GCST000012","neg_log_pval":33.69897000433602,"otg_id":"GCST000012","pubmed_id":"17293876"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":22.522878745280337,"otg_id":"GCST004894_3","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [South Asian]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=117775"],"gwas_catalog_id":"GCST006801","neg_log_pval":44.15490195998574,"otg_id":"GCST006801","pubmed_id":"26961502"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [additive model]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":219.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"10","position":114758349},"locus_GRCh38":{"chromosome":"10","position":112998590}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=390054"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.145693958198919,"otg_id":"SAIGE_250_23"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114798893},"locus_GRCh38":{"chromosome":"10","position":113039134}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes with ophthalmic manifestations","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":12.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114880342},"locus_GRCh38":{"chromosome":"10","position":113120583}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":8.397940008672037,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000148737","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"10","position":114880342},"locus_GRCh38":{"chromosome":"10","position":113120583}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["Hispanic or Latin American=8658"],"gwas_catalog_id":"GCST006145","neg_log_pval":13.221848749616356,"otg_id":"GCST006145","pubmed_id":"28838971"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":2161530},"locus_GRCh38":{"chromosome":"11","position":2140300}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["African American or Afro-Caribbean=23827"],"gwas_catalog_id":"GCST002560","neg_log_pval":7.522878745280337,"otg_id":"GCST002560_2","pubmed_id":"25102180"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":2178670},"locus_GRCh38":{"chromosome":"11","position":2157440}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [AA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":10.154901959985743,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":2197112},"locus_GRCh38":{"chromosome":"11","position":2175882}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":12.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":2197286},"locus_GRCh38":{"chromosome":"11","position":2176056}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":10.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":2213166},"locus_GRCh38":{"chromosome":"11","position":2191936}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":11.0,"otg_id":"GCST003400","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":2215089},"locus_GRCh38":{"chromosome":"11","position":2193859}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":7.698970004336019,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":2215089},"locus_GRCh38":{"chromosome":"11","position":2193859}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":9.0,"otg_id":"GCST007847_2","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000167244","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":2291050},"locus_GRCh38":{"chromosome":"11","position":2269820}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Conditioned]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.896196279044043,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408404},"locus_GRCh38":{"chromosome":"11","position":17386857}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":20.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":10.522878745280337,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":16.397940008672037,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.096910013008056,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":21.30102999566398,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":10.494850021680094,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":19.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000025","neg_log_pval":10.301029995663981,"otg_id":"GCST000025_2","pubmed_id":"17463249"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17408630},"locus_GRCh38":{"chromosome":"11","position":17387083}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2335"],"gwas_catalog_id":"GCST000024","neg_log_pval":10.154901959985743,"otg_id":"GCST000024_2","pubmed_id":"17463248"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":21.221848749616356,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2931"],"gwas_catalog_id":"GCST000028","neg_log_pval":10.154901959985743,"otg_id":"GCST000028","pubmed_id":"17463246"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":21.69897000433602,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000277","neg_log_pval":9.0,"otg_id":"GCST000277","pubmed_id":"19056611"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":17409572},"locus_GRCh38":{"chromosome":"11","position":17388025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [non-obese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000187486","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":17411821},"locus_GRCh38":{"chromosome":"11","position":17390274}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":9.301029995663981,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":72408055},"locus_GRCh38":{"chromosome":"11","position":72697010}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":7.301029995663981,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":72408055},"locus_GRCh38":{"chromosome":"11","position":72697010}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":8.698970004336019,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":72408055},"locus_GRCh38":{"chromosome":"11","position":72697010}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.0,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72428172},"locus_GRCh38":{"chromosome":"11","position":72717127}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":16.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72433098},"locus_GRCh38":{"chromosome":"11","position":72722053}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":24.045757490560675,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72433098},"locus_GRCh38":{"chromosome":"11","position":72722053}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":22.0,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72433098},"locus_GRCh38":{"chromosome":"11","position":72722053}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.0,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72433098},"locus_GRCh38":{"chromosome":"11","position":72722053}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":16.522878745280337,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72460762},"locus_GRCh38":{"chromosome":"11","position":72749717}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.269217724333611,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000214530","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"11","position":72460762},"locus_GRCh38":{"chromosome":"11","position":72749717}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.193820026016112,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":92668975},"locus_GRCh38":{"chromosome":"11","position":92935809}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":14.096910013008056,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92673828},"locus_GRCh38":{"chromosome":"11","position":92940662}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":17.397940008672037,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.154901959985743,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":29.221848749616356,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":15.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":15.522878745280337,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000134640","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92708710},"locus_GRCh38":{"chromosome":"11","position":92975544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":8.870954940112043,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":4328521},"locus_GRCh38":{"chromosome":"12","position":4219355}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":7.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":4374373},"locus_GRCh38":{"chromosome":"12","position":4265207}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":7.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":4374373},"locus_GRCh38":{"chromosome":"12","position":4265207}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.65169513695184,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":4384696},"locus_GRCh38":{"chromosome":"12","position":4275530}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":30.69897000433602,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":4384844},"locus_GRCh38":{"chromosome":"12","position":4275678}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":24.4145392704915,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":4384844},"locus_GRCh38":{"chromosome":"12","position":4275678}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":8.217634170939927,"otg_id":"NEALE2_20002_1223","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":4384844},"locus_GRCh38":{"chromosome":"12","position":4275678}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes | non-cancer illness code, self-reported","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":9.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000118971","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":4406281},"locus_GRCh38":{"chromosome":"12","position":4297115}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":7.698970004336019,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":27867727},"locus_GRCh38":{"chromosome":"12","position":27714794}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":8.698970004336019,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":27867727},"locus_GRCh38":{"chromosome":"12","position":27714794}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":7.522878745280337,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":27867727},"locus_GRCh38":{"chromosome":"12","position":27714794}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":11.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":27867727},"locus_GRCh38":{"chromosome":"12","position":27714794}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.154901959985743,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":27963507},"locus_GRCh38":{"chromosome":"12","position":27810574}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":11.045757490560675,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":27965150},"locus_GRCh38":{"chromosome":"12","position":27812217}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":16.0,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":27965150},"locus_GRCh38":{"chromosome":"12","position":27812217}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000087448","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":27965150},"locus_GRCh38":{"chromosome":"12","position":27812217}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":8.0,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000075035","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":108613151},"locus_GRCh38":{"chromosome":"12","position":108219374}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":7.522878745280337,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000075035","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":108618630},"locus_GRCh38":{"chromosome":"12","position":108224853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.221848749616356,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":121327809},"locus_GRCh38":{"chromosome":"12","position":120890006}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["Hispanic or Latin American=2584"],"gwas_catalog_id":"GCST001070","neg_log_pval":7.698970004336019,"otg_id":"GCST001070","pubmed_id":"21573907"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":121402932},"locus_GRCh38":{"chromosome":"12","position":120965129}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":11.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":121416650},"locus_GRCh38":{"chromosome":"12","position":120978847}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":9.698970004336019,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"12","position":121416650},"locus_GRCh38":{"chromosome":"12","position":120978847}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":7.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":121429194},"locus_GRCh38":{"chromosome":"12","position":120991391}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":13.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":121456616},"locus_GRCh38":{"chromosome":"12","position":121018813}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":8.522878745280337,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":121460686},"locus_GRCh38":{"chromosome":"12","position":121022883}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":7.698970004336019,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":121460686},"locus_GRCh38":{"chromosome":"12","position":121022883}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000135100","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"12","position":121460686},"locus_GRCh38":{"chromosome":"12","position":121022883}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000150967","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":123491572},"locus_GRCh38":{"chromosome":"12","position":123007025}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":8.0,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000150967","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":123640853},"locus_GRCh38":{"chromosome":"12","position":123156306}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000205502","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":62383155},"locus_GRCh38":{"chromosome":"15","position":62090956}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":16.69897000433602,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000205502","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":62394264},"locus_GRCh38":{"chromosome":"15","position":62102065}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":8.301029995663981,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000205502","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":62396389},"locus_GRCh38":{"chromosome":"15","position":62104190}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=7541"],"gwas_catalog_id":"GCST000787","neg_log_pval":13.045757490560675,"otg_id":"GCST000787","pubmed_id":"20818381"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000205502","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"15","position":62396389},"locus_GRCh38":{"chromosome":"15","position":62104190}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":8.301029995663981,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000205502","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":62409070},"locus_GRCh38":{"chromosome":"15","position":62116871}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.627087997029894,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000177508 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000177508 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000177508 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000177508","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":54490811},"locus_GRCh38":{"chromosome":"16","position":54456899}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":17.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000050820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":75243772},"locus_GRCh38":{"chromosome":"16","position":75209874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.449771646944907,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000050820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":75245937},"locus_GRCh38":{"chromosome":"16","position":75212039}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":13.397940008672037,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000050820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":75246035},"locus_GRCh38":{"chromosome":"16","position":75212137}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.301029995663981,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000050820","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":75247245},"locus_GRCh38":{"chromosome":"16","position":75213347}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=26805"],"gwas_catalog_id":"GCST002128","neg_log_pval":12.096910013008056,"otg_id":"GCST002128","pubmed_id":"23945395"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000174326","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":6940393},"locus_GRCh38":{"chromosome":"17","position":7037074}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["Hispanic or Latin American=8214"],"gwas_catalog_id":"GCST002317","neg_log_pval":14.301029995663981,"otg_id":"GCST002317","pubmed_id":"24390345"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000174326","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":6945087},"locus_GRCh38":{"chromosome":"17","position":7041768}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":10.096910013008056,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000174326","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":6945483},"locus_GRCh38":{"chromosome":"17","position":7042164}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":15.221848749616356,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000174326","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":6947453},"locus_GRCh38":{"chromosome":"17","position":7044134}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":13.301029995663981,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57838401},"locus_GRCh38":{"chromosome":"18","position":60171168}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.301029995663981,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57884750},"locus_GRCh38":{"chromosome":"18","position":60217517}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":11.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57884750},"locus_GRCh38":{"chromosome":"18","position":60217517}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":11.301029995663981,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57884750},"locus_GRCh38":{"chromosome":"18","position":60217517}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":7.522878745280337,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":57884750},"locus_GRCh38":{"chromosome":"18","position":60217517}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":9.698970004336019,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":19379549},"locus_GRCh38":{"chromosome":"19","position":19268740}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":14.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":19379549},"locus_GRCh38":{"chromosome":"19","position":19268740}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":11.301029995663981,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":19379549},"locus_GRCh38":{"chromosome":"19","position":19268740}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":12.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":19379549},"locus_GRCh38":{"chromosome":"19","position":19268740}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":11.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000213996","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":19407718},"locus_GRCh38":{"chromosome":"19","position":19296909}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=56799","African American or Afro-Caribbean=3571","East Asian=4735","Hispanic or Latin American=6499"],"gwas_catalog_id":"GCST003619","neg_log_pval":8.154901959985743,"otg_id":"GCST003619","pubmed_id":"27189021"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000130203 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130203 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000130203","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":45392254},"locus_GRCh38":{"chromosome":"19","position":44888997}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.72584215073632,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":46147527},"locus_GRCh38":{"chromosome":"19","position":45644269}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":12.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":46150182},"locus_GRCh38":{"chromosome":"19","position":45646924}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":15.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":46158513},"locus_GRCh38":{"chromosome":"19","position":45655255}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":18.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":46166604},"locus_GRCh38":{"chromosome":"19","position":45663346}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":11.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":46172278},"locus_GRCh38":{"chromosome":"19","position":45669020}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":11.154901959985743,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":46181392},"locus_GRCh38":{"chromosome":"19","position":45678134}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":11.522878745280337,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000010310","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":46181392},"locus_GRCh38":{"chromosome":"19","position":45678134}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":14.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27730940},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":24.30102999566398,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27730940},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":15.0,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27730940},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":15.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27730940},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":17.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27730940},"locus_GRCh38":{"chromosome":"2","position":27508073}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":14.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":27734972},"locus_GRCh38":{"chromosome":"2","position":27512105}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":16.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27741237},"locus_GRCh38":{"chromosome":"2","position":27518370}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":20.30102999566398,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27741237},"locus_GRCh38":{"chromosome":"2","position":27518370}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.072116589669292,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000084734","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":27742603},"locus_GRCh38":{"chromosome":"2","position":27519736}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=15000","South East Asian=2034","Asian unspecified=1783"],"gwas_catalog_id":"GCST001351","neg_log_pval":11.0,"otg_id":"GCST001351","pubmed_id":"22158537"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"20","position":42946966},"locus_GRCh38":{"chromosome":"20","position":44318326}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":7.698970004336019,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":42964514},"locus_GRCh38":{"chromosome":"20","position":44335874}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.397940008672037,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":42989267},"locus_GRCh38":{"chromosome":"20","position":44360627}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=20019"],"gwas_catalog_id":"GCST001213","neg_log_pval":9.522878745280337,"otg_id":"GCST001213","pubmed_id":"21874001"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":42989267},"locus_GRCh38":{"chromosome":"20","position":44360627}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":7.301029995663981,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":42989267},"locus_GRCh38":{"chromosome":"20","position":44360627}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":8.397940008672037,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":42989777},"locus_GRCh38":{"chromosome":"20","position":44361137}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":43001721},"locus_GRCh38":{"chromosome":"20","position":44373081}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":7.522878745280337,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":43042364},"locus_GRCh38":{"chromosome":"20","position":44413724}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":10.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":43042364},"locus_GRCh38":{"chromosome":"20","position":44413724}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":7.301029995663981,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000101076","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":43042364},"locus_GRCh38":{"chromosome":"20","position":44413724}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":10.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000100344","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":44324727},"locus_GRCh38":{"chromosome":"22","position":43928847}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":7.522878745280337,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000100344","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":44324727},"locus_GRCh38":{"chromosome":"22","position":43928847}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":9.698970004336019,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000100344","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":44324727},"locus_GRCh38":{"chromosome":"22","position":43928847}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":9.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000100344","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":44377442},"locus_GRCh38":{"chromosome":"22","position":43981562}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":11.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12329783},"locus_GRCh38":{"chromosome":"3","position":12288284}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.795880017344075,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12392272},"locus_GRCh38":{"chromosome":"3","position":12350773}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":16.0,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":17.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":13.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":18.522878745280337,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.221848749616356,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":18.69897000433602,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12393125},"locus_GRCh38":{"chromosome":"3","position":12351626}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":23.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":12394840},"locus_GRCh38":{"chromosome":"3","position":12353341}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":15.357832365595055,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000132170","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":12396913},"locus_GRCh38":{"chromosome":"3","position":12355414}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"The is a likely causal T2D variant (2C) for ENSG00000163581 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000163581 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000163581 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000163581","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"3","position":170766618},"locus_GRCh38":{"chromosome":"3","position":171048829}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":14.096910013008056,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6270056},"locus_GRCh38":{"chromosome":"4","position":6268329}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=1376"],"gwas_catalog_id":"GCST000478","neg_log_pval":8.0,"otg_id":"GCST000478","pubmed_id":"19734900"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6270056},"locus_GRCh38":{"chromosome":"4","position":6268329}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":15.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6270056},"locus_GRCh38":{"chromosome":"4","position":6268329}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":8.698970004336019,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":6289986},"locus_GRCh38":{"chromosome":"4","position":6288259}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":18.367542707815275,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":6299914},"locus_GRCh38":{"chromosome":"4","position":6298187}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":16.69897000433602,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6302519},"locus_GRCh38":{"chromosome":"4","position":6300792}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":20.154901959985743,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6302519},"locus_GRCh38":{"chromosome":"4","position":6300792}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":17.522878745280337,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6302519},"locus_GRCh38":{"chromosome":"4","position":6300792}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":24.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6302519},"locus_GRCh38":{"chromosome":"4","position":6300792}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":19.154901959985743,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6302519},"locus_GRCh38":{"chromosome":"4","position":6300792}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":33.221848749616356,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":6303022},"locus_GRCh38":{"chromosome":"4","position":6301295}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":7.522878745280337,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"4","position":6303022},"locus_GRCh38":{"chromosome":"4","position":6301295}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.366531544420413,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6303955},"locus_GRCh38":{"chromosome":"4","position":6302228}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":7.698970004336019,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000109501","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":6333669},"locus_GRCh38":{"chromosome":"4","position":6331942}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=455607"],"gwas_catalog_id":"GCST006868","neg_log_pval":8.397940008672037,"otg_id":"GCST006868","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000154122","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":14751305},"locus_GRCh38":{"chromosome":"5","position":14751196}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.723538195826756,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000154122","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":14751305},"locus_GRCh38":{"chromosome":"5","position":14751196}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":12.522878745280337,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000154122","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":14768092},"locus_GRCh38":{"chromosome":"5","position":14767983}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000154122","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"5","position":14847331},"locus_GRCh38":{"chromosome":"5","position":14847222}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":14.698970004336019,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000152359","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000152359","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.301029995663981,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000152359","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":75003678},"locus_GRCh38":{"chromosome":"5","position":75707853}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":17.0,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":102100576},"locus_GRCh38":{"chromosome":"5","position":102764872}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":8.397940008672037,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102247916},"locus_GRCh38":{"chromosome":"5","position":102912212}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.85078088734462,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102331465},"locus_GRCh38":{"chromosome":"5","position":102995761}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=455607"],"gwas_catalog_id":"GCST006868","neg_log_pval":13.397940008672037,"otg_id":"GCST006868","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":102338739},"locus_GRCh38":{"chromosome":"5","position":103003035}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":11.021363051615525,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":102338739},"locus_GRCh38":{"chromosome":"5","position":103003035}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":12.397940008672037,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102338811},"locus_GRCh38":{"chromosome":"5","position":103003107}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":14.154901959985743,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102338811},"locus_GRCh38":{"chromosome":"5","position":103003107}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.221848749616356,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102338811},"locus_GRCh38":{"chromosome":"5","position":103003107}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":16.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":102338811},"locus_GRCh38":{"chromosome":"5","position":103003107}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":15.397940008672037,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000145730","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":102422968},"locus_GRCh38":{"chromosome":"5","position":103087264}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":7.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":7226959},"locus_GRCh38":{"chromosome":"6","position":7226726}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":13.0,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":12.698970004336019,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":16.69897000433602,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":11.698970004336019,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":14.698970004336019,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":8.844663962534938,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7231843},"locus_GRCh38":{"chromosome":"6","position":7231610}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":9.0,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":7258617},"locus_GRCh38":{"chromosome":"6","position":7258384}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":10.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":7281654},"locus_GRCh38":{"chromosome":"6","position":7281421}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":7.698970004336019,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":7290437},"locus_GRCh38":{"chromosome":"6","position":7290204}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.0,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000124782","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":7290437},"locus_GRCh38":{"chromosome":"6","position":7290204}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":11.698970004336019,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":14898282},"locus_GRCh38":{"chromosome":"7","position":14858657}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":12.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":14898282},"locus_GRCh38":{"chromosome":"7","position":14858657}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.698970004336019,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":14898282},"locus_GRCh38":{"chromosome":"7","position":14858657}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":14.698970004336019,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":14898282},"locus_GRCh38":{"chromosome":"7","position":14858657}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":8.221848749616356,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":15053589},"locus_GRCh38":{"chromosome":"7","position":15013964}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":14.0,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":15063926},"locus_GRCh38":{"chromosome":"7","position":15024301}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.492144128304169,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":15063926},"locus_GRCh38":{"chromosome":"7","position":15024301}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":18.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":15064255},"locus_GRCh38":{"chromosome":"7","position":15024630}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":9.0,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Ed Mountjoy","description":"There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000136267","highest_confidence":"Medium"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":15064309},"locus_GRCh38":{"chromosome":"7","position":15024684}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.301029995663981,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":44174857},"locus_GRCh38":{"chromosome":"7","position":44135258}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.397940008672037,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106633","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":44248828},"locus_GRCh38":{"chromosome":"7","position":44209229}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=15000","South East Asian=2034","Asian unspecified=1783"],"gwas_catalog_id":"GCST001351","neg_log_pval":10.301029995663981,"otg_id":"GCST001351","pubmed_id":"22158537"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":127164958},"locus_GRCh38":{"chromosome":"7","position":127524904}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":9.096910013008056,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":127237312},"locus_GRCh38":{"chromosome":"7","position":127597258}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=1639"],"gwas_catalog_id":"GCST001919","neg_log_pval":9.698970004336019,"otg_id":"GCST001919","pubmed_id":"23532257"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":127246903},"locus_GRCh38":{"chromosome":"7","position":127606849}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [East Asian]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":12.397940008672037,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":127253550},"locus_GRCh38":{"chromosome":"7","position":127613496}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":11.698970004336019,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":127253550},"locus_GRCh38":{"chromosome":"7","position":127613496}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":73.39794000867204,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000106331","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":127253550},"locus_GRCh38":{"chromosome":"7","position":127613496}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":8.0,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000130675 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130675 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000130675","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":156983847},"locus_GRCh38":{"chromosome":"7","position":157191153}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":8.154901959985743,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":19819724},"locus_GRCh38":{"chromosome":"8","position":19962213}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":7.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000175445","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":19852310},"locus_GRCh38":{"chromosome":"8","position":19994799}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":7.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118024315},"locus_GRCh38":{"chromosome":"8","position":117012076}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=56799","African American or Afro-Caribbean=3571","East Asian=4735","Hispanic or Latin American=6499"],"gwas_catalog_id":"GCST003619","neg_log_pval":11.0,"otg_id":"GCST003619","pubmed_id":"27189021"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007517","neg_log_pval":29.221848749616356,"otg_id":"GCST007517","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=1022"],"gwas_catalog_id":"GCST000383","neg_log_pval":13.698970004336019,"otg_id":"GCST000383","pubmed_id":"19401414"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007515","neg_log_pval":46.69897000433602,"otg_id":"GCST007515","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=70127"],"gwas_catalog_id":"GCST005413","neg_log_pval":14.522878745280337,"otg_id":"GCST005413","pubmed_id":"29358691"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957"],"gwas_catalog_id":"GCST007518","neg_log_pval":35.096910013008056,"otg_id":"GCST007518","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":41.39794000867204,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":21.69897000433602,"otg_id":"GCST004894_2","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [EA]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=298957","South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"],"gwas_catalog_id":"GCST007516","neg_log_pval":47.0,"otg_id":"GCST007516","pubmed_id":"29632382"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes (adjusted for BMI)","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=407701"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":19.041914151478913,"otg_id":"SAIGE_250_2"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2335"],"gwas_catalog_id":"GCST000024","neg_log_pval":7.301029995663981,"otg_id":"GCST000024_2","pubmed_id":"17463248"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":29.522878745280337,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=4862"],"gwas_catalog_id":"GCST000025","neg_log_pval":7.301029995663981,"otg_id":"GCST000025_2","pubmed_id":"17463249"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [DGI+FUSION+WTCCC]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=2931"],"gwas_catalog_id":"GCST000028","neg_log_pval":7.301029995663981,"otg_id":"GCST000028","pubmed_id":"17463246"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=41646"],"gwas_catalog_id":"GCST003400","neg_log_pval":12.045757490560675,"otg_id":"GCST003400_2","pubmed_id":"26818947"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":118184783},"locus_GRCh38":{"chromosome":"8","position":117172544}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Japanese]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":23.69897000433602,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":118185025},"locus_GRCh38":{"chromosome":"8","position":117172786}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=47117"],"gwas_catalog_id":"GCST000712","neg_log_pval":8.0,"otg_id":"GCST000712","pubmed_id":"20581827"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":118185025},"locus_GRCh38":{"chromosome":"8","position":117172786}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":51.69897000433602,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":118185025},"locus_GRCh38":{"chromosome":"8","position":117172786}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["NR=60647"],"gwas_catalog_id":"GCST001550","neg_log_pval":7.3979400086720375,"otg_id":"GCST001550","pubmed_id":"22693455"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":118185025},"locus_GRCh38":{"chromosome":"8","position":117172786}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes [Lean]","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033","East Asian=18817","South Asian=20019","Hispanic or Latin American=2583"],"gwas_catalog_id":"GCST002352","neg_log_pval":17.69897000433602,"otg_id":"GCST002352","pubmed_id":"24509480"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"8","position":118185025},"locus_GRCh38":{"chromosome":"8","position":117172786}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":15.2518119729938,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000164756","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"8","position":118220270},"locus_GRCh38":{"chromosome":"8","position":117208031}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=15000","South East Asian=2034","Asian unspecified=1783"],"gwas_catalog_id":"GCST001351","neg_log_pval":13.698970004336019,"otg_id":"GCST001351","pubmed_id":"22158537"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":4287466},"locus_GRCh38":{"chromosome":"9","position":4287466}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["South Asian=13532","European=20298","NR=149821"],"gwas_catalog_id":"GCST004894","neg_log_pval":7.522878745280337,"otg_id":"GCST004894","pubmed_id":"28869590"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":4287466},"locus_GRCh38":{"chromosome":"9","position":4287466}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=191764"],"gwas_catalog_id":"GCST007847","neg_log_pval":11.096910013008056,"otg_id":"GCST007847","pubmed_id":"30718926"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":4289050},"locus_GRCh38":{"chromosome":"9","position":4289050}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=69033"],"gwas_catalog_id":"GCST005047","neg_log_pval":7.468521082957745,"otg_id":"GCST005047","pubmed_id":"22885922"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":4290085},"locus_GRCh38":{"chromosome":"9","position":4290085}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=459000"],"gwas_catalog_id":"GCST007077","neg_log_pval":8.301029995663981,"otg_id":"GCST007077","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":4291928},"locus_GRCh38":{"chromosome":"9","position":4291928}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["European=655666","South Asian=3650"],"gwas_catalog_id":"GCST006867","neg_log_pval":14.522878745280337,"otg_id":"GCST006867","pubmed_id":"30054458"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":4291928},"locus_GRCh38":{"chromosome":"9","position":4291928}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"ancestry":["East Asian=3712"],"gwas_catalog_id":"GCST001666","neg_log_pval":11.221848749616356,"otg_id":"GCST001666","pubmed_id":"22961080"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Ed Mountjoy","description":"The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.","source":"Type 2 Diabetes Knowledge Portal Effector Genes"}],"gene_id":"ENSG00000107249","highest_confidence":"High"},"metadata":{"comments":"Gold-standard derived from the list of effector genes at the T2D Knowledge Portal","date_added":"2019-07-17","reviewed_by":"Ed Mountjoy","set_label":"T2D Knowledge Portal ","submitted_by":"Ed Mountjoy","tags":["T2D"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":4293150},"locus_GRCh38":{"chromosome":"9","position":4293150}},"trait_info":{"ontology":["EFO_0001360"],"reported_trait_name":"Type 2 diabetes","standard_trait_name":"type II diabetes mellitus"}}
{"association_info":{"gwas_catalog_id":"GCST000760","otg_id":"GCST000760","pubmed_id":"20686565"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTLs in human liver, subcutaneous adipocytes, SORT1 expression arrays, EMSA","pubmed_id":"20686566"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs12740374 using the following methods: Luciferase, siRNA, gene knockdown and overexpression, measuring lipids and lipoproteins","pubmed_id":"20686566"}],"gene_id":"ENSG00000134243","highest_confidence":"High"},"metadata":{"comments":"Cohort: MDC-CC & PARC ","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":109818306},"locus_GRCh38":{"chromosome":"1","position":109275684}},"trait_info":{"ontology":["EFO_0000612"],"reported_trait_name":"Myocardial infarction","standard_trait_name":"myocardial infarction"}}
{"association_info":{"gwas_catalog_id":"GCST000489","otg_id":"GCST000489","pubmed_id":"19767754"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"Medium","curated_by":"Maya Ghoussaini","description":" 3C prostate cancer","pubmed_id":"21814516"}],"gene_id":"ENSG00000136997","highest_confidence":"Medium"},"metadata":{"comments":"Cohort: PRACTICAL ","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"8","position":128323181},"locus_GRCh38":{"chromosome":"8","position":127310936}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate carcinoma","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST000489","otg_id":"GCST000489","pubmed_id":"19767754"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"ChIP-seq, 3C prostate cancer, expression","pubmed_id":"21814516"}],"gene_id":"ENSG00000249859","highest_confidence":"High"},"metadata":{"comments":"Cohort: PRACTICAL","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"8","position":128323181},"locus_GRCh38":{"chromosome":"8","position":127310936}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate carcinoma","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004950","otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C in breast cancer","pubmed_id":"23540573"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs554219 using the following methods: Luciferase","pubmed_id":"23540573"}],"gene_id":"ENSG00000110092","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":69331642},"locus_GRCh38":{"chromosome":"11","position":69516874}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004950","otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C in breast cancer","pubmed_id":"23540573"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs78540526 using the following methods: Luciferase","pubmed_id":"23540573"}],"gene_id":"ENSG00000110092","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":69331418},"locus_GRCh38":{"chromosome":"11","position":69516650}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004950","otg_id":"GCST004950","pubmed_id":"25751625"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C in breast cancer","pubmed_id":"23540573"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs75915166 using the following methods: Luciferase","pubmed_id":"23540573"}],"gene_id":"ENSG00000110092","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":69379161},"locus_GRCh38":{"chromosome":"11","position":69564393}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST000150","otg_id":"GCST000150","pubmed_id":"18245381"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"3C, ChIP-seq, allele-specific expression, TALENs","pubmed_id":"24115442"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs1427407, rs7606173 using the following methods: reporter assays, transgenic mouse models","pubmed_id":"24115442"}],"gene_id":"ENSG00000119866","highest_confidence":"High"},"metadata":{"comments":"Cohort: SCD","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":60720246},"locus_GRCh38":{"chromosome":"2","position":60493111}},"trait_info":{"ontology":["EFO_0004576"],"reported_trait_name":"Fetal hemoglobin levels","standard_trait_name":"fetal hemoglobin measurement"}}
{"association_info":{"gwas_catalog_id":"GCST007039","otg_id":"GCST007039","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"4C-seq in mouse and zebrafish embryoe, 3C adult mouse brain, CHIA-PET ENCODE, human fibroblasts and MCF7, eQTL in brains, KO IRX3","pubmed_id":"24646999"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant Not specified: they refer to region of association using the following methods: reporter assays of fragments to assess enhancer activity","pubmed_id":"24646999"}],"gene_id":"ENSG00000177508","highest_confidence":"High"},"metadata":{"comments":"Cohort: GIANT","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":53800954},"locus_GRCh38":{"chromosome":"16","position":53767042}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity/T2D","standard_trait_name":"obesity"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C in breast cancer","pubmed_id":"25248036"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs4442975 using the following methods: Luciferase","pubmed_id":"25248036"}],"gene_id":"ENSG00000115461","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":217920769},"locus_GRCh38":{"chromosome":"2","position":217056046}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST007039","otg_id":"GCST007039","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs","pubmed_id":"26287746"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression","pubmed_id":"26287746"}],"gene_id":"ENSG00000176842","highest_confidence":"High"},"metadata":{"comments":"Cohort: Obesity ","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":53800954},"locus_GRCh38":{"chromosome":"16","position":53767042}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity","standard_trait_name":"obesity"}}
{"association_info":{"gwas_catalog_id":"GCST007039","otg_id":"GCST007039","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs","pubmed_id":"26287746"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression","pubmed_id":"26287746"}],"gene_id":"ENSG00000177508","highest_confidence":"High"},"metadata":{"comments":"Cohort: Obesity ","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":53800954},"locus_GRCh38":{"chromosome":"16","position":53767042}},"trait_info":{"ontology":["EFO_0001073"],"reported_trait_name":"Obesity","standard_trait_name":"obesity"}}
{"association_info":{"gwas_catalog_id":"GCST001445","otg_id":"GCST001445_2","pubmed_id":"22438815"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Allele-specific qRT-PCR, Overlap with epigenetic marks, EMSA, SB, eQTL, Chip-qRT-PCR","pubmed_id":"27096366"}],"gene_id":"ENSG00000145335","highest_confidence":"High"},"metadata":{"comments":"Cohort: PD","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":90637601},"locus_GRCh38":{"chromosome":"4","position":89716450}},"trait_info":{"ontology":["EFO_0002508"],"reported_trait_name":"Parkinson's disease","standard_trait_name":"Parkinson's disease"}}
{"association_info":{"gwas_catalog_id":"GCST000750","otg_id":"GCST000750","pubmed_id":"20676098"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"allele-specific Chip-qPCR, RNA immunoprecip, Chromatin conformation capture, eQTL","pubmed_id":"27526323"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs7463708 using the following methods: SiRNA, site-directed mutgenesis + reporter assays, mouse xenograft","pubmed_id":"27526323"}],"gene_id":"ENSG00000253438","highest_confidence":"High"},"metadata":{"comments":"Cohort: PC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"8","position":128103937},"locus_GRCh38":{"chromosome":"8","position":127091692}},"trait_info":{"ontology":["EFO_0001663"],"reported_trait_name":"Prostate carcinoma","standard_trait_name":"prostate carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST003845","otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C , overlap with reg elements","pubmed_id":"27601076"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs56069439 using the following methods: Luciferase","pubmed_id":"27601076"}],"gene_id":"ENSG00000127220","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC & OCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":17393925},"locus_GRCh38":{"chromosome":"19","position":17283116}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer ","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST003845","otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C , overlap with reg elements","pubmed_id":"27601076"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs56069439 using the following methods: Luciferase","pubmed_id":"27601076"}],"gene_id":"ENSG00000160117","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC & OCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":17393925},"locus_GRCh38":{"chromosome":"19","position":17283116}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast Cancer ","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004462","otg_id":"GCST004462","pubmed_id":"28346442"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C , overlap with reg elements","pubmed_id":"27601076"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs56069439 using the following methods: Luciferase","pubmed_id":"27601076"}],"gene_id":"ENSG00000127220","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC & OCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":17390291},"locus_GRCh38":{"chromosome":"19","position":17279482}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Ovarian cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004462","otg_id":"GCST004462","pubmed_id":"28346442"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, 3C , overlap with reg elements","pubmed_id":"27601076"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs56069439 using the following methods: Luciferase","pubmed_id":"27601076"}],"gene_id":"ENSG00000160117","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC & OCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":17390291},"locus_GRCh38":{"chromosome":"19","position":17279482}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Ovarian cancer","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks","pubmed_id":"27640304"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect)","pubmed_id":"27640304"}],"gene_id":"ENSG00000070193","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":44706498},"locus_GRCh38":{"chromosome":"5","position":44706396}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks","pubmed_id":"27640304"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect)","pubmed_id":"27640304"}],"gene_id":"ENSG00000112996","highest_confidence":"High"},"metadata":{"comments":"Cohort: BCAC","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":44706498},"locus_GRCh38":{"chromosome":"5","position":44706396}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST000760","otg_id":"GCST000760","pubmed_id":"20686565"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL","pubmed_id":"28388432"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs2277862 using the following methods: CRISPR","pubmed_id":"28388432"}],"gene_id":"ENSG00000214078","highest_confidence":"High"},"metadata":{"comments":"Cohort: PhLiPS Study","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"20","position":34152782},"locus_GRCh38":{"chromosome":"20","position":35564866}},"trait_info":{"ontology":["EFO_0004529"],"reported_trait_name":"Blood lipid (HDL, LDL, TG, PP, …)","standard_trait_name":"lipid measurement"}}
{"association_info":{"gwas_catalog_id":"GCST002221","otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL","pubmed_id":"28388432"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs10889356 using the following methods: CRISPR","pubmed_id":"28388432"}],"gene_id":"ENSG00000116641","highest_confidence":"High"},"metadata":{"comments":"Cohort: PhLiPS Study","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":63145439},"locus_GRCh38":{"chromosome":"1","position":62679768}},"trait_info":{"ontology":["EFO_0004529"],"reported_trait_name":"Blood lipid (HDL, LDL, TG, PP, …)","standard_trait_name":"lipid measurement"}}
{"association_info":{"gwas_catalog_id":"GCST002221","otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL","pubmed_id":"28388432"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs10889356 using the following methods: CRISPR","pubmed_id":"28388432"}],"gene_id":"ENSG00000132855","highest_confidence":"High"},"metadata":{"comments":"Cohort: PhLiPS Study","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":63145439},"locus_GRCh38":{"chromosome":"1","position":62679768}},"trait_info":{"ontology":["EFO_0004529"],"reported_trait_name":"Blood lipid (HDL, LDL, TG, PP, …)","standard_trait_name":"lipid measurement"}}
{"association_info":{"gwas_catalog_id":"GCST002221","otg_id":"GCST002221","pubmed_id":"24097068"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"eQTL","pubmed_id":"28388432"},{"class":"functional experimental","confidence":"High","curated_by":"Maya Ghoussaini","description":"Original publication looked at variant rs10872142 using the following methods: CRISPR","pubmed_id":"28388432"}],"gene_id":"ENSG00000111816","highest_confidence":"High"},"metadata":{"comments":"Cohort: PhLiPS Study","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":116337503},"locus_GRCh38":{"chromosome":"6","position":116016340}},"trait_info":{"ontology":["EFO_0004529"],"reported_trait_name":"Blood lipid (HDL, LDL, TG, PP, …)","standard_trait_name":"lipid measurement"}}
{"association_info":{"gwas_catalog_id":"GCST004441","otg_id":"GCST004441","pubmed_id":"27989323"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"NLRC4-inflammasome hyperactivity causes infantile-onset Macrophage Activation Syndrome and enterocolitis with extraordinary serum IL-18 elevation (NLRC4-MAS). Herein, we report a critically ill infant with severe, refractory NLRC4-MAS who showed sustained response to treatment with experimental IL-18 inhibition.","pubmed_id":"27876626"}],"gene_id":"ENSG00000091106","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":32489851},"locus_GRCh38":{"chromosome":"2","position":32264782}},"trait_info":{"ontology":["EFO_0004581"],"reported_trait_name":"Interleukin-18 levels","standard_trait_name":"interleukin 18 measurement"}}
{"association_info":{"gwas_catalog_id":"GCST003845","otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000171094","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":29119585},"locus_GRCh38":{"chromosome":"2","position":28896719}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000171681","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":14413931},"locus_GRCh38":{"chromosome":"12","position":14260997}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST005077","otg_id":"GCST005077","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000149311","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"GA","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":108345515},"locus_GRCh38":{"chromosome":"11","position":108474788}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000139618","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":32972626},"locus_GRCh38":{"chromosome":"13","position":32398489}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000064012","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":202123430},"locus_GRCh38":{"chromosome":"2","position":201258707}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000110092","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":69331418},"locus_GRCh38":{"chromosome":"11","position":69516650}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST005077","otg_id":"GCST005077","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000105173","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":30277729},"locus_GRCh38":{"chromosome":"19","position":29786822}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000183765","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":29272637},"locus_GRCh38":{"chromosome":"22","position":28876649}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST005077","otg_id":"GCST005077","pubmed_id":"29058716"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000005339","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":4106788},"locus_GRCh38":{"chromosome":"16","position":4056787}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000257923","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":101552440},"locus_GRCh38":{"chromosome":"7","position":101909160}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000119772","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"2","position":25129473},"locus_GRCh38":{"chromosome":"2","position":24906604}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000091831","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":151955914},"locus_GRCh38":{"chromosome":"6","position":151634779}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000066468","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GC"},"locus_GRCh37":{"chromosome":"10","position":123340431},"locus_GRCh38":{"chromosome":"10","position":121580917}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000107485","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"TG"},"locus_GRCh37":{"chromosome":"10","position":9088113},"locus_GRCh38":{"chromosome":"10","position":9046150}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST003845","otg_id":"GCST003845","pubmed_id":"27117709"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000102554","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":73957681},"locus_GRCh38":{"chromosome":"13","position":73383544}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000095015","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":56027240},"locus_GRCh38":{"chromosome":"5","position":56731413}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000136997","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":128372172},"locus_GRCh38":{"chromosome":"8","position":127359926}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000196712","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":29180996},"locus_GRCh38":{"chromosome":"17","position":30853978}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000152217","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":42411803},"locus_GRCh38":{"chromosome":"18","position":44831838}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000135111","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"12","position":115106688},"locus_GRCh38":{"chromosome":"12","position":114668883}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000168769","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"4","position":106073509},"locus_GRCh38":{"chromosome":"4","position":105152352}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000163513","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":30684907},"locus_GRCh38":{"chromosome":"3","position":30643415}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000185650","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":68979835},"locus_GRCh38":{"chromosome":"14","position":68513118}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"gwas_catalog_id":"GCST004988","otg_id":"GCST004988","pubmed_id":"29059683"},"gold_standard_info":{"evidence":[{"class":"functional observational","confidence":"High","curated_by":"Maya Ghoussaini","description":"Breast cancer driver genes","pubmed_id":"00000000"}],"gene_id":"ENSG00000183779","highest_confidence":"High"},"metadata":{"comments":"Cohort: Breast cancer driver genes","date_added":"2019-11-08","reviewed_by":"Maya Ghoussaini","set_label":"otg_curated_191108","submitted_by":"Maya Ghoussaini"},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"8","position":36849946},"locus_GRCh38":{"chromosome":"8","position":36992428}},"trait_info":{"ontology":["EFO_0000305"],"reported_trait_name":"Breast carcinoma","standard_trait_name":"breast carcinoma"}}
{"association_info":{"ancestry":["East Asian=1999"],"gwas_catalog_id":"GCST006137","neg_log_pval":18.397940008672037,"otg_id":"GCST006137","pubmed_id":"29953918"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"enzyme involved in folate metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000177000","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":11856378},"locus_GRCh38":{"chromosome":"1","position":11796321}},"trait_info":{"ontology":["EFO_0005111"],"reported_trait_name":"metabolite: folate","standard_trait_name":"folic acid measurement"}}
{"association_info":{"ancestry":["European=404196"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.97061622231479,"otg_id":"SAIGE_594_1"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"phosphatase","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000162551","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":21904374},"locus_GRCh38":{"chromosome":"1","position":21577881}},"trait_info":{"ontology":["EFO_0004253"],"reported_trait_name":"calculus of kidney and ureter","standard_trait_name":"nephrolithiasis"}}
{"association_info":{"ancestry":["European=215551","African American or Afro-Caribbean=57332","Hispanic or Latin American=24743"],"gwas_catalog_id":"GCST006612","neg_log_pval":256.52287874528037,"otg_id":"GCST006612","pubmed_id":"30275531"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PCSK9 regulates LDL via LDLR","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000169174","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":55505647},"locus_GRCh38":{"chromosome":"1","position":55039974}},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"treatment: statin use","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["European=359241"],"neg_log_pval":7.33164017904141,"otg_id":"NEALE2_6151_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"important function in bone marrow cells in the regenerative response of bone and cartilage after injulry","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000116678","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":66110284},"locus_GRCh38":{"chromosome":"1","position":65644601}},"trait_info":{"ontology":["EFO_0009515"],"reported_trait_name":"wrist fracture","standard_trait_name":"wrist fracture"}}
{"association_info":{"ancestry":["European=393873"],"gwas_catalog_id":"GCST007091","neg_log_pval":14.397940008672037,"otg_id":"GCST007091","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"collagen gene, involved in ossification","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000060718","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":103572927},"locus_GRCh38":{"chromosome":"1","position":103107371}},"trait_info":{"ontology":["EFO_1000786"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"osteoarthritis, hip"}}
{"association_info":{"ancestry":["European=25708"],"gwas_catalog_id":"GCST000679","neg_log_pval":70.20616772397125,"otg_id":"GCST000679","pubmed_id":"20453842"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PTPN22 encodes a protein tyrosine phosphatase involved in immune response","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000134242","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":114377568},"locus_GRCh38":{"chromosome":"1","position":113834946}},"trait_info":{"ontology":["EFO_0000685"],"reported_trait_name":"rheumatoid arthritis","standard_trait_name":"rheumatoid arthritis"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":13.096910013008056,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PHDGH encodes an enzyme involved in de novo serine biosynthesis","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000092621","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"1","position":120254506},"locus_GRCh38":{"chromosome":"1","position":119711883}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["European=344728"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_30260_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SPTA1 encodes spectrin, a cytoskeleton protein that helps define the cell shape","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000163554","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"1","position":158596438},"locus_GRCh38":{"chromosome":"1","position":158626648}},"trait_info":{"ontology":[],"reported_trait_name":"reticulocyte volume"}}
{"association_info":{"ancestry":["European=204402"],"gwas_catalog_id":"GCST007614","neg_log_pval":522.3979400086721,"otg_id":"GCST007614","pubmed_id":"30388399"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"gene for the measured protein","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000132693","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":159678816},"locus_GRCh38":{"chromosome":"1","position":159709026}},"trait_info":{"ontology":["EFO_0004458"],"reported_trait_name":"CRP levels","standard_trait_name":"C-reactive protein measurement"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":182.1308557348547,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"Factor V Leiden mutation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000198734","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"1","position":169519049},"locus_GRCh38":{"chromosome":"1","position":169549811}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg, DVT","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=393873"],"gwas_catalog_id":"GCST007091","neg_log_pval":9.221848749616356,"otg_id":"GCST007091","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"collagen galactosyltransferase","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000198756","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"1","position":183906245},"locus_GRCh38":{"chromosome":"1","position":183937111}},"trait_info":{"ontology":["EFO_1000786"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"osteoarthritis, hip"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":8.362829604311715,"otg_id":"NEALE2_22504","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MUC5AC encodes one of the principal mucins in lung.  This is the protein portion of mucus.","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000215182","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":1113133},"locus_GRCh38":{"chromosome":"11","position":1119225}},"trait_info":{"ontology":["EFO_0009824"],"reported_trait_name":"bring up phlegm/sputum/mucus on most days","standard_trait_name":"bringing up phlegm, sputum or mucus on most days, self-reported"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":19.56919957537582,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"encodes thrombin, the final step in the clotting cascade, converting fibrinogen to fibrin","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000180210","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":46761055},"locus_GRCh38":{"chromosome":"11","position":46739505}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg, DVT","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":7.81005233185522,"otg_id":"NEALE2_20002_1331","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TCN1 encodes an intrinsic factor which transports vitamin B12","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000134827","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":59623378},"locus_GRCh38":{"chromosome":"11","position":59855905}},"trait_info":{"ontology":["EFO_0005576"],"reported_trait_name":"pernicious anemia","standard_trait_name":"pernicious anemia"}}
{"association_info":{"ancestry":["European=346527"],"neg_log_pval":7.720768937672716,"otg_id":"NEALE2_2000","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GRM5 encodes a glutamate metabotropic receptor","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000168959","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"11","position":88732956},"locus_GRCh38":{"chromosome":"11","position":88999788}},"trait_info":{"ontology":["EFO_0009589"],"reported_trait_name":"worry too long","standard_trait_name":"worry measurement"}}
{"association_info":{"ancestry":["European=356530"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_1717","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"pigmentation gene","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000077498","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":89017961},"locus_GRCh38":{"chromosome":"11","position":89284793}},"trait_info":{"ontology":["EFO_0003784"],"reported_trait_name":"malignant neoplasms of skin","standard_trait_name":"skin pigmentation"}}
{"association_info":{"ancestry":["European=356530"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_1717","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"enzyme in melanin synthesis pathway","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000077498","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"11","position":89017961},"locus_GRCh38":{"chromosome":"11","position":89284793}},"trait_info":{"ontology":["EFO_0003784"],"reported_trait_name":"skin color","standard_trait_name":"skin pigmentation"}}
{"association_info":{"ancestry":["European=401024"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":15.23807216157947,"otg_id":"SAIGE_361"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AT3 is an atypical cadherin in brain, important for neurite outgrowth and establishment of polarity in the retina.","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000165323","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":92607866},"locus_GRCh38":{"chromosome":"11","position":92874700}},"trait_info":{"ontology":["EFO_0005773"],"reported_trait_name":"retinal detachment","standard_trait_name":"retinal detachment"}}
{"association_info":{"ancestry":["European=105318"],"gwas_catalog_id":"GCST006803","neg_log_pval":11.698970004336019,"otg_id":"GCST006803","pubmed_id":"29483656"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"DRD2 encodes a dopamine receptor which is the site of action for many antipsychotics","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000149295","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"11","position":113392994},"locus_GRCh38":{"chromosome":"11","position":113522272}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=393873"],"gwas_catalog_id":"GCST007091","neg_log_pval":24.0,"otg_id":"GCST007091","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"hormone regulating bone development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000087494","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"12","position":28014970},"locus_GRCh38":{"chromosome":"12","position":27862037}},"trait_info":{"ontology":["EFO_1000786"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"osteoarthritis, hip"}}
{"association_info":{"ancestry":["European=407648"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.954677021213342,"otg_id":"SAIGE_594"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TNFS11 may influence circulating calcium levels via bone resorption","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000120659","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"13","position":42701739},"locus_GRCh38":{"chromosome":"13","position":42127603}},"trait_info":{"ontology":["EFO_1000839"],"reported_trait_name":"urolithiasis","standard_trait_name":"bladder calculus"}}
{"association_info":{"ancestry":["European=329134"],"neg_log_pval":12.835647144215564,"otg_id":"NEALE2_1319","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"OR10G3 probably encodes an olfactory receptor.  Could it relate to enjoyment from smelling and eating fruit?","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000169208","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"14","position":22038125},"locus_GRCh38":{"chromosome":"14","position":21569994}},"trait_info":{"ontology":["EFO_0008111"],"reported_trait_name":"dried fruit intake","standard_trait_name":"diet measurement"}}
{"association_info":{"ancestry":["European=205327"],"gwas_catalog_id":"GCST007020","neg_log_pval":13.397940008672037,"otg_id":"GCST007020","pubmed_id":"30573740"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GSC, Goosecoid Homeobox, an important regulator of pattern formation and Wnt signaling","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000133937","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"14","position":95237215},"locus_GRCh38":{"chromosome":"14","position":94770878}},"trait_info":{"ontology":["EFO_0007825"],"reported_trait_name":"male balding pattern","standard_trait_name":"balding measurement"}}
{"association_info":{"ancestry":["European=408823"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.1331221856625,"otg_id":"SAIGE_172"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"pigmentation gene","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":28230247},"locus_GRCh38":{"chromosome":"15","position":27985101}},"trait_info":{"ontology":["EFO_0009259"],"reported_trait_name":"malignant neoplasms of skin","standard_trait_name":"skin carcinoma"}}
{"association_info":{"ancestry":["European=356530"],"neg_log_pval":314.5809997598978,"otg_id":"NEALE2_1717","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"tyrosine transporter","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000104044","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":28534777},"locus_GRCh38":{"chromosome":"15","position":28289631}},"trait_info":{"ontology":["EFO_0003784"],"reported_trait_name":"skin color","standard_trait_name":"skin pigmentation"}}
{"association_info":{"ancestry":["European=392109"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":16.609064892896622,"otg_id":"SAIGE_241_2"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"growth factor involved in thyroid gland development and thyroid hormone production","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140285","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"15","position":49706417},"locus_GRCh38":{"chromosome":"15","position":49414220}},"trait_info":{"ontology":["MONDO_0000334"],"reported_trait_name":"non-toxic goitre","standard_trait_name":"multinodular goiter"}}
{"association_info":{"ancestry":["European=406659"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":9.385102783966865,"otg_id":"SAIGE_351"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SMAD6 encodes a transcription factor important for cartilage and bone development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000137834","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":67034812},"locus_GRCh38":{"chromosome":"15","position":66742474}},"trait_info":{"ontology":["EFO_0009387"],"reported_trait_name":"nerve, nerve root and plexus disorders","standard_trait_name":"peripheral nervous system disease"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":115.46487811249987,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"caffeine metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140465","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":75027880},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":115.46487811249987,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"caffeine metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140465","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":75027880},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":115.46487811249987,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"caffeine metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140505","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"15","position":75027880},"locus_GRCh38":{"chromosome":"15","position":74735539}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=406659"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.510041520575165,"otg_id":"SAIGE_351"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ADAMTS17 encodes a extracellular matrix metaloprotease.  By analogy with ADAMTS10, ADAMTS17 may also play a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140470","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"15","position":100692953},"locus_GRCh38":{"chromosome":"15","position":100152748}},"trait_info":{"ontology":["EFO_0009387"],"reported_trait_name":"Nerve, nerve root and plexus disorders","standard_trait_name":"peripheral nervous system disease"}}
{"association_info":{"ancestry":["European=191843"],"gwas_catalog_id":"GCST003997","neg_log_pval":62.69897000433602,"otg_id":"GCST003997","pubmed_id":"27182965"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"RBFOX1 encodes a transcription factor involved in eye development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000078328","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":7459347},"locus_GRCh38":{"chromosome":"16","position":7409346}},"trait_info":{"ontology":["HP_0000545"],"reported_trait_name":"6 mm strong meridian angle","standard_trait_name":"Myopia"}}
{"association_info":{"ancestry":["European=404196"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":18.7594507517174,"otg_id":"SAIGE_594_1"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"uromodulin is a highly expressed kidney specific protein.","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000169344","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":20366507},"locus_GRCh38":{"chromosome":"16","position":20355185}},"trait_info":{"ontology":["EFO_0004253"],"reported_trait_name":"calculus of kidney and ureter","standard_trait_name":"nephrolithiasis"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":41.0,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GCSH encodes a component of the glycine cleavage system","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000140905","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"16","position":81110903},"locus_GRCh38":{"chromosome":"16","position":81077298}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":36.053639123304855,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"In addition to GATA1 and GATA2, there are hits for the so-called \"Friends of GATA\" or FOG.  These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000179588","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"16","position":88559699},"locus_GRCh38":{"chromosome":"16","position":88493291}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=299651"],"gwas_catalog_id":"GCST006986","neg_log_pval":307.69897000433605,"otg_id":"GCST006986","pubmed_id":"30531825"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"melanin production switch","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000258839","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"16","position":89985918},"locus_GRCh38":{"chromosome":"16","position":89919510}},"trait_info":{"ontology":["EFO_0003924"],"reported_trait_name":"red hair","standard_trait_name":"hair color"}}
{"association_info":{"ancestry":["European=353697"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_1727","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"melanin production switch","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000258839","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89986546},"locus_GRCh38":{"chromosome":"16","position":89920138}},"trait_info":{"ontology":[],"reported_trait_name":"Skin changes due to chronic exposure to nonionizing radiation"}}
{"association_info":{"ancestry":["European=353697"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_1727","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"melanin production switch","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000258839","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"16","position":89986546},"locus_GRCh38":{"chromosome":"16","position":89920138}},"trait_info":{"ontology":[],"reported_trait_name":"skin color"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":52.04034387198277,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PAF is a lipid signaling molecule mediating platelet aggregation. PAF-AH deactivates PAF. PAFAH1B1 encodes the regulatory subunit of PAF-AH","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000007168","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":1958536},"locus_GRCh38":{"chromosome":"17","position":2055242}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=408823"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":21.008330992620053,"otg_id":"SAIGE_172"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"tumor suppressor","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000141510","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"17","position":7571752},"locus_GRCh38":{"chromosome":"17","position":7668434}},"trait_info":{"ontology":["EFO_0009259"],"reported_trait_name":"malignant neoplasms of skin","standard_trait_name":"skin carcinoma"}}
{"association_info":{"ancestry":["European=426795"],"gwas_catalog_id":"GCST006980","neg_log_pval":40.30102999566398,"otg_id":"GCST006980","pubmed_id":"30598549"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"negative regulator of bone growth via wnt signaling pathway","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000167941","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"17","position":41798855},"locus_GRCh38":{"chromosome":"17","position":43721487}},"trait_info":{"ontology":["EFO_0003931"],"reported_trait_name":"wrist fracture","standard_trait_name":"bone fracture"}}
{"association_info":{"ancestry":["European=446000"],"gwas_catalog_id":"GCST007066","neg_log_pval":94.0,"otg_id":"GCST007066","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"transcription factor involved in limb development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000121075","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"17","position":59023998},"locus_GRCh38":{"chromosome":"17","position":60946637}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=446000"],"gwas_catalog_id":"GCST007066","neg_log_pval":150.0,"otg_id":"GCST007066","pubmed_id":"30595370"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"regulator of bone structure and function","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000177150","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"18","position":13719510},"locus_GRCh38":{"chromosome":"18","position":13719511}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"wrist fracture","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=354736"],"neg_log_pval":81.07626495694595,"otg_id":"NEALE2_23120_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MC4R is a well-known BMI gene.  It influences feeding behavior.","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000166603","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GTCT"},"locus_GRCh37":{"chromosome":"18","position":57850927},"locus_GRCh38":{"chromosome":"18","position":60183694}},"trait_info":{"ontology":["EFO_0004995"],"reported_trait_name":"arm fat mass (right)","standard_trait_name":"lean body mass"}}
{"association_info":{"ancestry":["European=394929"],"gwas_catalog_id":"GCST006433","neg_log_pval":29.096910013008056,"otg_id":"GCST006433","pubmed_id":"30048462"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TNFRSF11A encodes RANK, a key receptor regulating bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000141655","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"18","position":60054857},"locus_GRCh38":{"chromosome":"18","position":62387624}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"treatment with alendronate","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=406659"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.721246399047171,"otg_id":"SAIGE_351"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ADAMTS10 encodes a extracellular matrix metaloprotease which plays a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000142303","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":8670147},"locus_GRCh38":{"chromosome":"19","position":8605262}},"trait_info":{"ontology":["EFO_0009387"],"reported_trait_name":"Nerve, nerve root and plexus disorders","standard_trait_name":"peripheral nervous system disease"}}
{"association_info":{"ancestry":["European=215551","African American or Afro-Caribbean=57332","Hispanic or Latin American=24743"],"gwas_catalog_id":"GCST006612","neg_log_pval":300.0,"otg_id":"GCST006612","pubmed_id":"30275531"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LDLR is involved in lipoprotein regulation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000130164","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"19","position":11187324},"locus_GRCh38":{"chromosome":"19","position":11076648}},"trait_info":{"ontology":["EFO_0004611"],"reported_trait_name":"treatment: statin use","standard_trait_name":"low density lipoprotein cholesterol measurement"}}
{"association_info":{"ancestry":["European=360291"],"neg_log_pval":11.684659523372712,"otg_id":"NEALE2_1428_3","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"APOE drives LDL-cholesterol levels, perhaps leading to a dietary choice to switch from butter to margarine","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000130203","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"19","position":45411941},"locus_GRCh38":{"chromosome":"19","position":44908684}},"trait_info":{"ontology":["EFO_0008111"],"reported_trait_name":"margarine intake","standard_trait_name":"diet measurement"}}
{"association_info":{"ancestry":["European=361141"],"neg_log_pval":78.44592291862462,"otg_id":"NEALE2_20003_1140861958","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"APOE involved in lipoprotein regulation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000130203","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"19","position":45413233},"locus_GRCh38":{"chromosome":"19","position":44909976}},"trait_info":{"ontology":["CHEBI_9150"],"reported_trait_name":"treatment: statin use","standard_trait_name":"simvastatin"}}
{"association_info":{"ancestry":["European=91787"],"neg_log_pval":9.45496765241607,"otg_id":"NEALE2_22504","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FUT2 encodes a fucosyltransferase, responsible for the glycosylation portion of mucus","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000176920","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":49206417},"locus_GRCh38":{"chromosome":"19","position":48703160}},"trait_info":{"ontology":["EFO_0009824"],"reported_trait_name":"bring up phlegm/sputum/mucus on most days","standard_trait_name":"bringing up phlegm, sputum or mucus on most days, self-reported"}}
{"association_info":{"ancestry":["European=350061"],"neg_log_pval":20.08594099932527,"otg_id":"NEALE2_30530_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000105550","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":49259529},"locus_GRCh38":{"chromosome":"19","position":48756272}},"trait_info":{"ontology":["HP_0012603"],"reported_trait_name":"sodium in urine","standard_trait_name":"Abnormal urine sodium concentration"}}
{"association_info":{"ancestry":["European=360468"],"neg_log_pval":14.522878745280337,"otg_id":"NEALE2_1349","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000105550","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"19","position":49259529},"locus_GRCh38":{"chromosome":"19","position":48756272}},"trait_info":{"ontology":["EFO_0008111"],"reported_trait_name":"processed meat intake","standard_trait_name":"diet measurement"}}
{"association_info":{"ancestry":["European=406659"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":7.886056647693163,"otg_id":"SAIGE_351"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"EFEMP1 encodes fibulin-3, an extracellular matrix protein with a role in elastic fiber production which could directly contribute to the properties of the carpal ligament or other structures in the carpal tunnel","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000115380","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"2","position":56009382},"locus_GRCh38":{"chromosome":"2","position":55782247}},"trait_info":{"ontology":["EFO_0009387"],"reported_trait_name":"Nerve, nerve root and plexus disorders","standard_trait_name":"peripheral nervous system disease"}}
{"association_info":{"ancestry":["European=360806"],"neg_log_pval":9.227682694932648,"otg_id":"NEALE2_1418_6","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"LCT encodes lactase, necessary for break down of lactose","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000115850","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":136707982},"locus_GRCh38":{"chromosome":"2","position":135950412}},"trait_info":{"ontology":["EFO_0008111"],"reported_trait_name":"milk intake","standard_trait_name":"diet measurement"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":1631.5228787452804,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"CPS1 encodes an enzyme acting on the breakdown products of glycine catabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000021826","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"2","position":211543055},"locus_GRCh38":{"chromosome":"2","position":210678331}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["East Asian=110207"],"gwas_catalog_id":"GCST005980","neg_log_pval":1254.5228787452804,"otg_id":"GCST005980","pubmed_id":"29403010"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"the UGT1A1 encodes an enzyme which has UDP-glucuronosyltransferase activity against bilirubin","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000241635","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"2","position":234671462},"locus_GRCh38":{"chromosome":"2","position":233762816}},"trait_info":{"ontology":["EFO_0004570"],"reported_trait_name":"total bilirubin","standard_trait_name":"bilirubin measurement"}}
{"association_info":{"ancestry":["European=354798"],"neg_log_pval":10.226191621507935,"otg_id":"NEALE2_23114_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"bone morphogenic protein, growth factor influencing bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000125845","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":6709838},"locus_GRCh38":{"chromosome":"20","position":6729191}},"trait_info":{"ontology":["EFO_0004995"],"reported_trait_name":"leg predicted mass (right)","standard_trait_name":"lean body mass"}}
{"association_info":{"ancestry":["European=392109"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":10.661543506395395,"otg_id":"SAIGE_241_2"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"transcription factor important for thyroid endoderm development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000125798","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":22625447},"locus_GRCh38":{"chromosome":"20","position":22644809}},"trait_info":{"ontology":["MONDO_0000334"],"reported_trait_name":"non-toxic goitre","standard_trait_name":"multinodular goiter"}}
{"association_info":{"ancestry":["European=121296"],"gwas_catalog_id":"GCST005897","neg_log_pval":315.0,"otg_id":"GCST005897","pubmed_id":"29739929"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MC1R antagonist","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000101440","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":32665748},"locus_GRCh38":{"chromosome":"20","position":34077942}},"trait_info":{"ontology":["EFO_0004279"],"reported_trait_name":"Skin changes due to chronic exposure to nonionizing radiation","standard_trait_name":"suntan"}}
{"association_info":{"ancestry":["European=121296"],"gwas_catalog_id":"GCST005897","neg_log_pval":315.0,"otg_id":"GCST005897","pubmed_id":"29739929"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"MC1R antagonist","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000101440","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":32665748},"locus_GRCh38":{"chromosome":"20","position":34077942}},"trait_info":{"ontology":["EFO_0004279"],"reported_trait_name":"skin color","standard_trait_name":"suntan"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":9.184008739942152,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"protein C receptor, involved in clotting response","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000101000","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"GAA"},"locus_GRCh37":{"chromosome":"20","position":33724557},"locus_GRCh38":{"chromosome":"20","position":35136754}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg, DVT","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=354798"],"neg_log_pval":111.76709786992673,"otg_id":"NEALE2_23114_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GDF5 encodes a growth factor involved in limb and joint development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000125965","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"20","position":34025756},"locus_GRCh38":{"chromosome":"20","position":35437976}},"trait_info":{"ontology":["EFO_0004995"],"reported_trait_name":"leg predicted mass (right)","standard_trait_name":"lean body mass"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":153.24222071603972,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TUBB1 which contributes to the structure of the microtubules which are important for forming platelets from the megakaryocytes. Rare TUBB1 mutations cause congenital macrothrombocytopenia","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000101162","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"20","position":57597971},"locus_GRCh38":{"chromosome":"20","position":59022916}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":22.632124355053705,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https://","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000159216","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"21","position":36393747},"locus_GRCh38":{"chromosome":"21","position":35021450}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=404196"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.095825631715837,"otg_id":"SAIGE_594_1"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"a kidney-specific protein inivolved in calcium reabsorption","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000159261","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"21","position":37818871},"locus_GRCh38":{"chromosome":"21","position":36446573}},"trait_info":{"ontology":["EFO_0004253"],"reported_trait_name":"calculus of kidney and ureter","standard_trait_name":"nephrolithiasis"}}
{"association_info":{"ancestry":["European=7824"],"gwas_catalog_id":"GCST002443","neg_log_pval":177.30102999566398,"otg_id":"GCST002443_58","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"metabolite is a product of the encoded enzyme","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000093010","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"22","position":19951271},"locus_GRCh38":{"chromosome":"22","position":19963748}},"trait_info":{"ontology":["EFO_0005664"],"reported_trait_name":"metabolite: methylascorbic acid","standard_trait_name":"blood metabolite measurement"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":10.55425572432335,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"response to caffeine","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000128271","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"22","position":24771955},"locus_GRCh38":{"chromosome":"22","position":24375987}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=402950"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":23.554395796726403,"otg_id":"SAIGE_571"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PNPLA3 encodes a triacylglycerol lipase with high expression in the liver","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000100344","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"22","position":44324730},"locus_GRCh38":{"chromosome":"22","position":43928850}},"trait_info":{"ontology":["EFO_0001421","EFO_0001422"],"reported_trait_name":"disease of liver","standard_trait_name":"liver disease"}}
{"association_info":{"ancestry":["European=7824"],"gwas_catalog_id":"GCST002443","neg_log_pval":17.154901959985743,"otg_id":"GCST002443_44","pubmed_id":"24816252"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ARSA encodes the enzyme arylsulfatase A","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000100299","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"22","position":51063477},"locus_GRCh38":{"chromosome":"22","position":50625049}},"trait_info":{"ontology":["EFO_0005664"],"reported_trait_name":"metabolite: O-sulfo-tyrosine","standard_trait_name":"blood metabolite measurement"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":30.0,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"ALDH1L1 encodes an enzyme involved in the folate cycle","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000144908","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":125910381},"locus_GRCh38":{"chromosome":"3","position":126191538}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":10.522430206021097,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https://","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000179348","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":128201889},"locus_GRCh38":{"chromosome":"3","position":128483046}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":139.91119437332395,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"THPO encodes thrombopoietin, a growth factor driving platelet production","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000090534","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"3","position":184090242},"locus_GRCh38":{"chromosome":"3","position":184372454}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=79366"],"gwas_catalog_id":"GCST005367","neg_log_pval":307.6526555685888,"otg_id":"GCST005367","pubmed_id":"29343764"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GC encodes the vitamin D binding protein","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000145321","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"G"},"locus_GRCh37":{"chromosome":"4","position":72614267},"locus_GRCh38":{"chromosome":"4","position":71748550}},"trait_info":{"ontology":["EFO_0004631"],"reported_trait_name":"metabolite: vitamin D","standard_trait_name":"vitamin D measurement"}}
{"association_info":{"ancestry":["European=941280"],"gwas_catalog_id":"GCST007461","neg_log_pval":307.69897000433605,"otg_id":"GCST007461","pubmed_id":"30643251"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"alcohol metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000196616","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":100239319},"locus_GRCh38":{"chromosome":"4","position":99318162}},"trait_info":{"ontology":["EFO_0007878"],"reported_trait_name":"average weekly red wine intake","standard_trait_name":"alcohol consumption measurement"}}
{"association_info":{"ancestry":["European=941280"],"gwas_catalog_id":"GCST007461","neg_log_pval":307.69897000433605,"otg_id":"GCST007461","pubmed_id":"30643251"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"encodes alcohol dehydrogenase, regulating clearance rate for alcohol","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000196616","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":100239319},"locus_GRCh38":{"chromosome":"4","position":99318162}},"trait_info":{"ontology":["EFO_0007878"],"reported_trait_name":"alcohol consumption","standard_trait_name":"alcohol consumption measurement"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":23.63941415920316,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"Factor XI, a protease in the clotting cascade","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000088926","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"T"},"locus_GRCh37":{"chromosome":"4","position":187188094},"locus_GRCh38":{"chromosome":"4","position":186266940}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg, DVT","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=356530"],"neg_log_pval":307.6526555685888,"otg_id":"NEALE2_1717","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"melanocyte-specific transporter","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000164175","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"5","position":33951693},"locus_GRCh38":{"chromosome":"5","position":33951588}},"trait_info":{"ontology":["EFO_0003784"],"reported_trait_name":"skin color","standard_trait_name":"skin pigmentation"}}
{"association_info":{"ancestry":["European=215551","African American or Afro-Caribbean=57332","Hispanic or Latin American=24743"],"gwas_catalog_id":"GCST006614","neg_log_pval":93.15490195998575,"otg_id":"GCST006614","pubmed_id":"30275531"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HMGCR encodes an enzyme in the cholesterol biosynthetic pathway","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000113161","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":74656539},"locus_GRCh38":{"chromosome":"5","position":75360714}},"trait_info":{"ontology":["EFO_0004574"],"reported_trait_name":"treatment: statin use","standard_trait_name":"total cholesterol measurement"}}
{"association_info":{"ancestry":["Other=1097","NR=150064"],"gwas_catalog_id":"GCST003048","neg_log_pval":9.0,"otg_id":"GCST003048","pubmed_id":"26198764"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"Glutamate receptor involved in synaptic transmissions","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000155511","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":152608619},"locus_GRCh38":{"chromosome":"5","position":153229059}},"trait_info":{"ontology":["EFO_0000692"],"reported_trait_name":"schizophrenia","standard_trait_name":"schizophrenia"}}
{"association_info":{"ancestry":["European=205327"],"gwas_catalog_id":"GCST007020","neg_log_pval":266.39794000867204,"otg_id":"GCST007020","pubmed_id":"30573740"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"EBF1 contributes to hair growth through regulation of adipocyte maturation in the skin","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000164330","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"5","position":158343969},"locus_GRCh38":{"chromosome":"5","position":158916961}},"trait_info":{"ontology":["EFO_0007825"],"reported_trait_name":"hair.balding pattern 4","standard_trait_name":"balding measurement"}}
{"association_info":{"ancestry":["European=6880"],"gwas_catalog_id":"GCST003270","neg_log_pval":24.0,"otg_id":"GCST003270","pubmed_id":"26626624"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"cytokine involved in immune response","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000113302","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":158764478},"locus_GRCh38":{"chromosome":"5","position":159337470}},"trait_info":{"ontology":["EFO_0003778"],"reported_trait_name":"psoriatic arthropathy","standard_trait_name":"psoriatic arthritis"}}
{"association_info":{"ancestry":["European=404196"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":12.014124642691606,"otg_id":"SAIGE_594_1"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"a kidney specific sodium/phosphate transporter","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000131183","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"5","position":176799992},"locus_GRCh38":{"chromosome":"5","position":177372991}},"trait_info":{"ontology":["EFO_0004253"],"reported_trait_name":"calculus of kidney and ureter","standard_trait_name":"nephrolithiasis"}}
{"association_info":{"ancestry":["European=121296"],"gwas_catalog_id":"GCST005897","neg_log_pval":581.0,"otg_id":"GCST005897","pubmed_id":"29739929"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"IRF4 encodes a transcription factor involved in skin pigmentation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000137265","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"6","position":396321},"locus_GRCh38":{"chromosome":"6","position":396321}},"trait_info":{"ontology":["EFO_0004279"],"reported_trait_name":"melanocytic naevi","standard_trait_name":"suntan"}}
{"association_info":{"ancestry":["European=354798"],"neg_log_pval":24.351119148082883,"otg_id":"NEALE2_23114_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"bone morphogenic protein, growth factor influencing bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000153162","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":7706004},"locus_GRCh38":{"chromosome":"6","position":7705771}},"trait_info":{"ontology":["EFO_0004995"],"reported_trait_name":"leg predicted mass (right)","standard_trait_name":"lean body mass"}}
{"association_info":{"ancestry":["European=23986"],"gwas_catalog_id":"GCST002679","neg_log_pval":96.52287874528034,"otg_id":"GCST002679","pubmed_id":"25352340"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"HFE encodes the hemochromatosis","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000010704","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":26093141},"locus_GRCh38":{"chromosome":"6","position":26092913}},"trait_info":{"ontology":["EFO_0004461","EFO_0006332"],"reported_trait_name":"hemochromatosis","standard_trait_name":"iron biomarker measurement"}}
{"association_info":{"ancestry":["European=393873"],"gwas_catalog_id":"GCST007091","neg_log_pval":8.522878745280337,"otg_id":"GCST007091","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"bone morphogenic protein, involved in ossification","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000112175","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":55636940},"locus_GRCh38":{"chromosome":"6","position":55772142}},"trait_info":{"ontology":["EFO_1000786"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"osteoarthritis, hip"}}
{"association_info":{"ancestry":["European=287323"],"gwas_catalog_id":"GCST004346","neg_log_pval":41.69897000433602,"otg_id":"GCST004346","pubmed_id":"28537254"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"receptor involved in immune response","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000056972","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"G"},"locus_GRCh37":{"chromosome":"6","position":111929862},"locus_GRCh38":{"chromosome":"6","position":111608659}},"trait_info":{"ontology":["EFO_0000676"],"reported_trait_name":"psoriatic arthropathy","standard_trait_name":"psoriasis"}}
{"association_info":{"ancestry":["European=426795"],"gwas_catalog_id":"GCST006980","neg_log_pval":64.04575749056067,"otg_id":"GCST006980","pubmed_id":"30598549"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"activator of wnt signaling pathway, regulator of angiogenesis","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000146374","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"A"},"locus_GRCh37":{"chromosome":"6","position":127468274},"locus_GRCh38":{"chromosome":"6","position":127147129}},"trait_info":{"ontology":["EFO_0003931"],"reported_trait_name":"wrist fracture","standard_trait_name":"bone fracture"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":94.49028415733696,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"regulation of caffeine metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000106546","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":17284577},"locus_GRCh38":{"chromosome":"7","position":17244953}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=334659"],"neg_log_pval":94.49028415733696,"otg_id":"NEALE2_1498","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"regulation of caffeine metabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000106546","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":17284577},"locus_GRCh38":{"chromosome":"7","position":17244953}},"trait_info":{"ontology":["EFO_0004330"],"reported_trait_name":"coffee intake","standard_trait_name":"coffee consumption"}}
{"association_info":{"ancestry":["European=440328","East Asian=45564","South Asian=9144","African American or Afro-Caribbean=20687","Asian unspecified=555","Hispanic or Latin American=1247"],"gwas_catalog_id":"GCST005843","neg_log_pval":13.045757490560675,"otg_id":"GCST005843","pubmed_id":"29531354"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"TWIST1 is a transcription factor involved in cranial development and cerebral vein formation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000122691","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":19049388},"locus_GRCh38":{"chromosome":"7","position":19009765}},"trait_info":{"ontology":["HP_0002140"],"reported_trait_name":"stroke","standard_trait_name":"Ischemic stroke"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":33.15490195998574,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"PSPH encodes an enzyme involved in de novo serine biosynthesis","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000146733","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"C","reference":"T"},"locus_GRCh37":{"chromosome":"7","position":56079094},"locus_GRCh38":{"chromosome":"7","position":56011401}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["European=346635"],"neg_log_pval":9.289347081400459,"otg_id":"NEALE2_2247_1","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"SLC26A5 encodes prestin, a critical outer hair cell membrane protein essential for mechanical signal transduction","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000170615","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":103061825},"locus_GRCh38":{"chromosome":"7","position":103421378}},"trait_info":{"ontology":["EFO_0004238"],"reported_trait_name":"hearing loss","standard_trait_name":"hearing loss"}}
{"association_info":{"ancestry":["European=394929"],"gwas_catalog_id":"GCST006433","neg_log_pval":1699.1549019599856,"otg_id":"GCST006433","pubmed_id":"30048462"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"WNT16 encodes a signaling protein involved in regulation of bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000002745","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":120962164},"locus_GRCh38":{"chromosome":"7","position":121322110}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"wrist fracture","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=394929"],"gwas_catalog_id":"GCST006433","neg_log_pval":1699.1549019599856,"otg_id":"GCST006433","pubmed_id":"30048462"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"WNT16 encodes a signaling protein involved in regulation of bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000002745","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":120962164},"locus_GRCh38":{"chromosome":"7","position":121322110}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"heel bone mineral density","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=394929"],"gwas_catalog_id":"GCST006433","neg_log_pval":1699.1549019599856,"otg_id":"GCST006433","pubmed_id":"30048462"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"WNT16 encodes a signaling protein involved in regulation of bone growth","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000002745","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":120962164},"locus_GRCh38":{"chromosome":"7","position":121322110}},"trait_info":{"ontology":["EFO_0009270"],"reported_trait_name":"Fracture of ankle","standard_trait_name":"heel bone mineral density"}}
{"association_info":{"ancestry":["European=367725"],"gwas_catalog_id":"GCST006946","neg_log_pval":9.698970004336019,"otg_id":"GCST006946","pubmed_id":"29500382"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GRM8 encodes a glutamate metabotropic receptor","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000179603","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"7","position":126378842},"locus_GRCh38":{"chromosome":"7","position":126738788}},"trait_info":{"ontology":["EFO_0009589"],"reported_trait_name":"worry too long","standard_trait_name":"worry measurement"}}
{"association_info":{"ancestry":["European=257773"],"neg_log_pval":15.933081750658816,"otg_id":"NEALE2_1568","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"receptor for bitter taste","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000257138","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"C"},"locus_GRCh37":{"chromosome":"7","position":141673345},"locus_GRCh38":{"chromosome":"7","position":141973545}},"trait_info":{"ontology":["EFO_0007878"],"reported_trait_name":"average weekly red wine intake","standard_trait_name":"alcohol consumption measurement"}}
{"association_info":{"ancestry":["European=348284"],"neg_log_pval":43.29265980539296,"otg_id":"NEALE2_1309","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"OR2A7 encodes an olfactory receptor that may respond to sweet smells","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000243896","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"7","position":143723137},"locus_GRCh38":{"chromosome":"7","position":144026044}},"trait_info":{"ontology":["EFO_0008111"],"reported_trait_name":"fresh fruit intake","standard_trait_name":"diet measurement"}}
{"association_info":{"ancestry":["European=350471"],"neg_log_pval":80.9294929792367,"otg_id":"NEALE2_30090_raw","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"In addition to GATA1 and GATA2, there are hits for the so-called \"Friends of GATA\" or FOG.  These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000169946","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"A"},"locus_GRCh37":{"chromosome":"8","position":106581528},"locus_GRCh38":{"chromosome":"8","position":105569300}},"trait_info":{"ontology":["EFO_0007985"],"reported_trait_name":"platelet crit","standard_trait_name":"plateletcrit"}}
{"association_info":{"ancestry":["European=80003"],"gwas_catalog_id":"GCST007638","neg_log_pval":39.69897000433602,"otg_id":"GCST007638","pubmed_id":"30837465"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"GLDC encodes an enzyme involved glycine catabolism","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000178445","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":6550024},"locus_GRCh38":{"chromosome":"9","position":6550024}},"trait_info":{"ontology":["EFO_0009767"],"reported_trait_name":"metabolite: glycine","standard_trait_name":"glycine measurement"}}
{"association_info":{"ancestry":["European=356530"],"neg_log_pval":218.9201208247617,"otg_id":"NEALE2_1717","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"BNC2 encodes a transcription factor involved in skin pigmentation","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000173068","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"G"},"locus_GRCh37":{"chromosome":"9","position":16885017},"locus_GRCh38":{"chromosome":"9","position":16885019}},"trait_info":{"ontology":["EFO_0003784"],"reported_trait_name":"melanocytic naevi","standard_trait_name":"skin pigmentation"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":222.0545314148682,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"locus associated with increased risk of heart disease","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000147889","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":22098574},"locus_GRCh38":{"chromosome":"9","position":22098575}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"treatment with nicorandil","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["NR=296525"],"gwas_catalog_id":"GCST005194","neg_log_pval":222.0545314148682,"otg_id":"GCST005194","pubmed_id":"29212778"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"locus associated with increased risk of heart disease","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000147883","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":22098574},"locus_GRCh38":{"chromosome":"9","position":22098575}},"trait_info":{"ontology":["EFO_0000378"],"reported_trait_name":"treatment with nicorandil","standard_trait_name":"coronary artery disease"}}
{"association_info":{"ancestry":["European=392109"],"doi":"10.1038/s41588-018-0184-y","neg_log_pval":22.543633966870956,"otg_id":"SAIGE_241_2"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"transcription factor exclusively expressed in thyroid, involved in thyroid development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000178919","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"G","reference":"A"},"locus_GRCh37":{"chromosome":"9","position":100538470},"locus_GRCh38":{"chromosome":"9","position":97776188}},"trait_info":{"ontology":["MONDO_0000334"],"reported_trait_name":"non-toxic goitre","standard_trait_name":"multinodular goiter"}}
{"association_info":{"ancestry":["European=393873"],"gwas_catalog_id":"GCST007091","neg_log_pval":11.522878745280337,"otg_id":"GCST007091","pubmed_id":"30664745"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"transcription factor involved in limb development","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000136944","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":129386860},"locus_GRCh38":{"chromosome":"9","position":126624581}},"trait_info":{"ontology":["EFO_1000786"],"reported_trait_name":"arthrosis of hip","standard_trait_name":"osteoarthritis, hip"}}
{"association_info":{"ancestry":["European=360527"],"neg_log_pval":68.43321497559869,"otg_id":"NEALE2_6152_5","url":"http://www.nealelab.is/uk-biobank"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"blood type is a risk factor for blood clots","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000175164","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"T","reference":"C"},"locus_GRCh37":{"chromosome":"9","position":136143372},"locus_GRCh38":{"chromosome":"9","position":133267960}},"trait_info":{"ontology":["EFO_0003907"],"reported_trait_name":"Blood clot in the leg, DVT","standard_trait_name":"deep vein thrombosis"}}
{"association_info":{"ancestry":["European=205327"],"gwas_catalog_id":"GCST007020","neg_log_pval":282.52287874528037,"otg_id":"GCST007020","pubmed_id":"30573740"},"gold_standard_info":{"evidence":[{"class":"expert curated","confidence":"High","curated_by":"Eric Fauman","description":"AR encodes the androgen receptor, important for regulation of hair follicles","source":"Eric Fauman's Twitter list based on biological plausability"}],"gene_id":"ENSG00000169083","highest_confidence":"High"},"metadata":{"date_added":"2019-07-30","reviewed_by":"Ed Mountjoy","set_label":"Eric Fauman Twitter","submitted_by":"Eric Fauman","tags":["Fauman","Biological plausability"]},"sentinel_variant":{"alleles":{"alternative":"A","reference":"C"},"locus_GRCh37":{"chromosome":"X","position":66670566},"locus_GRCh38":{"chromosome":"X","position":67450724}},"trait_info":{"ontology":["EFO_0007825"],"reported_trait_name":"hair.balding pattern 4","standard_trait_name":"balding measurement"}}
